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CHAPTER I
REVIEW OF THE LITERATURE
I.

A.

HEPARINS

History of Heparin
While studying the thromboplastic action of cephalin, a medical

student named Jay Mcclean made the serendipitous finding of a phospholipid anticoagulant in liver extracts (McClean 1916).
1922,

a

water-soluble

glycosaminoglycan

Soon after, in

complex was

discovered by

Howell, and named heparin because of its abundance in liver (Howell
1922).

Through the work of Scott and Charles (1936), heparin became

available in sufficient purity and quantity to make its use in physiological and clinical experiments feasible.
and Yin,

in the early 1970s,

In vitro studies by Wessler

demonstrated that thrombosis could be

controlled by a block in the coagulation cascade which could lead to an
inhibition

of

thrombin

generation

and

an

inhibition

of

clotting

(Wessler 1974; Yin et al. 1973). Clinical trials by Kakaar et al. in
1979 have

contributed

to

the

heparins as therapeutic agents.

development

of

low molecular weight

Significant advances in the structure

activity relationship of low molecular weight heparins by Choay et al.
(1983) has lead to the chemical synthesis of a pentasaccharide which
contains the minimal binding site of heparin for antithrombin III (AT
III).

1

2

B.

The Biosynthesis of Heparin
Heparin is synthesized as a proteoglycan complex, by connective

tissue type mast cells.

The synthesis of the glycosaminoglycan is

initiated by attachment of a carbohydrate-protein linkage region to
serine residues of a specific polypeptide chain (Silbert 1967, Lindahl
et al. 1977).

After the linkage region is formed the polymer chain of

the glycosaminoglycan is assembled by the alternate attachment of Nacetylglucosamine

and glucuronic

acid.

This

initial synthesis

is

followed by postsynthetic modifications which can be divided into four
major categories.

Initially,

glucosamine residues are partially N-

deacylated and the exposed amino groups serve as acceptors of S04 - 3
ions in a transfer reaction with phosphoadenosyl phosphosulfate (PAPS).
Secondly, glucuronic residues are epimerized to iduronic acid moieties.
Thirdly, the iduronic acid residues and some glucuronic residues are
sulfated at the C-2 position.

Fourthly, the glucosamine moieties are

ester desulfated to a variable extent at C-3 and C-6 positions (Silbert
1967, Lindahl et al., 1977, Jacobson et al. 1979, Roden and Horowitz
1977).

The biosynthesis of heparin does not occur in a random manner,

although

the

regulation

of

these

complex

events

is

yet unclear.

Sulfation occurs preferentially in those regions of the chain where the
amino sugar residues have been N-deacylated and N-sulfated and where
glucuronic
1985).

residues

have been epimerized to 1-iduronic acid

(Casu

The final product of this synthetic pathway is termed heparin

proteoglycan or macromolecular heparin (Yurt et al. 1978; Robinson

et

al. 1978) and is thought to consist of a core protein of unknown size

3

with

glycosaminoglycan chains

of

30,000 to 100,000 daltons,

which

resembles a bottlebrush (Arnott and Winter 1977).
After heparin

is

synthesized,

different types of lysosomal enzymes:
the polypeptide chain,

(2)

it

can be modified by

three

(1) proteases which can cleave

endoglycosidases which can cleave between

glucuronic acid and glucosamine residues (Horner 1972; Oosta et al.

1982) and (3) exoglycosidases that remove monosaccharide units from the
nonreducing end of the "released" complex carbohydrate species (Neufield et al. 1975).

This degradation takes prior to purification of

the glycosaminoglycan.

C.

Biological Function of Heparin
Heparin ls primarily located in the mast cells of a variety of

organs, including the liver, lungs, heart, kidneys and intestines.

The

concomitant occurrence of heparin and histamine in mast cell granules
has lead to suggestions that these two biologically active compounds
may be stored together as an inactive complex (Unvas

1974).

An .in

vitro complex arising from the ionic binding between the ester sulphate
groups of the heparin and the amino groups of the histamine was taken
to support this hypothesis (Unvas 1974).

Ultrastructural analysis of

human lung mast cells demonstrates that the contents of the secretory
granules are packaged in a highly ordered crystalline array, suggesting
that such complexes occur

(Schwartz and Bradford 1986).

A unique

property of heparin in the mast cells is the high degree of sulfation
of heparin which creates an enormous electrostatic charge that can act
as a cation exchanger in the granule. In addition, heparin may function

4

to regulate

the osmotic pressure of the granule in the mast cell

(Caulfield et al. 1980).
There is no direct evidence that mast cells secrete heparin into
the bloodstream.
mastocytomas

Blood coagulability is generally not effected when

of varying

rodents, cattle,

degrees

of

differentiation

occur

in man,

cats and dogs, even when large tumors are present

(Sagher and Even-Paz 1967).
D.

Chemistry of Heparins
Heparin structure consists of a regular and an irregular region.

The

regular

region

contains

trisulfated

disaccharide

units

(I2s-

Ans,6s(alpha-l,4-linked L-iduronic acid 2-sulfate)-(D-glucosamine N,6disulfate))

which

are

sequences (Casu 1984).

interrupted by

other

usually

less

sulfated

Contained within the regular sequences of the

heparin regions is a unique sequence, a pentasaccharide, which binds
tightly to antithrombin III (AT III) with a Ka- 7xl0 6 M- 1 forming an
equimolar complex with and enhancing the inhibition of factor Xa by AT
III.

The pentasaccharide represents the minimal binding sequence of

heparin for AT III (Choay et al. 1983).
Approximately 30% of heparin preparations on a weight basis are
able to bind to AT III and potentiate the inhibition of the coagulation
proteases (Choay and Petitou 1986).
tions

have been described

Dietrich et al.

As many as 21 different subfrac-

in heparin,

1975) however,

(McDuffie

et

al.

1975

and

only 25% to 35% of a given heparin

preparation binds tightly to AT III and this high affinity fraction is
responsible for 85 to 90 % of the anticoagulant activity of heparin
(Lam et al. 1976).

Most heparin oligosaccharides which bind to AT III

5

affinity columns differ in size as well as internal composition

which

suggests that some residues may be either critical or essential for
activity while others may be nonessential fo,r activity (Casu et al.
1981).
Clinically used heparin is heterogenous with respect to structure, molecular size, degree of sulfation and anticoagulant activity.
Fragments of heparin have molecular weights which range from 6,000 to
more than 30,000 daltons with the largest fraction being between 10,000
and 15,000 daltons (Andersson and Barrowcliffe et al. 1979; Hook et
al., 1976).

The degree of sulfation contributes to the anticoagulant

activity of heparin.

A relationship exists between the anticoagulant

potency of a heparin and the linear charge density of a series of
heparin fractions (Hurst

et al. 1979).

fractions

molecular

with

similar

increasing charge density.

The anticoagulant activity of

weight

profiles

increases

with

However, differences in molecular weight

produce larger differences in anticoagulant potency than differences in
anionic density (Hurst
Heparins
preparations

et al. 1981).

obtained from various organs

from

the

same

and different heparin

organ contain differing proportions

of

regular and irregular sequences which include the linkage region or AT
III binding sequence.
proportion

of

the

Typically beef lung heparin contains a larger

regular

trisulfated disaccharide

heparin from porcine mucosal origin.

sequences

than

Electrophoresis of heparin in

cationic buffers provides further evidence of the heterogeneity of
heparin (Casu 1984).

In these systems, heparin can be subfractionated

into slow moving and fast moving components and preparations from beef

6

lung usually contain more slow moving species than porcine mucosal
heparins.
E.

Fractionated and Depolymerized Low Molecular Weight Heparins
Low molecular weight heparin fractions and fragments have been

prepared from conventional heparin by several methods.

Procedures such

as gel filtration, ion exchange chromatography, partition fractionation
and affinity chromatography separate the heparin structures based on
physiochemical characteristics without cleaving the heparin molecule.
Gel filtration has been used to elucidate the molecular weight of the
heparin components (Losito 1981).

Studies using specific molecular

weight components of heparin have shown that anticoagulant activity
increases with the size of the molecule and that anti Ila inhibition is
more dependant on molecular weight than is anti Xa activity (Andersson
Ion exchange chromatography has been used to separate

et al. 1979).
fractions

which

fractionation

have

varying

procedures

have

anticoagulant
been

used

to

activity.
produce

Partition

heparins

with

varying degrees of sulfation which parallel the anticoagulant activity
of heparins.

Low molecular weight heparin has also been fractionated

on affinity columns of substances such as AT III, heparin cofactor II,
or thrombin (Choay and Petitou 1986).
Low molecular weight heparin can also be produced by a variety
of techniques which cleave the heparin molecule including: heparinase
treatment, nitrous acid degradation, perioxadative oxidation followed
by either reduction and mild acid hydrolysis or alkaline cleavage
fractionation with dilute acid followed by re-N-sulfation of N-desulfated fragments or with chlorosulfonic acid (Casu 1984).
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End residues of fragments are typical of the specific method of
depolymerization.

Heparinase

splits

glycosidic

bonds

between

N-

sulfated glucosamine and iduronic 2-sulfate residues producing fragments terminating with 4,5-unsaturated iduronic acid 2-sulfate at the
nonreducing end and N-sulfated glucosamine at the reducing end (Linker
et al. 1977).

Nitrous acid splits glycosidic bonds between N-sulfated

glucosamine and uronic acid, producing fragments with 2, 5-anhydromannose at the reducing end (Cifonelli et al. 1976).
splits the C-2,
glycosidic

bonds

Periodate oxidation

C-3 bonds of nonsulfated uronic acids,
of modified

reduced) to acid (Casu 1984).

residues

labile

to

alkali

making the
or

(when

Direct acid hydrolysis preferentially

causes N-desulfation (Conrad 1981) while chlorosulfonic acid can be
used to depolymerize and resulfate heparin fragments in one step with
the end result being

a

"supersulfated"

heparin

fragment with ap-

proximately one extra sulfate group per disaccharide unit.
Apart from differences in the yield of these fragments from the
variety of fragmentation procedures, the method of depolymerization, in
theory, may influence the binding sequence to antithrombin III.

In

principle, nitrous acid could split some glycosidic linkages in the
region of the

active site for AT III and perioxadative cleavage could

conceivably modify the active site for AT III.

However, it has been

reported the 3-0 sulfo group on A*NS·6S has some stabilizing influence
of the corresponding glycosidic linkage (Casu 1981).

It has not been

determined whether the end group influences the anticoagulant activity
of heparin, however, end groups influence the metabolism of the heparin
(Linhart personal communication).
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Methods

which

fragment heparin may be preferred over

frac-

tionation techniques since the yield of low molecular weight heparin
obtained through chromatographic techniques is only about 10 to 15

%

with the use of carefully controlled depolymerization techniques nearly
100 % of the sample can be converted to the molecular weight range of
choice (Barlow and Petracek 1986).
F.

Qyerview of Hemostasis
Prior to a detailed discussion of the interaction of heparins

with

the

components of the hemostatic

system,

current knowledge on this subject is presented.

an overview of the
A schematic diagram of

the coagulation cascade is shown in Appendix I.
Blood normally circulates through the vascular system without
activation
hemorrhage.

of

the

coagulation

proteins

or

platelets

and

without

An injury to a vessel, however, initiates a complex chain

of events resulting in the formation of fibrin.
tained through

the

Hemostasis is main-

interaction of the coagulation and fibrinolytic

systems, platelets and the endothelium.

The process of coagulation may

be described as a waterfall or cascade involving cofactors, enzymes and
substrates.

Most coagulation enzymes are zymogens containing serine,

histidine and aspartic acid

in their

active

sites

in addition to

containing binding regions to cellular surfaces, phospholipids, cell
membranes and connective tissue.

The molecular assembly of cofactor,

enzyme and substrate is a recurrent theme in blood coagulation designed
for maximal efficiency and speed of molecular reactions.

Negatively

charged surfaces provide the reaction surface in the early part of the
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cascade while

later phospholipid or platelet membranes provide the

surface for reaction in the later part of the cascade.
The initiation of blood coagulation occurs through either the
activation of

the

intrinsic

or

extrinsic pathway.

The

intrinsic

pathway becomes activated when the coagulation factor XII comes in
contact with a

foreign surface such as

a damaged vessel wall or

prosthetic device and becomes activated to factor XIIa.

Factor XIIa in

the presence of ca+ 2 converts zymogen factor XI to factor IXa.

Factor

IXa in the presence of factor VIII and phospholipid activates factor X
to factor Xa.
The extrinsic system is involved in response to an injury in the
vessel wall and also converts factor X to factor Xa.

Components of the

extrinsic system include factor VII,

a vitamin K dependant enzyme,

tissue

phospholipid which

factor

or

thromboplastin,

a

acts

as

a

cofactor in the conversion of factor X to factor Xa by factor VIIa.
Once factor Xa is formed by either the extrinsic or intrinsic pathway,
it converts prothrombin to thrombin which cleaves fibrinogen to fibrin.
Thrombin occupies
limitation as

a central role

in hemostatic plug formation and

it acts on multiple substrates including fibrinogen,

factor XIII, factor V and factor VIII, platelet membrane glycoprotein V
and protein C (Colman et al.

1987).

The final

two steps of the

coagulation are termed the common pathway.
Platelets play an important role in coagulation by releasing
substances which stimulate vessel wall constriction and by forming a
primary platelet plug at a site of vessel injury.

Many of the coagula-

tion factors are attached to the platelet surface where activation of
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the

coagulation factors

takes

Platelets,

place.

upon activation,

release substances from their granules which influence blood coagulation.

One such substance released from the dense granules is platelet

factor 4 which complexes with heparin and neutralizes its activity.
Many plasma proteolytic inhibitors control and limit the extent
of coagulation and fibrinolysis.

C1

inhibitor

is the major plasma

inhibitor of factor XII (Liu et al. 1979), while alpha1 antitrypsin is
the major inhibitor of factor XIa (Ratnoff et al. 1977).

AT III is the

major inhibitor of factor Xa, XIa and thrombin (Colman et al. 1988).
The interaction between AT III and heparin is responsible for most of
the anticoagulant effects of heparin.
Fibrinolysis, a physiologic mechanism for limiting clot formation

resembles

the

coagulation

cascade

in

its

zymogens,

potentiation and inhibition and plasma inhibitors.
release

tissue

plasmin.

plasminogen activator

which

feedback

Endothelial cells

convert plasminogen

to

Once plasmin is produced locally on the hemostatic plug, the

potential for fibrin degradation exists.

An intricate balance exists

between

either

the

simultaneous

forces

which

coagulation and platelet aggregation.

promote

or

inhibit

The balance between profibrinol-

ytic and antifibrinolytic reactions, in addition to cellular mechanisms
may eventually lead to clot reduction (Colman et al. 1987).
G.

Mechanism of Action of Heparins
The primary mechanism of the anticoagulant actions of heparin

occurs through association of heparin with AT III, an

alpha2 globulin

with a molecular weight of approximately 64,000 daltons (Abligaard et
al. 1967).

Heparin forms a stable complex through binding allosteric
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lysyl residues on antithrombin III.

This results in a conformational

change in the protein and allows the critical arginine residue on AT
III to be more readily available to interact with the serine active
site in a specific activated enzyme.
and active

serine sites has

The reactivity between arginine

lead to

the hypothesis

that heparin-

antithrombin III complexes inhibit other serine proteases in addition
to thrombin (Rosenberg et al. 1975; Atha et al. 1987).

It has been

demonstrated in vitro that the heparin-antithrombin III complexes exert
their anticoagulant effects by inhibiting factors XIIa, XIa, Xa, IXa
and thrombin (Rosenberg et al. 1975).

Although most of the in vitro

anticoagulant activity of heparin can be related to heparin molecules
with high affinity for AT III, antithrombotic effects of heparin have
been described which are independent of AT III

(Ofosu et al. 1981).

These include potentiation of the effects of high affinity heparin by
low affinity heparin, binding of heparin to endothelium and the direct
inhibition of heparin on several thrombin dependant reactions including
factor V and factor VIII activation

(Hurst et al. 1983).

Heparin also

inhibits thrombin through heparin cofactor II, a glycoprotein of 65,600
daltons (Colman et al. 1987).

In vitro, the thrombin inhibitory effect

has been demonstrated at higher concentrations of heparin that is
necessary to inhibit thrombin through AT III (Andrew et al. 1986).
H.

In Vitro Effects of Heparins

1.

Anticoagulant and Antiprotease Effects
The heterogeneity and polydisperse nature of heparin does not

permit the
methods,

direct measurement of heparin concentration by chemical

rather,

measurement of heparin activity has been used to
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approximate the

actual concentration of heparin administered.

For

many years the anticoagulant activities of heparin have been evaluated
using nonspecific global assays such as the USP assay and APTT tests.
These assays, however, proved to be insensitive to the newly developed
low molecular weight heparins.

Newer assays have been developed which

are more sensitive to the antiprotease activities of heparin and are
useful in the monitoring of low molecular weight heparins.

These

assays include: serine protease inhibition assays such as anti factor

Xa and anti

factor

Ila methods,

serine protease generation tests,

fibrinopeptide A generation tests, thrombin generation tests as well as
complex combination tests such as the HeptestR which combines enzyme
generation,

protease

inhibition,

and clot formation

(Fareed et al.

1980).
A molecular weight dependence of the anticoagulant activity of
heparin has
assays.

been

demonstrated

Denton et al.

using

the

more

specific

antifactor

(1983) and Mardigian and Trillou (1983) have

determined that an octadecasaccharide was the minimum length of heparin
chain necessary to accelerate the neutralization of thrombin by AT III.
Low molecular weight heparins

of < 5,600 daltons do not show any

significant antithrombin activity.

This molecular weight corresponds

to the minimum size of heparin to accelerate thrombin inhibition in the
presence of AT III

(Oosta et al.

1981) .

Inhibition of factor Xa,

however, did not show a similar correlation to molecular weight. Unlike
the anti factor Ila effects of heparin. both low and high molecular
weight heparin molecules are capable of inhibiting factor Xa. The anti
Xa activity of heparin increases with decreasing molecular weight in
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both amidolytic and clot based assays (Lane et al. 1978; Andersson
al. 1979; Emanuele 1987).

et

Choay et al. (1980; 1983) and Lindahl and

Bjork (1983) determined that the minimal binding site of heparin for AT
Ill was restricted to a pentasaccharide sequence.
At

equigravimetric

concentrations,

unfractionated

heparin

contains greater anti Xa and anti Ila activity than many low molecular
weight heparins (Walenga 1986).
within a

When comparing antiprotease activities

single heparin preparation,

one would expect

to see

ap-

proximately equal anti Xa and Ila activity. A greater proportion of
anti Xa activity to anti Ila activity is
molecular weight heparin preparations

seen however with

(Walenga 1986).

low

This difference

in relative activity between low molecular weight heparin and unfractionated heparin is due to the fact that low molecular weight heparins
contain a greater proportion of oligosaccharides (>50%) which inhibit
factor Xa activity.

Commercial heparins contain only 5% saccharides

with a molecular weight< 4,200 daltons (the minimum weight required to
inhibit thrombin).
Some low molecular weight heparins can inhibit thrombosis in
vivo while possessing
(Walenga 1987).

minimal or no anticoagulant activity in vitro

New terminology has been introduced which expresses

the discrepancy between the in vitro and in vivo activities of these
antithrombotic

agents.

Anticoagulant

activity

is

defined as

ability to inhibit either the activation of prothrombin and/or
X or

the activated enzymes

Antithrombotic

activity

is

the

factor

(thrombin and factor Xa respectively).
defined

as

the

in vivo

prevention of
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thrombosis or the inhibition of the extension of established thrombi
(de Prost 1986).
2.

Interactions With Platelets
A wide spectrwn of in vitro results on the interaction of heparin

with platelets has been reported.

These

include the inhibition of

platelet aggregation and release (Han et al. 1974), potentiation both

in vitro and in vivo (Thompson et al. 1973; Heptinstal et al. 1977) or
no detectable effect (MacFarlane

et al. 1975).

These differences in

experimental results may depend upon the source of heparin or the
experimental protocol used in the studies.

Heparin blocks the action

of thrombin on platelets, while the other activities of platelets may
proceed despite the administration of heparin (Salzman et al. 1980).
Heparin enhances platelet release induced by ADP, however there is no
significant

effect

of

low molecular

weight

heparins

on platelets

(Fabris et al. 1983).
Heparin enhances platelet aggregation in citrated platelet rich
plasma after induction by various agonists such as ADP and epinephrine.
This action is blocked by substances that elevate cAMP and by EDTA but
not by inhibitors of the cyclooxygenase pathway (Salzman et al. 1980).
A molecular weight dependance of the enhancement of platelet aggregation by heparin has been reported.
heparin

(20,000

daltons)

were

Fractions of high molecular weight

more

reactive

with

platelets

fractions of low molecular weight heparin (7,000 daltons).

Brace

than
et

al. (1986) have demonstrated a molecular weight dependance on platelet
aggregation using subfractions of a low molecular weight heparin, PK
10169.

Preparation of high molecular weight heparin of high and low
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affinity were equally active in the induction of platelet aggregation.
No correlation between the anticoagulant, antifactor Xa, antifactor Ila
activities of the heparins and platelet aggregation was noted.
Heparin does not induce aggregation in washed platelets which
suggests that there is not a direct interaction between platelets and
heparin (Fabris et al. 1983; Westwick et al. 1986).

Binding of heparin

to AT III has been reported to inhibit the interaction of heparin with
platelets.

Shanberge et al.

(1986) have demonstrated that platelets

bind heparin but not heparin-AT III complexes.

Heparin has been shown

by O'Brien et al. (1969) and Fabris et al. (1983) to inhibit platelet
Heparin may alter the surface

release induced by collagen in PRP.

charge of platelets and interfere with platelet-collagen interactions.
3.

Heparins and Fibrinolysis
Heparin has a dual effect on fibrinolysis in vitro.

Levels

> 125 µg/ml of this agent inhibited fibrinolysis mediated by human
urokinase, human euglobulin fractions and human plasma, while lower
heparin concentrations (5 µg/ml) have been shown to enhance fibrinolysis in vitro (Von Kaulla et al. 1958).
(1986)

and

dependant

Fears

et

al.

stimulation

of

(1988)

have

More recently Paques et al.
demonstrated a

plasminogenolytic

and

concentration

fibrinogenolytic

activity of both urinary and tissue type plasminogen activators in the
presence of heparin.
effects

In the presence of soluble fibrin, however these

of heparin on tPA were attenuated

(Fears

et al.

1988).

Heparin also decreased the fibrin specificity of tPA and consequently
caused a cleavage of fibrinogen. This may be related to any increased
bleeding observed when these agents

are used in combination.

In
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addition, if these influences of heparin and fibrin also occur in vivo,
then, in the presence of heparin, the relative fibrin enhancement of
tPA will be diminished and the likelihood of systemic activation by tPA
Markwardt et al. (1977), have shown

is increased (Fears et al. 1988).

that heparin induces the release of plasminogen activator using an
isolated pig ear preparation.
I. In Vivo Effects of Heparin
1. Studies in Animal Models
The ideal ratio of the antifactor Xa and antifactor Ila activities of heparins needed to achieve optimal antithrombotic effects
has not been determined.

Antithrombotic effects which are achieved by

inhibiting factor Xa alone are limited in their control of various
thrombogenic triggers.

Better antithrombotic effects are achieved by

heparin or heparin-like substances capable of influencing the inactivation and or generation of thrombin.

The ability of heparin or a

heparinoid to potentiate the inactivation or the generation of thrombin
appears to be an important predictor of antithrombotic effect observed

in vivo (Buchanan et al. 1984).

Heparin fractions with predominately

anti factor Xa activities are likely to be weak inhibitors of thrombin
generation.

Heparin or

related substances which exhibit thrombin

inhibition are more active against thrombosis as demonstrated in a
modified Wessler

model

than

towards factor Xa activity.

agents

with

sole

inhibitory

activity

Although the anti Xa levels of standard

heparin and an octasaccharide were similar (0.28-32 U/ml), heparin (10
anti Xa U/kg) inhibited thrombus formation by 90%, while octasaccharide
(10 anti Xa U/kg)

inhibited thrombus

formation by 41%.

Dermatan
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represents a gravimetric amount 5

sulfate (500 µg/kg i. v.), which

times heparin and exhibits no anti Xa activity inhibited thrombus
formation by 95%.

Also higher doses of octasaccharide which increased

anti Xa to higher levels had no further effect on thrombus formation
(Buchanan et al. 1984).
Similarly,

Walenga

et

al.

(1987)

have

demonstrated

that

a

pentasaccharide representing the critical sequence required in heparin
for binding to AT III, however, devoid of any anti factor Ila activity
was capable of inhibiting thrombosis induced by four different thrombogenic challenges.

The agents used for the induction of thrombosis in

a modified Wessler model included thromboplastin, an activated prothrombin complex concentrate,

a nonactivated prothrombin complex con-

centrate administered simultaneously with Russell's viper venom, and
activated

factor X.

The studies

demonstrated that oligosaccharides

devoid of antifactor Ila activity but containing high antifactor Xa
activity were capable of inhibiting thrombosis induced in rabbit stasis
models, however, higher doses of these agents as compared to heparin
were required for this effect.
In the treatment of thrombosis, prophylaxis as well as therapeutic

intervention to inhibit thrombus extension is

important.

Low

molecular weight heparins (CY 216 and PK 10169) and heparin were shown
to be equipotent at doses of 42-62.5 anti Xa U/kg/hr in preventing the
accretion

of

jugular veins

125 1-fibrin onto
(Boneu et al.

venous

1985).

thrombi

preformed

in rabbit

Low molecular weight heparins,

therefore, could be used for the treatment as well as prophylaxis of
thrombosis.

The ED50 for the antithrombotic effects of low molecular
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weight heparins ranged from 40 to 80 µg/kg as compared to an

EDso

of

approximately 30 µg/kg for unfractionated heparin as demonstrated in a
stasis thrombosis model (Fareed et al. 1988).
Many theories have been proposed to explain the potentiation of
the actions of high affinity heparin oligosaccharides by low affinity
heparin in vivo. These include: the binding of low affinity heparin to
antiheparin

proteins

in plasma,

interactions

of

the

low affinity

heparin with vascular endothelial cells or providing an alternative
substrate to endoglycosidase enzymes located in platelets (Barrowcliffe
et al. 1984).

Two heparin fractions: one with high affinity to AT III

and one with low affinity to AT III were compared with unfractionated
heparin in both in vitro assays and in an experimental model of stasis
thrombosis (Merton et al. 1984).

Although the in vitro activity of

high affinity heparin was twice that of unfractionated heparin, the
high

affinity

unfractionated

heparin
heparin.

had

less
The

antithrombotic

low

inactive, both in vitro and in vivo.

affinity

activity

heparin

was

than

the

virtually

A mixture of 30 µg/kg of high

affinity heparin and 50 µg/kg of low affinity heparin given intravenously was

as effective as unfractionated heparin (80 µg/kg

i. v.).

These studies demonstrate that low affinity heparin potentiates the
actions of high affinity heparin in vivo.
With the development of low molecular weight heparins, it became
possible to dissociate the antithrombotic and hemorrhagic effects of
these agents, thus improving their therapeutic potential (Cade et al.
1984).

Low molecular weight heparins

produce

less bleeding than

unfractionated heparin, however no strong relationship exists between
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blood loss and the effects on antifactor Xa levels, APTT,

thrombin

clotting time as measured ex vivo (Cade et al. 1984).
Heparin fractions of low molecular weight with high antifactor
Xa activity/APTT activity ratios exhibit antithrombotic activity and
are associated with a reduced incidence of bleeding (Mattsson et al.
1985).

Doutremepuich et al.

(1986)

have demonstrated that a

low

molecular weight heparin, CY 216, had lower hemorrhagic effects than
heparin as measured in a rabbit ear blood loss model.
heparin (1408 anti-factor Xa U/kg) and CY 216
U/kg)

with similar anti Xa activities,

At doses of

(1600 anti-factor Xa

the blood loss values

heparin were significantly greater (p<.05) than for CY 216.

for

Studies on

the time course of antiprotease, antithrombotic and bleeding effects of
heparins in rats by Hobblelen et al. (1985) have shown that the time
response curves for the antithrombotic effects of heparins parallels
those of the antifactor Xa activity whereas the time response curves
for bleeding were more related to the effects on thrombin.
2.

Pharmacokinetics/Pharmacodynamics of Heparins
The pharmacokinetics of heparin are nonlinear, dose dependant,

time dependant and assay dependant

(Cocchetto and Bjornsson 1984).

These properties contribute to the variations seen in anticoagulation
for patients given a certain dose of heparin. Pharmacokinetic parameters depend upon the assay used to determine heparin activity.

APTT

activity has been reported to disappear faster than anti Xa activity
shortly after drug administration (de Swaart et al. 1982).

Four fold

variation in the t 1/2 of a low molecular weight heparin was seen by
Dawes et al.

(1986) and was dependant upon whether concentration was
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measured directly or anti Xa, or anti Ila methods were used (Dawes

et

al. 1986).

The dose and route of administration of heparin depends upon the
clinical indication.
and

is

given

either

Heparin is not effective by oral administration
by

deep

subcutaneous

injection,

intravenous injection or by intravenous infusion.

intermittent

The dose of heparin

is adjusted according to the patients coagulation test results.

The

APTT should be elevated to approximately 1. 5 to 2 times the control
value (Salzman 1975).
For subcutaneous administration of heparin, 5,000 U of heparin
is given initially by intravenous injection and followed by 10,000 to
20,000 U given subcutaneously. Then 8,000 to 10,000 U of a concentrated
solution are given every 8 hours subcutaneously.
intravenous injection of heparin,
administered every 4 to 6 hours.

For intermittent

5,000 to 10,000 U of heparin is
For continuous intravenous infusion,

an initial injection of 5,000 U of heparin then an additional 15,000 to
35,000 U are administered

over a period of 24 hours.

Patients

undergoing open heart surgery should receive an initial dose of 150
U/kg of heparin.

Frequently a dose of 300 U/kg is used for procedures

estimated to last less than 60 minutes; or 400 U/kg for those estimated
to last longer than 60 minutes.

Low dose heparin given prior to and

after surgery has been shown to reduce the incidence of postoperative
deep venous thrombosis.

The most widely used dose is 5,000 U, 2 hours

before surgery and 5,000 U every 8 to 12 hours after for 7 days until
the patient is fully ambulatory (Physician's Desk Reference 1989).
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a.

Absorption of Heparins
Heparin is not absorbed to any great extent by gastrointestinal

mucosa, due to its negatively charged high molecular weight components.
oral

absorption

of heparin

is

variable

because

of

its

uncertain

absorption from the G.I. tract and its instability in digestive juices,
in addition, intestinal flora has also been noted to degrade heparin
(Brufani

et al. 1982).

The N-sulfate groups of heparin are easily

hydrolyzed in acidic medium which may result in a substantial loss of
anticoagulant

activity.

daltons do not cross
heparins

(mean

While
the

heparins

of

molecular

intestinal barrier,

molecular

weight

weight

>6000

low molecular weight

approximately

4500

daltons)

are

absorbed from the gastrointestinal tract at very high doses (60 mg/kg).
Heparins have been complexed with bile salts, (Ziv et al. 1983;
Guarini et al. 1985) surface active agents (Stanzani et al. 1981) and
encapsulated within liposomes (Ueno et al. 1982) in order to facilitate
gastrointestinal

absorption

in

experimental

animals.

The

lower

molecular weight of the newly developed heparins has facilitated the
study of percutaneously applied low molecular weight heparins (Rodemer
et al. 1986).

Absorption of low molecular heparin in healthy subjects

was meager at the doses

studied

(100-250 anti Xa units).

It is

conceivable however, that with better carrier substances absorption by
percutaneous route could be improved.

The rate of absorption depends

upon the injection site and has been shown to exhibit intrastrain or
interstrain variations

in experimental animals.

Variations

in the

subcutaneous absorption between two strains of mice have been reported
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Variability in the subcutaneous absorption of unfrac-

by sue (1979).

tionated heparin has been reported in man, although these variations
decreased with decreasing molelcular weight, this variability could not
be correlated to any physical parameter such as age, height or weight.
A barrier

to

absorption exists which discriminates against larger

molecules such that the 6 fold variation in AUC values between subjects
observed with unfractionated heparin was reduced to 1. 5 fold for low
molecular weight heparin CY 222 (Dawes

et al. 1986).

It was generally assumed that the activity of heparins in vivo
resembled

their

profiles.

in

However,

vitro

anticoagulant

and

antiprotease

activity

differences between these two situations exist.

Investigators have shown that heparin is not inert as it circulates in
the plasma.

Endogenous heparin can bind to the glycocalyx and be

phagocytosed (Barzu et al. 1985).

While the uptake of heparin is well

documented, there is only indirect evidence for its eventual release in
an undegraded form (Mahadoo and Jacques 1979).

Extended anticoagulant

responses observed with more indirect routes of administration could be
related to either a slow absorption from the site of administration or
a slow release of heparin which is sequestered by the reticuloendothelial system.

The duration of anticoagulant response (paren-

theses indicate half life) increases with the route that allows for
greater cellular uptake of heparin as follows: intrapulmonary (14 days)
> subcutaneous (6-8 hrs)> intramuscular (4-6 hrs)> intravenous (2-4
hrs), (Mahadoo et al. 1979).
It has been postulated by Mahadoo et al. (1979), that a cellular
pool exists which modulates the level of heparin in the circulation and
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may be related to endothelial cell binding of heparin.
the size of the cellular pool causes
heparin to the circulating blood.

a

An increase in

decreased availability of

This pool may act as a storage depot

from which stored heparin is gradually released to the circulation.
The degree of cellular uptake varies between the different sites of
administration as follows:

lung >peritoneal cavity > skin > muscle

corresponds to the cell population of reticuloendothelial cells at the
site of administration (Mahadoo and Jaques 1979).

Heparin is rapidly

absorbed and metabolized after parenteral administration.

Although

after intrapulmonary administration 90% of the drug is absorbed in 24
hours while the anticoagulant response lasts for more than one week.
This

suggests

that

heparin

is

sequestered

and

released

into

the

circulation (Jaques et al. 1976).
Low molecular weight heparin is absorbed from subcutaneous sites
to a greater extent than standard heparin.
ministration of 7500 anti Xa U,
absorbed to a

After subcutaneous ad-

the anti Xa activity of heparin is

lesser degree than CY 216

(Harenberg et al.

1986).

Twelve hours after the administration of 5000 anti Xa IU of heparin and
a low molecular weight heparin, higher anti Xa levels were seen for the
low molelcular weight heparin than the unfractionated heparin ever
produced (Bergvist et al. 1983).
b.

Endogenous Distribution of Heparins
The polycomponent nature of heparin makes

distribution within the body difficult.
different molecular
sulfation,

it

is

species
not

the study of its

Since heparin contains many

with varying structures and degree

possible

to

uniformly

radiolabel

of

heparins.
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However, radiolabelling studies have been performed and have shown that
after intravenous administration, the anticoagulant activity of heparin
disappears exponentially with a slightly faster initial disappearance
which may be representative of endothelial uptake (Jacques 1979).
Once heparin enters the vascular compartment it binds to many
plasma proteins
fibronectin,

including

lipoproteins,

AT III,
and

albumin,

platelet

globulins,

factor

4

fibrinogen,

(Cocchetto

and

Bjornsson 1984). Heparin is also taken up by vascular endothelium and
tissue macrophages (Mahadoo 1978).
The distribution of 35 s heparin fragments (1 mg/kg i. v.) was
studied in rats by Larsen et al. (1984).

Low levels of radioactivity

were present in all organs and tissues with an overall recovery of
radioactivity of 94.4 %.

78% of organ bound radioactivity was as-

sociated with the liver, kidneys and intestines.

The highest disposi-

tion of radioactivity was found in the liver while the highest specific
activity

(dose/gram)

was

associated with

the

kidneys.

The organ

distribution of heparin and low molecular heparin is similar.

Both

drugs exhibit a selective distribution in various organs especially
those endowed with reticuloendothelial tissue (Danishefsky and Eiber
1959).
c. Half Life of Heparins
The t1;2 of low molecular weight heparin is usually 2 to 3 times
the t1;2 of unfractionated heparin and is dependant on the dose, route
of administration and assay used to
(Lockner et al.

1986;

Fareed et al.

increases with increasing dose (Estes

detect anticoagulant activity
1986).

The t1;2

et al. 1969).

of heparin
The immediate
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mechanism underlying the dose dependant kinetics of heparin, in rats,
appears to be a decrease in total clearance and an increase in app~rent
vd with increasing dose (Bjornsson et al. 1981).
In primates, the t1;2 of unfractionated heparin (250 µg/kg i.v.)
as measured by the HeptestR is approximately 30 minutes while the t1;2
of low molecular weight heparin CY 216
(Emanuele 1987).

(1 mg/kg i. v.)

is 1 hour

After subcutaneous administration, the half life of

CY 216 is longer than for unfractionated heparin.

The t1;2 of CY 216

(1 mg/kg s.c.) is reported to be 144 minutes while the t1;2 of unfractionated heparin

(1 mg/kg sc)

is 94 minutes as determined by the

HeptestR (Emanuele 1987).
Binding to plasma proteins such as the AT Ill increases the t1;2
of heparin.

AT Ill heparin complexes disappear more slowly from the

circulation than heparin which is not bound to AT Ill.

The t1;2 of a

hexadecasaccharride complexed to AT Ill and a dodecasaccharide complexed to AT Ill is 30 times longer than that of heparin and 10 times
longer than AT III-heparin complexes in rabbits (Mattsson et al. 1985).
The encapsulation of heparin in liposomes also increases the t1;2 of
intravenously administered heparin three times

in rats

(Kim et al.

1986).
In addition to having an increased t1;2 which permits once daily
injections of low molecular weight heparins, these drugs also exhibit
increased bioavailability as compared to heparin after subcutaneous
injection (Palm and Mattson 1987).
FragminR,

is

The low molecular weight heparin,

86% bioavailable after subcutaneous administration as

compared to 10% for unfractionated heparin (Lockner et al. 1986).
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d.

Metabolism of Heparins
In 1945, Monkhouse and Dickie observed that heparin had a longer

survival time in the circulation after blocking the reticuloendothelial
system (RES) of rabbits with thorotrast (Monkhouse and Dickie 1954).
This

suggests

that heparin is

eliminated via the RES.

Heparin is

desulfated by N-sulfatases and sulfamidases of the liver and subsequently depolymerized into oligosaccharides
1984).

Other

investigators

have

(Cocchetto and Bjornsson

shown that cells

of the RES

can

phagocytose heparin and store it for varying lengths of time (Oh et al.
1973).

Endothelial cells

which have
greater

a

selectively bind those chains of heparin

higher

molecular

anticoagulant

activity.

weight,

greater

Fragments

charge

density

released back

into

and
the

circulation exhibit low· anti Ila activity but retain their anti Xa
activity (Barzu et al. 1987).

Heparin structural determinants for the

anti Xa activity are more resistant to enzymatic attack in comparison
to

those

responsible

Barbati 1987).

for

the

antithrombin activity

(Mastacchi

and

Endocytosis may be followed by depolymerization of

internalized heparin by lysosomal enzymes.
Heparins are differentially metabolized by kidneys.
lar weight heparin is a poorer substrate for

renal lysosomal

tivators than unfractionated heparin (Mastacchi and Barbanti
e.

Low molecuinac-

1987).

Clearance of Heparins
The liver and kidneys play a fundamental role in the elimination

of heparin.

Heparin elimination is prolonged in rabbits with renal

dysfunction and with reticuloendothelial systems that are blocked by
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various agents (Palm and Mattson 1987).

In humans, cirrhosis of the

liver leads to an increase in the half life of heparin (Teien 1977).
severe impairment of renal function does not alter the half life of
standard heparin but prolongs the t1;2 of low molecular weight heparin
(Goudable et al. 1986).

Clearance of heparin activity may

result from

a combination of saturable and a nonsaturable mechanisms (De Swart
1982).

The saturable mechanism may be related to heparin binding to

the endothelium and reticuloendothelial cells

(Dawes and Pepper 1979)

while nonsaturable mechanisms may be related to renal elimination of
heparin (Piper 1947).
Only small amounts of heparin are excreted unchanged in the
urine which suggests that circulating metabolites of heparin exist in
plasma.

In addition, the extent of urinary excretion of heparin is

dependant upon the molecular weight of heparin.

Low molecular weight

heparin is cleared more readily by the kidneys.

By 5 hours, in rats,

54% of injected heparin,

83% of hexasaccharides and 89% of disac-

charides are present in the urine (Larsen et al. 1986). The mechanism
through which heparin and low molecular weight heparin are cleared by
the kidneys differs.

Standard heparin is cleared through by an active

and saturable cellular mechanism while low molecular weight heparin is
cleared by renal filtration (Goudable et al. 1986).
Boneu et al. (1987) studied the disappearance of 125 1 heparin in
rabbits and found a dose dependant increase in the biologic t1;2 of
heparin due to a decrease in the total clearance of the anticoagulant.
Saturable mechanisms of elimination predominate at low therapeutic
doses

of heparin,

(<100

antifactor Xa

U/kg)

while

nonsaturable
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mechanisms predominate at higher doses (Boneu et al. 1987).
saturable mechanisms
molecular weight

However,

contribute little to the disappearance of low

heparins.

These

agents

are

nonsaturable routes such as renal excretion.

cleared primarily by
Low molecular weight

heparins also exhibit dose dependant clearances.

Longer biological

effects have been observed for low molecular weight heparin than for
heparin at low doses.

However, at higher doses, low molecular weight

heparins are cleared faster than standard heparin (Boneu et al. 1987;
Samama et al. 1989).
Factors such as affinity to AT III, and molecular weight influence the disappearance rates of heparin.

Heparin molecules with

varying degrees of affinity to AT III are cleared at different rates.
Equigravimetric
times faster

amounts of 125 I-low affinity heparin disappeared 3

than 125 I-standard heparin

(de

Swart 1984).

AT III

heparin complexes disappear more rapidly from the plasma than free AT
III.

125 I AT III disappears according to a double exponential curve

with a half life in the second phase of 56.8 in the absence of heparin
and 33. 7 hours in the presence of heparin (de Swart et al.

1984).

Molecular weight also influences the disappearance rate of heparins.
CY 222 an ultra low molecular weight heparin (mean Mr of 2,500 daltons)
was cleared faster than CY 216 with a mean Mr of 4,500 daltons (Dawes
et al. 1986).
3.

Interactions With Platelets
Clinical complications of heparin therapy involving platelets

include bleeding and thrombocytopenia.

Two thrombocytopenic syndromes

have been described in patients receiving heparin.

The first involves
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a transient, minor reduction in platelet count which occurs shortly
after intravenous injection. In the second case, a more severe throm1

bocytopenia occurs 5 to 9 days after the initiation of heparin therapy.
Approximately 5% of all patients on heparin therapy may develop this
severe type of thrombocytopenia which may be associated with arterial
thrombosis, stroke, heart attack or death (Kelton et al. 1986).
Low molecular weight heparins exhibit reduced platelet reactivity, and have been used in clinical situations where it was desirable to minimize any platelets effects which may be induced by the

unfractionated heparin (Horellou et al. 1984).

Low molecular weight

heparins have been useful in the treatment of heparin induced thrombocytopenia.

Appropriate laboratory tests, however,

should be per-

formed before low molecular weight heparin is administered to patients
who are suffering from thrombocytopenia in order to test for cross
reactivity between heparin antibodies and low molecular weight heparins
(Messmore et al. 1983).
4.

Heparin and Fibrinolysis
Many

investigators

substances enhance

have

reported

that

heparin

and

related

fibrinolytic activity in both animal models and

human volunteers (Fareed et al. 1985; Arnesson et al. 1987; Paques
al. 1986).

et

Increased fibrinolytic activity after the administration of

heparin may depend upon molecular weight and degree of sulfation of the
heparin, enzyme activation or induction of tPA synthesis.
al.

(1982)

determined

that

the

activation

of

Vinazzer

fibrinolysis

et

partly

depends on the molecular weight and degree of sulfation of the heparin.
In a rabbit model of thrombolysis, low molecular weight heparins CY 216
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and CY 222 were shown to have a more pronounced potentiation of the

effects of rtPA (recombinant tissue plasminogen activator) and scUPA
(single chain urokinase plasminogen activator) than with unfractionated
heparin (Stassen et al.

1987).

Another possible mechanism for in-

creased fibrinolytic activity in the presence of heparin involves the
activation of factor XII and kallikrein (Fareed et al. 1985).
ly,

Recent-

it has been shown that heparin induces the synthesis of tPA in

human fibroblasts in the presence of an endothelial cell growth factor
(Rappaport et al. 1986).
Vairel et al.

(1983)

have demonstrated a decrease in anti-

thrombotic activity of heparin in a rabbit model after administration
of a fibrinolytic inhibitor, epsilon amino caproic acid.

This suggests

that some of the antithrombotic activity of heparin may be related to
fibrinolytic effects induced by heparin.
Low dose

heparin

(5000

IU)

in women undergoing surgery for

mammary hyperplasia has been shown to increase tPA antigen before and
after venous

stasis,

with no differences

inhibitor activity between groups.

in plasminogen activator

This suggests that the increase in

activity may due to an increase in tPA synthesis in the endothelium
(Arnesen et al. 1987).
5.

Lipolytic Effects of Heparin
Besides inhibiting the coagulation process,

administration of

heparin has a marked effect on the metabolism of plasma lipids (Persson
et al. 1985) .

Heparin releases two forms of lipoprotein lipase into

the circulation upon in vivo administration.

One form of lipoprotein

lipase is released from the liver and the release of this lipase is
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resistant

to

protamine

neutralization.

The

release

of the other

lipoprotein lipase is inhibited by protamine and catalyzes the hydrolysis of plasma triglycerides and induces rapid lipolysis in the bloodstream (Krauss et al. 1974).

This leads to a substantial elevation in

the plasma level of free fatty acids and partial glycerides (Persson et
al. 1985; Nilsson-Ehle et al. 1980).
heparins

as

antithrombotic

agents

The use of low molecular weight
is associated with lower plasma

lipolytic activity than with standard heparin (Persson et al. 1987).
Subcutaneous administration of 5000 anti Xa units resulted in significantly higher anti factor Xa activity but a

lower release

of

lipoprotein lipase and hepatic lipase than heparin.
6.

Toxicity of Heparins
Acute,

subacute

and chronic

toxicological

studies

of a

low

molecular weight heparin were performed by Borelli and Bertolli (1986)
in rats. 10 mg/kg of heparin presented effects similar to those shown
by the low molecular weight heparin (20 mg/kg). A low molecular weight
heparin

(OP/LMWH)

elicited no

evidence of teratogenicity when ad-

ministered by subcutaneous route during the period of organogenesis to
pregnant rats at doses up to 10 mg/kg/day.

In reproductive studies

there were no effects on conception or pregnancy in male or female rats
at dosages up to 10 mg/kg/day,

by subcutaneous route

(Bertoli and

Borelli 1986).
Adverse effects associated with the therapeutic use of heparin
in man can be categorized into three groups.

These are complications

resulting from acute heparin administration, chronic heparin therapy
and those associated with heparin neutralization.

Acute complications
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associated with heparin therapy include anaphylaxis, transient thrombocytopenia, arterial embolism and the most frequent complication of
heparin therapy, hemorrhage (Gervin 1975).
With the development of purified forms of heparin, anaphylaxis
has become a rare complication of heparin therapy.
tic reactions to heparin,
development,

were

a

Frequent anaphylac-

noted during the early period of heparin

result

of allergic

taminants rather than to the drug itself.

responses

to heparin con-

Highly purified forms of

heparin have decreased the incidence of anaphylaxis which now occurs in
less than 1 % of all persons receiving heparin.

constriction,

lacrimation,

However, mild broncho-

urticaria and rhinitis may occur in ap-

proximately 5 per cent of patients (Chernoff 1950).
Thrombocytopenia may occur four to seven days after the initiation

of

therapy

and

may be

complicated by

significant bleeding.

Arterial emboli have been reported in a limited number of occurrences,
7 to 15 days after the onset of subcutaneously or intramuscularly
administered heparin therapy.
platelet aggregates

in a

The emboli are composed primarily of

fibrin matrix.

These occur only in the

arterial system and may result from heparin induced platelet aggregation (Gervin 1975).
The most frequent complication of heparin therapy is hemorrhage
with the incidence of hemorrhage during heparinization being from 8 to
33%.

A wide spectrum and severity of hemorrhage during heparin therapy

may occur and may vary from mild mucosal oozing to massive intracranial, intrathoracic, gastrointestinal or genitourinary bleeding (Gervin
1975).

Patients with low body weight or small stature manifest a
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greater prolongation of in vitro clotting times than persons with an
average size and weight (Gervin 1975).
tion between heparin dosage,
studies and hemorrhage.

However, there is no correla-

prolongation of

in vitro coagulation

Elderly women, however, may have a 50% greater

incidence of bleeding during heparinization than the population at
large.
Recent attention has been directed to the intraoperative use of
small doses of heparin.

The treatment of patients with small doses of

subcutaneously administered heparin is called the minidose regimen for
heparinization and consists of subcutaneous administration of 5,000 to
10,000 IU prior to and at given intervals after surgical procedures
(Gervin 1975).
II.
A.

PROTAMINE
History of Protamine
Friedrick Miescher began investigations of the cell nucleus in

1874 which led to the identification of a nitrogenous base bound to
nuclear material of Rhine salmon sperm heads and he named this substance protamine (Miescher 1874).

In 1928, Kossel classified prota-

mines into 3 groups according to the number and kinds of amino acids
each contained.
amino acid.
mines.

Monoprotamines contain only arginine as their basic

Clupeine, salmine and iridine are examples of monoprota-

Diprotamines contain two kinds of basic amino acids: arginine

plus either lysine or histidine.

Cyprinine, crenilabrine and barbine

are reported to belong to the group containing histidine and arginine.
Triprotamines contain all three basic amino acids and include prota-

mines such as sturine (Kossel 1928).

Among proteins studied at that
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time, protamines possessed the simplest amino acid compositions and
M.eischer and his colleagues established the fundamentals of protein
chemistry using protamines as prototypes (Horrow 1985).
In 1900, Thompson demonstrated that protamine possessed slight
anticoagulant activity and speculated that if protamine was complexed
to heparin, the activity of heparin may be prolonged in a way analogous
to the way protamine prolongs the activity of insulin.

However, the

complexation of protamine with heparin has found other therapeutic uses
since that time when Thompson initially speculated about the use of

protamine with heparin.

In 1938, Crafoord stated that it was not

advisable to administer heparin earlier than 4 hours after finishing an
operation because there may be difficulty in controlling hemorrhage in
heparinized patients during the operation (Jorpes et al. 1939).

When

patients are treated with heparin it is sometimes desirable to neutralize its activity in order to control any bleeding which may occur as a
result of its administration.

Chargraff and Olson, in 1937, demonstra-

ted that protamine may be used to neutralize the anticoagulant action
of heparin and this use of protamine would allow the interruption of
heparin activity at any time (Chargaff and Olson, 1937).

B.

Biosynthesis of Protamine
Protamine is synthesized in the cytoplasm on ribosomes which are

present in high concentration during the period of rapid protamine
synthesis (Gatewood 1989).
rapidly.

Lysine

These ribosomes incorporate arginine very

incorporation

on

these

ribosomes

is

very

slow

suggesting that these structures are principally engaged in protamine
synthesis (Ling et al. 1969).

Protamine appears in the nuclei at a

35

late stage of spermatogenesis and this newly synthesized protamine
progressively replaces histones in combination with DNA.

When prota-

mine synthesis begins, histone synthesis declines and eventually ceases
(Ingles

et al.

1966;

Ling et al.

1969).

Although his tones are

structurally conserved, protamines differ considerably from one species
to another (Gusse et al. 1983).
phosphorylated by

adenosine

phosphorylation occurs

at

The newly synthesized protamine is

triphosphate

the

in

the

hydroxyl groups

cytoplasm.

of serine

This

residues,

considerably reduces the net charge of protamine and may alter its
interaction with DNA (Marushige et al. 1969).

C.

Biological Function of Protamines
Relative amounts of the protamine components (C1, C11, and C111)

present

in

spermatid nuclei

spermatogenesis.

vary

the

different

stages

of

Relative amounts of C1 decrease, while C111 increase

during testis maturation.

This is probably as a result of differing

rates of synthesis of each component.
individual

during

protamine

components

The independent synthesis of the

suggests

that,

in

spite

of

their

similarities, individual protamines may have specific functions (Ling
et al. 1971).
There are two probable functions of protamine in the formation
of sperm cells: (a) the clustering of DNA into the sperm head and (b)
the total repression of gene expression in the totally differentiated
sperm cell.

It is possible that packing is the primary function of

protamine and that repression of gene expression occurs only as a
consequence of the packaging of DNA which makes the genome unavailable
for

transcription

(Ling et al.

1971).

Sequence-specific packaging
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would suggest distinct structural and functional roles for the nucleohistone and nucleoprotamine in late spermatogenesis or early development
or both.

Human sperm DNA is packaged into nucleohistone and nucleopro-

tamine in a sequence specific manner (Gatewood et al. 1988).
In a pure system, using labelled thrombin and AT III, protamine
inhibits the inactivation of thrombin (Cobel-Geard and Hassouna 1983).
In clotting assays,

protamine sulfate has

an inhibitory effect on

thrombin in the conversion of fibrinogen to fibrin.
concentration dependent, partial anq reversible.

This inhibition is

It is postulated that

the mode of neutralization of alpha thrombin by protamine is similar to
the mechanism by which thrombin is inhibited by AT III with its natural
substrate fibrinogen (Cobel-Geard and Hassouna 1983).
D.

Chemistry of Protamine
Protamines are a mixture of simple basic proteins containing

several

components which

are

similar

in structure

and amino acid

content. Protamines contain mostly arginine although alanine, serine,
pro line, valine, glycine,
et al. 1973).

isoleucine and threonine are present (Ando

Thes~amino acids have been isolated from the sperm of

several mammals,

including the boar,

mouse and human (Tobita et al. 1982).

ram,

rat,

guinea pig,

rabbit,

Protamines can also be prepared

from various types of fish including herring, salmon and trout.
The molecular weight of various protamines have been determined
by a number of chemical methods and found to be between 4500 and 5000
daltons (Ling et al. 1971).

Therefore, protamines contain approximate-

ly 30 amino acid residues.

Fractionation techniques such as counter-

current

distribution

and

chromatography

on paper,

alumina or

ion
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exchange columns have revealed the presence of more than one component
in each protamine examined (Ling et al. 1971).
inherent part of protamines.
often

found

among

Heterogeneity is an

Differences in amino acid composition are

specimens

prepared from the same species.

of

protamines

supposed

to

have

been

The discrepancy most often occurs in

the fractions of lower molecular weight.

Deviations of this kind may

be accounted for by differences in the maturity and freshness of the
starting materials and method of isolation and purification (Ando et
al. 1973).
Commercially

available

protamine

is

currently prepared

salmon milt, consisting of secretion-laden male gonads.
filtered milt

is heated with alcohol

(defatted),

from

The ground and

precipitated with

alcohol and sodium chloride, then heated, filtered and depyrogenated.
The dried powder, prepared by various manufacturers is packaged and
marketed as either powder (Upjohn Company,

Kalamoazoo, MI;

Institut

Choay, Paris, France) or solution (Eli Lilly and Company, Indianapolis,

IN), (Horrow 1985).
E.

Toxicity of Protamine
Toxicity associated with the administration of protamine sulfate

includes:

cellular

derangements,

complement

hemodynamic reactions and anaphylaxis.

activation,

adverse

High doses of protamine sulfate

can cause mast cell and basophil degranulation with subsequent release
of histamine (Frater et al. 1984).

Protamine also can cause platelet

agglutination and formation of platelet aggregates.

Positively charged

polymers such as polybrene and protamine could adhere to negatively
charged platelet membrane and induce platelet aggregation by forming
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bridges between adjacent platelets in a ca+ 2 independent interaction
(Eika 1972).

Protamine administration in experimental animals causes a mild,
transient granulocytopenia and thrombocytopenia
1985;Eika et al. 1971).

(Al-Mondhiry et al.

Protamine is toxic to rats, guinea pigs and

mice with an intravenous LD50 of approximately 100 mg/kg.
Injection of protamine into rabbits causes a rapid transient
fall

in platelet number with pulmonary symptoms such as

coughing, increased respiration and cyanosis (Horrow 1985).

transient
Protamine

also precipitates fibrinogen in rabbits (Eika and Godal 1971; Gans
al. 1966).

et

Cardiovascular changes also occur including: hypotension,

decrease in systemic vascular resistance,

an increase in peripheral

vascular resistance and increase in cardiac index occur after protamine
sulfate administration (Jaques et al. 1949; Conzen et al. 1989).
Recently
carboxypeptidase
Heparin competes

it
N,

has

been

the

with

inactivator

that

(18 U/ml)

protamine

of anaphylatoxins

carboxypeptidase N for

concentrations of heparin
protamine.

demonstrated

and kinins.

protamine.

it reverses

inhibits

At high

the inhibition by

Thus by blocking the inactivation of the mediators released

in shock, protamine inhibition of carboxypeptidase N my be partially
responsible

for

the catastrophic

reaction which can occur in some

patients (Tan et al. 1989).
Low dose protamine pretreatment attenuates the adverse effects
of

intravenously

heparin
protamine

administered protamine

anticoagulation
compared with

in

clinical

saline

which

settings.

is

used

to

reverse

Pretreatment

solution prevented

the

with

hypotension
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(+6vs. -16 mmHg p.< 0.01) observed with protamine reversal of heparin.
Protamine

pretreatment

lessened

the

thrombocytopenia

found

during

reversal as compared with saline pretreatment (Wakefield et al. 1986).
Although

rare,

major

reactions

to

protamine which

simulate

anaphylaxis occur and have been associated with an allergic reaction to
fish.

Neutral protamine insulin contains protamine and it has been

shown that the incidence of major protamine reaction was 27 % (4/15) in
the NPH insulin dependant diabetics vs. 0.5% (3/636) in those with no
history of NPH insulin use (Stewart

et al. 1984).

Although protamine has been shown to have in vitro anticoagulant
effects, overdoses of protamine of as much as 800 mg/70 kg had minimal
effects on the coagulation mechanisms of both patients and volunteers.
These effects consisted of a slight increase in the Lee-White coagulation time without a concomitant increase in the

APTT (Ellison et al.

1971).
F.

Other Agents Which Neutralize Heparin Effects
In addition to protamine,

several other agents interact with

heparin to neutralize its activity, however, protamine is used most
widely because it the least toxic of the other antagonists.
(hexadimethrine bromide)
to

Polybrene

a synthetic heparin antagonist is used in

clinical

laboratories

neutralize

the

anticoagulant

heparin.

In dogs, polybrene has been associated with reduced cardiac

output and increased pulmonary vascular resistance.

effects

These changes are

greater than those demonstrated with the use of protamine.

Polybrene

has been demonstrated to inhibit factor XII activation (Castenda
al, 1967).

of

et
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Conley,
exhibited

an

in 1948, observed that patients with thrombocytopenia
increased

sensitivity

to

heparin

and suggested

that

platelets could antagonize the anticoagulant effect of heparin. Human
platelets

contain a heparin-neutralizing protein known as

factor 4

(PF4)

platelet

which is located with other proteins in the alpha

granules of platelets and released during platelet aggregation (Dawes
et al. 1982).
Protamine is superior to histones in neutralizing heparin.
antiheparin potency of different histone fractions

The

shows differences

between fractions (lysine rich histone > crude histone > arginine-rich
histone).

Poly-DL-lysine is shown to have a wider range of neutraliza-

tion than protamine (Fabian and Aronson 1980).
Histidine rich glycoprotein also

binds heparin and interferes

with its interaction with AT III resulting in a neutralization of its
anticoagulant activity.

In purified systems, histidine rich glycopro-

tein and high affinity heparin react with apparent 1:1 stoichiometry to
form

a

dissociation constant of

7 nM compared

to

a

dissociation

constant of 65 to 200 nM for AT III-heparin complexes (Lijnen et al.
1983; Fabian and Aronson 1980).

Another physiological heparin-neutral-

izing substance is S protein, a major inhibitor of the assembly of the
S protein,

membrane attack complex of complement.
vitronectin,

effectively

7,200.

This

heparin,

histidine

is unlike
rich

also known as

neutralized oligosaccharides
the

of Mr

2,400-

two other physiological inhibitors

glycoprotein

and

platelet

factor

4.

of
In

addition, S protein/vitronectin neutralized the anti factor Xa activity
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of a synthetic pentasaccharide comprising the antithrombin III binding
sequence of heparin (Lane et al. 1987).

III.

A,

fROTAMINE-HEPARIN-INTERACTIONS
Molecular Aspects of Heparin-Protamine Interactions
Many factors influence the interaction of heparin with protamine

which include:
weight of a

charge type,

charge density and individual molecular

given heparin or protamine.

In view of the opposite

surface charge of protamine, the neutralization of heparin activity is
assumed to result from intermolecular charge neutralization (Schiele

and Heuck 1986).

In general, heparin which has high anticoagulant

activity also possesses high charge density.

In addition stronger

polycation binding is observed as the charge density of the heparin is
increased.

Degree of neutralization of heparin by protamine depends

upon the source of heparin (Lowary et al. 1971) .
requires

more

protamine

sulfate

than porcine

neutralization to occur (Racanelli et al. 1989).

Beef lung heparin

mucosal heparin

for

Each mg of protamine

sulfate neutralizes approximately 90 USP Units of heparin of beef lung
origin or 115 USP Units of heparin derived from intestinal mucosa (The

Upjohn Company, Kalamazoo Michigan, package insert).
Poly-L-lysine has a greater positive charge than protamine
binds to heparin more strongly than does protamine.

and

In addition poly-

1-lysine neutralizes heparin over a larger range of concentrations than
protamine.

The binding strengths of both complexes decrease as the

degree of sulfation of the heparin participating in the complex is
reduced.

Partial N-desulfation of heparin decreases the proportion of

binding sites with high affinity for AT III.

A complex of partially N-
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d,esulfated heparin and protamine binds more weakly than corresponding
heparin-antithrombin III complexes (Jones et al. 1986).
Dawes and Pepper (1982) have shown that the degree of sulfation,
position

of

sulfate

residues

and

molecular

determinants of heparin affinity for protamine.

weight

are

important

In addition, protamine

-binds to chondroitin-4-sulfate with greater affinity than chondroitin6-sulfate.

These two chondroitin sulfates differ only by the position

of sulfate substitution.

Higher molecular weight glycosaminoglycans

bind with lower affinity to protamine than the lower molecular weight

glycosaminoglycans (Dawes and Pepper 1982).
'Whether protamine binds to heparin to form an equimolar complex
or a ternary complex has not yet been determined.

Using 125 1 heparin

and chromatographic techniques, Dawes and Pepper (1982) speculated that
each molecule of protamine binds one molecule of glycosaminoglycan

irrespective of molecular weight.

A heparin poly-L-lysine complex is

formed by the nonstoichiometric binding of poly-L-lysine around a rigid
heparin molecule.

Jones et al. (1986) using fluorescence techniques

have determined that the heparin protamine complex is probably a large
cross linked stoichiometric structure.

In vitro 1 mg protamine totally

bound 1 mg of heparins as determined by HPLC,

after the heparin-

protamine complex was sedimented by centrifugation (Huang 1989).

I.

In Vitro Interactions of Protamine and Heparin
Many

in vitro

experiments

have

been performed

in order to

elucidate the mechanism of the neutralization of heparin by protamine.
Protamine sulfate binds to heparin and (1) either prevents the formetion of the heparin AT III complex or (2)

disrupts the activated
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heparin-AT III complex (Hubbard and Jennings 1985).

Neutralization of

heparin in plasma by protamine represents an equilibrium reaction in
which an excess of protamine is necessary to maintain heparin protamine

complexes.
occurring

If this excess is lost, through metabolism by a naturally
protaminase

antithrombin
Okajima et

activity
al.

the

complexes

dissociate

is

reestablished

so

(Shanberge

that
et

al.

1987).

(1981) have demonstrated that protamine dissociates

heparin-AT III complexes by means of binding to heparin.
when protamine

immediate

sulfate

is

added

In vitro,

to heparinized human plasma,

activated heparin-antithrombin Ill complex is broken.

the

AT Ill is freed

and able to reestablish its original slow antithrombin activity.

In

neutralized plasma, antithrombin Ill exists in its native state and can
be reactivated by any free heparin to become a potent inhibitor of

factor Xa and factor Ila (Kitani et al. 1980).
Conventional heparin is neutralized more effectively in vitro by
protamine than is low molecular weight heparin (Racanelli et al. 1985;

Gram et al.

1988).

Protamine

chloride

inhibited

the

clot based

antifactor Xa activity 95% for conventional heparin and only 55% for

low molecular weight heparin, while thrombin inhibition was completely
neutralized.

At equigravimetric concentrations of a low molecular

weight heparin fragment and protamine, only 25% of the antifactor Xa
activity was neutralizable by protamine sulfate. Protamine neutralization is not related to the anticoagulant potency of heparins.

concentrations of unfractionated heparin (0 .17 µg),

At

heparan sulfate

(0.6 µg), or low molecular weight heparin (1.65 µg) which prolonged the

APTT to a similar degree; low molecular weight heparin required more
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protamine sulfate by weight than unfractionated heparin for complete
neutralization

of APTT

activity.

Neutralization

of

the

anti Xa

activity of unfractionated heparin required 4 µg of protamine sulfate
to neutralize

1 µg

of unfractionated heparin.

12 µg of protamine

sulfate was required to completely neutralize the anti Xa activity of 1
µg of low molecular weight heparin (Hubbard and Jennings 1985).
Two hypotheses have been proposed to explain the different
behavior of protamine with regard to heparin and low molecular weight
heparin.

This differential interaction may be could be related to the

size of the anticoagulant molecule.

Either protamine sulfate can bind

to a long chain more easily or low molecular weight heparin induces the

generation of protamine-resistant anti Xa activity in vivo

(Thomas

1984).

Nonspecific interactions between protamine sulfate and plasma
proteins

such

as

PF4

and histidine

rich

glycoprotein inhibit

binding of protamine sulfate to heparins (Lane et al. 1987).

the

There-

fore, more protamine sulfate is required to neutralize heparin activity
in a plasma system as compared to a purified system.

Unfractionated

heparin, heparan sulfate and low molecular weight heparins were all
neutralized completely by 4 µg

protamine

sulfate

for

every 1 µg

glycosaminoglycan when the antifactor Xa clotting assay was carried out
using purified AT III in the absence of plasma.
Platelet factor 4, released from platelet granules, neutralizes
the in vitro activity of heparin in a similar manner to protamine
•ulfate.

0.8 U/ml of heparin was totally neutralized by 15 µg/ml of

Platelet factor 4 and by 16 µg/ml of protamine sulfate in vitro.

In
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C)ther studies, 1. 0 U of heparin was neutralized by PF4 or protamine
(lS-20 µg/ml).

This represents a 2: 1 (protamine :heparin) ratio as

aeasured by the kaolin cephalin clotting time,

the thrombin clotting

time, and modified Yin Wessler antifactor Xa clotting assays (Michalski

However, complexes formed between heparin and either

et al. 1978).

platelet factor 4 or protamine are not equivalent.

When heparinized

plasma is treated with an excess of platelet factor 4, in contrast to
protamine no large platelet factor 4-heparin-complexes form which are

able to activate AT III (Shanberge et al. 1987).
The action of protamine and platelet factor 4 is complimentary.
Vben a neutralizing dose of protamine was added to plasma supplemented

platelet

with

factor

4

and heparin,

the

protamine

displaced the

platelet factor 4 from its complexes with heparin (Shanberge et al.

1987).

This phenomenon has also been observed in rabbits by Cella et

al. (1987) and may have clinical significance.

Platelet factor 4 may

stabilize heparin-protamine complexes even if excess of protamine no
longer remains, since platelet factor 4 is not broken down in plasma as
protamine is (Shanberge et al. 1987).

The amount of protamine needed

to neutralize heparin following extracorporeal bypass procedures may be
less when large amounts of platelet factor 4 are released.

In

vitro

heparinized

plasmas

are

protamine and PF4 in all assay systems.
~

readily

neutralizable

by

However neutralization of~

heparinized plasmas are dependant upon the assay used to determine

heparin activity. Ex vivo antifactor Xa activity differs from in vitro
anti factor Xa activity.

Only 1/2 of the antifactor Xa activity of

injected heparin could be neutralized,

even heparin (0. 68 U/ml is
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approximately 4. 5 g/ml) obtained

~

vivo

lized by 320 µg/ml platelet factor 4.

was not completely neutraIn addition only 50% of this

heparin activity could be removed using a column of ECTEOIA-cellulose
(Michalski

et

al.

1978).

A possible

explanation for

the

lack of

neutralization of the anti Xa activity of injected heparin could be

that heparin administered intravenously binds tightly to AT III while
still

retaining

anti Xa

activity or

that

intravenous

injection of

heparin releases cellular or intravascular components that interact
with the anti Xa assay but not with other assays
1978).

(Michalski et al.

Hubbard and Jennings have speculated that heparan sulfate may

be released upon
cans may be

heparin administration and that these glycosaminogly-

less

neutralizeable

by protamine

sulfate

(Hubbard and

Jennings 1985).
C.

In Vivo Interactions of Protamine and Heparin
Many animal models have been used to study the bleeding, anti-

thrombotic effects and endogenous cellular interactions after neutralization

of

heparins

by

protamine neutralizes

It

protamine.

the anti protease,

has

been

demonstrated

that

anti thrombotic and antihemo-

static effects of heparin to different degrees (Diness and Ostergaard
1986).
APTT

In a rat tail bleeding model and vena caval ligation model,
and

heparin

antifactor

were

Xa,

hemorrhagic

completely

neutralized

protamine sulfate (3 mg/kg i. v.).

and
at

antithrombotic

effects

of

equigravimetric

dosages

of

Equivalent doses with respect to

antithrombotic potency of heparin and a low molecular weight heparin
(LHN-1) was administered to rats.

The hemorraghic effect of a large

dose of LHN-1 in this experimental model was efficiently counteracted
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by protamine sulfate, however higher doses of protamine sulfate were

required to neutralize the anti thrombotic effects.

The hemorrhagic

effects were neutralized even though some~ vivo activities were still
present (Diness and Ostergaard 1986).
Similar

results

have

been

reported by Doutremepuich

et

al.

(1985) and Racanelli et al. (1988) using low molecular weight heparin
CY 216 in rabbits.

Protamine did not neutralize all the biologic

effects of CY 216, but completely neutralized the bleeding time when
protamine was administered in the ratio of 1 antiheparin U to 2 IC anti
Xa U of CY 216 (Doutremepuich et al. 1985).

Dogs have also been used to study whether total reversal of

heparin immediately after endarterectomy has an adverse effect on the
thrombogenicity of

1982).

the

endarectomized vessel wall

(Chandler et al.

Scanning electron microscopy revealed nearly total coverage of

exposed collagen of
leukocytes,

the

media with

flattened

little fibrin and no thrombi.

platelets,

scattered

No differences were seen

between those dogs which received protamine reversal and those which
did not.

Therefore total reversal of heparin does not increase the

thrombogenicity of endartectomized vessels (Chandler et al. 1982).
It has been demonstrated in dogs that protamine neutralization
of

low

molecular

weight

heparin

causes

less

thrombocytopenia

as

compared to protamine neutralized heparin although neutropenia occurred
equally in both groups .

No differences were seen in eicosanoid or

complement factors after protamine reversal of unfractionated heparin
as compared to low molecular weight heparin (Lindblad et al.

1987).

Protamine did not reverse the elevated antifactor Xa levels in low
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aolecular weight heparin anticoagulated dogs

to the same degree as

unfractionated heparin.

D.

Igxicity of Heparin-Protamine Complexes
The

cardiovascular

changes

which

occur

after protamine

ad-

ministration are dependant upon the route of administration and whether
tbe heparin-protamine complex is formed before the protamine reaches

Plasma histamine levels were significantly higher after

the lungs.

right atrial injection.
the lungs

Histamine is released as protamine traverses

following right atrial injection and produces peripheral

vasodilation.

Histamine has been shown to have an H2 receptor-mediated
It may be possible that protamine

positive inotropic effect in man.

degranulates mast cells directly while protamine-heparin complexes do
not.

Heparin-protamine

complexes

may

be

involved

in

complement

activation (Frater et al. 1982).

The administration of heparin followed by protamine results in a
more severe cytopenia than protamine administration alone which lasts
30 to over 60 minutes.

125 1- labelled protamine in the presence of

heparin binds tightly to platelets and granulocytes.

Sequestration of

the coated cells in the lungs results in transient granulocytopenia and

thrombocytopenia (Al-Mondirhy, 1985).
A decrease in f ibrinogen concentration has also been observed
during cardiopulmonary bypass.

Although the initial decline occurs

during the

of cardiac bypass,

first

five minutes

another drop

fibrinogen concentration is always observed immediately
neutralization (Gans et al. 1966).

in

after heparin

Cardiopulmonary bypass procedures

often result in significant thrombocytopenia.

Further decrease of the
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platelets due to protamine could pose a serious threat in the immediate

postoperative period (Al-Mondirhy 1985).
Dose dependant activation of the complement system by heparinprotamine complexes has been shown in man.

A significant increase in

activated components of the complement system (C3d, C3a, C4a and C4d)
were obtained in patients after the administration of protamine sulfate
(Best et al. 1984; Kirklin et al. 1986).

Peak levels of C3a and C4a

were seen in samples taken 10 minutes after protamine administration.

C4d peak levels were obtained at 5 hours.

The level of C3a, 3 hours

after cardiopulmonary bypass with protamine administration has been
shown to be a risk factor for postoperative morbidity (Kirklin et al.

Protamine acts as a substrate for C reactive protein, a potent

1986).

activator

of the complement system at Cl (Frater et al. 1984).

activation of
heparin

the

classic

Also

complement pathway occurs by protamine-

polycation-polyanion. complexes.

In

vitro

combination

of

protamine sulfate and heparin, but neither heparin nor protamine alone
resulted in a increase in C3a and C4a levels (Kirklin et al. 1986).
Activation of complement may cause an increase in vascular permeability
and could contribute to the pathogenesis of noncardiogenic pulmonary
edema (Best et al. 1984).
Adverse

reactions

which

occur

after

the

administration

of

protamine include:hypotension, anaphylactoid responses and catastrophic
pulmonary vasoconstriction.

Rapid administration of protamine results

in pulmonary vasoconstriction.

Rapid administration of protamine

results in systemic hypotension in most patients (Horrow 1985), however
Coulon

et al.

(1982) speculate that even a small dose of protamine

so
sulfate will change systolic blood pressure.

Anaphylactoid responses

to protamine are characterized by edema of the skin, mucosa, viscera
decreased systemic vascular resistance and bronchospasm (Horrow 1985).

Antihistamines, aminophylline and steroids are employed in the treatment of anaphylactic reactions after protamine administration (Stoelti-

Catastrophic

ng 1983).

pulmonary vasoconstriction

(type

III)

is

accompanied by right ventricular dilation, pulmonary arterial hypertension, decreased left ventricular filling pressure and systemic hypertension,

decreased

hypotension.
protamine

(10

left

ventricular

This

syndrome

has

mg)

and

resolve

may

filling

occurred

pressure

after

and

minimal

spontaneously

systemic
doses

(Horrow

of

1985).

Treatment with isoproterenol or epinephrine has been successful in the
reversal of these effects (Lowenstein et al. 1983).

IV.

A.

CLINICAL IMPLICATIONS OF PROTAMINE NEUTRALIZATION OF HEPARINS
Protamine Neutralization of Heparin in Patients
Reversal

tributed

of

the

significantly

anticoagulant activity of heparin has
to

the

field

of

cardiovascular

con-

surgery.

Monitoring of a patient's state of anticoagulation during this procedure is crucial (Bull et al. 1975) since the amount of heparin required

to produce an arbitrary prolongation in clotting times has been shown
to vary 3 fold from patient to patient and

the rapidity with which the

administered heparin dose disappears from the blood may vary fourfold.
76% of patients receiving common doses of heparin during cardiopulmonary bypass were

found to have plasma heparin levels

that were

potentially too low (<1.7 U/ml; recommended level is 2 U/ml), (Umlas et
al. 1983).
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During cardiopulmonary bypass, high doses of heparin ( 3 mg/kg
i. v.) are used to prevent thrombosis in patients amd to prevent clot
formation within the heart lung machine (Shanberge et al. 1986).

such high doses

of heparin are

used which

result

Since

in hemorrhage,

neutralization by protamine sulfate is necessary.
Many

different

protocols

have

been used

for

the

protamine

neutralizaton of heparin activity by protamine after cardiopulmonary
Some of these protocols are based on arbitrary amounts of

bypass.

protamine to neutralize a given amount of heparin while others are
calculated from known heparin-protamine interactions.
measure

heparin

levels

accurately

and

rapidly

The inability to

has

prevented

the

accurate prediction of the minimum dosages necessary to reverse heparin
(Umlas et al. 1983).

Reversal of heparin in patients has been shown to follow the
same .in vitro pattern of dissociation of the neutralization of the anti
Xa and anti

1985)

Ila activities were observed in vitro (Racanelli et al.

Incomplete neutralization of the lipoprotein lipase, hepatic

triglyceride lipase and factor Xa activities of a low molecular weight
heparin by protamine chloride has been shown in patients (Harenberg et
al. 1985).

Similarly, after the administration of protamine chloride

to patients who received either (7,500 or 18,750) anti Xa units of CY
216, the inhibition of factor Xa was reduced to approximately 40
inhibition.

Similar

results

were

obtained with

a

different

molecular weight heparin of similar molecular weight range.

%

low

Therefore

the molecular weight range of a low molecular weight heparin seems to
be a more important determinant for protamine neutralization than the

52
J1ethod of preparation of the heparin (Harenberg et al.

n.tI-2•

anti Xa and anti Ila activities and APTT

1986).

In

activity of unfrac-

tionated heparin were neutralized with a gravimetric protamine:heparin
ratio of 1.6 to 1, 1.3 to 1 and 2 to 1 respectively.

Anti Ila and APTT

activity induced by a low molecular weight heparin PK 10169 returned to
baseline

completely at a protamine: heparin ratio of 1 and 2 respec-

tively while anti Xa activity was not completely neutralized at a
gravimetric protamine: heparin ratio of S to 1.

Since the direct cause of blood loss is not always easy to
determine, abnormal bleeding during or after cardiopulmonary bypass has

serious

been a

problem.

Residual

heparin

(due

to

an

inadequate

neutralizing dose of protamine), anticoagulation induced by excessive
protamine, thrombocytopenia and a variety of other conditions such as
disseminated

intravascular

coagulation,

platelet

dysfunction

and

fibrinolysis have all been postulated as causes for abnormal bleeding
in patients undergoing cardiopulmonary bypass (Umlas et al. 1983).
Bleeding times have been reported to be prolonged in patients
after administration of unfractionated heparin and CY 216.

Heparins

may interact with platelets at the surface of the vessel wall by some
unknown mechanism and thereby cause bleeding (Harenberg et al. 1986). A
platelet

effect

is

suspected

to

prolong

the

bleeding

time

since

substances which influence platelet function prolong this test whereas
Vitamin K antagonists such as coumadin have no effect of bleeding time
(Harenberg et al. 1986).
In a study by Massanet-Castel (1986) patients which were treated
prophylactically

with

heparin,

exhibited

normal

or

only

slightly
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In 3 patients given protamine because of hemor-

increased bleeding.

rhage, mean anti Xa and anti Ila levels were 2.3 an 0.54 U/ml respectively before and 1.32-0.06 U/ml respectively after neutralization.

A

correlation between bleeding, anti Xa and anti Ila activities was not
clearly evident.

The dose of protamine which was used to neutralize

low molecular weight heparin PK 10169 was 2 mg for every 1 mg of PK
10169 as compared to 1. 3 mg of protamine for every 1 mg of unfrac'Whether the difficulty in reversing the anti Xa

donated heparin.

activity constitutes a clinical drawback for the use of low molecular
weight heparins remains to be seen (Massonet-Castel et al. 1986).

B.

Heparin Rebound
In 1956,

Kolff et al.

first described heparin rebound as a

"treacherous phenomenon in which heparin is neutralized by protamine
sulfate and the clotting time becomes normal in a matter of minutes.
However protamine seems to be eliminated from the blood before heparin
is, thus leaving the heparin uncovered as demonstrated by protamine"
(Ellison et al. 1974).

Heparin rebound is defined as the reappearance

of hypocoagulability after adequate neutralization

(Pifarre et al.

1981) which is restored to normal by further protamine administration
(Gollub et al. 1967).

Protamine neutralization of the heparin activa-

tion of antithrombin III in plasma, in vitro, represents an equilibrium
reaction in which by mass action, heparin remains complexed only in the
presence of an excess of protamine (Kitani et al. 1980).
Many possible explanations have been suggested for the rebound
of anticoagulant activity after protamine administration which include:
heparin may be released by red blood cell breakdown, heparin may escape
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from the circulation into the extravascular space and return via the
lymphatics

and

thoracic

duct

to

the

circulation many hours

protamine has been administered and cleared.

more

commonly

observed with

cardiopulmonary

procedures

hypothermia,

procedure

after

Heparin rebound may be
since hypothermia during

produces

elimination of heparin which may contribute

a
to

decrease

in

the

the phenomenon of

heparin rebound (Cohen et al. 1977).

The whole

blood activated clotting

time

is widely used to

monitor heparin anticoagulation during cardiopulmonary bypass and to

predict the neutralizing dose of protamine sulfate (Piffare et al.
1981).

Recent reports suggest that this assay system may not give a

true reflection of the plasma heparin levels and may give inaccurate
predictions of the required protamine dose (Esposito et al. 1983).

The

accurate diagnosis of heparin induced bleeding is difficult to determine and it is not uncommon to empirically administer additional doses
of protamine in the face of post bypass bleeding, especially if the

APTT is prolonged (Ellison et al. 1974).
Postoperative heparin rebound was investigated in 50 patients
undergoing cardiopulmonary bypass
preoperatively.

The

administered was

1.25:1.

overall
One

who

mean
hour

received 2 mg/kg of heparin

ratio
after

of protamine
heparin was

to

heparin

completely

neutralized, 26 patients (52%) had circulating heparin and required an
additional dose of protamine averaging 70 mg (Piffarre et al. 1981).
In another clinical situation, heparin rebound was observed in 29% of
cases which correlated with circulating load (i.u. x 10 3 ) of heparin

administered.

The ratio of protamine sulfate to circulating load of

55
heparin was

lower

(Kesteven et al.

than 1.6
1986).

in all

cases which

In another study,

exhibited heparin rebound (Gollub

exhibited rebound

20 out of 40 patients

1967).

The occurrence of heparin rebound depends upon the ratio of
protamine to heparin.

- patients who

Low incidence of heparin rebound was reported in

received an excess of protamine after cardiopulmonary

bypass as compared to those who received the minimum amount as determined by titration methods (Shanberge et al. 1986).

In another study

(Ellison et al. 1974), every patient who received the minimal dose of
protamine exhibited, rebound phenomenon at some time between one and
five hours after neutralization.
with clinical bleeding

In three cases rebound was associated

which necessitated additional protamine.

In

contrast none of the patients who received a larger dose of protamine
exhibited rebound (Gollub 1967). He suggested that patients be given
the dose of protamine that is indicated by titration plus an additional
10 mg of protamine per liter of blood volume (usually 50 mg of additional protamine).

Using this regimen, there was no danger of excess

protamine administration and there was a noticeable decrease in the
incidence and magnitude of heparin rebound in this study.
Other factors which may cause heparin rebound include increased
heparin binding

to

plasma

proteins,

the

specific

protamine and the length of the bypass procedure.

anion

bound to

Heparin bound to

other proteins such as alpha2 macroglobulin may be able to activate any
fresh antithrombin III produced by the patient or administered through
infusion of blood or plasma (Shanberge and Sridhar

1981).

Protamine

sulfate inactivates those heparin fractions that are bound to AT III
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but not those bound to alpha2 macroglobulin.

derivatives is not influenced by the specific anion which is

mine

bound to them.
the

The stability of prota-

But rather, differences are acquired in the course of

manufacturing

influence

the

procedure

stability of

involved

in

their

preparation

the protamine preparation.

which

Commercial

protamine chloride is stable in the presence of plasma enzymes, whereas
the sulfate is degraded (Benayahu and Aronson 1983).

Heparin rebound

could be reproduced with the sulfate but not with the chloride anion.
The length of cardiopulmonary bypass influences the amount of protamine
required postoperatively (Pifarre et al. 1981).

In vitro heparin is neutralized at a gravimetric ratio of 1:1;
therefore in vitro studies may seriously underestimate the required
dose of protamine sulfate following surgery (Shanberge et al. 1986).
In clinical situations 1.3 mg of protamine is used to neutralize 100 U
of heparin (Massonnet-Castel et al. 1986).

Other investigators have

questioned the necessity of protamine reversal of heparin following
bypass surgery,

(Castenda et al.

1967).

It may be advantageous to

prolong the period of heparinization of the patient into the early
postoperative period, if bleeding is not profuse.
C.

Clinical Trials With Low Molecular Weight Heparins
Over the last decade, there has been a considerable amount of

interest in the clinical use of low molecular weight heparin (Messmore
et al.

1985).

Low molecular weight heparins have been studied in

randomized clinical trials to evaluate their effectiveness as well as
the risk/benefit ratio of their routine use in postoperative prevention
of deep venous thrombosis and pulmonary embolism (Samama et al. 1989).
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several clinical studies have been conducted in which a low
molecular weight heparin has been compared with standard unfractionated
heparin

following

general

and

orthopedic

surgery

and

in

general

Studies have also been performed in which low molecular

medicine.

weight heparins were compared to a placebo. A low molecular weight
heparin, FragminR was studied in patients undergoing general surgery by
Bergvist et al.

Low rates of thrombosis were found in both

(1986).

treatment groups, 6% versus 4 % and no statistical significance between
In a trial by Kakaar (1985), using the low

the drugs was observed.
molecular

weight

heparin,

FraxiparineR,

there was

a

statistically

significant reduction in postoperative venous thrombosis in patients
who received FraxiparineR.

Similarly, in a study by Encke and Breddin

(1988) where control groups received heparin 5000 U twice or three

times daily, a significant difference was observed which supported the
greater efficacy of FraxiparineR.

In other studies by Koller et al.

(1986) and Schmitz-Huebner et al.

(1984) thrombosis rates were low in

both groups however no statistical significance between groups was

observed.
Studies have shown that fixed-dose

subcutaneous heparin ad-

ministration is partially effective in the prevention of deep vein
thrombosis after total hip replacement surgery (Bergvist et al. 1980)
and

adjusted

improvement

low-dose

heparin

(Leyvraz et al.

administration

1983).

leads

to

significant

It was the ref ore important to

determine if low molecular weight heparins would be more useful during
orthopedic surgery than heparin.

In studies of patients undergoing hip

surgery, the incidence of thrombosis was substantially reduced by low
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aolecular weight heparin, EnoxaparinR, from 42 % to 12 % as compared to
placebo (Turpie et al. 1986).

These results may be compared with those

obtained after a single injection of 40 mg of EnoxaparinR to patients
undergoing hip

surgery in a double blind study.

The frequency of

thrombosis as assessed by phlebography was significantly lower with low
aolecular weight heparin than with three

injections of 5000 IU of

heparin (Planes et al. 1988).

Prophylactic
patients

at

high

heparin
risk

is

for

often

used

in hospitalized medical

thromboembolism.

Two

hundred

seventy

patients confined to bed rest and over 65 years of age were studied in
a randomized double-blind trial (Dahan et al. 1986) comparing 60 mg of

BnoxaparinR to a placebo over a 10-day period.

EnoxaparinR produced a

atatistically significant (p<. 05) reduction in isotopically detectable
venous thrombosis

(3% versus 9%).

trial (six in each group)

Twelve patients died during the

and autopsy revealed three fatal recent

pulmonary embolism in the placebo group and one in the treated group

(Samama et al. 1989).

The incidence of bleeding varied markedly in the clinical trials
of low molecular weight heparins.

This variation may be due

to

differences in the criteria used to define clinical important bleeding
and also was dependant on the doses selected for the studies.

out of five

studies,

the

incidence

of bleeding was

In three

significantly

greater in the low molecular weight heparin group than in the unfrac-

tionated heparin group

(Bergvist et al.

Schmitz-Huebner et al.

1984).

1986,

1986;

Koller et al.

1986;

In the study reported by Koller,

in

there was a 48 % rate of bleeding in 23 patients who received
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FragminR compared to a 10
tionated heparin.

%

rate in patients who received unfrac-

This trial was terminated because of excess hemor-

rhage in the experimental group.

The incidence of bleeding was low for

clinical trial of 0RG 10172 heparinoid and for FraxiparineR.
8

There was

2 % rate of bleeding as compared to a 4 % rate for placebo.

Kakaar

(1985) reported a 5 % rate of bleeding in patients undergoing abdominal

surgery who received FraxiparineR compared to a bleeding rate of 3.5 %
in patients who received unfractionated heparin.

A correlation (r-.54)

between~ vivo anti Xa levels produced by low molecular weight heparin
and clinically important bleeding was reported.

Low molecular weight heparin EnoxaparinR has been studied in 15
patients who underwent surgery with extracorporeal circulation which
required reversal by protamine sulfate (Massonnet-Castel et al. 1986).

ln vitro,

anti Xa and anti Ila activities and APTT activities of

heparin were neutralized by a protamine:heparin ratio of 1.6, 1.33 and
2 respectively.

Anti Ila activity and APTT induced by EnoxaparinR were

completely neutralized a protamine to heparin ratio of 1 and 2 respectively, while anti Xa activity was incompletely neutralized at a ratio

of 5.

In patients which did not receive protamine a good correlation

was observed between doses of EnoxaparinR infused,
levels and blood loss.

anti Ila plasma

In patients who received protamine because of

hemorrhage, bleeding was stopped, however a poor correlation between
bleeding, anti Xa or anti Ila activities was observed (Massonnet-Castel
1986).

CHAPTER II
STATEMENT OF PURPOSE
Protamine neutralization of the hemorrhagic effects of heparin has
contributed to the widespread therapeutic acceptance of heparin.

The

routine use of heparin during surgical procedures such as cardiopulmonary
bypass could not have been possible without the use of protamine as an
antagonist.

Although protamine has been used for decades to antagonize

the bleeding effects of heparin, the biochemical and pharmacologic aspects
of this interaction are still not completely understood.

In addition,

heparin protamine complexes are known to exert a variety of toxic effects
which are not fully investigated at this time.

Furthermore, with the

development and increased clinical use of low molecular weight heparins,
it is important to better characterize the interaction of protamine with
heparins.
Although protamine is administered primarily to neutralize the
bleeding effects of heparin, this antagonist also influences several other
activities of heparin.

In addition, protamine has been shown to prolong

clotting tests (Gans 1962), produce thrombocytopenia (Al-Mondhiry 1985),
accelerate fibrin monomer polymerization and inhibit thrombin (Cobel-Geard
1983).

Since administration of protamine alone exerts effects on the

hemostatic system, the study of the neutralization of heparin activity by
protamine becomes complicated.

It is the purpose of this dissertation to

compare the protamine neutralization of heparin and a well characterized
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low molecular weight heparin (CY 216), in terms of their anticoagulant,
antiprotease, antithrombotic and pharmacodynamic actions.
These studies provide integrated data on the differences between
the neutralization profiles of heparin and a low molecular weight heparin
(CY 216).

Such information is needed to optimize the use of protamine

especially for the neutralization of low molecular weight heparins.

A

better understanding of protamine-heparin interactions as investigated in

this study may lead to safer use of these agents.
A series

of

in

vitro

neutralization of the heparins

assays

used

to

included global

specific chromogenic substrate based assays.

study

the

protamine

clotting assays

and

Use of these assays allowed

for an integrated approach to profile the potency, sites of action and

degree of neutralization of these heparins by protamine.

Thrombosis involves a disruption of the delicate balance between
blood vessels, platelets and coagulation factors.

To address this area,

two defined models of thrombosis, a modified version of the classical
Wessler stasis thrombosis model (Wessler 1974) and a laser-induced model
of thrombosis as developed by Breddin (1982) were used.

Pharmacologically

defined studies were carried out to approximate the current clinical use
of heparins and focus on the antagonism of the antithrombotic effects of
heparins by protamine.
Since hemorrhage also is a multifactorial process involving many
hemostatic components, two animal models of blood loss which have been
Widely utilized in the study of heparins and other anticoagulant drugs,
were used to study the antagonism of heparin and CY 216 by protamine. The

relevance of ex vivo anticoagulant and antiprotease activities to the
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observed blood loss and its antagonism was extensively addressed in this

investigation.
The pharmacodynamic time course parameters of both heparin and CY
216 prior to and after the administration of protamine were determined
utilizing an established pharmacokinetic model.

A unique feature of this

study is the use of a nonhuman primate (maccaca mulatta) model whose
hemostatic profile has been found to approximate the human hemostatic

system (King 1989).

Intravenous and subcutaneous pharmacodynamic studies

provided timely information on whether protamine alters the time course
parameters of heparin or CY 216 and whether the observed protamine

neutralization

of heparin

and

CY

216

was

assay

dependent.

This

information is of crucial importance in the understanding of heparin
rebound.

This study also represents the first comprehensive approach to

establish the differences

in the

in vitro protamine neutralization

profiles and pharmacologic behavior of heparin and a low molecular weight
heparin.

The biochemical and pharmacologic experiments included in this
investigation have

been used

as

model

interactions of heparin with protamine.

systems

to

investigate

the

This dissertation thus emphasizes

the need of an integrated approach to obtain crucial pharmacologic data
on the interactions of polycomponent drugs.

This may have a direct impact

on the clinical management of patients administered heparin and protamine.

CHAPTER III
MATERIALS AND METHODS
I.

MATERIALS

A.

Antithrombotic Drugs

1.

Heparin
Porcine

mucosal

heparin

Institute (Paris, France).

(lot

H503)

was

obtained from Choay

The mean molecular weight of heparin as

determined by a computerized gel permeation chromatographic system was
11,000 dal tons.
IU/mg.

The anticoagulant potency of this heparin is 165

The analytical and molecular weight profiles of heparin (lot H

503) are shown in Appendices II and III respectively.
2.

Low Molecular Weight Heparin
CY 216 (lot P 533 XH), a low molecular weight heparin, produced

from porcine mucosal heparin by nitrous
obtained from Choay Institute

(Paris,

acid depolymerization was

France).

This low molecular

weight heparin has a mean molecular weight of 5,000 daltons and is
characterized by a narrower molecular weight distribution than heparin.
Eighty per cent of the chains of CY 216 have a molecular weight within
the range of 2,400-7,200 daltons which corresponds to 4 to 12

disac-

charide

chains

units.

Dodeca-,

tetradeca-,and hexadecasaccharidic

account for 50% of the molecular species composing CY 216.

In addition

25% of the chains contain a specific pentasaccharide sequence that
enables them to bind to AT III with high affinity (Lormeau 1989).
potency of CY 216 is 226 IC AXa U/mg and 58 USP U/mg.
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The

The analytical
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and molelcular weight profiles of CY 216 (lot P 533 XH) are shown in
Appendices IV and V respectively.
B.

frotamine Sulfate
Protamine sulfate obtained from Choay Institute was produced from

salmon sperm and contains 138 UAH/mg.

The mean molecular weight of

this protamine as determined by HPLC is 4,000 daltons.

The analytical

and molecular

are

shown in

was

purchased

weight

profiles

of

protamine

sulfate

Appendix VI and VII respectively.

c.

Spermidine
Spermidine

(N-(3-aminopropyl)-1,4-butanediamine)

from Sigma Chemical Co. (St. Louis MO).
D.

Reagents
All reagents obtained for use in the assays were of analytical

grade.

All drugs and reagents used in the studies were stored in

desiccated storage containers at appropriate temperatures.
1.

Clotting Assays
Automated APTT,

a rabbit brain phospholipid reagent containing

micronized silica as an activator, was obtained from General Diagnostics (Morris Plains, NJ)

in lyophilized form and reconstituted with

distilled water according to manufacturer's instructions.
FibrindexR human thrombin was purchased from Ortho Diagnostic
Systems, Inc.

(Raritan NJ) in lyophilized form and was reconstituted

with saline to obtain a 5 NIH U/ml solution. The thrombin solutions
were adjusted using normal human plasma to give a 20.0 ± 2.0 second

clotting time using the thrombin time assay.

Aliquots of thrombin were

frozen at -70°c for periods of not more than 6 weeks.
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HeptestR reagents were obtained from Haemachem (St. Louis, MO)
and included bovine factor Xa and RecalmixR.

This reagent contains

optimal concentrations of calcium chloride and brain cephalin in a
bovine plasma fraction.

The reagents were obtained in lyophilized form

and reconstituted according to manufacturer's instructions.

2.

Amidolytic Assays
Reagents used for amidolytic anti Xa and amidolytic anti Ila

assays include:
Buffer consisting of O. 050 M Tris (hydroxymethyl aminomethane,
TrizmaR HCL,;Sigma Chemical Co., St. Louis, MO) 0.175 M sodium chloride
(Sigma Chemical Co.),

and 0.0075 M EDTA (Sigma Chemical Co.) were

prepared at pH 8.4 at room temperature.
Bovine Factor Xs! was obtained from Enzyme Research Laboratories
(South Bend,

IN)

in lyophilized form.

This preparation was recon-

stituted in 1.0 ml Tris buffer, diluted 1:4 in saline and stored at-

700c for periods up to 6 weeks. Factor Xa was calibrated for the anti
Xa amidolytic assay by adjusting the above solution to produce a change
of 0.600 to 0.700 mau (maximal activity unit)/minute in the assay blank
at 405 nm.
Stock solutions (10 NIH U/ml) of FibrindexR
reconstituted with saline and stored at -70°c.

human thrombin were

A working solution of

thrombin was calibrated for the anti Ila amidolytic assay by adjusting
a 10. 0 NIH U/ml solution to produce a change of O. 600 to O. 700 mau
(maximal activity unit)/minute in the assay blank at 405 nm.
Chromogenic

substrates

used

in

the

amidolytic

assays

were

purchased from American Diagnostica (Greenwich, CT). Spectrozyme xaR
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cca 3ocDHG-Gly-Arg-pNA) was reconstituted with distilled water to obtain
a final concentration of 2.5 mM and was used in the amidolytic anti Xa
assay.

Spectrozyme

THR

(HDCT-Ala-Arg-pNA)

was

reconstituted with

distilled water to obtain a final concentration of 1.0 mM and was used
in the amidolytic anti Ila assay.
3. Pooled Plasma Preparations
For the in vitro studies, human plasma was obtained from the
Loyola University Medical Center Blood Bank.

All plasma preparations

were screened for the presence of HIV (Abbott Laboratories, Chicago,
IL) and hepatitis B virus (Abbott Laboratories, Chicago, IL) and
to be negative.

found

The fresh frozen plasma packs obtained from 5 donors

were thawed at 37° C, pooled (lot numbers for pool I: 1190423, 1190468,
1190464, 1190322, 1190469, lot numbers for pool II: 1317061, 1192592,
3142912, 1247780, 1196245) aliquoted in 10 ml volumes and frozen at700c for a period of not more than 2 months.

Immediately before its

use, pooled plasma was thawed at 37° C.
a.

Normal Monkey Plasma Preparation (NMP)
Primates were anesthetized with ketamine HCL (10 mg/kg i.v.) and

blood was drawn from the popliteal vein using a 21 gauge 3/4 inch
butterfly needle and centrifuged at 4°c, 1200 x g for 20 minutes.
Plasma from a minimum of 5 primates was pooled and aliquoted in 10 ml
volumes.

The pooled monkey plasma (NMP) was frozen in plastic tubes

at -70°c for not more than 2 months.
b.

Normal Rabbit Plasma Preparation (NRP)
'White New Zealand rabbits were anesthetized with intramuscular

injections

of xylazine

(20 mg/kg)

and ketamine

(80 mg/kg).

After
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induction of anaesthesia, blood was drawn by cardiac puncture using a
vacutainerR technique into tubes containing 3.8 % citrate (1:10).
blood was centrifuged at 4°C, 1200 x g for 20 minutes.

The

Plasma from a

minimum of 5 rabbits was pooled and aliquoted in 5 ml volumes.

The

pooled rabbit plasma (NRP) was frozen in plastic tubes at -70°C for not
more than 2 months.
c.

Normal Rat Plasma Preparation (NratP)
Rats were anesthetized with ketamine HCL (40 mg/kg i .m.) and

Xylazine (20 mg/kg i.m.).

Blood was drawn from the inferior vena cava

using a 22 gauge needle and a syringe into tubes containg 3.8 % citrate
(1:10).

5 ml of blood was drawn from each rat. The blood was centri-

fuged at 4° C, 1200 x g for 20 minutes.

Plasma from a minimum of 5

rats was pooled and aliquoted in 5 ml volumes.

The pooled rat plasma

(NratP) was frozen in plastic tubes at - 70°c for not more than 2
months.
4.

Thrombogenic Agents
Thrombogenic

challenges

used

in

the

modified

rabbit

stasis

thrombosis model included: prothrombin complex concentrate (PCC) and
Russell's

viper venom

(RVV).

KonyneR brand of human prothrombin

complex concentrate containing factors II, VII, IX and X was obtained
from Cutter Laboratories, Lot 3125-50-3.
saline to

50.0 U/ml.

PCC was reconstituted with

Russell's viper venom (RVV),

lot 027F9461

obtained from Sigma Chemical Co. and was reconstituted to 0.1 U/ml with
saline immediately before use.
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5.

Anaesthetics
VetalarR (ketamine hydrochloride) anaesthetic was obtained from

Parke-Davis,

(Morris

Plains,

NJ)

as a 100 mg/ml

solution.

After

intramuscular injection, VetalarR produces rapid analgesia with mild
.cardiac

stimulation

and respiratory

depression.

RompunR

(xylazine)

analgesic was obtained from Bayvet Division of Miles Laboratories, Inc.
(Shawnee, KS) as a 100 mg/ml solution.

Xylazine is a non-narcotic

sedative, analgesic and muscle relaxant.
Beuthanasia-pR euthanasia solution was
Corporation (Kenilworth, NJ).

obtained from Schering

Each ml of beuthanasia contains 390 mg

pentobarbital sodium and 50 mg phenytoin sodium in addition to inactive
ingredients.
E.

Animals
A colony of mature rhesus monkeys (macaca mulatta) consisting of

2 males and 10 females,

housed in the animal research facility of

Loyola University Medical Center, were used for the pharmacodynamic
time course studies.

The animal research facility is accredited by the

American Association for the Accreditation of Laboratory Animal Care
and the health of the primates was monitored by a licensed doctor of
veterinary medicine.

All primates were maintained on a standard diet

of Purina monkey chow, fruit, molasses sandwiches, had free access to
water and were exposed to a regular 12 hour light/dark cycle.

The

primates weights ranged from 5.7 to 14.2 kg. The average weight of the
primates was 8.6 ± 2.2 kg (mean± S.D.).

No differences between

the

coagulation parameters of male and female primates are observed (Schalm
1975) and females in menses were not included in the studies.

69
Male

New

Zealand

rabbits

(oryctolagus

cuniculus)

ranging

in

weight from 2.5 to 3.0 kg were obtained from Langshaw Farms (Augusta,
MI).

Rabbits were housed in the Loyola University Medical Center

animal research facility.

Environmental conditions included a 12 hour

light/12 hour dark cycle.

They were fed a standard diet of WayneR

Rabbit Ration and water ad libitum.

All animals were allowed to

acclimate to the facilities for a minimum of 7 days post transport.
Male Sprague Dawly rats

(rattus norvegicus) ranging in weight

from 240 to 260 g were obtained from Harlan (Indianapolis, IN).
rats

were

research

housed
facility.

in

the

University Medical

Environmental

light/12 hour dark cycle.
rodent lab blocks.

Loyola

conditions

The

Center animal

included

a

12

hour

They were fed a standard diet of Wayne

All animals were allowed to acclimate to the

facilities for a minimum of 7 days post transport.
Male Wistar rats (rattus norvegicus) ranging in weight from 200
to 250 g, used for the laser-induced thrombosis model, were housed in
the accredited animal research facility of J.W.
Frankfurt, West Germany.

Goethe University,

All animals were allowed to acclimate to the

facilities for a minimum of 7 days post transport.
F.

Analytical Instrumentation
Waters™ 840 Data and Chromatography Control Station manufactured

by Millipore Corporation (Millford MA) was used to run high performance
liquid chromatography (HPLC) analyses.

This system uses Waters Expert

TM chromatography software (Version 6. 2) and consisted of a Waters™
WISP, a Waters™ 510 HPLC pump, a Waters™ 410 Differential Refractometer and a Waters™ 490 Programmable Multiwavelength Detector.
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TSK 2000

SW VIII column Beckman Instruments Inc.

(Arlington

Heights IL).
FibrometerR, manufactured by Becton Dickinson and Co. (Rutherford, NJ) is an electromechanical instrument used for clot detection at

Spectrophotometer

Model

35R

and

Model

DU7R

manufactured

by

Beckman Instruments, Inc.
Hycel Cell Counter 300, (Houston TX)
Argon Laser CR2R manufactured by Coherent (Palo Alto, CA).
Microscope with interference contrast objectives and condensers
and a 100 x water immersion objective was supplied by Leitz Wetzlar,
Germany.
Surgical instruments used include scalpels with No. 20 blades,
Metzenbaum dissecting scissors, tissue forceps and haemostats.
AccutempR Surgical Cautery manufactured by Concept, Inc. (Clearwater, FL) was used to cut through tissue while producing a minimal
amount of bleeding.
An IBM PC-XT computer and a Blue Chip IBM compatible PC were used
for

word processing,

graphics

and

statistics.

The software used

included: Word Perfect 4. 2R (Word Perfect Corporation,

Orem, Utah),

SigmaplotR (Jandel Scientific, Sausolito, CA), PCNONLINR (Statistical
Consultants, Lexington, KY), and SystatR (Systat Inc., Evanston IL).
II. METHODS
A.

Physiochemical Profiling of Heparin, CY 216 and Protamine
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1.

Molecular Weight Determination
In order to determine the molecular weight profile of heparin, CY

216 and protamine,

gel permeation chromatography (Losito 1981) was

performed on a Waters 840 Data and Chromatography and Control Station
which utilized Waters Expert™ chromatography software.
calculated not only mean molecular weight,
indicate molecular weight distribution.
from

The system

but also values which

These values were calculated

the chromatographic char,cteristics of standards with similar

molecular composition on a TSK 2000 SW VIII column.

Thus prior to use,

the column was calibrated with anionic polymers consisting of sulfated
glucuronic acid, uronic acid and glucosamine (Emanuele 1988).

Values

for retention time (RT) and polymer dispersity (D) were determined, and
used along with molecular weights of the standards to calculate a
calibration curve.

This curve was

calculated by third polynomial

regression and yielded polynomial coefficients (D 0
characterized the average standard curve.

,

D1, D2, D3) that

The following equation was

used:

MW - D0 + D1 (RT)+ D2 (RT)2 + D3 (RT)3
The molecular weight of the heparin and CY 216 were determined
from their chromatographic characteristics under the following conditions:
Columns: TSK 2000 SW VIII (Beckman)
Mobile Phase: Na2S04 0.5 M
Detector:

UV 205 run

Flow Rate:
Sample:

1 ml/min

20 µl of heparin or CY 216 (10 mg/ml)
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The

molecular weight

of

protamine

was

determined under

the

following conditions:
columns: TSK 2000 (Beckman)
Mobile Phase: Na2S04 0.5 M
Detector:

UV 205 nm

Flow Rate: 1.0 ml/min
Sample:

20 µl of protamine (10 mg/ml)

2. NMR spectra
The 1H NMR spectra of heparin, CY 216, protamine and a heparinprotamine complex were obtained in collaboration with Professor Casu of
Institute Ranzoni, Milan, Italy.
spectrometer

A BrukerR AC 200 nuclear magnetic

was used to obtain the 1H spectra.

Each agent was

dissolved in deuterated water (D20) at 20% and a full span spectra was
recorded according to a method described previously (Casu 1984).
To prepare a complex between heparin and protamine sulfate, 20 mg
of protamine was suspended in 0.5 ml of 0.1 N DCl, mixed well and 1 mg
of heparin was added.

This solution was incubated for 1 hour and a lH

NMR spectrum of this mixture was obtained.

A control spectrum of

protamine was also determined using the same conditions.
B.

In Vitro Methods

1.

Clotting Assays
The activated partial thromboplastin time (APTT), thrombin time

and HeptestR are global clot based assays.

These tests are sensitive

to many factors which can influence the coagulation system by inhibiting a variety of enzymatic processes.

The end point of all clotting
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tests is the formation of fibrin which is detected by a fibrometer, an
instrument which mechanically detects clot formation.
APTT is a test used to screen the intrinsic pathway of coagulation
(factors XII, XI, IX, VIII, X, V, II, I) and for monitoring heparin
therapy.

It is based on the measurement of time to clot after citrated

platelet poor plasma has

been activated by a platelet substitute

(phospholipid), silica activator and calcium chloride.

The assay was

performed by mixing 100 µl of citrated plasma with 100 µl of automated
APTT reagentR and incubating for 5 minutes at 37°c. 100 µl of calcium
chloride (0.025 M) prewarmed to 37°c was then added.
was determined immediately by a fibrometer.

The time to clot

Any clotting time which

was prolonged more than 150 seconds was reported as >150 seconds which
is the upper limit of the linear range of this assay.
Thrombin clotting time measures the conversion of fibrinogen to
fibrin based on the time to clot after the addition of a known amount
of thrombin to plasma.

The assay was performed by incubating citrated

plasma (200 µl) at 37°c for 3 minutes at which time 100 µl of 5 U/ml
human thrombin was added.
by a fibrometer.

The time to clot was determined immediately

Any clotting time which was prolonged more than 150

seconds was reported as >150 seconds which is the upper limit of the
linear range of this assay.
HeptestR was performed according to manufacturer's instructions.
The fundamental principle of the HeptestR heparin assay involves the
ability of heparin or its derivatives to catalyze the inactivation of
exogenous bovine activated factor X by antithrombin III in the presence
of naturally occurring antagonists in the plasma sample.

HeptestR
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measures the anticoagulant property of heparin through the combined

anti Xa/anti Ila actions of the drug.

Citrated plasma (100 µl) was

incubated with bovine factor Xa (100 µl) for exactly 120 seconds, at
which time 100 µl of RecalmixR was added to the mixture and immediately
the time to clot was determined by a fibrometer.

Any clotting time

which was prolonged more than 300 seconds was reported as >300 seconds
which is the upper limit of the linear range of the HeptestR.
2.

Amidolytic Assays
Amidolytic assays are characterized by an enzymatic reaction in

which an oligopeptide synthetic substrate of semi-specific 1ructure is
cleaved by a given enzyme to release an attached chromophore (para
nitroaniline).

Enzyme activity is determined by measuring the increase

in absorbance of the free chromophore which is generated, in comparison
to the original substrate, per minute at 405 nm (Fareed 1980, 1983;
Hoppensteadt 1985)

One advantage of amidolytic assays is the ability

to directly quantitate specific enzymes rather than indirectly as in
the case of the global assays.

This technique,

however,

measures

amidolytic activity on a semi-specific substrate which may not directly
correspond

to

the

specific

function

of

the

enzyme

in coagulation

processes.
The amidolytic anti Xa assay provided a measure of absolute
heparin concentration which is proportional to the inhibition of factor
Xa by heparin.

The assay was performed in the following manner: 375 µl

of buffer (pH 8 .4) was equilibrated with 25 µl of plasma sample at
37°c. 50 µl of 0.5 nkat/ml bovine factor Xa was added and allowed to
react for exactly 2 minutes, at which time 50 µl of substrate (Spectro-
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zyme Xa 2.5 mM) was added.
4os nm for one minute.

The change in absorbance was recorded at

% Inhibition of factor Xa activity was calcu-

lated as shown below.
% Inhibition

The

plasma sample delta A q05 nm/min - 1
plasma blank delta A 405 nm/min

amidolytic

anti

Ila measures

the

x 100

inhibition of

thrombin

(factor Ila) which is proportional to the heparin concentration.

The

assay was performed in the following manner: 400 µl of buffer pH 8.4

was equilibrated with 25 µl of plasma sample at 37°c.

25 µ1 of 10.0

NIH U/ml human thrombin was added and incubated for exactly one minute
at which time, 50 µl of spectrozyme TH 1 mM was added. The change in
absorbance was recorded at 405 nm for one minute.

%

Inhibition of

factor Ila activity was calculated as shown on the next page.
% Inhibition

plasma sample delta A q05 nm/min - 1
plasma blank delta A 405 nm/min

x 100

C. In Vitro Studies
1. Baseline Values of NHP, NMP, NRP and NratP
Human plasma obtained from Loyola University Blood Bank (NHP),
and plasma obtained from primates (NMP), rabbits (NRP) and rats (NratP)
was used to determine the clotting and amidolytic baseline values of
these

plasma

preparations.

These

experiments

were

performe~

in

triplicate on separate days.
2.

In Vitro Supplementation of Heparin or CY 216 to NHP, NMP, NRP and

NratP
Heparin or CY 216 was supplemented in a concentration range of 0
to 10 µg/ml to NHP, NMP, NRP and NratP.

APTT, HeptestR, amidolytic
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anti Xa and amidolytic anti Ila assays were performed on these samples.
3.

In

Vitro Supplementation of Protamine to NHP, NMP, NRP and NratP
Protamine sulfate

NMP,

NRP and NratP.

(10 and 100 µg/ml)

was supplemented to NHP,

Additional protamine concentrations (1 mg/ml and

10 mg/ml) were supplemented to NHP.

APTT, HeptestR, amidolytic anti Xa

and amidolytic anti Ila assays were performed on these samples.
4.

In

Yit[Q Neutralization of Heparin and CY 216 by Protamine In

Pooled Plasma Preparations
Heparin or CY 216 was supplemented to NHP or NMP to obtain a
final concentration of 5 µg/ml.
heparin

(5

µg/ml)

and

Protamine sulfate was added to the

CY 216

(5 µg/ml)

protamine concentrations of 2. 5,
activity

was

determined

by

solutions

to

5. 0 and 10. 0 µg/ml.

the

APTT

and

obtain final
Anticoagulant

thrombin

time

methods.

1

Antiprotease activity was determined by the HeptestR, amidolytic anti
Xa and amidolytic anti Ila assays.

The experiment was repeated five

times on different days using the same pool.
5.

In

Vitro Neutralization of Heparin and CY 216 by Spermidine In NHP

Heparin or CY 216 was
concentration of 5 µg/ml.
µg/ml)

and

CY

216

(5

µg\ml)

supplemented to NHP to obtain a
Spermidine was added to
solutions

to

obtain

final

the heparin

final

(5

spermidine

concentrations of 2.5, 5.0 and 10.0 µg/ml.

Anticoagulant activity was

determined by the APTT and thrombin time.

Antiprotease activity was

determined by the amidolytic anti Xa and amidolytic anti Ila methods.
The experiment was repeated three times on different days using the
same pool.
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D.

Rat Laser-Induced Thrombosis Studies
The

in vivo antagonism of heparin and CY 216

sulfate was

studied in a

by pro~amine

rat model of laser-induced thrombosis.

(Breddin et al. 1982; Weichert et al. 1983, 1984, 1986; Racanelli et
al. 1989)

This model provided a dynamic environment in which platelet

activation and subsequent thrombus formation in rat mesenteric vessels
can be visualized.
Experiments

were performed after anesthetizing

the

rats with

Nembutal ( 60 mg/kg i. p. ) .

The abdomen were shaved and a small ab-

dominal incision was made.

Drugs were injected via the tail vein for

intravenous

and

administration

administration.

A portion of

behind
the

the

neck

for

subcutaneous

rat mesentery was

exposed and

positioned on an optical stage. In these studies the laser damage was
produced by exposing terminal mesenteric venules of 25-30 um diameter
to 0.05 Watts of laser energy for 1/30th of a second.

Laser damage to

the endothelium was visualized through the microscope and antithrombotic effect was calculated in terms of the number of laser injuries
required to produce a defined thrombus.

Laser injuries were produced

in 3 distinct areas of the mesentery per rat.

At the end of the

experiment blood was drawn from the inferior vena cava and the rat was
sacrificed by cardiac

incision.

The

experimental schedule was as

follows:
Intravenous Studies:
0

5

Inject
Inject
Heparin Protamine
or CY 216

20 (minutes)
Produce
Laser
Injury
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subcutaneous Studies:

0

120

Inject
Heparin
or CY 216

Inject
Produce
Protamine Laser
Injury

E.

140 (minutes)

Rat Tail Bleeding Studies
A modified version of the rat tail bleeding time (Dejana 1982)

was

used to determine the hemorrhagic effect of heparin, CY 216 and

protamine as well as bleeding time after antagonism of heparin and CY
216 by protamine. The rats were anaesthetized with KetalarR (40 mg/kg
i.m.) and the tail was cleansed with an alcohol swab.

Two mm of the

distal end of the tail was transected using a scalpel.

Blood from the

incision site was soaked with a piece of filter paper very carefully so
as not to disrupt any hemostatic plug formation.

Heparin (2 mg/kg i.v.

and 2.5 mg/kg s.c.) and CY 216 (2 mg/kg i.v. and 2.5 mg/kg s.c.) and
protamine (1, 2, and 2.5 mg/kg i.v.) were studied in this model.
The experimental schedule was as follows:
Intravenous Studies:
0

5

10 (minutes)

Inject
Heparin
or
CY 216

Inject
Protamine

Transect
Tail

Subcutaneous Studies:
0

115

120 (minutes)

Inject
Heparin or CY 216

Inject

Transect
Protamine Tail
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F.

Rabbit Stasis Thrombosis Studies
The antithrombotic effects of heparin, CY 216 and protamine were

studied in a modified stasis thrombosis model (Fareed et al.

1985).

White New Zealand male rabbits were anaesthetized with Xylazine (20

mg/kg i.m.) and KetalarR (80 mg/kg i.m.).

If the rabbits showed signs

of being too lightly anesthetized during the procedure,
injections

of KetalarR

(25

mg/kg

i .m.)

were

additional

administered.

After

induction of anaesthesia, the rabbits were weighed, their neck area was
shaved and positioned for surgery.

Baseline blood samples were drawn

by cardiac puncture using a VacutainerR.

neck area was made using a scalpel.

A vertical incision in the

A blade, forceps and cautery were

utilized to surgically isolate the jugular veins from the fascia.

The

dissection was done carefully so as not to damage or traumatize the
vessels and collateral vessels were cauterized.

A 2 to 3 cm segment of

each jugular vein (including the bifurcation) was isolated and silk
sutures were

loosely tied around each branch of

without interfering with blood circulation.

the jugular vein

The exposed neck area was

kept moist with saline soaked gauze squares.
An intravenous line was set up with a 23 gauge, 3/4 inch butterfly needle in the rabbit marginal ear vein.

Heparin or CY 216 was

injected and allowed to circulate for 5 minutes at which time, blood
for tl vivo analysis was drawn by cardiac puncture.

Immediately after

the blood draw, PCC (25 U/kg) was administered through the marginal ear
vein followed by RVV (0 .1 U/kg) which was allowed to circulate for
exactly 20 seconds.

At this time the isolated jugular vein segments

were ligated and stasis produced.

A schematic diagram of the isolated
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jugular veins ar shown in Appendix VIII.

analysis,

Blood was drawn for

five minutes post PCC/RVV injection.

after stasis

time,

the

~

vivo

Exactly 10 minutes

isolated jugular segments were removed and

placed in a petri dish with saline.

The blood clots were visually

examined and graded according to the following method.

In this system

+ o represented blood with no evidence of clotting,+ 1 represents some
ainute clots however mostly blood, + 2 represents a large amount of
small clots, +3 represents large clots with some free red blood cells,

+ 4 represents a fully formed casted clot with no blood.

A schematic

diagram of the clot grading system which was used is shown in Appendix
IX.

Rabbits were euthanized with BeuthanasiaR (15 mg/kg i.v.).

experimental schedule was as follows:

rtravenous Studies:
0

5

Draw Blood
Then
Inject
Heparin

Inject
Protamine

or
CY 216

•

I

' - blood

10
Draw Blood
Inject
PCC/RVV
Then
Ligate
Vessel

Subcutaneous Studies:

l
0

Draw Blood
Then
Inject
Heparin

or
CY 216

245
Inject
Protamine

'

l-

15
Draw
Blood

20 (min)
Remove
Vessels
and
Evaluate
Clots

blood draw

255
Draw Blood
Inject
PCC/RVV
Then
Ligate
Vessel

l

265
Draw
Blood

275 (min)
Remove
Vessels
and
Evaluate
Clots

The
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G.

Rabbit Ear Blood Loss Studies
A modified version of the rabbit ear blood loss model (Cade et.

al. 1984), was used to compare the hemorrhagic potential of heparin, CY
The rabbits were anesthetized with Xylazine (10

216, and protamine.

mg/kg i.m.) and KetalarR (40 mg/kg i.m.). After induction of anaesthesia,

an intravenous line was set up with a 23 gauge,

3/4 inch

butterfly needle inserted in the large marginal ear vein through which
heparin, CY 216 and protamine were administered.

The rabbit ear was

immersed in a saline bath at 37°c and an area free of major blood
vessels was selected.

Using a scalpel, five uniform incisions of full

thickness were made in the area which was free of major blood vessels
as shown in the Appendix X.

Immediately after the incisions were made,

the rabbit ear was immersed in the saline bath and the red blood cells
were collected for 10 minutes. The saline was collected and the red
cells were counted using a HycelR cell counter.

Heparin (2 mg/kg i.v.)

and CY 216 (2 mg/kg i.v.) and protamine (1, 2 and 3 mg/kg i.v.) were
Heparin (1 mg/kg s.c.) and CY 216 (1 mg/kg s.c.) were also

studied.

studied. The protocol used to study blood loss is in this model is
shown below.

After the experiment the rabbits were returned to their

cages and used for the stasis thrombosis experiments, no less than one
week later (Emanuele 1987; Boneu 1987).

I Intravenous
0

Studies:

5

Draw
Inject
Blood
Protamine
Then
Inject
Heparin or CY 216

blood draw

I

10

Draw
Blood
Then Make
Incisions
and Collect RBCs

20 (min)
Count
RBCs
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Subcutaneous Studies'

~

115

Draw
Blood
Then
Inject
Heparin
or
CY 216

J- blood draw
130 (min)
Count
RBCs

120

Inject
Draw
Protamine Blood
Then Make
Incisions
and
Collect RBCs

Protamine sulfate was administered at a dose of 2 .1 mg/kg i. v.
and blood was drawn as shown below:

l

0

1

2

=blood draw

3 (hours)

The plasma samples were centrifuged and frozen at - 70° C.

The

pharmacodynamics of protamine were assayed indirectly by supplementing
the plasma of the primates which received protamine (2 .1 mg/kg i. v.)
with heparin in order to obtain a final heparin concentration of 2. 5
µg/ml.

APTT, thrombin time, HeptestR, amidolytic anti Xa and amido-

lytic anti Ila assays were performed.

The ability of protamine in the

plasma sample to neutralize the exogenously added heparin was indicative of the protamine concentration in the plasma.

Additional in vitro

studies were carried out where APTT, thrombin time, HeptestR, amidolytic anti Xa and amidolytic anti Ila assays were performed on the ex
vivo plasma samples after protamine administration.
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}I.

IJ.me Course of the Pharmacodynamic Effects of Heparin and CY 216 in

_nimates
The time course of pharmacodynamic activity of heparin, CY 216,
and protamine sulfate was studied using a primate model (Fareed 1985).

In addition, the time course of the neutralization of heparin and CY
216 by protamine was studied.
Baseline blood samples were drawn from all of the primates prior
to beginning
profiles

the

were

study.

Chemistry,

determined by

the

coagulation and hematological

Loyola

University Medical

department of clinical chemistry as shown in Appendix XI.
primates that were profiled,
health reasons.

Center

Of the 12

two were excluded from the study for

The remaining 10 primates were divided into 2 groups

consisting of 5 primates each.

These two groups were used alterna-

tively for the duration of the study.

Each primate was only used once

weekly which provided adequate time for drug clearance (Emanuele 1987).
A one month rest period was given to the primates between the intra-

venous and subcutaneous time course studies.

The primates were grouped

-

in a random manner as shown below.
Group I

Group II

M73

M70

M74

M75

M76

M2722

M2730

M3630

M3064

M4777

All pharmacodynamic time course experiments began at the same
time of the day (9:00 to 9:30 a.m.).

Prior to blood sampling the
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animals were anesthetized with KetalarR (10 mg/kg i.m.).

Approximate-

ly 10 minutes after injection, the primates were removed from their
cages and baseline blood samples were drawn from the popliteal vein.
All drugs were injected through syringes incorporating sterile, pyrogen
free 0.2 um Nalgene filters (Nalge Co. Rochester NY).

Primates were

returned to their cages and monitored as they recovered from their
anesthetic.

Studies

have

shown

that

repeated

administration

of

KetalarR does not have an effect on the primate coagulation profile
(Fareed et al. 1985).
1.

Heparin and CY 216 Pharmacodynamics

a.

Intravenous Studies
After 0 hour blood samples were drawn from each primate, heparin

or CY 216 were administered at doses of 0.35 mg/kg i.v. and 0.7 mg/kg
i. v.

Blood samples

(2. 7 ml)

were collected according to methods

previously described in this section,
containing 0. 3 ml of 3. 8
plasma.
below.

The experimental schedule for the intravenous studies is shown

lI

1

sodium citrate and centrifuged to obtain

The number in parentheses refers to primate group numbers.

•0 5

l

%

into siliconized glass tubes

30

2

i-blood draw
minutes

l

3

4

5

1.

Heparin 0.35 mg/kg i.v. (I)

2.

Heparin 0.70 mg/kg i.v. (II)

3.

CY 216 0.35 mg/kg i.v. (II)

4.

CY 216 0.70 mg/kg i.v. (I)

I
6

hours
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The clotting tests APTT,

thrombin time and HeptestR were per-

formed on fresh samples and plasma was frozen for subsequent in vitro
analysis.
For the neutralization studies heparin (0.7 mg/kg i.v.) or CY 216
(0. 7 mg/kg i. v.) was administered and protamine was given 5 minutes
after heparin administration.

Blood samples were drawn as shown below.

Blood was drawn at time 0 and then heparin or CY 216 was injected.

11 I I
f I
O5

15

2

1

30
3

,-blood draw
minutes
4

5

f
6

hours

The above schedule was used for the following studies.

The

number in parentheses represents the primate group number.
11 Heparin 0.7 mg/kg i.v. w/ Protamine Sulfate 0. 7 mg/kg i.v. (I)

2. Heparin 0.7 mg/kg i.v. w/ Protamine Sulfate 1.4 mg/kg i.v.(II)
3. Heparin 0.7 mg/kg i.v. w/ Protamine Sulfate 2.1 mg/kg i.v.(II)
4. CY 216 0.7 mg/kg i.v. w/ Protamine Sulfate 0. 7 mg/kg i. v. (I)

5. CY 216 0.7 mg/kg i.v. w/ Protamine Sulfate 1.4 mg/kg i.v.(II)
6. CY 216 0.7 mg/kg i.v. w/ Protamine Sulfate 2 . 1 mg/kg i. V. (I)
b.

Subcutaneous Studies
Heparin and CY 216 were administered at O. 7 mg/kg s. c. by a

single bolus injection to a site in the lower abdomen for all primates
except M4777.

This primate received a divided dose in order to keep

the volume injected less than 1 ml. Blood samples were drawn as shown
below.
injected.

Blood was drawn at time O and then heparin or CY 216 was

t
0

=blood draw

l

I

' '

6

4

2

86

9

12 (hours)

The above schedule was used for the following studies.

The

number in parentheses represents the primate group number.
1. Heparin 0.7 mg/kg s.c. (I)
2. CY 216 0.7 mg/kg s.c.

(II)

Blood was drawn by the following schedule for primates which
received protamine in addition to heparin (0. 7 mg/kg s. c.) or CY 216
(0.7 mg/kg s.c.).

Protamine was administered immediately after the 4

hour blood draw .

•

0

I
2

,-blood draw
4

I

6

9

12 (hours)

1. Heparin 0.7 mg/kg s.c. w/ Protamine Sulfate 0.7 mg/kg i.v. (I)
2. CY 216 0.7 mg/kg s.c. w/ Protamine Sulfate 0.7 mg/kg i.v. (I)
3. CY 216 0.7 mg/kg s.c. w/ Protamine Sulfate 0.7 mg/kg i.v. (II)
Studies on the neutralization of heparin (0.7 mg/kg s.c.) or CY
216 (0. 7 mg/kg s. c.) by protamine were carried out at the following
doses of protamine sulfate.

The number in parentheses refers to the

primate group number.
1. Heparin 0.7 mg/kg s.c. w/ Protamine Sulfate 0.7 mg/kg i.v.(II)
2. CY 216 0.7 mg/kg s.c. w/ Protamine Sulfate 0.7 mg/kg i.v. (I)
3. CY 216 0.7 mg/kg s.c. w/ Protamine Sulfate 1.4 mg/kg i.v.(II)
2. Calculation of Pharmacodyrtamic Time Course Parameters
Pharmacodynamic time course parameters for the intravenous and
subcutaneous

studies

were

determined

from

concentrations

(µg/ml)
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obtained from calibration curves of heparin or CY 216 supplemented to

NMl' as determined by the HeptestR and amidolytic anti Xa assays.

These

two assays were chosen to calculate the pharmacodynamic time course
parameters

since

they

primarily measure

activity is commonly used to monitor
therapy.

anti

Xa

activity.

This

low molecular weight heparin

In addition, these assays demonstrated the greatest linearity

over the concentrations studied and only the linear portion of the

calibration curves were used. If a primate sample was determined to be
out of range of the curve, it was diluted 1:5 in normal monkey plasma,
read off the curve and multiplied by the dilution factor (Sie et al.

1989).

The calibration curves of heparin and CY 216 supplemented in

NMP are shown in the Appendix XII.
Pharmacodynamic

time

course

parameters were

determined using

noncompartmental methods as described by Gibaldi (1984).

The

pharm-

acodynamics of intravenously or subcutaneously administered heparin and
CY 216 were characterized in terms of area under the concentration
curve (AUC), area under the moment curve (AUMC), mean residence time

(MRT),

plasma clearance

(Clp)

and apparent volume of distribution

(Vd). Area under the curve and AUMC

were calculated using PCNONLIN

software (Statistical Consultants, Lexington, KY).
The mean residence

time

(MRT)

is the time when 63. 2% of an

intravenous dose has been eliminated.

The concept is similar to the

biologic half life when 50% of the dose has been eliminated.
calculated by the ratio of the AUMC to AUC.
MRT - 60(min) x AUMC
AUC

MRT is
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plasma clearance was determined by the following formula:

Clp - DOSE x _1__
AUC
60(min)
Apparent volume of distribution was determined by the following
formula:
Vd - dose x AUMC x 1 liter
(AUC)(AUC) 1000 ml
Bioavailability after subcutaneous administration was calculated
by the following formula:
Bioavailability

mean
mean

Protamine Neutralization Index

AUC (s,c, dose)
AUC (i.v. dose)
(PNI)

(Bjornsson personal com-

munication) was calculated by the following formula:
PNI - 1 - post protamine AUC
(mean) pre protamine AUC
In order to calculate PNI values for the primate studies, it was
necessary to use the mean value for the protamine neutralization, since
the experiments were performed using groups and not all of the primates
were used for all of the studies.
For the amidolytic assays, % neutralization was calculated by the
following formula:
% Neutralization - post protamine ug/ml - 1

pre protamine µg/ml
% N were calculated at 30 minutes for intravenous studies and at

245 minutes for the subcutaneous studies for the primates.

In the

rabbit studies, % N was calculated after 10 minutes for the intravenous
studies and after 120 minutes for the subcutaneous studies.

%

N was
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not calculated for the APTT, thrombin time and HeptestR data since many
values were outside of the linear range of the assay.
I.

Statistical Analysis

l. Data Presentation
The experimental data was compiled as mean± S.E. (standard error
of the mean) .

The sample mean was the average of the measurements

within each experimental group.

The standard error of the mean (S.E.)

was reported along with the mean in order to provide an indication of

the precision of estimation of the population mean. The S.E. was also
used in order to facilitate comparison of the means of one group to
another.

The S.E. was calculated by dividing the standard deviation

(S.D.) by the square root of the number in the experimental population.
S.E. - S.D.
nl/2
The data in the figures was represented as mean ± S. E.

Error

bars were drawn using the SigmaplotR software and the error bars are
not shown if they are not larger than the size of the symbol in the
figure.
2.

Statistical Tests
Statistical tests performed on the experimental data include:

Students t-test (unpaired),

one way ANOVA,

Newman Keuls multiple comparison test,

two way ANOVA, Students-

Kruskal Wallis nonparametric

ANOVA, nonparametric multiple comparison test and linear regression.
All tests with the exception of the Kruskall-Wallis nonparametric ANOVA
and the linear regression tests were performed utilizing Systat.

The

linear regressions were performed utilizing Sigmaplot and the nonparametric tests were calculated manually.

All test statistics were
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calculated at a significance level of .05.
H, and

a.

Critical values fort, F,

q distributions were obtained from Zar (1984).

Student's t test
The

student's

heparin group

to

t

the

test was used to compare the means from the
means

from

pharmacodynamic time course data.
of the

analyses

which

indicates

the

CY

216

group

in the primate

Two tailed t tests were used for all
the

mean value

obtained could be

greater or less than the mean value from the other group.
b.

Analysis of Variance
The one way AN0VA was used to compare the effect of a single

factor on a

single variable although different factor levels exist.

The one way AN0VA was used to compare several group means after a
treatment.

The test for the equality of means is a one-sided variance-

ratio test as shown below:
F - group mean square
error mean square.
The critical value for this test is F alpha (l),(k-l)(N-k) where
N -

total number of data points

and k - number of groups.

calculated F is at least as large as the critical value,
rejected.

If the

then H0

is

The AN0VA does not determine where the differences between

means exist,

if indeed this

test concludes that a

ference does exist between the means.

significant dif-

If the AN0VA revealed a sig-

nificant difference, the Student-Newman-Keuls multiple comparison test
was used to

determine

the

location of the

differences between the

means.
The two way AN0VA simultaneously analyzes the effect of more than
one factor on a group mean.

This test considers the effects of two
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factors independently of each other.
values are obtained.

For a two way ANOVA,

three F

F values for Factor A, Factor Band the interac-

tion between Factors A and Bare obtained.

An interaction between two

factors indicates that the effect of one factor is not independent of

-the presence of a particular level of the other factor.
c.

Student-Newman-Keuls Test
The Student-Newman-Keuls

test was applied in addition to the

ANOVA to determine which means were statistically different from the

other.

This multiple comparison was selected since it is more powerful

and widely

1984).

accepted than the other multiple comparison tests

(Zar

The test statistic q is calculated and the critical value is

qa lpha, DF, p where p is the number of means in the range of means

being tested.
q - XP>--:.-.XA
S.E.
If the number of groups (k) were equal, the S.E. was calculated as

S.E. - (s 2/n) 1 / 2
where s 2 - error mean square.
If the number within each group were not equal, the S.E. was calculated

as

For S.E. n- number of data points in each level, v- with in cells
degrees

of

freedom.

Newman-Keuls

performed following 2 way ANOVAs.

multiple

comparison

tests

were

The comparisons were made between

the levels of a fixed effects factor having more than two levels.
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d,

Kruskall-Wallis Test
The Kruskal Wallis nonparametric ANOVA was used to test for

differences between the clot scores obtained in the stasis thrombosis
11<>del.

The Kruskal Wallis test statistic H was calculated as
H - l.2...__Ri 2 - 3(N

+ 1)

N(N+l)ni
where N - total number of observations in all groups, ni - number of

observations in group I and Ri - sum of ranks of ni observations in a
group.
e.

Nonparametric Multiple Comparison Test
Nonparametric

multiple

nonparametric Kruskal-Wallis

comparison

tests

were

used

when

the

test was applied and significant dif-

ference between means was obtained.

Nonparametric comparisons are

performed in a similar manner to the Tukey test, however the rank sums
are used instead of means.
S. E.

The S.E. was calculated as
{n{nk}(nk+l)
12

f. Simple Regression
Simple

regression

relationship between

~

inhibition of thrombosis.

analysis

was

performed

to

establish

the

vivo activity and either blood loss or

%

The coefficient of determination R2 was

computed using SigmaplotR solftware and the r value was reported.
average number of data points used to calculate each r value was 10.

The

Chapter IV
RESULTS

A.

In Vitro Studies

1. Molecular Weight Profiles of Heparin, CY 216 and Protamine

The molecular weight profile for heparin as determined by a high
pressure liquid chromatographic (HPLC) method as previously described

by Losito

(1981)

is

shown in Appendix III.

Heparin exhibited a

polydisperse molecular weight profile with a mean molecular weight of
11,000 daltons.
The molecular weight profile for CY 216 as determined by a high
pressure liquid chromatographic (HPLC) method using a UV detector is
shown in Appendix V.

CY 216 exhibited a polydisperse molecular weight

profile with a mean molecular weight of 5,200 daltons.
The molecular weight profile for protamine as determined by a
high pressure liquid chromatographic (HPLC) method using a UV detector
is shown in Appendix VII.

Protamine exhibited a polydisperse molecular

weight profile with a mean molecular weight of 4,000 daltons.
The

molecular

weight

profiles

for

heparin

and

CY

216

were

obtained in collaboration with Institut Choay.
2.

NMR Spectra of Heparin, CY 216 and Protamine
Proton NMR spectra were also used to profile heparin, CY 216, and

protamine.

The 1H NMR spectras were obtained in collaboration of

Professor Casu of Institute Ronzoni, Milan Italy.
measured with

a

Bruker HX-270

spectrometer
93

The spectra were

operating

at

300 MHz.
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Chemical shifts were measured with reference to internal TSP.

The lH

NMR spectrum (300 MHz, D20) of heparin is shown in Appendix XIII.

This

spectrum shows the regular regions consisting of GlcNS03 and IdoA-2S
residues of the regular sequences of heparin.
with the proposed structure of heparin.

This data is consistent

Appendix XIV shows a com-

parable spectrum of CY 216 which was obtained under identical conDifferences between the spectral

ditions as the heparin spectrum.

characteristics of heparin and CY 216 were observed in the region of 34.5 ppm.

Furthermore the spectra demonstrated the presence of anhydro-

aannose residues which are present at the terminal end groups of some
low molecular weight heparins.

Appendix XV shows the NMR spectrum of

protamine and a complex formed between heparin and protamine.

The

spectrum obtained for protamine was markedly different than the spectra
obtained for

the heparins.

Preliminary analysis of this heparin-

protamine complex data demonstrates a chemical shift in the 3.4-3.6 ppm
region (see box) as shown in Appendix XV.
3. Baseline Values of NHP, NMP,

NRP and NratP in the Clotting and

Amidolytic Assays.
Human pooled plasma was obtained from Loyola University Blood
Bank (NHP),

and pooled plasma obtained from primates (NMP), rabbits

(NRP) and rats (NratP) were used in this study.

Baseline values of

these plasma preparations were determined in the clotting and amidolytic assays and statistical analysis was performed by a one way ANOVA.
The results are shown in Table 1.

Variations in the baseline APTT

values for NHP, NMP and NratP were observed.

The baseline values for

NRP and NratP were

(p<.05)

significantly different

from NHP.

The
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baseline clotting values obtained for NHP and NMP were similar as
determined by the thrombin time, however the baseline values for NRP
and NratP were significantly longer (p<.05) as compared to NHP.

The

values were similar for NHP and NMP as determined by the HeptestR (15.5
and 20.5 seconds) respectively, however, the NratP baseline value was

significantly longer (p<.05)

than NHP at 56.6 seconds. The baseline

chromogenicity of NMP as determined by the amidolytic anti Xa and
amidolytic anti Ila assays were slightly higher than for the other
plasma samples studied.

However, % inhibition of amidolytic factor Xa

or amidolytic factor Ila activity was calculated as a ratio.

Any

variations between the absorbances of the plasma samples were minimized
after the calculation of % inhibition was performed.

Control values

for the amidolytic assays were designated as 0% inhibition.
4.

In Vitro Supplementation of Protamine Sulfate to NHP, NMP, NRP and

NratP
The in vitro results of protamine sulfate supplementation to the
various plasma preparations in a concentration range of O - 100 µg/ml
are shown in Table 2.

Additional concentrations of protamine (1 and 10

mg/ml) were supplemented to NHP in order to demonstrate the effects of
high concentrations of protamine on human plasma. These concentrations
of protamine were larger than doses which would be administered to a
patient after cardiopulmonary bypass.
NRP was more sensitive to the effects of protamine in the in
vitro assays than the other plasma preparations.

NHP was not sig-

nificantly prolonged, (as determined by a one way ANOVA), by protamine
sulfate until the protamine concentration reached 1 mg/ml.

Protamine

96
(100 µg/ml)

did not have any effect on the absorbance values as

determined by the amidolytic anti Xa and amidolytic anti Ila methods in
any of the plasma systems as shown in Table 2.
5. l!! Vitro Supplementation of Heparin and CY 216 to NHP, NMP, NRP and
NratP
Heparin or CY 216 was supplemented to NHP, NMP, NRP and NratP in
a concentration range of 0 to 10 µg/ml.
obtained as

previously

described

Plasma preparations were

in methods.

The experiment was

performed on 3 separate days using aliquots of the same frozen pooled
plasma preparations.

APTT, HeptestR, amidolytic anti Xa and amidolytic

anti Ila assays were performed on these samples.
The anticoagulant effects of heparin supplemented to the various
plasma systems as determined by the APTT are shown in Figure 1. In a
concentration range of 0-10 µg/ml,

heparin produced a similar dose

dependant prolongation of NHP and NMP.

In addition dose dependant

increases in the APTT were observed for NRP and NratP.
in NRP were stronger than for NHP,

The responses

whereas NratP exhibited weaker

responses.
The anticoagulant effects of CY 216 supplemented to the plasma
systems as determined by the APTT are shown in Figure 2.

NRP was also

prolonged to the same degree although the curve was shifted along they
axis due to variations in baseline values for NRP.

NratP was less

sensitive to the effects of CY 216 than the other plasma preparations
as determined by the APTT.
The antiprotease activity of heparin in various plasma systems as
determined by the HeptestR is shown in Figure 3.

At the lower con-
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centrations, heparin prolonged NHP, NMP and NratP to the same extent,
however, a divergence in this activity was seen at concentrations> 5
µg/ml.

The HeptestR was very sensitive to the effects of heparin (5

µg/ml)

supplemented to NRP and a prolongation of > 300 seconds was

observed.
The antiprotease activity of CY 216 in the various plasma systems
as determined by the HeptestR is shown in Figure 4.

CY 216 prolonged

NHP and NMP in a similar manner while CY 216 prolonged the HeptestR to
a slightly lesser degree as compared to heparin.
also prolonged to the same extent,

NRP and NratP were

although the NratP baseline was

elevated as compared to the other plasmas.
The

amidolytic

anti

Xa

activity

of

heparin supplemented to

various plasma systems is shown in Figure 5. In a concentration range
of 0-10 µg/ml, heparin produced a similar dose dependant increase in
the inhibition of amidolytic anti Xa activity of NHP and NMP.

NRP and

NratP

it was

also

produced

a

dose

dependant

inhibition,

however

somewhat weaker than the response of NHP.
The amidolytic anti Xa activity of CY 216 supplemented to various
plasma systems is shown in Figure 6. CY 216 in a concentration range of
0-10 µg/ml, produced a similar dose dependant increase in the inhibition of amidolytic anti Xa activity of NHP and NMP, however the assay
exhibited the most sensitivity to the antiprotease effects of CY 216
supplemented to NHP.
inhibition,

however

response of NHP.

NRP and NratP also produced dose
these

responses

dependant

were somewhat weaker than the

NRP was less sensitive to the antiprotease effects of

cY 216 than the other plasma preparations.
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The

amidolytic

anti

Ila

activity of heparin supplemented to

vari ous plasma systems is shown in Figure 7. In a concentration . range

of o-1.25 µg/ml, heparin produced a similar dose dependant increase in
the inhibition of amidolytic anti Ila activity of NHP and NMP.

However

NMP reached the upper limit of the linear range of this amidolytic anti
NRP and NratP

Ila assay at a lower concentration than did the NHP.

also

produced

similar

dose

dependant

inhibition,

however

it

was

somewhat weaker than the response of NHP.

The

amidolytic

anti

Ila

activity of CY

216 supplemented to

various plasma systems is shown in Figure 8. In a concentration range

of 0-10 µg/ml, CY 216 produced a similar dose dependant increase in the
inhibition of amidolytic anti Ila activity of NHP,
however,

NRP and NratP,

the assay exhibited the greatest sensitivity to the anti-

protease effects of CY 216 supplemented to NMP.
The numerical values for the data plotted in Figures 1-8 are
shown in Appendix XXIII.

A comparison of the amidolytic anti Xa and

anti Ila activities of heparin is shown in Appendix Xlle.

A comparison

of the amidolytic anti Xa and anti Ila activities of CY 216 is shown in
Appendix Xllf.

6.

In Vitro Protamine Neutralization of Heparin and CY 216 in NHP
The

in vitro protamine neutralization of heparin and CY 216

supplemented to NHP or NMP as determined by the APTT is shown in Figure
9.

At a concentration of 5 µg/ml, CY 216 only slightly prolonged the

APTT, while heparin prolonged the APTT to> 150 seconds.

degree of neutralization of heparin by protamine

A progressive

(0-10 µg/ml)

was
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noted.

At equigravimetric concentrations of heparin and protamine (5

µg/ml) a complete neutralization of APTT activity was seen.
The in vitro protamine neutralization of heparin and CY 216 in
NHP or NMP as determined by the thrombin time assay is shown in Figure
10.

Heparin (5 µg/ml) prolonged the thrombin time to a greater extent

than CY 216 (5 µg/ml).

Complete neutralization of the thrombin time

activity of heparin was seen at a gravimetric protamine to heparin
ratio of 1:1 while the thrombin time activity of CY 216 was completely
neutralized at a gravimetric protamine to CY 216 ratio of 1:2.
The in vitro protamine neutralization of heparin and CY 216 in
NHP or NMP as

determined by

the HeptestR is shown in Figure 11.

Heparin (5 µg/ml) prolonged the HeptestR to a greater extent than CY
216 (5 µg/ml).

Almost complete neutralization of the HeptestR activity

was seen at a gravimetric protamine to heparin ratio of 2:1.

Only a

slight degree of neutralization of HeptestR activity was seen at a
gravimetric protamine to CY 216 ratio of 2:1.
The in vitro protamine neutralization of heparin and CY 216 in
NHP or NMP as determined by the amidolytic anti Xa assay is shown in
Figure 12.

Heparin (5 µg/ml)

inhibited the amidolytic activity of

factor Xa to a greater extent than CY 216 (5 µg/ml).

Almost complete

neutralization of the amidolytic anti Xa activity of heparin was seen
at a protamine to heparin ratio of 1: 1.

Only a slight degree of

neutralization of amidolytic anti Xa activity was seen at a gravimetric
protamine to CY 216 ratio of 2:1.
The in vitro protamine neutralization of heparin and CY 216 in
NHP or NMP as determined by the anti Ila assay is shown in Figure 13.
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Heparin (5 µg/ml) inhibited amidolytic factor Ila activity to a greater
extent than CY 216 (5 µg/ml).

Almost complete neutralization of the

anti Ila activity of heparin and CY 216 was seen at a gravimetric
protamine to heparin (or CY 216) ratio of 1:1.
The numerical values for the data plotted in Figures 9-13 are

shown in Appendices XXIIIi and XXIIIj.
7.

.In Vitro Neutralization of Heparin and CY 216 By Spermidine In

NHP
The in vitro neutralization of heparin by spermidine in NHP is

shown in Table 3.
effect

on

the

Supplementation of spermidine (10 µg/ml) had no

clotting or

amidolytic

assays.

Heparin

(5

µg/ml)

prolonged the APTT and thrombin time assays to> 150 while the HeptestR
was prolonged to a lesser degree by heparin (5 µg/ml).

Heparin (5

µg/ml) exhibited substantial inhibition of the amidolytic anti Xa and
amidolytic anti Ila activity.
of

the

anticoagulant

protamine.

and

Spermidine was a less potent antagonist

antiprotease

activities

of heparin than

The APTT and thrombin time activity of heparin (5.0 µg/ml)

remained prolonged to> 150 seconds even after supplementation of a two
fold gravimetric

amount of spermidine.

The anti

Ila activity of

heparin was neutralized to a greater degree than the other activities.
In contrast,

complete neutralization of the anticoagulant and anti-

protease activity of heparin was

observed at two fold gravimetric

concentrations of protamine or less.
The in vitro neutralization of CY 216 by spermidine in NHP is
shown in Table 4.

CY 216 (5.0 µg/ml) prolonged the APTT to a lesser

degree than heparin (5.0 µg/ml).

No neutralization of the APTT or
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. HeptestR activity was seen by spermidine (2.5, 5.0, or 10 µg/ml) while
complete neutralization of the APTT activity was noted at a spei:midine
concentration of 1 mg/ml.

In contrast, HeptestR activity was only

partially neutralized by spermidine (1 mg/ml).

The amidolytic anti Xa

activity of CY 216 was less neutralizeable than the amidolytic anti Ila

It is interesting to note that the amidolytic

activity of CY 216.

activity was neutralized to a greater degree than the thrombin time

clotting activity which suggests that there may be specific structural
requirements

for

the neutralization of the different activities of

heparin as determined by the laboratory assays.
B. In Vivo Studies

1. Rat Model of Laser-Induced Thrombosis
a. Antithrombotic Effects of Protamine

The effects of protamine sulfate on laser induced thrombosis in
rats is shown in Figure 14.

An increase in number of laser injuries

required to produce a defined thrombus is related to the antithrombotic
effect of the drug.

Protamine (0.74 mg/kg i.v.) increased the number

of laser injuries however this increase was not significant (p>.20) as

determined by an unpaired student t test.
b.

Intravenous Studies
Protamine antagonism of heparin

( 1 mg/kg

i. v. )

induced model of thrombosis is shown in Figure 15.
i.v.)

significantly

(p<.05),

(as

determined by

in the laser

Heparin (1 mg/kg
a

one

way ANOVA)

increased the number of laser injuries needed to produce a defined
thrombus.

This increase correlates to antithrombotic effect in this

model. Protamine (0.32 mg/kg i.v.) did not reduce the number of laser
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injuries needed to produce a defined thrombus and therefore did not
antagonize the anti thrombotic activity of heparin (1 mg/kg i. v.).

A

protamine concentration of (0.64 mg/kg i.v.) was needed to sufficiently
antagonize these antithrombotic effects.
Protamine antagonism of CY 216

( 1 mg/kg i. v. )

induced model of thrombosis is shown in Figure 16.
i.v.)

significantly

(p<.05),

(as

determined by

in the

laser

CY 216 (1 mg/kg
a

one

way ANOVA)

increased the number of laser injuries required to produce a defined

thrombus in the laser model of thrombosis.

A protamine concentration

of (0.74 mg/kg i.v.) completely antagonized the antithrombotic effects
of CY 216.
c.

Subcutaneous Studies
The effect of subcutaneously administered heparin and CY 216 is

• hown in Figure 17 .

Both heparin and CY 216 at doses of (10 mg/kg

• .c.) significantly (p <.05),

(as determined by a one way ANOVA),

increased the number of laser injuries required to produce a defined
thrombus.
The numerical values for the data plotted in Figures 14-17 are

shown in Appendix XXIVa.
2. Rabbit Stasis Thrombosis Model
A rabbit
antithrombotic
~rotamine

stasis
effects

thrombosis

model

was

of heparin and CY

neutralization profiles

of

these

used

216

to

evaluate

the

and the comparative

drugs.

Ex vivo blood

Samples were analyzed to determine the ex vivo levels of the various
activities at the time thrombosis was induced.

Prothrombin complex

concentrate and Russel's viper venom were administered to rabbits as a
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thrombogenic

challenge

methods section.

and clots were

graded as

described in the

Antithrombotic effects were studied after intravenous

and subcutaneous administration of heparin or CY 216 in addition to
protamine sulfate.
a. Protamine Sulfate
The antithrombotic activity of protamine sulfate in a rabbit
stasis thrombosis model is shown in Figure 18.

Concentrations of up to

500 µg/kg i.v. did not have any significant (p>.10), (as determined by
a Kruskall Wallis test), inhibitory effect upon thrombus formation in
this model.
The

APTT,

thrombin

time,

HeptestR,

amidolytic

anti

Xa

and

amidolytic anti Ila results of rabbits administered protamine sulfate
(100 and 500 µg/kg i.v.) are shown in Table 5.

Protamine sulfate did

not exhibit any significant effects

(as determined by an

(p>. 20),

unpaired t test), upon the clotting tests or amidolytic at the doses of
protamine which were used during the stasis thrombosis experiments.
b.

Heparin
The anti thrombotic activity of heparin (25,

i.v.) is shown in Figure 19.

50 and 100 µg/kg

Heparin produced significant (p<.05), (as

determined by a Kruskall Wallis test), dose dependant inhibition of
clot formation at the three doses studied.
The APTT,
istered

thrombin time and HeptestR results of rabbits admin-

heparin (25, 50 and 100 µg/kg i. v.) as demonstrated by the

APTT, thrombin time and HeptestR are shown in Table 6.

Heparin (100

µg/kg i.v.) produced a significant (p<.05), (as determined by a one way
ANOVA) prolongation of the APTT and HeptestR.

Thrombin time was more
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sensitive to the effects of heparin than the other clotting tests.

A

significant elevation (p<.05) was observed for heparin (50 µg/kg ~.v.).
Statistical analysis was not performed on the heparin (100 µg/kg i.v.)
thrombin time data since an indefinite number

(>

150 seconds) was

obtained as a result.
The ex vivo amidolytic anti Xa and amidolytic anti Ila activity
of rabbits administered heparin (25, 50 and 100 µg/kg i.v.) is shown in
Figure 20.

Heparin produced an inhibition of the amidolytic action of

factors Xa and Ila in a dose dependant manner.

Significant (p<.05)

anti Xa activity was seen for heparin (100 µg/kg i.v.) and significant
anti Ila activity was seen for heparin (50 µg/kg i. v. and 100 µg/kg
i.v.) as determined by a two way ANOVA.
Correlation coefficients were calculated to determine the extent
of the relationship between the circulating ex vivo pharmacodynamic
activity of
thrombosis

intravenously administered heparin and
in a

stasis

thrombosis

obtained for all of the tests.
coefficient (r-.552).

model.

%

inhibition of

Poor correlations were

Anti Ila had the best correlation

The other r values are as follows:

APTT-.002,

thrombin time -.352, HeptestR -.144, anti Ila -.515.
c.

CY 216
The antithrombotic activity of CY 216 (25, 50 and 100 µg/kg i.v.)

is shown in Figure 21.

CY 216 produced a dose dependant inhibition of

thrombosis while CY 216

(100 µg/kg i.v.) significantly (p<.05)

in-

hibited clot formation as compared to the control group as determined
by a Kruskall Wallis test.
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The APTT, thrombin time and HeptestR results of rabbits administered CY 216 (25, 50 and 100 µg/kg i.v.) is shown in Table 7.

CY 216

( 25 µg/kg i. v.) did not have a significant effect upon the clotting
CY 216

tests.

(50 µg/kg i.v.) significantly (p<.05) prolonged the

thrombin time while CY 216 (100 µg/kg) significantly (p<.05) prolonged
the thrombin time and HeptestR as determined by a one way ANOVA.

The fili vivo anti Xa and anti Ila activity of rabbits administered
CY 216 (25,

50 and 100 µg/kg i. v.) is shown in Figure 22.

Minimal

inhibition (<10%) of factor Xa and factor Ila was shown for CY 216.
Correlation

coefficients

were

calculated

to

determine

the

relationship between the circulating ex vivo pharmacodynamic activity

of intravenously administered CY 216 and% inhibition of thrombosis in
a stasis thrombosis model.

Poor correlations were obtained for all of

HeptestR had the best correlation coefficient (r-.806).

the tests.

The other r values are as follows:

APTT-.152, thrombin time -.570,

anti Xa -.306 and anti Ila -.311.
d.

Protamine Antagonism of the Effects of Heparin and CY 216

1. Intravenous Studies
The clot scores obtained after protamine neutralization of either
heparin (100 µg/kg i.v.) or CY 216 (100 µg/kg i.v.) is shown in Figure
23.

Protamine completely antagonized the anti thrombotic activity of

heparin (100 µg/kg i. v.) at equigravimetric amounts of protamine and
heparin.

The antithrombotic activity of

CY 216 (100 µg/kg i.v.),

however, was not completely antagonized even at a gravimetric ratio
protamine

to

heparin ratio

of

2:1.

This

residual antithrombotic
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activity which remained after protamine was significant (p<. 05)

as

compared to the control group as determined by a two way ANOVA.
The coagulation parameters of rabbits administered intravenous
heparin or CY 216 and protamine as determined by the APTT, thrombin
time and HeptestR are shown in Table 8.
completely neutralized

the

thrombin

Protamine (200 µg/kg i. v.)

time and HeptestR activity of

heparin (100 µg/kg i. v.) and CY 216 (100 µg/kg i. v.). The HeptestR
activity of heparin was neutralized to a

greater degree

than the

HeptestR activity of CY 216.
The

~

vivo anti Xa activity after protamine neutralization of

heparin or CY 216 in rabbits is shown in Figure 24.
a significant

(p<.05)

activity which

was

Heparin exhibited

degree of inhibition of amidolytic factor Xa

completely

neutralized by

inhibited factor Xa by approximately 10 %

protamine.

CY 216

while only a slight degree

of neutralization of the anti Xa activity of CY 216 was seen.
The~ vivo anti Ila activity after protamine neutralization of
heparin or CY 216 in rabbits is shown in Figure 25.

Heparin exhibited

significant (p<.05), (as determined by a two way ANOVA), inhibition of
amidolytic

anti

Ila

protamine sulfate.

activity which

was

completely neutralized by

CY 216 administration

did not have any effect on

this activity.
Poor correlation coefficients were obtained for residual activity
after heparin neutralization and clot score (r-. 246 for APTT, r-. 685
for thrombin time, r-.107 for HeptestR, r-.246 for anti Xa and r-.148
for anti Ila).

The correlation obtained for residual activity after CY
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216 neutralization and clot score (r-.185 for APTT, r-.001 for thrombin
time, r-.433 for HeptestR, r-.473 for anti Xa and r-.153 for anti Ila).
2.

Subcutaneous Studies
Clot scores obtained in the rabbit stasis thrombosis after the

administration of heparin (1 mg/kg s.c.) or CY 216 (1 mg/kg s.c.) and
subsequent antagonism by protamine sulfate (1 mg/kg i.v.) are shown in
Figure 26. Heparin (1 mg/kg s.c.) and CY 216 (1 mg/kg i.v.) exhibited
significant (p<.05), (as determined by a two way ANOVA) inhibition of
thrombus formation as compared to the control group.

Protamine sulfate

(1 mg/kg i. v.) completely antagonized the anti thrombotic effects of
heparin (1 mg/kg s.c.).
bosis

as

compared to

CY 216 exhibited a
control,

however,

30% inhibition of throm-

this

was not significant.

Protamine sulfate did not antagonize the antithrombotic effects of CY
216 (1 mg/kg s.c.).
The

coagulation parameters of rabbits administered subcutaneous

heparin or CY 216 and protamine sulfate are shown in Table 9.

Assay

dependant differences in the neutralization of heparin and CY 216 were
observed.

The APTT was not significantly (p>.50), (as determined by a

two way ANOVA) prolonged after heparin or CY 216 administration.

The

thrombin time for heparin (1 mg/kg s. c.) was prolonged to a greater
extent than after the administration of CY 216.
protamine administration,

After equigravimetric

the thrombin time activity of CY 216 was

completely neutralized while this activity of heparin was substantially
neutralized however not to baseline levels.

The HeptestR was sig-

nificantly (p<.05) prolonged by heparin (1 mg/kg s.c.) and by CY 216 (1
mg/kg s.c.).

Protamine completely neutralized the HeptestR activity
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of heparin, however not all of HeptestR activity of CY 216 was neutralized.
Heparin (1 mg/kg s.c.) and CY 216 (1 mg/kg s.c.) significantly
(p<.05) inhibited amidolytic factor Xa activity as shown in Figure 27.
This activity was not neutralized by protamine

(1 mg/kg i. v.)

to

control levels.
Heparin

(1 mg/kg s. c).

and CY 216

(1 mg/kg s. c.)

exhibited a

significant (p<.05), (as determined by a two way ANOVA), inhibition of
the amidolytic activity of factor Ila as shown in Figure 28. Protamine
neutralized this activity of heparin to a greater degree than CY 216.
The numerical values for the data plotted in Figures 18-27 are
shown in Appendix XXIVg - XXIVj.
3.

Rat Tail Bleeding Model

a.

Intravenous Studies
The effects of saline, protamine (1 mg/kg i.v.), heparin (2 mg/kg

i. v.) and CY 216 (2 mg/kg i. v.) are shown in Figure 29.

Heparin (2

mg/kg i.v.) significantly (p <.05), (as determined by a one way ANOVA),
prolonged the bleeding time while CY 216 or protamine had lesser
effects on the bleeding time.
The

antagonism of

the bleeding effects

of intravenously ad-

ministered heparin and CY 216 by equigravimetric doses of protamine are
shown in Figure 30.

Heparin (2 mg/kg i.v.) significantly (p<.05), (as

determined by a one way ANOVA) prolonged the bleeding time in this
model, however, the bleeding time returned to control values after the
administration of protamine

(2 mg/kg i. v.).

CY 216 did not sig-

nificantly prolong the bleeding time in rats as compared to the control
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group and subsequent protamine administration had no further effect on
the bleeding time after subcutaneous administration of CY 216.

b.

Subcutaneous Studies
The antagonism of subcutaneously administered heparin and CY 216

in a rat tail bleeding model is shown in Figure 31.

Heparin (2.5 mg/kg

s.c.) or CY 216 at (2.5 mg/kg s.c.) did not significantly (p>.50), (as

determined by a one way ANOVA) , prolong the bleeding time which was
determined

2 hours

after

drug

administration.

Administration of

protamine did not further affect the bleeding time.
The numerical values for the data plotted in Figures 29-31 are
shown in Appendix XXIVb.

4. Rabbit Ear Blood Loss Model
The antagonism of heparin or CY 216
studied in a rabbit ear model.

induced blood loss was

Heparin and CY 216 were administered by

intravenous and subcutaneous routes of administration and blood samples
were obtained by cardiac puncture. Plasma was analyzed using the APTT,

thrombin time,

HeptestR,

amidolytic anti Xa and amidolytic anti Ila

methods.
a.

Intravenous Studies

1.

Protamine Sulfate
The effect of protamine sulfate in a rabbit ear model of blood

loss is shown in Figure 32.

As previously described in methods, the

red blood cells resulting from 5 full thickness cuts in the medial
portion of the rabbit ear were collected in 1 liter of saline for 10
minutes at 37°c. The cells were counted using a HycelR cell counter and
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blood loss was reported as RBCs x 10 9/liter.

Protamine sulfate (2 and

3 mg/kg i.v.) did not increase blood loss as compared to control.
Figure

33.

demonstrates

protamine sulfate

ex vivo anticoagulant effect of

(2 and 3 mg/kg i.v.)

·determined by the APTT.
manner,

the

however this

administered to rabbits as

Protamine prolonged the APTT in a dose related
increase in clotting time was not significant

(p>.01) as determined by a one way ANOVA.
The effects of protamine sulfate administration to rabbits as
determined by

the

thrombin time,

HeptestR,

amidolytic anti Xa and

amidolytic anti Ila methods are shown in Table 10.

Protamine (2 and 3

mg/kg i. v.) did not prolong th.e clotting times to any great extent or
have any

effect on the amidolytic anti Xa or amidolytic anti Ila

assays.

2.

Heparin
The effect of heparin (1 and 2 mg/kg i.v.) is shown in Figure 34.

Heparin produced a

dose

related increase

in blood loss which was

significant (p <.05) as compared to control as determined by a one way

ANOVA.
The effects of heparin administration to rabbits as determined by
the APTT, thrombin time and HeptestR are shown in Table 11.

The high

doses of heparin used in the rabbit ear blood loss studies significant-

ly prolonged the clotting times to > 150 seconds for the APTT and
thrombin time and> 300 seconds for the HeptestR.
The ex vixo amidolytic anti Xa activity after heparin administration to rabbits is shown in Figure 35.

Heparin produced a dose related

inhibition of the amidolytic action of factor Xa.

Heparin (2 mg/kg
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i.v.) caused a significant (p <.05) inhibition of factor Xa as compared
to control as determined by a one way ANOVA.
Similarly, heparin inhibited the amidolytic action of factor Ila
in a dose related manner.

of

activity

heparin

after

~

Figure 36 shows the
intravenous

vivo anti Ila

administration

to

rabbits.

Heparin (1 and 2 mg/kg i.v.) significantly (p <.05) inhibited factor

Ila as compared to control as determined by a one way ANOVA.

Correlation

coefficients

were

calculated

to

determine

the

relationship between circulating pharmacodynamic activity and heparininduced blood loss.

Poor correlations (r-.690 for anti Xa and r-.564

for anti Ila) were obtained for the laboratory tests.
3.

CY 216
The effect of CY 216 (1, 2 and 3 mg/kg i. v.) in a rabbit ear

model of blood loss is shown in Figure 37.

related

increase

in blood loss.

CY 216

CY 216 produced a dose
(3 mg/kg i. v.)

produced

significant (p < 0.05) increase in blood loss as compared to control as
determined by a one way ANOVA.
The effects of CY 216 administered to rabbits as determined by
the APTT, thrombin time and HeptestR are shown in Table 12.

The high

doses of heparin used in the rabbit ear blood loss studies significantly prolonged the clotting times to > 150 seconds for the APTT and
thrombin time and> 300 seconds for the HeptestR.
The

~

vivo amidolytic anti Xa activity of CY 216 after ad-

ministration to rabbits is shown in Figure 38.

CY 216 increased the

inhibition of the amidolytic factor Xa activity in a dose related
manner.

Significant

(p<.05)

inhibition

of

amidolytic

factor

Xa
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activity was seen at the three doses studied (1, 2 and 3 mg/kg i.v.) as
compared to control as determined by a one way ANOVA.
Similarly, CY 216 produced a dose dependant inhibition of the
amidolytic action of factor Ila.

Figure 39 shows the ex vivo amido-

lytic anti Ila activity of CY 216 after administration to rabbits.

CY

216 (1, 2 and 3 mg/kg i.v.) significantly (p <.05) inhibited factor Ila
as compared to control as determined by a one way ANOVA.
Correlation

coefficients

were

calculated

relationship between circulating ex vivo
induced-blood

loss.

Poor

correlations

to

determine

activity and
were

obtained

the

the CY 216
(r-.515

for

HeptestR, r-.102 for anti Xa and r-.186 for anti Ila) for the various
laboratory tests.
4.

Protamine Antagonism of the Effects of Heparin and CY 216

a.

Intravenous Studies
The protamine antagonism of heparin (2 mg/kg i.v.) and CY 216 (2

mg/kg i.v.) induced blood loss is shown in Figure 40.
i.v.) produced a significant

(p <.05),

Heparin (2 mg/kg

(as determined by a two way

ANOVA), increase in blood loss as compared to control. The blood loss
induced by CY 216 was completely antagonized by an equigravimetric
amount of protamine, however a two fold gravimetric amount of protamine
was needed to completely antagonize the blood loss induced by heparin.
Ex

vivo

coagulation

parameters

as

determined

by

thrombin

time

and HeptestR obtained after heparin or

the

APTT,

CY 216

protamine administration in rabbits are shown in Table 13.

and

Although

the clotting times were significantly prolonged by heparin (2 mg/kg
i.v.) and CY 216 (2 mg/kg i.v.), protamine completely neutralized the
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,APTT activity at equigravimetric amounts of protamine and heparin or CY

216 .

The thrombin time activity was completely neutralized at a

gravimetric heparin (or CY 216) to protamine ratio of 1: 2.
protamine

(3

mg/kg

i.v.)

significantly

neutralized

the

Although
HeptestR

activity of heparin (2 mg/kg i. v.), CY 216 was not completely neutral-

ized at this dose.

Significant (p<.05), (as determined by a two way

ANOVA), activity remained after protamine (3 mg/kg i.v.) administration

to rabbits which received

CY 216 (2 or 3 mg/kg i.v.) as compared to

the control group.

The~ vivo amidolytic anti Xa activity after protamine neutralization of heparin or CY 216 administered to rabbits is shown in Figure
41.

Both heparin

and

CY

216

significantly

(p<.05)

inhibited the

amidolytic actions of factor Xa as determined by a two way ANOVA.
Protamine

(2 and 3 mg/kg i. v.)

completely neutralized the anti Xa

activity of heparin, however these doses of protamine did not complete-

ly neutralize the anti Xa activity of CY 216.

Significant (p<.05)

inhibition of factor Xa remained after protamine (2 and 3 mg/kg i.v.)
administration.

The ex vivo anti Ila activity after protamine neutral-

ization of heparin or CY 216 in rabbits is shown in Figure 42. Both
heparin and CY 216 caused a significant increase in the inhibition of
factor Ila. Protamine (2 and 3 mg/kg i.v.) completely neutralized this
activity.
The correlation coefficients obtained for residual activity after
heparin neutralization and blood loss are as follows: r-.421 for APTT,
r•.765 for thrombin time, r-.391 for HeptestR, r-0 for anti Xa and r-0
for anti Ila.

The correlation obtained for residual activity after CY
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216

neutralization and blood loss are as follows:

r-.576 for APTT,

t-9.812 for thrombin time, r-.460 for anti Xa and r- 0 for anti Ila.

b.

Subcutaneous Studies
Heparin and CY 216 (3 mg/kg s.c.) did not increase the blood loss

which was determined 2 hours after the administration of these agents.
,rotamine (3 mg/kg i.v.) administration to rabbits did not have any

additional effects on blood loss as shown in Figure 43.
The neutralization of heparin (3 mg/kg s.c.) and CY 216 (3 mg/kg
1

.c.) by equigravimetric protamine as determined by APTT, thrombin time

and HeptestR is shown in Table 14.

Although the clotting times were

elevated by heparin (3 mg/kg s. c.), protamine completely neutralized

the APTT and thrombin time activity at a gravimetric protamine to
heparin ratio of 1:1.

After administration of heparin (3 mg/kg s.c.)

the HeptestR clotting time was significantly prolonged (p<.05),
determined by a two way ANOVA).

Protamine (3 mg/kg i.v.) neutralized

the HeptestR activity to almost control levels.
did not prolong the APTT.

(as

CY 216 (3 mg/kg s.c.)

The thrombin time activity of CY 216 (3

• g/kg s. c.) was completely neutralized at equigravimetric protamine
dose

and CY 216

(3 mg/kg s.c.) significantly (p<.05) prolonged the

HeptestR, however, this activity was not neutralized by protamine (3

• g/kg i. V. )

•

The~ vivo amidolytic anti Xa activity after protamine neutralization of heparin or CY 216 in rabbits is shown in Figure 44.

Both

heparin (3 mg/kg s.c.) and CY 216 (3 mg/kg s.c.) exhibited significant
(P<.05) inhibition of amidolytic factor Xa activity as determined by a

two way ANOVA.

Heparin (3 mg/kg s.c.) produced an inhibition of the
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amidolytic action of factor Xa which was completely neutralized by
protamine (3 mg/kg i.v.) while, this activity of CY 216 (3 mg/kg s.c.)
was not completely neutralized.
The~ vivo amidolytic anti Ila activity after protamine neutralization of heparin or CY 216 in rabbits is shown in Figure 45.

Both

heparin (3 mg/kg s.c.) and CY 216 (3 mg/kg s.c.) exhibited significant
(p<.05) inhibition of amidolytic factor Ila activity as determined by a
two way ANOVA. The amidolytic anti Ila activity of heparin (3 mg/kg
s.c.) and CY 216 (3 mg/kg s.c.) was completely neutralized by protamine
( 3 mg/kg i. v. ) .
The numerical values for the data plotted in Figures 32-45 are
shown in Appendix XXIV.
5.

Protamine Administration to Primates
The time course of the anticoagulant effects of protamine (2 .1

mg/kg i. v.) administration to primates is shown in Figure 46.

This

dose of protamine had minimal effects on clotting as determined by the
APTT, thrombin time and HeptestR assays.
time

activity was

A slight decrease in thrombin

seen immediately after protamine

administration,

however this activity returned to control values by 30 minutes.
The time course of the antiprotease effects protamine (2.1 mg/kg
i. v.) in primates as determined by amidolytic anti Xa and anti Ila
assays is shown in Figure 47.

Protamine (2.1 mg/kg i.v.) had no effect

on amidolytic anti Xa activity,

however,

it produced a significant

increase (p<.05),(as determined by a two way ANOVA), in the inhibition
of factor Ila as compared to control values.

As

shown earlier in

Figures 46 and 4 7, the clotting and amidolytic methods were not very
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sitive to the effects of protamine sulfate.

In order to determine

the time course of protamine sulfate activity in primates,

ex vivo

plasma samples obtained from the primates administered protamine (2.1

mg/kg i.v.) were supplemented with heparin (25 µg/ml to obtain a final
•heparin concentration of 2. 5 µg/ml.

The degree of neutralization of

the HeptestR activity for the heparin (2.5 µg/ml) by protamine in the
exvivo plasma sample was an indirect measure of the circulating levels
of protamine activity.

48.

The results from this study are shown in Figure

At 5 minutes after supplementation a measurable amount decrease in

heparin activity suggesting protamine activity.

Statistical analysis

by a two way ANOVA revealed no significant differences

in HeptestR

activity at the dosages studied, however this data suggests that the
t1;2 of protamine is less than 30 minutes.
6.

Time Course of The Protamine Neutralization of Heparin and CY

216 in Primates
Protamine neutralization of the pharmacodynamic time course of
intravenously and subcutaneously administered heparin and CY 216 was
studied in the primate (Macaca mulatta) .
216 was determined using APTT,

Activity of heparin and CY

thrombin time,

anti Xa and amidolytic anti Ila methods.

HeptestR, amidolytic

Pharmacodynamic time course

parameters were calculated from concentrations obtained from HeptestR
and amidolytic

anti Xa

activity

data which was

extrapolated from

calibration curves of heparin or CY 216 supplemented to NMP.
a. Intravenous Administration
The time course of APTT activity of heparin (0. 7 mg/kg i. v.)
prior to and after neutralization by protamine sulfate ( 0. 7, 1. 4 and
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2 .1

mg/kg

heparin,

i. v. )

is

shown

in Figure

After

49.

administration of

the clotting time was > 150 seconds and remained elevated

above baseline until 3 hours after injection.
of APTT activity was

mg/kg i. v.

Complete neutralization

seen immediately after protamine sulfate

and 2 .1 mg/kg i. v.) administration.

However,

(1.4

significant

(p<.05) APTT activity remained 5 minutes after protamine (0. 7 mg/kg
i.V.)

administration

as

determined

by

a

two

way

ANOVA.

Partial

neutralization of the APTT activity of heparin by protamine sulfate
(0.7 mg/kg i.v.) was observed.
The time course of thrombin time activity of heparin (0.7 mg/kg

i.v.) prior to and after neutralization by protamine sulfate (0.7, 1.4
and 2 .1 mg/kg i. v.)

is shown in Figure 50.

After administration of

heparin, the clotting time was> 150 seconds and returned to baseline
at 6 hours.

Complete neutralization of thrombin time activity was

seen for protamine

(1. 4

and 2 .1 mg/kg i. v.)

at 60 minutes.

Wide

variation in the neutralization by protamine (0.7 mg/kg i.v.) was seen
during the first hour after protamine administration.
The time course of HeptestR activity of heparin (0.7 mg/kg i.v.)
prior to and after neutralization by protamine sulfate (0. 7, 1. 4 and
2.1 mg/kg i.v.) is shown in Figure 51.

After administration of heparin

(0.7 mg/kg i.v.), the clotting time was> 300 seconds and returned to
baseline values by 6 hours.

Protamine sulfate substantially neutral-

ized the HeptestR activity of heparin (0.7 mg/kg i.v.).

Complete

neutralization of HeptestR activity by protamine (2 .1 mg/kg i. v.) was
seen at 1 hour while complete neutralization of HeptestR activity by
protamine (1.4 and 0.7 mg/kg i.v.) occurred by 3 hours.
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The time course of the amidolytic anti Xa activity of heparin
(0.7 mg/kg i.v.) prior to and after neutralization by protamine sulfate
(0.7, 1.4 and 2.1 mg/kg i.v.) is shown in Figure 52.

After administra-

tion of heparin (0.7 mg/kg i.v.), the% inhibition of amidolytic factor
xa activity was 92% which returned to baseline activity by 6 hours.
Dose dependant protamine neutralization of this anti Xa activity was
seen.
The time course of the amidolytic anti Ila activity of heparin
(0.7 mg/kg i.v.) prior to and after neutralization by protamine sulfate
(0.7, 1.4 and 2.1 mg/kg i.v.) is shown in Figure 53.

After administra-

tion of heparin (0.7 mg/kg i.v.) the% inhibition of factor Ila was 91
% which did not completely return to baseline until 6 hours. At the 3
hour time period, complete neutralization of the
activity of heparin was
administered.

seen with all doses

amidolytic anti Ila
of protamine

sulfate

The time course of APTT activity of CY 216 (0. 7 mg/kg

i.v.) prior to and after neutralization by protamine sulfate (0.7, 1.4
and 2.1 mg/kg i.v.) is shown in Figure 54.

CY 216 (0.7 mg/kg i.v. and

0. 35 mg/kg i. v.) prolonged the clotting time to a lesser degree than
heparin at the same dose.

Complete neutralization of the APTT activity

of CY 216 was seen after the administration of protamine (0.7, 1.4 and
2 . 1 mg/kg i. V. )

•

The time course of thrombin time activity of CY 216 (0. 7 mg/kg
i.v.) prior to and after neutralization by protamine sulfate (0.7, 1.4
and 2 .1 mg/kg i. v.) as shown in Figure 55.

CY 216 (0. 7 mg/kg i. v.)

prolonged the clotting time to a lesser degree than heparin at the same
dose.

While neutralization of the thrombin time activity of CY 216 was
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seen after the administration of protamine (1.4 mg/kg i.v.).

Complete

neutralization of thrombin time activity by protamine (0.7 mg/kg i.v.)
was seen at 1 hour.
The time course of HeptestR activity of CY 216 (0.7 mg/kg i.v.)
prior to and after neutralization by protamine sulfate (0. 7, 1. 4 and
2 .1 mg/kg i. v. )

is shown in Figure 56.

prolonged the HeptestR to> 300 seconds.

CY 216

(0. 7 mg/kg i. v.)

CY 216 (0.7 mg/kg i.v.) did

not prolong the HeptestR to the same extent as did the same concentrations of heparin.

Protamine sulfate (0.7, 1.4 and 2.1 mg/kg i.v.) did

not neutralize the HeptestR activity of CY 216 to any significant
extent.
The time course of the amidolytic anti Xa activity of CY 216 (0.7
mg/kg i. v. ) prior to and after neutralization by protamine sulfate
(0.7, 1.4 and 2.1 mg/kg i.v.) is shown in Figure 57.

Inhibition of the

amidolytic actions of factor Xa by CY 216 (0.7 mg/kg i.v.) was seen for
over 6 hours.

Dose dependant neutralization of this activity of CY 216

was seen by protamine

( 0. 7 mg/kg i. v. ) .

Statistically significant

(p<. 05) differences in neutralization were seen after protamine (0. 7
mg/kg i.v.) and protamine (2.1 mg/kg i.v.) as determined by a two way

ANOVA.

Complete neutralization of the factor Xa inhibition was not

seen at these doses of protamine studied.
The time course of amidolytic anti Ila activity of CY 216 (0. 7
mg/kg i. v. ) prior to and after neutralization by protamine sulfate
(0.7, 1.4 and 2.1 mg/kg i.v.) is shown in Figure 58.

Inhibition of the

amidolytic action of factor Ila by CY 216 (0.7 mg/kg i.v.) was seen at
3 hours.

Dose dependant neutralization of the anti II activity of CY
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216 (0.7 mg/kg i.v) was seen, with complete neutralization of anti Ila
activity at 3 hours.

With protamine (0.7 mg/kg i.v.), a slight rebound

of anti Ila activity which returned to baseline after 3 hours.
b.

Subcutaneous Studies
The

time

course of HeptestR activity after administration of

heparin (0.7 mg/kg s.c.) prior to and after neutralization by protamine
sulfate (0. 7 mg/kg i. v.) as shown in Figure 59.

Protamine was ad-

ministered at 4 hours, at a time when the heparin activity was strong.
complete neutralization of the HeptestR activity of heparin was seen at
this time.
As shown in Figure 60,

CY 216 was not readily neutralized by

protamine sulfate in the HeptestR assay.
amount

of

protamine

sulfate

did

subcutaneously administered CY 216.

not

Even two fold gravimetric

neutralize

this

activity of

At 9 hours, after the administra-

tion of protamine the HeptestR clotting time was prolonged to almost
two times the baseline levels.
The time course of the neutralization of heparin (0.7 mg/kg s.c.)
as shown in Figure 61.

Low levels of amidolytic anti Xa inhibition

were noted after the administration of heparin (0.7 mg/kg s.c.) and no
changes in the amidolytic anti Xa activity after protamine administration of this activity was seen.

Heparin contains less low molecular

weight components than CY 216 and therefore exhibits less anti Xa
activity after subcutaneous administration.
The

time

course of

activity of CY 216

the neutralization of amidolytic anti Xa

(0.7 mg/kg s.c.)

is shown in Figure 62. After

protamine administration, at 4 hours, CY 216 inhibited the amidolytic
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anti Xa activity approximately 50 %.

As time continued, this activity

of the group of primates which received protamine closely followed the
time course of the group which received CY 216 (0.7 mg/kg s.c.). This
data suggests that protamine initially neutralized the anti Xa activity
of CY 216 but failed to neutralize the activity of CY 216 which was
absorbed at a later time period.
c. Pharmacodynamic Time Course Parameters
Pharmacodynamic time course parameters were calculated using a
noncompartmental model as previously described in methods.

Concentra-

tions (µg/ml) were obtained after extrapolation from calibration curves
of anti Xa or HeptestR activity of heparin and CY 216 after supplementation to NMP.
The numerical values for the data plotted in Figures 49-62 are
shown in Appendix XXV.
1.

Anti Xa

a. Intravenous Studies
The

pharmacodynamic

time course parameters

for heparin

(0. 35

mg/kg i.v). and CY 216 (0.35 mg/kg i.v). as calculated from amidolytic
anti Xa activity data are shown in Table 15.
parameters reveal that the AUC:
heparin, Clp: heparin> CY 216

A comparison of these

CY 216 > heparin , MRT:

and Vd: heparin> CY 216.

CY 216 >

The AUC, MRT

and Clp of CY 216 were significantly (p<.05) than the similar parameters for heparin as determined by an unpaired student's t test.
Table 16 shows the pharmacodynamic time course parameters for
heparin (0.7 mg/kg i.v). and CY 216 (0.7 mg/kg i.v.) as calculated from
amidolytic anti Xa activity data.

A comparison of these parameters
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reveal that the AUC: heparin> CY 216, MRT: CY 216 > heparin, Clp: CY
216 > heparin, Vd: CY 216 > heparin.

However there was no significant

(p>.10) difference between the AUC, MRT, Clp and Vd values of heparin
(0. 7 mg/kg i. v).

and CY 216

(0. 7 mg/kg i. v.)

as determined by an

unpaired student's t test.
When protamine sulfate was administered in equigravimetric doses
to heparin (0. 7 mg/kg i. v.) or CY 216 (0. 7 mg/kg i. v.), the

pharm-

acodynamic time course parameters obtained are shown in Table 17.

A

comparison of these parameters revealed that the AUC: CY 216 > heparin,

MRT: CY 216 > heparin, PNI: heparin> CY 216.

However, AUC and PNI

values after equigravimetric neutralization of heparin or CY 216 by

protamine (0.7 mg/kg i.v.) were significantly different as determined
by an unpaired student's t test.
When protamine sulfate (1.4 mg/kg i.v.) was administered in a two
fold gravimetric dose to heparin (0.7 mg/kg i.v.) or CY 216 (0.7 mg/kg
i.v.), the pharmacodynamic time course parameters obtained are shown in
Table 18.

A comparison of these parameters revealed that following:

AUC: CY 216 > heparin, MRT: CY 216 > heparin and PNI: heparin> CY 216.
The AUC of CY 216 (0.7 mg/kg i.v.) and protamine (1.4 mg/kg i.v.) was
significantly greater (p <.05) than the AUC of heparin (0.7 mg/kg i.v.)
and protamine (1.4 mg/kg i.v.) as determined by an unpaired student's t
test.

The PNI was also significantly (p<.05) greater

for heparin (0.7

mg/kg i.v) and protamine (1.4 mg/kg i.v.) than CY 216 (0.7 mg/kg i.v.)
and protamine (1.4 mg/kg i.v.).
When protamine sulfate

(2 .1 mg/kg i. v) was administered in a

three fold gravimetric dose of heparin (0.7 mg/kg i.v.) and CY 216 (0.7
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mg/kg

i.v.),

the

primate

pharmacodynamic

obtained are shown in Table 19.
revealed that following:

time

course

parameters

A comparison of these parameters

AUC: CY 216 > heparin, MRT: heparin> CY 216,

and PNI: heparin > CY 216.

The AUC of CY 216 (0. 7 mg/kg i. v.) and

protamine (2 .1 mg/kg i. v.) was significantly greater (p<. 05) than the
AUC of heparin (0. 7 mg/kg i. v.) and protamine (2 .1 mg/kg i. v.) as
determined by an unpaired student's t test.

The PNI was significantly

greater (p<.05) for heparin (0.7 mg/kg i.v.) and protamine (2.1 mg/kg
i.v.) than for CY 216 (0.7 mg/kg i.v) and protamine (2.1 mg/kg i.v.).
In

summary,

while

studying

administered heparin and CY 216,

the

neutralization

intravenously

the AUC of CY 216 was generally

greater than the AUC of heparin after neutralization by protamine
sulfate.
heparin,

In most cases the MRT of CY 216 was longer than that of
in most cases.

After protamine administration,

the PNI of

heparin was greater than the PNI of CY 216 which indicated that heparin
was more neutralizable than CY 216 as determined by the anti Xa method.
b. Subcutaneous Studies
The pharmacodynamic time course parameters for heparin (0.7 mg/kg
s.c.) and CY 216 (0.7 mg/kg s.c.) as calculated from amidolytic anti Xa

activity data are shown in Table 20.

A comparison of these parameters

revealed that the AUC: CY 216 > heparin, MRT: CY 216 > heparin, Clp:
heparin> CY 216, and Vd: heparin> CY 216.
CY 216

(0.7 mg/kg s.c.)

The AUC, MRT, Clp, Vd of

were significantly different

(p<.05)

than

similar parameters of heparin (0. 7 mg/kg s. c.) as determined by an
unpaired student's t test.
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When protamine

was

administered

in equigravimetric

doses

to

primates which received heparin (0.7 mg/kg s.c.) or CY 216 (0.7 mg/kg
s.c.), the following pharmacodynamic time course parameters which were

obtained are shown in Table 21. A comparison of these parameters reveal
that the AUC: CY 216 > heparin, MRT: heparin> CY 216, PNI:
CY 216.

heparin>

The AUC of CY 216 was significantly (p<.05) greater than the

AUC of heparin as determined by an unpaired student's t

test.

No

significant differences were seen between the other pharmacodynamic
time course parameters.
When protamine was administered in two fold gravimetric doses to
primates given CY 216, the pharmacodynamic time course parameters which
were obtained are shown in Table 22.

There was no difference in the

time course parameters of CY 216 (0.7 mg/kg s.c.) and protamine (0.7 or
1. 4 mg/kg i. v. ) .
2. HeptestR

a. Intravenous Studies

The pharmacodynamic time course parameters

for heparin

(0. 35

mg/kg i. v.) and CY 216 (0. 35 mg/kg i. v.) as calculated from HeptestR

activity data are shown in Table 23.

A comparison of these parameters

reveal that the AUC: CY 216 > heparin, MRT:

CY 216 > heparin, Clp:

heparin> CY 216, Vd: heparin> CY 216. Significant differences were
seen for AUC, MRT (p<.05) and Clp (p<.05) of heparin and CY 216 as

determined by an unpaired student's t test.
The pharmacodynamic time course parameters for heparin (0.7 mg/kg
1. v.) and CY 216 (0. 7 mg/kg i. v.) as calculated by the HeptestR are
shown in Table 24.

A comparison of these parameters reveal that the
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AUC: CY 216 > heparin, MRT: heparin> CY 216, Clp: heparin> CY 216,
Vd:

heparin > CY 216.

Significant

(p<.05)

differences were

seen

between the AUC and MRT values of heparin (0.7 mg/kg i.v.) and CY 216

(0.7 mg/kg i.v.) as determined by an unpaired student's t test.
'When protamine sulfate was administered in equigravimetric doses
to heparin (0.7 mg/kg i.v.) and CY 216 (0.7 mg/kg i.v.), the

pharmaco-

dynamic time course parameters which were obtained are shown in Table
25.

A comparison of these parameters reveal that the AUC:

>heparin, MRT: CY 216 > heparin, PNI: heparin - CY 216.

CY 216

However, the

AUC was the only parameter of CY 216 which was significantly (p<.05)
different from heparin as determined by an unpaired student's t test.
'When protamine sulfate was administered in twice

gravimetric

dosages to heparin (0. 7 mg/kg i. v.) and CY 216 (0. 7 mg/kg i. v.) the
following primate pharmacodynamic time course parameters were obtained
as shown in Table 26. A comparison of these parameters reveal that the

AUC: CY 216 >heparin, MRT: heparin> CY 216, PNI: heparin> CY 216.
the AUC,

MRT and PNI values of CY 216

administration

of

two

fold

gravimetric

(0.7 mg/kg i.v.) after the
amounts

of protamine were

significantly (p<.05) different as determined by an unpaired student's
t test.
When protamine sulfate was administered in three times gravimetric dosages to heparin (0.7 mg/kg i.v.) and CY 216 (0.7 mg/kg i.v.)
the

following

primate

pharmacodynamic

obtained as shown in Table 27.

time

course

parameters were

A comparison of these parameters reveal

that the results are AUC: CY 216 >heparin, MRT: CY 216 > heparin, PNI:
heparin> CY 216.

After protamine (2.1 mg/kg i.v.) neutralization of
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heparin (0.7 mg/kg i.v.) and CY 216 (0.7 mg/kg i.v.) the AUC and PNI of
CY 216 was significantly (p<.05) different than for heparin.
b. Subcutaneous Studies
The pharmacodynamic time course parameters for heparin (0.7 mg/kg
s.c.) and CY 216 (0.7 mg/kg s.c.) as calculated from HeptestR activity

data are shown in Table 28.

A comparison of these parameters reveal

that the AUC: CY 216 > heparin, MRT:heparin > CY 216, Clp: heparin> CY
216, Vd: heparin - CY 216. The AUC was the only parameter which was
significantly (p<.05) different between the heparin and CY 216 groups.
Bioavailability after subcutaneous administration of heparin and CY 216
as determined by the amidolytic anti Xa assay was calculated.

CY 216

(0.7 mg/kg s.c.) exhibited 80% greater bioavailability than heparin
(0.7 mg/kg s.c.)
The pharmacodynamic time course parameters for heparin (0.7 mg/kg
s.c.) with protamine (0.7 mg/kg i.v.) and CY 216 (0.7 mg/kg s.c.) with

protamine (0.7 mg/kg i.v.) as calculated from the HeptestR method are
shown in Table 29.

A comparison of these parameters reveal that the

results are AUC: CY 216 > heparin, MRT:
heparin> CY 216.
and PNI

CY 216 > heparin and PNI:

Significant (p<.05) differences between the AUC, MRT

of heparin and CY 216 were observed as determined by an

unpaired student t test.
The primate pharmacodynamic time course parameters obtained when
protamine (1.4 mg/kg i. v.) was administered to primates given CY 216
(0. 7 mg/kg s. c.) are shown in Table 30.

A comparison of these para-

meters reveal that the AUC < for CY 216 (0.7 mg/kg s.c.) and protamine
(0.7 mg/kg i.v.) than for CY 216 (0.7 mg/kg s.c.) and protamine (1.4
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mg/kg i.v.) than when equigravimetric protamine was given to neutralize
CY 216 (0.7 mg/kg s.c.).

The MRT and PNI were slightly increased as

compared to CY 216 (0.7 mg/kg s.c.) and protamine (0.7 mg/kg i.v.).
7. Comparative% Neutralization of Heparin and CY 216 in the
Animal Models
Per cent neutralization values of the ex vivo activities obtained
in

the

animal

methods.

models

were

calculated

as

previously

described

in

These calculations provided a means of comparison of the

degree of neutralization observed in the animal models at the various
doses studied. Per cent neutralization values which were calculated at
gravimetric

protamine

to heparin

ratio

of 1:1,

2:1

and

3:1 were

compared for the intravenous studies are shown in Table 31 (anti Xa)
and Table

32

(anti

Ila).

Per cent neutralization values for the

subcutaneous studies are shown in Table 33 (anti Xa) and Table 34 (anti
Ila).

Lower

% neutralization values

were

observed

for

CY

216

as

compared to heparin as determined by the amidolytic anti Xa and anti
Ila assays.

In rabbits, the amidolytic anti Ila activity was complete-

ly neutralized at a gravimetric protamine to heparin ratio of 2: 1,
while the amidolytic anti Xa activity was not completely neutralized.
After subcutaneous
neutralization
administration.

administration of heparin a decreased amount of

was observed for most cases as compared to intravenous

CHAPTER V
DISCUSSION
Heparin has been used effectively as an antithrombotic drug for
over 50 years, however its multicomponent structure makes the complete
elucidation of its mechanism of action difficult.
is

heterogenous

molecular size

with

respect

to

(Andersson 1979),

internal

Commercial heparin

structure

(Casu

1984),

degree of sulfation (Hurst et al.

1979) and anticoagulant activity (Hurst et al. 1981). The molecular
heterogeneity within heparin preparations contributes to the complexity
of the interaction of this drug with components of the hemostatic
system.

Heparin

interacts

with

platelets

(Salzman 1980),

plasma

proteins (Rosenberg et al. 1985) and the endothelium (Barzu 1985) and
depending upon the dose and route of administration produces anticoagulant, antithrombotic or antihemostatic effects.
The anticoagulant effects of heparin are the result of heparin
forming a complex with AT III and inhibiting activated coagulation
factors via this plasma cofactor.
used for many years
global tests such as

This activity of heparin has been

to monitor heparin therapy through the use of
the APTT and thrombin time.

heparin is differentially related to molecular weight.

This effect of
Anticoagulant

activity decreases with decreasing molecular weight while both low and
high molecular weight heparins can exert antithrombotic activity.
The antithrombotic effects of heparin are related to the ability
of heparin to

inhibit thrombus

formation
128

in vivo.

Components

of

r
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heparin with high affinity to antithrombin III can exert antithrombotic
effects and low affinity heparin can potentiate these effects_ (Barrowcliffe 1984).
Antihemostatic

effects

of

heparin

occurring

after

high

dose

administration may result from the inhibition of coagulation enzymes
and platelets and cause bleeding. The antihemostatic effects of heparin

are influenced by a number of variables including dose and patient
characteristics.
Fractionation and depolymerization of heparin by a variety of
techniques (Casu 1985) results in the production of heparin derivatives
with a

decreased molecular weight,

an increased ability to

factor Xa and a decreased ability to inhibit thrombin.

were developed
antithrombotic

in order
activity

that

the

inhibit

These compounds

heparin derivatives would retain

and exhibit reduced hemorrhagic potential.

Low molecular weight heparins are currently being developed clinically
for the prophylaxis and therapy of thrombosis (Samama 1989) and these
therapeutic agents exhibit certain advantages as compared to heparin.
At equivalent doses,
compared to

standard heparin in man

Huebner et al.
daily

1984;Turpie et al.

subcutaneous

compared to

they cause a decreased amount of blood loss as

injections

for

(Kakaar et al.

1985;

Schmitz-

1986) and they only require once
the prophylaxis

of thrombosis

as

2-3 times daily for heparin.

Low molecular weight heparins

exhibit decreased anticoagulant

activity per mg as determined by clotting tests such as the APTT and
thrombin time.
ules

with

a

These agents contain a decreased proportion of molecmolecular

weight > 5600

daltons which is

the minimum
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molecular weight required to inhibit thrombin.

The degree of prolong-

ation of the APTT by heparins is related to the% of compounds of low
molecular

weight

heparin with

a

molecular

weight

less

than

5600

daltons.
A large proportion of the molecules contained within low molecular
weight heparins inhibit factor Xa.

This factor occupies a central

position in the coagulation cascade where the extrinsic and intrinsic
pathways meet to form the common pathway of coagulation.

v,

Factors Xa,

phospholipid and ca+ 2 form the prothrombinase complex which is

involved in the formation of thrombin.
exhibit

antithrombotic

actions

through

Low molecular weight heparins
the

inhibition of

generation, while unfractionated heparins, inhibit

thrombin

thrombin generation

in addition to thrombin activity.
Low molecular weight heparin produce less antihemostatic effects
than equivalent dosages of heparin (Kakaar et al. 1986).

This decrease

in blood loss may be related to a decreased proportion of components
with high molecular weight and high charge density contained within the
low molecular weight heparin.

These components are reported to inhibit

thrombin and collagen-induced platelet aggregation (Cade 1984).
Although the use of low molecular weight heparin is associated
with less bleeding than heparin, under certain circumstances it may be
necessary to neutralize the blood loss induced by low molecular weight
heparin.

These instances include: overdose or reversal of anticoag-

ulation following procedures involving extracorporeal circulation such
as cardiopulmonary bypass and hemodialysis for renal failure.

Although

protamine

bleeding

is

administered

specifically

to

neutralize

the
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induced

by

heparin,

protamine

also

influences

the

anticoagulant,

antiprotease and antithrombotic activities of the heparins.
Protamine has been used for many years to neutralize the bleeding
induced by heparins,

and protamine antagonism of heparin has been

associated with a variety of adverse effects.

In addition, assays with

increased sensitivity toward low molecular weight heparins have been
developed which

can

detect

activities

completely neutralizable by protamine.
exhibit

a

differential

(Racanelli et al.

degree

of

of

heparins

which

are

not

Protamine has been shown to

neutralization

in

these

assays

Although in vitro assays are useful to

1985) .

predict the hemorrhagic potential of heparins, the relevance of ex vivo
laboratory parameters of experimental animals and patients receiving
heparin and protamine requires further investigation.
Preliminary

in vitro

studies

(Racanelli

et

al.

1985)

have

demonstrated that low molecular weight heparins exhibit characteristic
protamine neutralization profiles which differ significantly from the
neutralization

profiles

of

heparin.

In

addition,

the

protamine

neutralization profile of heparin and low molecular weight heparins are
assay dependant.

After supplementation of heparin and CY 216 in vitro

to NHP, the clotting and anti Ila activities of the heparins are more
readily neutralized by protamine than the anti Xa activities of the
heparins.
A variety of approaches utilizing in vitro assays and in vivo
models of thrombosis and bleeding were used to study the antagonism of
heparin and CY 216 by protamine. The in vitro assays were targeted to
different sites

in the

coagulation cascade

in order

to provide a

132
sensitive means of determining the activity of the heparins.

Animal

models of thrombosis with differing activation mechanisms, and animal
aodels of bleeding were utilized to address the in vivo antagonism of

heparins.

'in

This integrative approach was used to determine whether the

vivo neutralization profiles of heparin and CY 216 were similar and

whether partial neutralization of low molecular weight heparins which
was observed in vitro contributes

to hemorrhagic or antithrombotic

The current study also

determined whether protamine ad-

effects.

ministration

altered the pharmacodynamic time

heparin and CY 216.

An integrated approach

course parameters of
to the study of the

neutralization of heparin and CY 216 has provided information on the
endogenous behavior of the heparins after antagonism by protamine which

aay

influence the management of patients undergoing antithrombotic

therapy.
A. The Assessment of the Potency of Heparins

When heparin was first introduced into therapeutic use,

its in

yitro anticoagulant action was equated with its in vivo antithrombotic
effects.
ideal

However, the mechanism of action of heparin is complex and an

assay

for

heparin has

not

yet

been

developed.

"Laboratory

evaluation of the efficacy of heparin therapy is an inherently complex
problem, as it entails the assessment of the effects of a variable and
heterogenous mixture of substances on a complex biological system whose
actions and interactions are incompletely understood"
The assays in routine use for

(Gawoski 1987).

determining heparin potency are

either based upon the overall anticoagulant activity of heparin or on
specific properties of heparin such as the inactivation of thrombin or
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factor Xa (Dawes et al. 1986.) .

The APTT remains the most commonly

used assay for monitoring heparin effects, however it is less sensitive
to the

effects of low molecular weight heparin since

it measures

thrombin inhibition rather than the inhibition of the other activated
coagulation factors such as factor Xa.

An amplification mechanism

within the coagulation cascade exists such that a ten fold fold molar
increase occurs at each step in the cascade and only a low level of
thrombin

is

required

to

generate clot

formation

(McFarlane

1964).

Nearly a complete inhibition of factor Xa which is generated during
clotting is required to inhibit thrombin generation, therefore the APTT
may be more sensitive to components of heparin which inhibit thrombin
rather than factor Xa (Ofosu et al. 1985).

Plasma based global assays

such as APTT which use physiologic concentrations of activators and
inhibitors may be more sensitive to agents which inhibit thrombin as
opposed to the other coagulation factors.
Recently, more specific tests have been developed where activated
enzymes are supplemented to heparinized plasma in order to identify the
various sites of heparin action.

The HeptestR which was developed by

Yin (1983), represents a modified version of the APTT which is more
sensitive to low molecular weight heparins since exogenous factor Xa is
used.

This clot based anti Xa/Ila method, may have an advantage over

amidolytic assays in that it utilizes undiluted plasma and a clotting
endpoint.

Arnidolytic assays have been useful in the study the neutral-

ization of heparins and have added a degree of specificity in the
determination of coagulation enzyme inhibition.

Isolated enzyme assay

systems, however, may not reflect the physiologic or true function of
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the coagulation enzymes and inhibitors because they use diluted plasma
and synthetic substances.

It was necessary, therefore in these studies to determine heparin
concentration indirectly by using assays which measure heparin activThe in vitro clotting assays were used in these studies to

·ity.

determine the collective action of the heparins on the coagulation
system.

Although these assays are similar in their method of end point

detection (clot

formation),

they differ

in the sensitivity to the

various sites within the coagulation cascade to which the heparins are
targeted.

The APTT measures the intrinsic system, the thrombin time

assay measures the conversion of fibrinogen to fibrin and the HeptestR

measures the collective inhibitory effects at the level of factor Xa
and factor Ila.

The amidolytic anti Xa and amidolytic anti Ila assays,

on the other hand, measure the specific ability of the heparins to
inhibit the amidolytic activity of factor Xa or factor Ila.
B.

Selection of Doses Used in the Studies
Gravimetric

amounts

of

heparin,

CY

216

and

protamine

compared in the in vitro assays and in the animal models.

were

Adminis-

tration of the drugs was carried out in gravimetric amounts for several
reasons.

First,

administration of polycomponent drugs on a unitage

basis introduces a bias toward the specific activity on which the unit

is based.

Studies by Fareed et al.

(1988) have shown that potency

adjustment of low molecular weight heparins based upon amidolytic anti
Xa activity does not minimize the variations of the heparins observed
in other in vitro assays or in animal models of thrombosis and bleed-

ing.

Second, it is not appropriate to administer molar amounts of the
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Using the mean molecular weight to calculate approximate

heparins.

molar amounts of an equigravimetric amount of CY 216 and heparin, it
was

found

molecules

that

CY

216

as heparin.

contains

approximately

twice

However,

since heparin and CY 216 are dis-

tributed over a fairly wide molecular weight range,
was not very accurate.

Furthermore,

in addition

the

number

of

this calculation
to

containing

a

heterogenous mixture of components with varying chain lengths, heparins
also exhibit internal structural microheterogenity since all heparin
components do not contain the identical chemical sequences (Casu 1985).
Differences are noted in the degree of sulfation (Hurst

1979) and

affinity toward AT III (Casu 1985) of the individual heparin molecules.
A series of experiments were performed in order to investigate
the feasibility of using molar amounts in the study of the antagonism
of heparin and CY 216.

A laser-induced thrombosis model was used for

these studies.

One mg amounts of heparin and CY 216 were converted to

apparent molar

amounts,

as

shown

in Appendix XVI,

quantity of protamine was administered to rats.

and

this

molar

No additional inform-

ation about the comparative protamine neutralization of heparin and CY
216

was

obtained when

equimolar amounts.
molar
degree

amounts

the

drugs

led to

doses

in

completely opposite conclusions

of

these

drugs

equivalent molar amounts were used
heparin appeared

administered

approximate

In fact, comparisons of heparins based on apparent

of protamine neutralization

gravimetric

were

to be

activity of CY 216.

of heparin
are

and CY

administered.

regarding the
216

as

when

When apparent

the antithrombotic activity of

less neutralizeable

than the

anti thrombotic

As our studies have demonstrated using the rabbit
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stasis thrombosis model and as others have reported (Dinness 1986), the

antithrombotic effects of heparin were neutralized to a greater degree
than the antithrombotic effects of low molecular weight heparins by
protamine.

In addition,

the

therapeutic

use

of heparin

involves

administration of U/mg amounts of heparin to gravimetric amounts of
protamine.
The doses which were used in the animal experiments were selected
in order that the plasma concentrations were in the approximate range
of clinically used heparin and protamine.

Appendix XVII shows the

doses used in the animal models and the doses of heparin and protamine

used for cardiopulmonary bypass at Foster G. McGaw Hospital.

Higher

doses (1-3 mg/kg) of heparin and CY 216 were required to induce blood
loss in the animal models than were required to inhibit thrombosis (25100 µg/kg). The doses used in the rat tail bleeding model and rabbit
ear blood loss model were in the approximate range of doses which are
used during cardiopulmonary bypass procedures.

The gravimetric ratio

of protamine:heparin of 1.4:1 which was used in the primate studies was
similar to the ratio of protamine to heparin which is used clinically
(1.3 mg of protamine to 1 mg of heparin).
C.

Molecular Weight Determination
Gel permeation chromatography was used to determine the molecular

weight profiles of heparin, CY 216 and protamine.

This technique has

been previously utilized to determine the molecular weight of glycosaminoglycans
molecular

(Losito
weight

et
of

al.

1981)

polycomponent

and was

useful

compounds

since

relies almost exclusively on size for separation.

to

determine

this

the

procedures

Although the elution
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profiles of both heparin and CY 216 were bell-shaped,

the molecular

weight distribution of CY 216 was narrower than that of heparin.
The frequency and molecular weight distribution averages of heparin and
CY 216 were also determined.

Although the molecular weight distri-

bution profile of protamine was narrower

than the heparins,

the

elution profile of protamine was characteristic of a compound containing more than one chemical species.

Of the three compounds, CY 216

exhibited the lowest mean molecular weight (5400 daltons), followed by
protamine (4,000 daltons) then heparin (11,000 daltons).

Determination

of the molecular weight of these agents was important in the understanding of their interactions.
D.

NMR Spectra of Heparin, CY 216 and Protamine
Until recently, the complete analysis of the 1H NMR spectrum of

heparin has not been feasible since several signals overlap heavily
even at resolutions at 270 MHz instruments.
signal broadening due

to

Another problem has been

the effect of the viscosity of the con-

centrated solutions used for the NMR analysis (Gatti et al.

1979).

Casu and coworkers have used a resolution enhancement method which was
originally utilized for the study of proteins,
proton signals.

to assign all of the

This approach has now provided us with a complete

elucidation of the structure of heparin.
In collaboration with Casu and coworkers, we have compared the 1H
NMR. spectra of heparin and CY 216.

While the NMR spectra of heparin

was consistent with the known structure of heparin, CY 216 exhibited
signals which differed from heparin signals.

These signals of CY 216
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were

characteristic

of

the

presence of anhdromannose

residues

and

partial desulfation.
Utilizing

this

technique,

it

was

demonstrated

that

heparin

induces a spectral shift in the 3.3-3.6 ppm region after complexation
with protamine.

This finding has not been previously reported and

requires

validation.

further

The

nature

of

this

shift with

low

molecular weight heparins may provide some useful information on the
interaction and binding region of heparins with protamine.
E.

In Vitro Studies on Heparin and CY 216 and Their Interaction with

Protamine
1.

Comparison of Pooled Animal Plasma Preparations
The focus of this dissertation was to use established animal

models of bleeding and thrombosis and extrapolate the results to the
human plasma response.

Since the animal models used in the studies

incorporated three different animal species (rats,

rabbits and pri-

mates) it was necessary to compare the in vitro baseline responses of
the plasma preparations in the clotting and amidolytic assays to a
standard normal human plasma preparation.

A study of in vitro baseline

responses of the plasma preparations facilitated the evaluation of the
~

vivo results.
The APTT, thrombin time and HeptestR activity of NratP differed

significantly (p<.05) from NHP as determined by a one way ANOVA.

The

thrombin time and HeptestR baseline values were elevated while the APTT
baseline values were decreased as

compared to NHP.

The baseline

clotting values for NRP were elevated as compared to NHP and the degree
of this

elevation was

dependant on the individual clotting tests.
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These differences may be related to compositional variations between
the plasma preparations.
that of NHP.

The composition of NRP differs greatlr from

All coagulation factors

of NRP except factor X and

fibrinogen are elevated 2 to 18 fold as compared to NHP
1987).

(Walenga

Nonhuman primates demonstrate marked similarities to humans in

almost all aspects of their anatomy, endocrinology and physiology and
these similarities underlie the value of these animals for appropriate
studies in neurobiology, immunology, pathology, cardiology and psychology (King et al.

1989).

Evaluation of baseline clotting values

confirmed reports that the clotting activity of NHP and NMP was very
similar.
2.

The In Vitro Effects of Protamine on Plasma
In vivo administration of protamine has been reported to in-

fluence the hemostatic system in a variety of ways.
reported

to

decrease

fibrinogen

levels

(Gans

Protamine has been
1962;

Godal

1960),

aggregate platelets by direct effects (Eika et al. 1972) and produce
thrombocytopenia and leukopenia (Al-Mondhiry 1985, Eika et al. 1971).
However, Ellison et al. (1971) have shown that overdoses of protamine
(800 mg/70 kg) had minimal effects on the coagulation mechanisms of
both patients and volunteers.

Therefore studies were carried out in

order to determine whether protamine had any effect on the in vitro
clotting tests and amidolytic assays used in these studies.

This

information was needed in order to evaluate the~ vivo data.

After

administration of

2 drugs

such as

heparin and protamine,

it was

necessary to determine the individual contribution of each drug to the
prolongation of clotting time and amidolytic activity.

The APTT was
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significantly (p<.05) prolonged,

(as determined by a one way ANOVA)

after the in vitro supplementation of protamine (100 µg/kg i. v.) to
NHP,

NMP,

NRP and NratP.

The extent of the prolongation of the

clotting times of the plasma preparations was similar.
In order to test the effect of high concentrations of protamine
on the laboratory assays, protamine (1 mg/ml and 10 mg/ml) was supplemented to NHP.

Protamine sulfate (1 mg/ml) prolonged the APTT to> 150

seconds, however, had no effect on the other tests.
of protamine is much greater than is routinely

This concentration
achieved clinically.

Protamine (10 mg/ml) significantly prolonged all of the clotting tests
and exhibited
protamine
turbid.

at

inhibition of amidolytic anti Xa activity,
this

concentration also

caused

the

however,

plasma to become

The effects of protamine may be nonspecific and it is unlikely

that these effects of protamine occur under physiological conditions.
The APTT was most sensitive

to

the anticoagulant effects of

protamine and was the only test which exhibited significant anticoagulant and antiprotease effects in all of the plasma preparations. The
other assays were relatively insensitive to protamine.
3.

In

Vitro Supplementation of Heparin and CY 216 to Various Plasma

Preparations
Although the constituents of primate plasma are similar to human
plasma,

differences between rat,

reported (Schalm 1975).
it was necessary to

rabbit and human plasma have been

Before beginning the animal experimentation,

compare the

in vitro heparinizability of the

various animal plasma preparations in order to determine the extent the
plasma differences might have on heparin and CY 216 anticoagulant and
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antiprotease activities.

Varying levels of endogenous neutralizing

agents like PF4 can modify the activity of heparin and CY ~16 to
varying degrees and may influence their in vitro activity profiles in

the plasma preparations.
After

supplementation

preparations,

the APTT was

supplemented to NHP and NMP.

of

heparin

and

CY

equally sensitive

216

to

the

plasma

to the heparins when

The baseline APTT value for NRP was

elevated as compared to the other plasma preparations therefore at CY
216 (2. 5 µg/ml)

the APTT was prolonged to > 150 seconds.

The APTT,

however, exhibited less sensitivity to heparin supplemented to NratP.
In addition,
anticoagulant

since heparin must bind to AT III
effects,

differing

levels

of

AT

in order to exert
III

in

the

plasma

preparations could result in variations in heparin and CY 216 activity.
Even though the APTT is less sensitive to the effects of low
molecular weight heparin than to heparin, a similar pattern of clotting
time elevation was seen for CY 216 and heparin after supplementation to
the various plasmas.

Since the APTT was relatively insensitive to the

anticoagulant effects of CY 216 and it was important to determine the
global clotting activity of CY 216 the HeptestR was used to determine
CY 216 activity in the plasma preparations.

This assay which has

recently developed is sensitive to the collective effects of heparins
and other substances which

inhibit factor Xa and factor

Ila.

The

HeptestR exhibited increased sensitivity to the effects of heparin and
to CY 216 supplemented to NRP than to the other plasma preparations.
The clotting assays

(APTT and HeptestR) were more sensitive to NRP
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which may be related to increased clotting factor levels in NRP as
compared to the other plasma preparation.
The% inhibition of factor Xa and factor Ila by heparin and CY
216,

in general,

followed a similar pattern in the various plasma

preparations, however once again the response of NHP to heparin and CY
216 was most similar to the NMP response.

Equigravimetric amounts of

heparin exhibited greater clotting and amidolytic activity than CY 216

when supplemented in vitro to NHP, NMP, NRP and NratP.
4.

.In Vitro Neutralization of Heparin and CY 216 by Protamine
Although many different animal plasmas were studied in vitro, the

primary objective of these studies was to relate the data obtained from
the animal models to what occurs in human plasma.

Therefore the in

vitro neutralization of heparin and CY 216 was studied only in NHP.
Although

heparin

and

CY

216

exhibited

assay

dependant

protamine

neutralization in vitro, significant differences between the neutralization profiles of heparin and CY 216 were noted.
these

differences

the

ratios

of protamine

to

In order to compare
heparin required to

completely neutralize the activity of the heparins in the individual
assays were determined.
Differential neutralization of the activities of heparin and CY
216 was noted.

All of the in vitro activities of heparin except

amidolytic factor Xa activity were completely neutralized at a protamine to heparin ratio of 2: 1.

However the activities of CY 216 were

neutralized to varying degrees depending upon the test.

In general,

the activity of CY 216 and heparin in the assays which primarily
measure the inhibition of thrombin (thrombin time and amidolytic anti
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Jla assays) were neutralized more readily than the assays which measure
anti Xa activity

(amidolytic

anti

Xa method and HeptestR).

The

activity of CY 216 in the thrombin time assay was completely neutralized at a protamine to CY 216 ratio of 1:1, while the amidolytic anti
Xa activity of CY 216 was neutralized by a protamine to CY 216 ratio of

2:1.

The HeptestR was only slightly neutralized at a protamine to CY

216 ratio of 2:1.

A comparison of the protamine to heparin (or CY 216)

ratios at which complete neutralization occurred for the in vitro and

in

vivo studies in shown in the Appendix XVIII and XIX respectively.

All of the anticoagulant and antiprotease activities of heparin and all
activities except for the anti Xa activity of CY 216 in the primates
was neutralized at a gravimetric 1:1 ratio.

The anti Xa activity of CY

216 after administration to the primates was completely neutralized by
a 2: 1 protamine to CY 216 ratio.

In general both in vitro and in

rabbits, the activity of heparin was more readily neutralizeable than
CY 216.
5.

In Vitro Neutralization of a Chemically Synthesized Pentasaccharide

by Protamine
The in vitro neutralization of a chemically synthesized pentasaccharide by protamine has been studied by Walenga (1987).

Although

pentasaccharide itself is not present in CY 216, the neutralization of
pentasaccharide can be considered as a good model for some ultra low
moleclular weight oligosaccharides which are present in CY 216.

The

pentasaccharide posseses the minimum binding region of heparin which is
able to induce a conformational change in AT III thus increasing the
inhibitory activity of this protein towards factor Xa.

However, this
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. activity was not neutralizeable by a 30 fold gravimetric excess of
protamine.

In addition, the heptestR activity of pentasacchari~e was

neutralized approximately

60%

and

the

anti

Xa

activity of penta-

saccharide was neutralized approximately 90 % by polybrene.

It is not

. 1cnown whether the lack of neutralization of the pentasaccharide by
protamine is due

to a lack of binding of protamine to the penta-

saccharide due to molecular size or charge characteristics or whether

the lack of neutralization of pentasaccharide is due to the inability
of protamine to disrupt a formed pentasaccharide-AT III complex.

Since

polybrene was able to neutralize the anti Xa and heptestR activity of
the pentasaccharide more readilly than protamine, the charge density of
the neutralizing agent may be important.
istics may be required for

Other structural character-

the neutralization of the antiprotease

activities of oligosaccharides.

Vitronectin has been shown to ef-

ficiently neutralize oligosaccharides of Mr 2,400 - 7,200 daltons (Lane
1987).
6.

In Vitro Neutralization of Heparin and CY 216 by Spermidine
Protamine has been used clinically to antagonize the hemorrhagic

effects of heparin for many years and much information is known about
this interaction of heparin with protamine.

However, less is known

about the interaction of protamine with low molecular weight heparins.

The

primary

intent

clinically relevant
polybasic agents.

of

this

dissertation was

to

obtain practical

information of the interaction of heparin with

Therefore, protamine was selected to antagonize the

effects of the heparins.

However it was also of interest to study the

interaction of the heparins with chemically defined polybasic sub-
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stances such as spermidine since this agent has a defined

structure.

Studies were performed on the interaction of heparin and CY 216 with
spermidine to compare the

in vitro protamine neutralization of the

heparins to the spermidine neutralization profiles in order to investigate whether assay dependant neutralization of heparin and CY 216
exists when a pure substance was used as the neutralizing agent.

Spermidine was less potent as an antagonist to the anticoagulant
and antiprotease effects

addition,

spermidine

neutralization profile.

of heparin and CY 216

exhibited

a

than protamine.

characteristic

assay

In

dependant

These preliminary studies indicated that the

differential neutralization of heparins after protamine and spermidine
antagonism may be related to differences in their chemical structure,
charge distribution or molecular weight.

A comparison of the structure

of spermidine

in Appendix XX.

and protamine

is

shown

Protamine

contains proteins of differing amino acid length which contain mostly
arginine.

Spermidine, on the other hand is a positively charged linear

polyamine.

Systematic structure activity studies are needed to further

characterize

the

differential neutralization of the

in vitro anti-

coagulant and antiprotease activities of heparin and CY 216.
F.

In Vivo Studies

1.

In Vivo Studies on the Effects of Protamine
Protamine sulfate

( 200 µg/kg

i. v. ;

2 and 3 mg/kg

i. v. )

was

administered to rabbits in the doses which were used to antagonize
heparin and CY 216 in the stasis thrombosis and the rabbit ear blood
loss

experiments.

No

significant effect of protamine

clotting and antiprotease activity was seen at these doses.

on ex vivo
Similarly,
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administration of protamine (2.1 mg/kg i.v.) to primates had no effect
upon clotting or amidolytic anti Xa activities.

Protamine exerted a

significant (p<.05) effect on the amidolytic anti Ila assay. This may
be related to a report that protamine act as a competitive inhibitor of
. thrombin- fibrinogens interaction and can also act as a substrate for
thrombin

(Cobel-Geard

1983).

The

observed

amidolytic

anti

Ila

activity may result from protamine acting as a secondary substrate for
thrombin. Therefore less synthetic substrate is cleaved by thrombin and
it appear that thrombin is inhibited after protamine administration in
this assay.
It was not possible to administer increased amounts of protamine
to the primates to determine whether higher doses of protamine would
exert increased ex vivo anticoagulant effects since some primates did
not tolerate protamine administration very well.

Although protamine

was administered very slowly as a bolus injection, certain primates
vomited after administration of this drug.

Similar reactions have been

observed when

been

other

protein

drugs

have

administered

to

the

primates.
2. Animal Models Used To Study The Antithrombotic Effects of Heparin
and CY 216 and Protamine
Animal models

of

thrombosis

have contributed to

the

current

knowledge of thrombosis and have been useful in the study and development of newer therapeutic agents.

In the present studies, two es-

tablished animal models of thrombosis were utilized.

A modified

version of the classic Wessler model (Wessler 1974) of venous thrombosis and a laser-induced model of thrombosis (Weichert 1984) were used
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to study the differential protamine neutralization of heparin and CY
216.

Since many factors can trigger thrombosis, it was necessa~y to

use models with different activation mechanisms in order to investigate
the neutralization of the anti thrombotic activity of heparins.

This

has provided an opportunity to determine whether similar potency and
neutralization profiles
differing mechanisms.

are obtained when thrombosis is

induced by

These two thrombosis models differ in the animal

species used, type of vessel under investigation, degree of blood flow,
thrombogenic stimuli and method of end point detection.
Factors

which

promote

thrombosis

include:

vascular

damage,

stimulation of platelet aggregation and intravascular activation of
blood coagulation (Hirsh et al. 1983).

A central hypothesis describing

the initiation of thrombosis focuses on endothelial cell injury and
resultant thrombus formation.

Endothelial damage exposes the underly-

ing subendothelium to platelets which adhere, release their cytoplasmic
constituents and aggregate at the surface.
Although endothelial injury may result in thrombosis, it is not a
prerequisite in all cases.
1771,

stasis alone,

thrombosis.

As first described by Hewson as early as

after a period of a several hours can induce

However, usually a thrombogenic stimulus or challenge must

be present for

thrombosis

to occur.

Although patients are often

described as being in a hypercoagulable state, the triggering mechanism
for thrombosis is rarely evident.

In animals and presumably in humans

as well, a thrombus can be induced in an area of stasis within minutes
when such agents as serum, serum factors, endotoxin and ellagic acid
are present (Colman et al. 1987).
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Blood flow is also an important factor in the progression of
thrombogenesis.

Thrombi usually do not form in normal vessels from

which the endothelium has been removed if flow is laminar, however, if
blood flow is disturbed materials released by adherent platelets and

thrombin can accumulate in the vortices and thrombi may form.
For many years the Wessler thrombosis model has been the accepted
model used in the evaluation of antithrombotic drugs.

It is based on a

fundamental concept of Virchow (1856) in which thrombosis is described
as resulting from a hypercoagulable state, localized diminished flow
(or stasis) and cellular interactions.

The hypercoagulable state in

the present studies was produced after the injection of PCC and RVV.
PCC contains a complex of human factors II, VII, IX and X, RVV (Russell's viper venom) activates factor X to Xa.

When used in combina-

tion, these agents produce high levels of factor Xa, which is thought
to be the primary target of low molecular weight heparin and causes an
activation of coagulation and subsequent

clot

formation.

PCC

is

standardized in terms of vitamin K dependant factors, therefore the use
of batches of the agents can result in reproducible results.
Localized diminished flow,

the

second component in Virchow' s

triad is achieved in the stasis thrombosis model through the use of
ligatures.

Following infusion, the surgically isolated jugular veins

were ligated and localized stasis in addition to hypercoagulable blood,
produced clot formation within the jugular veins.
Although the Wessler model is still widely used,

experimental

data and clinical observation has shown that endothelial damage alone
is sufficient to produce thrombosis and that complete stasis is rarely
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found during the progression of thrombosis

in man.

Therefore this

model possesses certain limitations (the use complete stasis and the

lack of any endothelial injury)
relevant as other models.

and may not be as physiologically

The thrombotic stimulus in the laser-induced

thrombosis model, namely, endothelial damage is thought to be a more
physiologically relevant stimulus for thrombosis.
While
blood

flow

stasis

is

is

integral

an

an important parameter in the 'Wessler model,
parameter

of

the

laser-induced model.

complete blood flow is maintained in the vessels under investigation
throughout the entire experiment and any blockage to flow which occurs
is a direct result of thrombus formation.

In the laser model, after

the laser injury is produced any blood elements which become coagulated
as a result of the laser injury are swept away by the blood flow and
the several seconds elapse before the first platelets stick to the
damaged vessel wall area.

Therefore,

it is unlikely that thrombus

formation results form coagulable protein but rather forms as a result
of platelets becoming activated after interaction with the subendothelium

('Weichert 1983;

1984;

1986).

As the experiment is carried

out, blood flow carries away any platelet aggregates which initially
form and break apart from the growing thrombus.
a.

Antithrombotic Effects of Protamine
Protamine

is

administered clinically to

antagonize the hemor-

rhagic effects which sometimes occur during antithrombotic therapy with
heparins.

Administration of protamine has been shown to

influence

coagulation proteins (Gans 1962; Godal 1960) and platelets (Eika 1972:
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Al-Mondhiry 1985).

It was

interesting to note that protamine ad-

ministration to rabbits and rats exhibited antithrombotic effects.
Protamine (100 and 740 µg/kg i. v.) produced a slight nonsignificant

degree

of

inhibition

of

thrombosis

in

the

rabbit

stasis

thrombosis model and the laser-induced thrombosis model respectively.
Protamine was much less potent as an antithrombotic agent than the
heparins in the stasis thrombosis model, however protamine was nearly
as potent as heparin and CY 216 in the laser-induced thrombosis model
which is very sensitive to platelet-vessel wall interactions.

The

antithrombotic activity of protamine in the laser model may be related
to protamine effects on platelets (Al-Mondhiry 1985; Eika 1971) and
inhibition of platelet-vessel wall interactions.
b. Intravenous and Subcutaneous Antithrombotic Actions of Heparin and

CY 216
Equigravimetric amounts of heparin were more potent than CY 216
in both the stasis thrombosis and the laser-induced thrombosis models.
However, in the stasis thrombosis model, complete neutralization of the
antithrombotic effects of heparin

were observed at equigravimetric

amounts of protamine, while significant (p<.05),(as determined by a two
way ANOVA)

antithrombotic

equigravimetric protamine.

activity of CY
In the

216

were observed after

laser-induced thrombosis model,

heparin and CY 216 were completely neutralized by protamine.
differing results between models may be

The

related to the activation

mechanisms used to induce thrombosis in the models.

In the stasis

model, the primary activator is targeted toward the coagulation system
While,

in the laser-induced thrombosis model, damaged endothelium is
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the primary activator for

While in the laser

thrombosis to occur.

aodel, although damaged endothelium activates platelets,
to stabilize

the platelet aggregates which form.

fibrin helps

The differential

degree of neutralization of CY 216 observed in the stasis thrombosis
·aodel may be

related

to

components within CY 216 which can still

inhibit the coagulation system after protamine administration.

These

effects may be related to amidolytic anti Xa inhibition, however this

is unlikely since the levels of amidolytic anti Xa activity were very
low after the administration of CY 216 (100 µg/kg i. v.) used in the

stasis

thrombosis

experiments.

In

addition,

correlations

between

antiprotease activity and% inhibition of thrombosis were poor ranging
from ( . 002

- . 806)

depending upon the as say used.

Bianchini et al.

(1985) found a similar lack of correlation between in vitro activity

and antithrombotic effects of heparins.

Perhaps some mechanism exists

which is responsible for this antithrombotic activity after protamine
antagonism of CY 216 which is not measurable at this time.
Significant

antithrombotic

activity

was

observed

after

ad-

ministration of heparin (1 mg/kg s. c.) and CY 216 (1 mg/kg s. c.) to
rabbits.

Similarly, significant ex vivo activity was observed. The

anti Ila activity of heparin and CY 216 was completely neutralized,
while the anti Xa activity after subcutaneous administration of heparin

and CY 216 was not neutralized. Once again there was a poor relationship between mt vivo
antithrombotic activity.

activity and protamine neutralization of the
In the intravenous studies, CY 216 exhibited

significant antithrombotic activity with slight mt vivo antiprotease
activity after subcutaneous administration of CY 216. Therefore mt vivo
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antiprotease activity is not the only determinant of antithrombotic
activity.
3.

Hemorrhagic Effects of Heparins
Many animal models have been used to determine the hemorrhagic

potential of drugs.

Two models used in this study,

the rabbit ear

blood loss model and the rat tail bleeding model, exhibit differential
sensitivity

to

hemostatic

and

physiologic

components

including:

platelets, coagulation factors, blood pressure, and smooth muscle.

The

differential sensitivity of the models may be related to the type of
vessels which were transected during the experiments to induce blood
loss.
In 1934, when heparin was being developed for clinical use,
was

thought

it

that surgical patients who would receive heparin might

bleed to death.

However,

the administration of heparin to patients

since that time without the occurrence of spontaneous hemorrhage, even
during major operations has disputed this concern (Jaques 1973).
hemorrhage

to

occur after

the

administration of heparin means

For
that

several factors of hemostasis may be deranged simultaneously (Jaques
1949).

Abnormalities in the normal hemostatic mechanism which can lead

to bleeding include:

defects in blood vessels,

a

deficiency in the

number of circulating platelets, abnormal platelet function, defects in
blood coagulation and excess fibrinolytic activity (Hirsh 1983).
hemorrhagic

The

risk of heparin could be theoretically influenced by a

number of variables including (1)

the dose of heparin (2) the anti-

coagulant effect of heparin as measured by a laboratory test (3) the
route of heparin administration and (4) patient characteristics such as
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concurrent

administration of

clinical view is

that

antiplatelet

drugs.

A commonly held

the risk of bleeding increases with either

increasing doses of heparin or with the heparin response as reflected
by .in vitro coagulation tests.

Bleeding is more likely to occur when

'an .in vitro test of coagulation is excessively prolonged.
In the rabbit ear model of blood loss, as developed by Cade

et

al. (1984), 5 uniform incisions were made in the lower portion of the
rabbit ear and the incisions were standardized in such a manner that
the microcapillary section of the rabbit ear was transected as shown in
Appendix X.

In the rat tail transection model a 2 mm section of the

distal end of the tail vein was transected.

These differences in

methodology may lead to differing sensitivities of the models to agents

The rat tail transection bleeding model is

which induce blood loss.

sensitive to the effect of platelets as well as coagulation factors

(Dejana 1982), whereas the rabbit ear bleeding model is more sensitive
to primary hemostasis (Cade et al. 1984) which involves the adherence
of platelets to damaged endothelium after an injury.
molecular

weight

heparin have

been

reported

to

Heparin and low
decrease

platelet

adhesiveness in vivo which may cause a prolongation in the rat tail
transection bleeding model (Harenberg 1985;Weichert and Breddin 1986).
Differences in methodology between the rat tail bleeding time and
the rabbit ear blood loss model include: animal species, temperature,
method of end point detection and number of determinations which can be
performed per animal.
temperature has

Dejana et al. (1982)

an effect

on bleeding

have demonstrated that

times.

Tail

transection

bleeding times in the rat were shown to be significantly shorter at
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370c than at 23°c.

This result is in agreement with the fact that

bleeding times measured in human fingers are prolonged at tempe~atures
below 37°c (Copley 1974).

One advantage of the rabbit ear blood loss

model as compared to the rat tail bleeding model is that in the rabbit
. model temperature is more tightly controlled. In this model, the red
cells are collected in a saline bath at 37° C.

Also this method of end

point detection is more precise than the measurement of bleeding time
in the

rat

tail bleeding model

where

bleeding

time

was

visually

determined as the time when bleeding stopped. A practical advantage of
the rabbit ear blood loss model is that 2 blood loss determinations can
be made per rabbit (one determination on each ear) whereas only one
determination can be performed on each rat.
a.

Effect of Protamine in the Blood Loss Models
Protamine administration had a differential effect in the two

blood loss models.

The rabbit ear model of blood loss was not effected

by protamine (1 and 2 mg/kg i.v.) while the rat tail bleeding model was
The prolongation in the rat

prolonged by protamine (1 mg/kg i. v.).

tail model may be due to inhibition of primary hemostasis.

Protamine

has been shown to exhibit antithrombotic effects in the rat laser model
of thrombosis.

These

antithrombotic

effects

of protamine may be

related to inhibition of platelet adhesion and this mechanism may cause
an increase in bleeding time in the rat model.

b. Intravenous and Subcutaneous Studies On the Hemorrhagic Effects of
Heparin and CY 216
Good agreement between the

results

of blood loss

induced by

heparin and CY 216 was observed in the two bleeding models. Heparin (2
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mg/kg i.v.) produced a significant (p<.05),(as determined by a one way
ANOVA), amount of blood loss as compared to the control groups in both

models.

CY 216 produced less blood loss than heparin at equigravi-

metric concentrations as determined by both models.

CY 216 (2 mg/kg

i.v.) did not produce a significant increase in blood loss,

however,

the blood loss induced by CY 216 (3 mg/kg i.v.) was significant (p<.05)
as compared to the control group, as determined by a one way ANOVA.
216 produced approximately 67

%

CY

of the blood loss induced by equi-

gravimetric amounts of heparin as determined by the rabbit ear blood
loss model.

Low molecular weight heparins are not endowed with any

special properties which would allow

the

clinician

dangers of hemorrhagic side effects (Thomas 1986).
rhagic effects of heparins are dose dependant,

to

ignore

the

Since the hemor-

the true efficacy of

these new antithrombotic agents may not be completely realized if
improper doses are administered.
Even though heparin (2 mg/kg i.v.) exhibited a greater amount of
amidolytic anti Xa activity than CY 216 (2 mg/kg i.v.), the activity of
heparin was more readily neutralized than the corresponding activity of
CY 216.

Anti Xa potency of heparins may not be directly correlated to

the extent of neutralization.

Differential interactions of heparin and

low molecular weight heparin with protamine may be related to the size
of the anticoagulant molecule.

Either protamine sulfate binds to long

chains more easily than to a shorter chains (Thomas 1984) or protamine

may have to bind with a certain affinity to the components of heparin
which inhibit factor Xa for neutralization to occur (Massonet-Castel
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1986).

A schematic

representation of

the

binding of heparin

to

protamine is shown in the Appendix XX.II.
Blood

samples

drawn

10

minutes

after

the

administration of

heparin or CY 216, allowed for the ex vivo analysis of blood levels of
. amidolytic anti Xa and amidolytic anti Ila activity at the time when
the blood loss determinations were initiated.
antiprotease activity and

blood loss

heparin or CY 216 were calculated.

Correlations between

after the administration of

Poor correlations between~ vivo

activity and blood loss were obtained for CY 216 (r-.102 for anti Xa,
r-.186 for anti Ila). The correlation for HeptestR and CY 216-induced
blood loss was better (r-.515).

It seems therefore that the hemor-

rhagic side effects of CY 216 are somewhat dissociated from their
antiprotease activity.

Similar correlations between the amidolytic

anti Xa and amidolytic anti Ila activities and heparin-induced blood
loss (r-.690 for anti Xa) and (r-.564 for anti Ila) were obtained.
A poor correlation between blood loss and~ vivo activity
protamine neutralization of heparin and CY 216 was seen.

after

Heparin

produced a greater amount of blood loss than CY 216 at equigravimetric
doses and also exhibited greater amidolytic anti Xa and amidolytic anti
Ila activity than CY 216 at equivalent doses. However, it was interesting to note that although the blood loss induced by CY 216 was completely neutralized by protamine while the amidolytic anti Xa activity
of CY 216 was not.

Significant amounts of amidolytic anti Xa activity

of CY 216 remained after two fold gravimetric amounts of protamine was
administered to rabbits.
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No significant increase in blood loss was seen after subcutaneous
administration of heparin (3 mg/kg s.c.) or CY 216 (3 mg/kg s.c.) to
rabbits,

even though significant ex vivo

activity was observed in

several assays. Similarly, there was no increase in blood loss after
subcutaneous administration of heparin (2. 5 mg/kg s. c.) or CY 216 (2. 5
mg/kg s . c . ) to rats .

Reports have shown that bleeding occcurs more

frequently when heparin is given therapeutically in large doses than

when it is administered prophylactically in small doses (Colman 1987).
The amidolytic anti Ila activity of subcutaneously administered heparin
and CY 216 and the amidolytic anti Xa activity of heparin was complete-

ly neutralized by protamine.
cutaneously

administered

CY

However,
216

was

the anti Xa activity of subnot

neutralized.

The

results

correspond with the in vitro and other in vivo protamine neutralization
profiles of these heparins.
4.

Pharmacodynamic Effects of Heparin and CY 216 and their Modulation

By Protamine
Pharmacokinetics by the strict sense of the word refers to the
processes by which a drug enters and is moved around within the body
(thus reaching its site of action) and is eliminated.

Thus the term

pharmacokinetics embraces the (1) absorption, (2) distribution and (3)
elimination of drugs but not their action.

Pharmacodynamics, on the

other hand refers specifically to the activity of drugs (Bourne et al.
1986).

Since heparin is a polycompnent drug which exerts its effects

at various sites of action, it was not possible to directly measure the
concentration of the active components of heparin.
necessary

to

determine

pharmacodynamic

activities

Therefore it was
of

heparin

and
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correlate activity data to concentration through the use of calibration
curves.

The pharmacokinetics of heparin are more properly termed time

course of pharmacodynamic effects.

In order to directly compare the activity of heparin and CY 216

.in vivo, a noncompartmental model was used to calculate pharmacodynamic
time

course

parameters

in primates.

Noncompartmental methods

for

calculating pharmacodynamic time course values are based on statistical
moment theory and utilize calculations of area under the concentration

curve which is a simple expression of drug disposition (Gibaldi et al.
1982).

To date, statistical moments have been applied to pharmaco-

kinetic

and

biopharmaceutic

absorption and distribution.

processes

dealing primarily with

drug

These concepts were initially used in the

biomedical literature by Perl and Samuel (1969) to analyze cholesterol
input and output in man and by Oppenheimer et al. (1975) in describing
the disposition of iodothyronine.

Noncompartmental analysis is not "model independent" but rather
is based on a model with a far more restricted structure and realm of
applicability

than

multicompartmental

models.

A major

conceptual

advantage of a noncompartmental model is that any number of recircula-

tions or exchanges can occur with any number of noncentral pools, none
of which has to be identified with any physiological structures (Di
Stefano 1984). A diagrammatic representaion of a noncompartmental model
is shown in Appendix XX.I.
Study of the time course of the neutralization of the heparins
presented some interesting problems.

It was not possible to calculate

all of the pharmacodynamic time course parameters after neutralization
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of

the

heparins

by

protamine

since

the

initial heparin-protamine

activity level (concentration) at time 0 must be known in order to
calculate Clp and Vd.

This value could not be obtained from the data

since heparin was administered 5 minutes prior to protamine.

The study

was designed in this way in order to simulate the protamine neutralization of heparin in patients.

In order to calculate Vd and Clp of

heparin and protamine an in vitro heparin-protamine complex would have
to be administered to the primates and the calculations determined.
a.

Differential Neutralization of Heparin and CY 216 By Protamine
Assay dependant protamine neutralization after administration of

heparin (0. 7 mg/kg i. v.) and CY 216 (0. 7 mg/kg i. v.) was observed in
the primates.

Both heparin and CY 216 exhibited strong anticoagulant

and antiprotease effects.

After the administration of protamine, the

degree of neutralization of these effects varied with the laboratory
assays and heparin and CY 216 exhibited characteristic neutralization

profiles in the primates.
The HeptestR activity of heparin was the only activity which was
completely neutralized by equigravimetric protamine, while the APTT and
thrombin time activities of heparin were completely neutralized at a
two fold gravimetric amount of protamine.

The neutralization patterns

of amidolytic anti Xa and amidolytic anti Ila activity of heparin were
very similar.

Varying degrees of neutralization of the activities were

seen up to 3 hours.

The APTT, thrombin time, and anti Ila activities

of CY 216 were completely neutralized by equigravimetric protamine.

A

dose dependant neutralization of the amidolytic anti Xa of CY 216 was
seen.

Complete neutralization of the amidolytic anti Xa activity of CY
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216

was

not

protamine.

observed

at

three

fold

gravimetric

concentrations

of

Virtually no neutralization of the HeptestR activity of CY

216 was seen after administration of three fold gravimetric amounts of
protamine.
b. Intravenous Studies
Protamine neutralization of the pharmacodynamic time course of
intravenously

administered

primate (macaca mulatta).
mined using APTT,

heparin

and

CY

216

was

studied

in

the

Activity of heparin and CY 216 was deter-

thrombin time,

amidolytic anti Ila methods.

HeptestR,

amidolytic anti Xa and

Pharmacodynamic time course parameters

were calculated from concentrations obtained from HeptestR and amidolytic anti Xa activity data which was extrapolated from calibration
curves of heparin or CY 216 supplemented to NMP.

It was not possible

to calculate pharmacodynamic time course parametres for the anti Ila
data since a large proportion of the data points were out side of the
linear

range.

Also

after

protamine

administration,

the

anti

Ila

activity of the heparins was completely neutralized therefore it was
not possible to calculate area under the curve with only a few data
points.

To determine the anti Ila time course parameters, it would be

necessary

to

use

lower

doses

of

the heparins

and draw blood more

frequently.
1.

Area Under the Concentration Curve (AUC)
Increasing the doses of heparin and CY 216 administered to the

primate groups from O. 35 mg/kg i. v.

to O. 7 mg/kg i. v.

dose dependant increase in AUC values .

resulted in a

In most cases as the doses

doubled the AUC values increased more than two fold.

This is related
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to decreases in the plasma clearance which were observed as the dose of
heparin was

increased as determined by the amidolytic anti Xa and

HeptestR methods.

Similar findings have been reported by Worth and

Estes (1969) and Bjornsson et al. (1981).
In general, the differences between the time course parameters of
heparin and CY 216 lessened as the dose was increased to 0. 70 mg/kg
i.v.

At lower doses, differences between drugs may be more pronounced

since drug elimination mechanisms do not become saturated and dosedependant pharmacodynamics are not apparent at lower doses.

The AUC

for CY 216 as determined by the amidolytic anti Xa method did not
increase proportionately with the

increase

related to the plasma clearance of CY 216.

in dose.

This may be

The Clp for CY 216 as

measured by the amidolytic anti Xa method was not dose related, while
the Clp decreased with increasing dose as determined by the HeptestR.
From

the

AUC values

of heparin and CY

216

after

protamine

administration it was apparent that both heparin and CY 216 demonstrated characteristic protamine neutralization profiles as determined by
the amidolytic anti Xa assay and HeptestR. Comparison of AUC values
provided a means of quantitating the activity and degree of neutralization of the heparins over an extended period of time rather than at one
certain time period. Both assays demonstrated that the~ vivo activity
of CY 216 was less neutralizable by protamine than the~ vivo activity
of heparin.
2.

Mean Residence Time (MRT)
Increasing the doses of heparin administered to the primates from

0. 35 mg/kg i. v.

to 0. 7 mg/kg i. v. resulted in a significant (p<. 05)
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dose dependant increase in the MRT as determined by the HeptestR but
not the amidolytic anti Xa method.

Once again differences in sen-

sitivity of the assays may lead to different pharmacodynamic time
course parameters.

Differences in MRT values could also be related to

intergroup differences within the primate groups.

Increasing the dose

of CY 216 from 0.35 mg/kg i.v. to 0.7 mg/kg i.v., however, resulted in
a significant (p<. 05) decrease in MRT values as determined by both
methods.

Protamine (0.7, 1.4 or 2.1 mg/kg i.v.) administration did not

have any significant effect on the MRT valued of heparin or CY 216
determined by both methods.
3. Plasma Clearance (Clp)
Increasing the dose given to the primates from 0.35 to 0.70 mg/kg
i.v.

significantly

(p<.05)

determined by both methods.
Clp of CY 216 was noted.

decreased

the

clearance

of heparin as

In contrast, no significant change in the
This may be related to the differing route

and kinetics involved in their elimination of heparin and CY 216.
Heparin is primarily cleared by the liver and kidneys (Palm and Mattson
1987)

from a combination of saturable and nonsaturable mechanisms.

(DeSwart 1982)

The saturable mechanism of heparin clearance involves

binding to the endothelium (Dawes and Pepper 1979) while the nonsaturable mechanisms may involve renal elimination (Piper 1947).

Low

molecular weight heparins, on the other hand, are cleared primarily via
the kidneys through renal filtration (Goudable et al. 1986).

Certain

routes of elimination such as endothelial cell binding may become
saturated for heparin and renal and hepatic elimination may predominate
and as a result, clearance may increase with increasing dose.
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4.

Apparent Volume of Distribution (Vd)
A significant

(p<.05)

dose

dependant

decrease

in

the Vd of

heparin was observed as the dose of heparin was doubled as determined
by the amidolytic anti Xa method but not as determined by the HeptestR.

Intuitively

one would not expect the Vd to decrease as

the

dose

increased.

This anomalous result was not found with the HeptestR,

which suggest that an assay which measures the collective activities of
heparin may be a more reliable method for determining heparin pharmacodynamic time course parameters than a specific assay.

Although both Vd

values for heparin and CY 216 < 0. 05 1/kg which indicated that the
drugs remained within the plasma compartment. The Vd of heparin was
generally greater than for CY 216 which may be related to the increasing endothelial affinity of heparin with increasing molecular weight.
No significant dose related change in the Vd of CY 216 was noted by

either method.
5.

Protamine Neutralization Index (PNI)
PNI values were calculated for intravenously administered heparin

and CY 216 after neutralization by protamine.

These values provided a

means of quantitating the degree of neutralization of the drugs over an
extended time period.

PNI values were generally greater for heparin

than for CY 216 as determined by both methods, however no difference
was found between the PNI values of heparin and CY 216 at a gravimetric
protamine to heparin (or CY 216) ratio of 1.

A greater PNI value was

observed at a gravimetric protamine to heparin ratio of 3:1 as deter-

mined by the amidolytic anti Xa method.
c.

Subcutaneous Administration
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Protamine neutralization of the pharmacodynamic time course of
subcutaneously administered heparin and CY 216 was studied in the
primate (macaca mulatta).

Pharmacodynamic time course parameters were

calculated from concentrations obtained from HeptestR and amidolytic
anti Xa activity data which was extrapolated from calibration curves of
heparin or CY 216 supplemented to NMP.

1.

Area Under the Concentration Curve (AUC)
The AUC values for CY 216 (0. 7 mg/kg s. c.) were increased as

compared to heparin (0.7 mg/kg s.c.).

Since the degree of absorption

after subcutaneous administration of a drug depends upon

molecular

weight, greater antiprotease activity was observed after subcutaneous

administration of CY 216.

Heparin exhibits an increased mean molecular

weight as compared to CY 216 and was not substantially absorbed

after

subcutaneous administration. After protamine administration to heparin
(0.7 mg/kg s.c.) or CY 216

(0.7 mg/kg s.c.) a decrease in the AUC

values were observed as determined by the amidolytic anti Xa method but
not the HeptestR.
2.

Mean Residence Time (MRT)
The MRT of CY 216 (0. 7 mg/kg s. c.) was longer than the MRT of

heparin

(0. 7 mg/kg s. c.)

as

method.

This is consistent with literature reports (Palm and Mattson

1987; Lockner et al. 1986).

determined by the

amidolytic anti Xa

It was interesting to note that the MRT

values for CY 216 (0. 7 mg/kg s. c.) were not greater than the MRT for
heparin (0.7 mg/kg s.c.) as determined by the HeptestR.

However this

result may be related to the large standard errors which were obtained
for the MRT values after subcutaneous administration of heparin and CY

165
216.

There was no significant effect of protamine on the MRT values of

CY 216 (0.7 mg/kg s.c.) as determined by both methods, or for h~parin
(0. 7 mg/kg s. c. )

as

determined by the amidolytic

However the MRT for heparin (0.7 mg/kg s.c.)
less

after

the

administration

of

anti Xa method.

was significantly (p<.05)

protamine

as

determined by

the

subcutaneous

ad-

HeptestR.
3. Plasma Clearance (Clp)
The

plasma

clearance

values

ministration of heparin (0. 7 mg/kg)
heparin (0. 7 mg/kg i. v.).

obtained after

were increase as compared to

The Clp of CY 216 (0. 7 mg/kg s. c.) was

increased as compared to CY 216 (0.7 mg/kg i.v.) as determined by the
HeptestR and amidolytic anti Xa methods.

The clearance values were

dependant upon the method of calculation used in the noncompartmental
model.

Clearance was calculated as Clp -

absorption of heparin was very poor.

(dose)/(AUC), however the

Therefore the clearance values

calculated by this method reflect the poor absorptive characteristics
of heparin after subcutaneous administration rather than the actual
clearance.

The plasma clearance for CY 216 as determined by the

HeptestR was greater than as determined by the amidolytic anti Xa
method.

Once again this result may be related to the absorptive

characteristics of CY 216 and the sensitivity of the assay.

HeptestR

measures both low molecular weight components which inhibit factor Xa
and high molecular weight components which may inhibit factors Xa and
Ila.

Since high molecular weight components are not absorbed as well

as low molecular weight components, it may appear that more heparin
molecules are cleared while actually they may not have been absorbed.
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4.

Apparent Volume of Distribution (Vd)
The Vd values for heparin (0.7 mg/kg s.c.) and CY 216 (0.7_ mg/kg

s.c. ) were low (<0.05 1/kg) which indicates after absorption, the drugs

remain in the plasma compartment.

The Vd for CY 216 (0.7 mg/kg s.c.)

was 10 fold lower than the Vd for heparin as determined by both methods
and the Vd for CY 216 (0.7 mg/kg s.c.) as determined by the HeptestR
The Vd approximates the apparent volume into which a drug distributes
and is not a real volume.

Low values for Vd may have been obtained

since the equation used to calculate Vd:
Vd - dose x AUC x 1 liter
(AUMC)(AUMC} 1000 ml
is inversely related to the AUMC.

This value which is related to the

AUC was elevated 3 fold as compared to the AUMC for CY 216 (0.7 mg/kg
s.c.) as determined by the HeptestR.

Once again differing sensitiv-

ities

variations

of

the

assays

contributed

to

in

the

calculated

parameters.
5. Protamine Neutralization Index (PNI)
PNI

values

were

calculated

for

subcutaneously

heparin and CY 216 after neutralization by protamine.

administered

The activities

of CY 216 were less neutralizeable than heparin as determined by the
amidolytic anti Xa method as compared to the HeptestR.

It is interest-

ing to note that a lesser degree of neutralization after subcutaneous
administration
administration.

of

both

drugs

occurred

as

compared

to

intravenous

The activity of the drugs was neutralized approximate-

ly SO% less after subcutaneous administration.
d.

Practical Implications of Protamine Interactions with Heparin and

cY 216
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1. The Relevance of Laboratory Tests in the Assessment of Heparin
and CY 216 After Neutralization By Protamine

Very

limited

comparative

information

on

the

interaction

of

protamine with heparin and low molecular weight heparins is available.
The information which is available is limited in that it does not
address the practical considerations of the interaction of protamine
with low molecular weight heparin such as the relevance of

~

vivo

activity of low molecular weight heparins to thrombosis or bleeding
after neutralization by protamine

or low molecular weight heparin

rebound.
The current studies have
activity as

addressed the

relevance of

~

vivo

determined by anticoagulant and antiprotease assays to

bleeding and antithrombotic effects.

These tests may have some limited

value in the prediction of which patients will exhibit blood loss after
the administration of heparin or low molecular weight heparin.

After

heparin administration to rabbits in the blood loss studies, the anti
Xa (r-.690) and anti Ila (r-.564) correlation coefficients were similar
as well as the correlation coefficient obtained after administration of
CY 216 to rabbits as determined by the HeptestR (r-.515).

However the

correlation coefficient for CY 216 as determined by the amidolytic anti
Xa (r-.102) and anti Ila (r-.186) methods were poor.
After protamine neutralization, the thrombin time exhibited the
best correlation coefficients (r-. 765 for heparin),
216)

for blood loss and

activity .

(r- . 812 for CY

The use of particular laboratory

tests to measure heparin and low molecular weight heparin activity may
not necessarily be sensitive to the effects of the heparins after
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protamine neutralization.

Although the studies were limited, the data

suggests that of the tests used, either amidolytic anti Xa or amidolytic anti Ila assay would be useful to predict the hemorrhagic effects
of heparin however these tests do not predict the hemorrhagic potential
of CY 216 as well as the HeptestR.
heparin and CY 216,
increased blood loss.

the

After protamine neutralization of

thrombin time

assay best correlated with

These results demonstrate an important con-

sideration in the clinical monitoring of patients who receive heparins.

a.

Heparin Rebound
Many factors may contribute to the phenomenon of heparin rebound

which include: the recirculation of heparin (Gollub 1967), hypothermia

(Gollub 1967) and the protamine to heparin ratio administered (Kesteven
et al. 1986).

Although the whole blood activated clotting time is

widely used to predict the neutralizing dose of protamine sulfate
(Piffare et al. 1981), this assay may not always give a true reflection
of the dose of protamine required to neutralize heparin (Esposito et
al.

1983).

One objective of this dissertation was to investigate

whether the individual activities of heparin and CY 216 exhibited any
characteristic rebound patterns in the primate pharmacodynamic model.
At these doses studied, no significant degree of heparin rebound was
observed although a slight decrease in thrombin time was observed after
the administration of protamine.

The

neutralization of this activity

may appear as a slight degree of rebound, however protamine is known to
have fibrinoplastic effects (Hougie 1958) which may be related to the
shortening of the thrombin time and this apparent rebound of thrombin
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time activity

No physical signs of heparin rebound such as increased

blood loss were observed in the primates.
b.

Clinical Indications for Low Molecular Weight Heparins
In

certain

clinical

conditions,

such

as

atherosclerosis

and

diabetes (0 Brien 1984) and during procedures such as cardiopulmonary
bypass and renal dialysis, platelets become activated and release PF4.

Since platelet factor 4 is known to neutralize the effects of heparins
in a similar manner to protamine,

(Racanelli 1987),

it may be ad-

vantageous for low molecular weight heparin to retain antithrombotic
activity
polybasic

and

amidolytic

proteins.

anti

This

Xa

activity

dissociation

after

of

the

complexation with
antithrombotic

and

hemorrhagic activity of low molecular weight heparins after protamine
reversal is a unique property not found in heparin.
c.

Future Studies
The current studies have addressed such practical issues as the

relevance of

anticoagulant and antiprotease activity of heparins after

neutralization by protamine, however many areas concerning the interaction of heparins have not been addressed.
to better understand

the

interaction of

Further studies are required
these

drugs.

Systematic

structure activity studies are needed to characterize the interaction
of heparins and protamine on the molecular level.

The role of

protamine neutralization of low molecular weight heparins as determined
by newly developed assays which measure thrombin antithrombin complex
formation or thrombin generation may provide additional insight into
the exact mechanism of protamine antagonism of heparins.

More exten-

sive studies on the rebound of low molecular weight heparins after
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protamine administration should be carried out to see if these agents
exhibit rebound phenomenon in a way analogous to heparin.

Also the

bemodynamic effects of the protamine reversal of low molecular weight
heparin therapy should be

addressed.

Protamine antagonism of low

molecular weight may provide therapeutic benefits as compared to the
protamine antagonism of heparin.

CHAPTER VI
SUMMARY AND CONCLUSIONS
Significant differences between the protamine neutralization of
heparin and CY 216 have been observed both in vitro and in animal models
of hemorrhage and thrombosis.
1.

protamine

The APTT was more sensitive to in vitro supplementation of
than

the

thrombin

time,

HeptestR,

amidolytic

anti

Xa

or

amidolytic anti Ila assays.
2.

NHP and NMP exhibited

similar activity in the clotting tests,

amidolytic anti Xa and amidolytic anti Ila assays after supplementation
of heparin or CY 216 as compared to NRP and NratP.
3.
protamine

The in vitro neutralization profiles of heparin and CY 216 by
differed

characteristics.

significantly

and

demonstrated

assay

dependant

Most activities of heparin were completely neutralized

at an equigravimetric protamine concentration, while the amidolytic anti
Ila and thrombin time activities of CY 216 were neutralized to a greater
extent than the amidolytic anti Xa and HeptestR activities.
4.

Administration of protamine sulfate (0.74 mg/kg i.v.) resulted

in antithrombotic activity in the laser-induced thrombosis model and
rabbit stasis thrombosis model.
5.

Both heparin and CY 216 exhibited significant inhibition of

thrombosis in the laser-induced thrombosis model and the rabbit stasis
thrombosis model.

At concentrations of 25 µg/ml and 50 µg/ml, heparin was
171

172

aore potent as an antithrombotic agent than equivalent gravimetric amounts
of CY 216.
6.

Protamine

neutralized

the

antithrombotic

intravenously administered heparin and CY

216

in the

activity

of

laser-induced

thrombosis model to a similar extent, however, the heparins exhibited
differential neutralization in the rabbit stasis thrombosis model.
antithrombotic

activity of heparin was

The

completely neutralized at

a

gravimetric protamine to heparin ratio of 1:1, while CY 216 (100 µg/kg
1.v.) exhibited significant (p<.05) antithrombotic activity even after the
administration of equigravimetric protamine.
7.

Poor

correlations

coefficients

were

obtained

between

intravenously administered heparin and% of thrombosis in a rabbit stasis
thrombosis model.

The correlation coefficients ranged from .002 for the

APTT to .515 for the amidolytic anti Xa assay.

Similarly, correlation

coefficients were obtained for CY 216 and % inhibition

of thrombosis

which ranged from .152 for the APTT to .806 for the HeptestR.

8.

Heparin and CY 216

(1 mg/kg s.c.)

exhibited significant

antithrombotic activity in the rabbit stasis thrombosis model.

This

activity of heparin was completely neutralized by protamine (1 mg/kg i.v.)

while the antithrombotic activity of CY 216 was not completely neutralized
by equigravimetric protamine.

9.

Protamine sulfate (2 and 3 mg/kg i.v.) had no effect on blood

loss in the rabbit ear model while an equivalent amount of protamine
produced an in increase in bleeding time in the rat tail transection
bleeding model.

The rat tail transection data was associated with large
172
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standard deviations.

In addition, protamine administration alone caused

a prolongation of bleeding time which makes the interpretation of these
experiments difficult.

10.

CY

216

produced

approximately

60%

less

blood

loss

as

equigravimetric amounts of heparin as determined by a rabbit ear blood
loss model.

The blood loss induced by CY 216 exhibited a poor correlation

to amidolytic anti Xa (r-.102) and arnidolytic anti Ila (r-.186) activity.
CY 216 induced blood loss demonstrated a better correlation to the HeptestR
(r-.515).

Heparin-induced blood loss exhibited poor correlations to

amidolytic anti Xa (r-.690) and amidolytic anti II (r-.564) activity.
11.

Subcutaneous administration of heparin or CY 216 (3 mg/kg s.c.)

did not produce an increase in blood loss in the rabbit ear model.

A

similar result was obtained in the rat tail transection model where
heparin or CY 216 (2. 5 mg/kg s. c.) did not increase the bleeding time
after tail transection.
12.

The differential neutralization observed for heparin and CY 216

in vitro was observed in vivo as well.

The anticoagulant and antiprotease

activities of heparin were neutralized to a greater degree than the
similar activities of CY 216.
Xa

In general, assays which measure the anti

activity of CY 216 were less neutralizeable than assays which measure

thrombin inhibition.
13.

After

intravenous

and

subcutaneous

administration

of

equigravimetric doses of heparin and CY 216 to primates, the AUC of CY 216
was greater than for heparin as determined by the amidolytic anti Xa assay
and HeptestR.
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14.

In the intravenous studies the anticoagulant and antiprotease

activities of heparin were more readily neutralized by protamine than the
activities of CY 216.
15. Neutralization after subcutaneous administration of heparin and
CY 216 was dependant upon the bioavailability and time course of the
drugs.

In general, heparin was neutralized more readily than CY 216.
16.

A greater dose dependant decrease in the AUC of heparin was

seen after increasing doses of protamine were administered.

Above a

protamine to heparin (or CY 216) ratio of 2:1, the PNI of heparin was
significantly greater than the PNI value for CY 216.

CHAPTER VII
TABLE 1
BASELINE VALUES OF NHP, NMP, NRP AND NratP

Test

NHP

NMP

NRP

NratP

APTT (seconds)

30.5 ± 2.2

24.4 ± 0.7

56.6 ± 0.8 *

16.1 ± 0.9 *

Thrombin Time
(5 U/ml)
(seconds)

21.1 ± 0.9

31.3 ± 3.6

42.3 ± 2.9 *

HeptestR
(seconds)

15.5 ± 1.2

20.5 ± 1. 7

25.3 ± 0.6

Anti Xa
(% Inhibition)

0 ± 0

0 ± 0

0 ± 0

0 ± 0

Anti Ila
(% Inhibition)

0 ± 0

0 ± 0

0 ± 0

0 ± 0

>150

56.6 ± 0.8 *

Data represents a mean± S.E. N=3. Statistical Analysis was performed
for each laboratory test by a one-way ANOVA, followed by a Newman-Keuls
multiple comparison test. * represents a significant (p <.05)
difference from NHP.
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Table 2·. Da,ta rep.:esents a mean ± S. E. , N=3.
Statistical anaiysis was performed for each laboratory test by a one way
ANOVA, follow~d by a Newrnan-Keuls multiple comparison test.
* represents a significant difference (p <.05) from NHP.
** Pr_otamine caused turbidity in the solution which may be related to
the experimental result.
N.D. - not.determined.

TABLE 2
IN VITRO SUPPLEMENTATION OF PROTAMINE TO
NHP, NMP, NRP AND NratP

r--r--..-I

Test

Protamine
Concentration

NHP

NMP

NRP

NratP
16.1 ± 0.9
15.6 ± 1.1
29.5 ± 5.2
N.D.
N.D.

APTT (seconds)

0
10
100
1
10

µg/ml
µg/ml
µg/ml
mg/ml
mg/ml

30.5 ± 2.2
38.9 ± 1.2
50.2 ± 0.6
>150
>150

24.4 ± 0.7
26.5 ± 0.7
51.1 ± 3.7
N.D.
N.D.

56.6 ± 0.8*
96.5 ± 8.3*
154.0 ± 15.3*
N.D.
N.D.

Thrombin Time (5 ULml}
(seconds)

0
10
100
1
10

µg/ml
µg/ml
µg/ml
mg/ml
mg/ml

21.1 ± 0.9
24.7 ± 0.7
23.8 ± 1.9
19.7 ± 0.8
>150

31. 3 ± 3.6
34.6 ± 4.3
33.8 ± 1.9
N.D.
N.D.

42.3 ± 2.9*
30.7 ± 3.6
32.3 ± 3.7
N.D.
N.D.

>150
>150
>150
N.D.
N.D.

HeI!testR (seconds)

0
10
100
1
10

µg/ml
µg/ml
µg/ml
mg/ml
mg/ml

15. 5 ± 1. 2
18.0 ± 0.2
23.0 ± 0.5
27.3 ± 2.8
>300

20.5 ± 1. 7
23.1 ± 1.2
25.7 ± 4.0
N.D.
N.D.

25.3 ± 0.6
28.9 ± 1.2
28.3 ± 2.5
N.D.
N.D.

56.6 ± 0.8*
63.3 ± 0.8*
56.2 ± 3.1*
N.D.
N.D.

Anti Xa (% Inhibition}

0
10
100
1
10

µg/ml
µg/ml
µg/ml
mg/ml
mg/ml

0
4.6
0
1
53.3

0 ± 0
0 ± 0
2.0 ± 2.0
N.D.
N.D.

0 ± 0
0 ± 0
2.5 ± 1.5
N.D.
N.D.

0 ± 0
0 ± 0
0 ± 0
N.D.
N.D.

Anti Ila (% Inhibition}

0
10
100
1

µg/ml
µg/ml
µg/ml
mg/ml

0 ± 0
1. 2 ± 0
0 ± 0

0 ± 0
0 ± 0
0.3 ± 0.3

0 ± 0
2.6 ± 1.5
5.0 ± 1.8

10 mg/ml

±
±
±
±
±

0
3.3
0
1**
3.0

0 ± 0
0 ± 0
6.4 ± 3.8
0 ± 0
0 ± 0

N.D.

N.D.

N.D.

N.D.

N.D.

N.D.

178

TABLE 3
IN VITRO NEUTRALIZATION OF
HEPARIN BY SPERMIDINE

APTT
(seconds)

Thrombin
Time
(seconds)

Heptest
(seconds)

Anti Xa
%I

Anti Ila
%I

NHP

30.1 ± 0.3

22.3 ± 4.8

15.4 ± 0.1

0 ± 0

0 ± 0

NHP +
Spermidine
(10 Mg/ml)

36.2 ± 0.3

20.6 ± 0.3

16.7 ± 0.4

0 ± 0

0 ± 0

Heparin
(5.0 Mg/ml)

>150

>150

115.2 ± 5.8 44.0 ± 1.5 81.0 ± 1.1

Heparin
(5.0 Mg/ml
and
Spermidine
(2.5 Mg/ml)

>150

>150

108.9 ± 2.2 52.7 ± 0.6 85.0 ± 1.0

Heparin
(5.0 Mg/ml)
and
Spermidine
(S.0 Mg/ml)

>150

>150

111.3 ± 3.9 49.5 ± 1.6 81.0 ± 3.3

Heparin
(S.0 Mg/ml
and
Spermidine
(10.0 Mg/ml)

>150

>150

106.2 ± 5.3 49.0 ± 4.4 67.3 ± 3.2

Heparin
(5.0 Mg/ml)
and
Spermidine
(1.0 mg/ml)

109.3

>150

95.7

66

54

Data represents a mean± S.E., N=3, (except for heparin and spermidine
1.0 mg/ml) where data has an N=l.
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TABLE 4

IN VITRO NEUTRALIZATION OF
CY 216 BY SPERMIDINE

APTT
(seconds)

Thrombin
Time
(seconds)

Heptest
(seconds)

Anti Xa
%I

NHP

30 .1 ± 0. 3

22. 3 ± 0 .1 15. 4 ± 0 .1

0 ± 0

0 ± 0

NHP

+
Spermidine

36. 2 ± 0. 3

20. 6 ± 0. 2 16. 7 ± 0. 4

0 ± 0

0 ± 0

CY 216
(5.0 Mg/ml)

48.0 ± 2.4

>150

68.9 ± 5.7

38.5 ± 2.6 30.8 ± 3.2

CY 216
47.2 ± 2.4
(5.0 Mg/ml)
and
Spermidine
(2.5 Mg/ml)

>150

46 . 2 ± 4. 1

14. 0 ± 1. 8

2 . 7 ± 0. 4

46.4 ± 2.3

>150

72 . 4 ± 1. 7

15 . 7 ± 1. 2

8 . 0 ± 0. 1

CY 216
44.7 ± 0.7
(5.0 Mg/ml)
and
Spermidine
(10 Mg/ml)

>150

64. 1 ± 4. 6

17 . 3 ± 2 . 9

0 . 3 ± 0. 0

148

43.8

45

0

CY 216
(5.0 Mg/ml)
and
Spermidine
(5.0 Mg/ml)

CY 216
(5.0 Mg/ml)
and
Spermidine
(1 mg/ml)

36.8

Anti Ila
%I

Data represents a mean± S.E., N = 3, (except for CY 216 and spermidine
1.0 mg/ml) where data has an N - 1.
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TABLE 5

COAGULATION PARAMETERS OF RABBITS ADMINISTERED
INTRAVENOUS PROTAMINE SULFATE

Treatment

APTT
(seconds}

Thrombin Time
(5 U/ml)
(seconds}

HeptestR
(seconds}

Saline Control

83.9 ± 1.0

32.0 ± 4.1

Protamine
100 Mg/kg i.v.

102.3 ± 9.0

35.3 ± 3.3

Protamine
500 Mg/kg i.v.

97.6

45.6

Anti Xa Anti Ila
(% I}

(%

30.8 ± 3.8

0 ± 0

0 ± 0

28.7 ± 4.2

0 ± 0

0 ± 0

0

0

41.3

I}

Saline or protamine was administered to groups of rabbits (N-5) and
allowed to circulate for 10 minutes. Protamine (500 ug/kg i.v.) group
contained 2 rabbits. Blood was drawn by cardiac puncture just prior to
thrombogenic challenge. APTT, thrombin time, HeptestR, amidolytic anti
Xa and amidolytic anti Ila assays were performed. The results represent
a mean± S.E. Statistical analysis was performed for the APTT results
by an unpaired t-test (two tailed), t=l.649, df-6, p >.20, N.S.
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TABLE 6

COAGULATION PARAMETERS OF RABBITS
ADMINISTERED INTRAVENOUS HEPARIN

Treatment

APTT
(seconds)

Thrombin Time
(5 U/ml)
(seconds)

HeptestR
(seconds)

1.0

32.0 ±

4.1

30.8 ±

3.8

Heparin
25 Mg/kg i.v.

124.7 ± 13.2

46.7 ±

4.4

44.9 ±

9.7

Heparin
50 Mg/kg i.v.

111.2 ± 17.2

132.3 ± 57.1*

76.8 ± 10.6

Heparin
100 Mg/kg i.v.

146.8 ± 29.7*

>150

128.9 ± 27.7*

Saline Control

83.9 ±

Saline or protamine was administered to groups of rabbits (N-5) and
allowed to circulate for 10 minutes. Blood was drawn by cardiac
puncture just prior thrombogenic challenge. APTT, thrombin time, and
HeptestR were performed. The results represent the mean± S.E.
Statistical analysis was performed by a one-way ANOVA.
for APTT, F(3,16)=5.847 p <.05
for thrombin time, F(3,16)-7.028 p <.05
for HeptestR, F(3,16)=5.352 p <.05
Newman-Keuls multiple comparison tests were also performed.
* represents a significant difference from the control group
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TABLE 7

COAGULATION PARAMETERS OF RABBITS
ADMINISTERED INTRAVENOUS CY 216

Treatment

APTT
(seconds)

Thrombin Time
(5 U/ml)
(seconds)

HeptestR
(seconds)

Saline Control

83.9 ±

1.0

32.0 ±

4.1

30.8 ±

3.8

CY 216
25 Mg/kg i.v.

58.0 ±

6.4

37.0 ±

1.6

42.4 ±

4.1

CY 216
50 Mg/kg i.v.

49.1 ± 14.4

50.7 ±

9.3*

42.1 ±

2.1

CY 216
100 Mg/kg i.v.

67.7 ± 12.9

49.1 ± 10.1*

63.6 ± 11.8*

Saline or protamine was administered to groups of rabbits (n=S) and
allowed to circulate for 10 minutes. Blood was drawn by cardiac
puncture just prior to thrombogenic challenge. APTT, Thrombin time, and
HeptestR were performed. The results represent the mean± S.E.
Statistical analysis was performed by a one way ANOVA for each
individual assay followed by a Newman-Keuls multiple comparison test.
for APTT;F(3,12)=.468 p >50, N.S.
for thrombin time:F(3,12)=19.860, p <.05
for HeptestR:F(3,12)=5.488, p <.05
* represents a significant difference from the control group.
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Table 8 .· .-. S~line ,. heparin or CY 216 was administered to groups of
rabbits (N-5) and allowed to circulate for 5 minutes at which time
protamine was administered to groups which received heparin or CY 216.
Blood was drawn 5 minutes after protamine administration or 10 minutes
after saline administration for the control group. A thrombogenic
challenge was· administered immediately after blood draw. APTT, thrombin
time, and·HeptestR were performed. The results represent the mean±
S.E. Statistical analysis was performed by a two-way ANOVA.
for APTT
Factor A (drug treatment):F(2,36)-2.655 p >.10 N.S.
Factor B (protamine concentration):F(2,36)-4.365 p <.05
Factor Ax B:F(4,36)-3.288 p >.10 N.S.
for thrombin time
Factor A (drug treatment):F(2,36)-55.707 p <.05
Factor B (protamine concentration):F(2,36)-65.638 p <.05
Factor Ax B:F(4,36)-56.264 p <.001
for HeptestR
Factor A (drug treatment):F(2,36)-7.142 p <.05
Factor B (protamine concentration):F(2,36)-7.443 p<.05
Factor Ax B:(4,36)-4.198 p>.05 N.S.
Newman-Keuls multiple comparison tests were also performed.
*
represents a significant difference from the control group.
**
represents a significant difference from the heparin (100
µg/kg i.v.) and protamine (100 µg/kg i.v.) group.
represents a significant difference from the CY 216 (100 µg/kg
***
i.v.) and protamine (100 µg/kg i.v.) group.

.

,
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TABLE 8

COAGULATION PARAMETERS OF RABBITS ADMINISTERED
INTRAVENOUS HEPARIN OR CY 216 AND PROTAMINE

APTT
(seconds)

Thrombin Time
(5 U/ml)
(seconds)

Saline Control

83.9 ± 1.0

32.0 ± 4.1

Heparin
100 Mg/kg i.v.

146.8 ± 29.7

>150

128.9 ± 27.7*

Heparin
100 Mg/kg i.v.
and Protamine
100 Mg/kg i.v.

57.6 ± 10.2

40.3 ± 5.2

37.2 ± 6.8

Heflarin
10 Mg/kg i.v.
and Protamine
200 Mg/kg i.v.

122.9 ± 12.3**

37.5 ± 1. 9

47.0 ± 2.0

CY 216
100 Mg/kg i.v.

67.7 ± 12.9

49.1 ± 10.7*

63.6 ± 11.8*

CY 216
100 Mg/kg i.v.
and Protamine
100 Mg/kg i.v.

58.0 ± 13.6

34.1 ± 3.4

46.2 ± 4.1

38.4 ± 3.1

43.4 ± 1. 3

Treatment

CY 216
100 Mg/kg i. v.
and Protamine
200 Mg/kg i.v.

113.0 ± 6.6***

HeptestR
(seconds)
30.8 ± 3.8
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Table 9; :::Salin~, . heparin or CY 216 was administered to groups of
rabbits' (N-5'-) a~d allowed to circulate for 5 minutes at which time
protamine.wai'administered to groups which received heparin or CY 216.
Blood was drawn 5 minutes after protamine administration or 10 minutes
after saline administration for the control group. Thrombogenic
challenge was ~dministered immediately after blood draw. APTT, thrombin
time, and HeptestR were performed. The results represent the mean±
S.E. Statistical analysis was performed by a two-way ANOVA.
for APTT
Factor A (drug treatment):F(2,24)-1.032 p >.SO N.S.
Factor B (protamine concentration):F(l,24)-.33 p >.50 N.S.
Factor Ax B:F(2,24)-2.793 p >.10 N.S.
for thrombin time
Factor A (drug treatment):F(2,24)-12.245 p <.05
Factor B (protamine concentration):F(l,24)-2.401 p <.05
Factor Ax B:F(2,24)-1.061 p >.50 N.S.
for HeptestR
Factor A:F(2,24)-2.999 p >.10 N.S.
Factor B:F(l,24)-.184 p >.SO N.S.
Factor Ax B:F(2,24)-1.982 p >.20 N.S.
Newman-Keuls multiple comparison tests were also performed.
* Represents a significant difference from the control group.
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TABLE 9

COAGUI.ATION PARAMETERS OF RABBITS ADMINISTERED
SUBCUTANEOUS HEPARIN OR CY 216 AND PROTAMINE

APTT
(seconds)

Thrombin Time
(5 U/ml)
(seconds)

Saline Control

83.9 ± 1.0

32.0 ± 4.1

30.8 ± 3.8

Heparin
1 mg/kg s.c.

61. 0 ± 10. 5

128.8 ± 13.4*

62.4 ± 12.4*

Heparin
1 mg/kg s.c.
and Protamine
1 mg/kg i.v.

78.8 ± 18.7

85.9 ± 25.1*

39.5 ± 5.7*

CY 216
1 mg/kg s.c.

95.4 ± 4.4

54.8 ± 8.9

42.7 ± 12.2*

CY 216
1 mg/kg s.c.
and Protamine
1 mg/kg i.v.

73.7 ± 12.0

37.8 ± 5.2

58.4 ± 10.2*

Treatment

HeptestR
(seconds)
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TABLE 10

COAGUIATION PARAMETERS AFTER INTRAVENOUS
PROTAMINE ADMINISTRATION IN RABBITS

Treatment (N)

Thrombin Time
(5 U/ml)
(seconds)

HeptestR
(seconds)

Anti Xa

Anti Ila

(% I)

(% I)

Saline Control (5)

30.1

± 3.3

24.8

± 3.0

0

Protamine
2 mg/kg i.v. (4)

37.0

± 1.5

26.4

± 3.7

2.0

Protamine
3 mg/kg i.v. (3)

33.2

± 7.3

22.4

± 0.7

0

±0

0

±0

± 1. 7

0

±0

±0

0

±0

Saline or protamine was administered to rabbits and allowed to circulate
for 10 minutes. Blood was drawn by cardiac puncture just prior to blood
loss determination. Thrombin time, HeptestR, amidolytic anti Xa and
amidolytic anti Ila assays were performed. The results represent a mean
± S.E.
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TABLE 11

COAGULATION PARAMETERS AFTER INTRAVENOUS
HEPARIN ADMINISTRATION IN RABBITS

Treatment (N)
Saline Control (5)

APTT
(seconds)

Thrombin Time
(5 U/ml)
(seconds)

HeptestR
(seconds)

83.2 ± 11.5

30.l ± 3.3

24.8 ± 3.0

Heparin
1 mg/kg i.v. (6)

>150

>300

>271. 5

Heparin
2 mg/kg i.v. (14)

>150

>300

>300

Saline or heparin was administered to rabbits and allowed to circulate
for 10 minutes. Blood was drawn by cardiac puncture just prior to blood
loss determination. Thrombin time, HeptestR, amidolytic anti Xa and
amidolytic anti Ila assays were performed. The results represent a mean
± S.E.
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TABLE 12

COAGULATION PARAMETERS AFTER INTRAVENOUS
CY 216 ADMINISTRATION IN RABBITS

Treatment (N)

APTT
(seconds)

Thrombin Time
(5 U/ml)
(seconds)

Saline Control (5)

83.2 ± 11.5

30.1 ± 3.3

24.8 ± 3.0

CY 216
1 mg/kg i.v. (5)

>150

>150

138.1 ± 7.0 *

CY 216
2 mg/kg i.v. (13)

>150

>150

>296.1 ± 3.9

CY 216

>150

>150

>300

HeptestR
(seconds)

Saline or CY 216 was administered to rabbits and allowed to circulate
for 10 minutes. Blood was drawn by cardiac puncture Just prior to blood
loss determination. APTT, Thrombin time, and Heptest were performed.
The results represent a mean± S.E. Statistical analysis for the
heptestR data was performed by an unpaired t test (two tailed).
t=6.332, df=8, p <.05. * represents a significant difference from the
control group.
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Table 13. S�line,, heparin, or CY 216 was administered to rabbits and
allowed to circulate for 5 minutes at which time protamine was
administered _to groups which received heparin or CY 216. Blood was
drawn 5 minutes after protamine administration or 10 minutes after
saline administration for the control group. Blood loss was determined
immediately after the blood draw. APTT, thrombin time, and HeptestR
were performed. The results represent the mean± S.E. Statistical
analysis was performed by a two way ANOVA.
for thrombin time
Factor A (drug treatment):F(2,36)=34.960 p <.05
Factor B (protamine concentration):(2,36)=37.654 p <.05
Factor Ax B:F(4,36)=12.382 p <.05
for HeptestR
Factor A (drug treatment):F(2,36)=22.275 p <.05
Factor B (protamine concentration):F(2,36)=19.477 p <.OS
Factor Ax B:F(4,36)=5.684 p <.05
Newman-Keuls multiple comparison tests were also performed.
*
represents significant difference from control group.
**
represents a significant difference from CY 216 (2 mg/kg i.v.)
and protamine (3 mg/kg i.v.) group.
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TABLE 13

COAGUIATION PARAMETERS OF RABBITS ADMINISTERED INTRAVENOUS
HEPARIN OR CY 216 AND PROTAMINE

Treatment (N)

APTT
(seconds)

Thrombin Time
(5 U/ml)
(seconds)

HeptestR
(seconds)

83.2 ± 11.5

32.0 ± 3.1

24.8 ± 3.0

>150

>150

>300

82.7 ± 11.5

>150

166.o ± 55_5*

87.6 ± 7.5

33.4 ± 2.4

58.4 ± 3.7

CY 216
2 mg/kg i.v. (13)

>150

>150

CY 216
2 mg/kg i.v. (6)
and Protamine
2 mg/kg i.v.

111.3 ± 24.5

73.3 ± 18.8**

CY 216
2 mg/kg i.v. (5)
and Protamine
3 mg/kg i.v.

108.1 ± 14.5

47.1 ± 10.5

Saline Control (5)
Heparin
2 mg/kg i.v. (14)
Heparin
2 mg/kg i.v. (6)
and

Protamine

2 mg/kg i.v.

Heparin
2mg/kg i.v. (5)
and Protamine

3 mg/kg i.v.
>296.1 ± 3.9
138.1 ± 45.5*

153 ± 47.l*
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TABLE 14

COAGULATION PARAMETERS OF RABBITS ADMINISTERED SUBCUTANEOUS
HEPARIN OR CY 216 AND PROTAMINE

Treatment (N)
Saline Control (5)
Heparin
3 mg/kg s . c . ( 5)
Heparin
3 mg/kg s.c. (5)
and Protamine
3 mg/kg i.v.

APTT
(seconds)
83.2 ± 11.5
>130.8 ± 11. 7
80.1 ±

9.0

CY 216
3 mg/kg s . c . ( 5)

89.2 ± 18.4

CY 216
3 mg/kg s.c. (5)
and Protamine
3 mg/kg i.v.

71.7 ± 16.7

Thrombin Time
(5 U/ml)
(seconds)
32.0 ± 3.1
>150

24.8 ±

3.0

>216.9 ± 49.4

27.5 ± 2.0

>150
31.0 ±

HeptestR
(seconds)

42.3 ±

7.3

67.7 ± 18.5*
3.1

62.9 ± 12.5*

Saline, heparin or CY 216 was administered subcutaneously to rabbits and
allowed to circulate for 125 minutes at which time protamine was
administered to groups which received heparin or CY 216. Blood was
drawn 5 minutes after protamine administration or 130 minutes after
saline administration for the control group. Blood loss was determined
immediately after blood draw. APTT, thrombin time, and HeptestR were
performed. The results represent the mean± S.E. Statistical analysis
was performed bl a two way ANOVA.
for Heptest
Factor A (drug treatment):F(2,17)-10.131 p <.05
Factor B (protamine concentration):F(l,17)-8.902 p <.05
Factor Ax B:F(2,17)-10.365 p <.05
¼Newman-Keuls multiple comparison test was also performed.
represents a significant difference from the control group.
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TABLE 15

COMPARATIVE PHARMACODYNAMIC TIME COURSE
PARAMETERS OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

Anti Xa
Heparin
(0,35 mgLkg i.v, l

CY 216
(0,35 mgLkg i,v, l

AUC (µg-hr-m- 1 )

5.97 ± 0.70

14.91 ±

2.46*

AUMC (µg-hr 2 -ml- 1 )

7.83 ± 1.60

33.08 ±

7.93

MRT (min)

77.4

± 8.68

127.80 ± 12.05*

Clp (ml-min- 1 - kg- 1 )

1.00 ± 0.20

0.43 ±

o.05*

Vd (l-kg- 1 )

0.08 ± 0.01

0.05 ±

0.01

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-4 for heparin (0.35 mg/kg i.v.) group.
N-5 for CY 216 (0.35 mg/kg i.v.) group. Statistical analysis was
performed by an unpaired student's t-test:
for AUC:t-3.340, df-8, p <.05
for MRT:t-3.244, df-8, p <.05
for Clp:t-2.555, df-8, p <.05
for Vd:t-1.716, df-8, p >.10 N.S.
* represents a significant difference from the heparin (0.35 mg/kg i.v.)
group.
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TABLE 16

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

Anti Xa
Heparin
(0.7 mg/kg i.v.)

CY 216
( 0 • 7 mg/kg i. v. )

AUC (µg-hr-ml- 1 )

22.41 ± 3.06

19.32 ± 2.37

AUMC (µg-hr 2 -ml- 1 )

21.50 ± 4.25

24.02 ± 4.78

MRT (min)

55.80 ± 5.74

71.40 ± 8.04

Clp (ml-min- 1 -kg- 1 )

0.55 ± 0.07

0.65 ± 0.09

Vd (l-kg- 1 )

0.03 ± 0.01

0.05 ± 0.00

Primate pharmacodynarnic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-5 for heparin (0.7 mg/kg i.v.) group.
N-5 for CY 216 (0.7 mg/kg i.v.) group. Statistical analysis was
performed by an unpaired student's t-test:
for AUC:t-0.853, df=9, p >.20 N.S.
for MRT:5-1.549, df-9, p >.10 N.S.
for Clp:t-0.832, df-9, p >.20 N.S.
for Vd:t-1.332, df-9, p >.20 N.S.
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TABLE 17

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

Anti Xa
Heparin (0.7 mg/kg i.v.)
with
Protamine (0,7 mg/kg i.v,)

CY 216 (0.7 mg/kg i.v.)
with
Protamine (0,7 mg/kg i,v,)

AUG
(µg-hr-ml- 1 )

3.73 ±

0.60

8. 26 ±

AUMC
(µg-hr 2 -ml- 1 )

6 .09 ± 1. 35

15.52 ±

MRT (min)
PNI

93.00 ± 13.90
0.83 ± 0.01

1. 35*

3.63

112.70 ± 15.30
0.57 ±

0.04*

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-4 for heparin (0.7 mg/kg i.v.) and
protamine (0.7 mg/kg i.v.) group. N-4 for CY 216 (0.7 mg/kg i.v.) and
protamine (0.7 mg/kg i.v.) group. Statistical analysis was performed by
an unpaired student's t-test:
for AUC:t-3.084, df-7, p <.05
for MRT:t-0.862, df-7, p >.20 N.S.
for PNI:t-3.109, df-7, p <.05
* represents a significant difference from the heparin (0.7 mg/kg i.v.)
with protamine (0.7 mg/kg i.v.) group.
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TABLE 18

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

Anti Xa
Heparin (0.7 mg/kg i.v.)
with
Protamine (1.4 mg/kg i.v.)

AUC

3.60 ± 0.74

CY 216 (0.7 mg/kg i.v.)
with
Protamine (1.4 mg/kg i.v.)
9.50 ±

0.98*

19.19 ±

2.89

(µg-hr-ml- 1 )
AUMC

6.88 ±

2.37

(µg-hr 2 -ml- 1 )

MRT (min)
PNI

102.60 ± 17.14
0.84 ±

0.02

124.80 ± 20.80
0.51 ±

0.06*

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-5 for heparin (0.7 mg/kg i.v.) and
protamine (1.4 mg/kg i.v.) group. N-4 for CY 216 (0.7 mg/kg i.v.) and
protamine (1.4 mg/kg i.v.) group. Statistical analysis was performed by
an unpaired student's t-test:
for AUC:t-4.614, df-8, p <.05
for MRT:t-0.800, df-8, p >.20 N.S.
for PNI:t-5.281, df-8, p <.05
* represents a significant difference from heparin (0.7 mg/kg i.v.) and
protamine (1.4 mg/kg i.v.) group.
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TABLE 19

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

Anti Xa
Heparin (0.7 mg/kg i.v.)
with
Protamine (2.1 mg/kg i.v.)

CY 216 (0.7 mg/kg i.v.)
with
Protamine (2.1 mg/kg i.v.)

AUC
(µg-hr-ml- 1 )

2.35 ±

0.21

5.14 ± 0.64*

AUMC
(µg-hr 2 -ml- 1 )

8.43 ±

3.81

5.27 ± 1.34

67.80 ± 48.00

58.20 ± 7.50

MRT (min)
PNI

0.90 ±

0.01

0.73 ±

.02*

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-4 for heparin (0.7 mg/kg i.v.) and
protamine (2.1 mg/kg i.v.) group. N-3 for CY 216 (0.7 mg/kg i.v.) and
protamine (2.1 mg/kg i.v.) group. Statistical analysis was performed by
an unpaired student's t-test:
for AUC:t-3.788, df-6, p <.05
for MRT:t-1.334, df-6, p >.20 N.S.
for PNI:t-4.362, df-6, p <.05
* represents a significant difference from heparin (0.7 mg/kg i.v.) and
protamine (2.1 mg/kg i.v.) group.
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TABLE 20

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

Anti Xa
Heparin (0.7 mg/kg s.c.)
4. 33 ± .1. 33

AUMC
(µg-hr 2 -ml- 1 )
MR.T (min)
Clp
(ml-min- 1 -kg- 1 )

CY 216 (0.7 mg/kg s.c.)
31.61 ±

4.32*

20.23 ±

6.64

178.24 ± 29.89

276.00 ±

6.46

335.10 ± 11.87*

3.70 ±

0.44

o.39 ±

o.05*

0.01 ±

0.00

0.001 ±

o.oo*

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-5 for heparin (0.7 mg/kg s.c.) and
protamine (0.7 mg/kg i.v.) group. N-4 for CY 216 (0.7 mg/kg s.c.) and
protamine (0.7 mg/kg i.v.) group. Statistical analysis was performed by
an unpaired student's t-test:
for AUC:t-6.683, df-8, p <.05
for MRT:t-3.006, df-8, P <.05
for Clp:t-2.988, df-8, p <.05
for Vd:t-2.813, df-8, p <.05
* represents a significant difference from heparin (0.7 mg/kg s.c.) and
protamine (0.7 mg/kg i.v.) group.
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TABLE 21

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

Anti Xa
Heparin (0.7 mg/kg s.c.)
with
Protamine (0.7 mg/kg i.v.)

AUC

CY 216 (0.7 mg/kg s.c.)
with
Protamine (0.7 mg/kg i.v.)

2.58 ±

0.41

22. 70 ± 1.40*

13.56 ±

2.00

107.58 ± 8.05

330.60 ± 37.00

286.10 ± 3.59

(µg-hr-ml- 1 )
AUMC

(µg-hr 2 -ml- 1 )
MRT (min)
PNI

0.40 ±

0.09

0.20 ± 0.06

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-5 for heparin (0.7 mg/kg s.c.) and
protamine (0.7 mg/kg i.v.) group. N-4 for CY 216 (0.7 mg/kg s.c.) and
protamine (0.7 mg/kg i.v.) group. Statistical analysis was performed by
an unpaired student's t-test:
for AUC:t-13.843, df-8, p <.05
for MRT:t-1.058, df-8, p >.20 N.S.
for PNI:t-1.655, df-8, p >.10 N.S.
* represents a significant difference from heparin (0.7 mg/kg s.c.) with
protamine (0.7 mg/kg i.v.) group.
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TABLE 22

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

Anti-Xa
CY 216 (0.7 mg/kg s.c.) with
Protamine (1,4 mg/kg i.v.)

AUC (µg-ml -l)

22.30 ± 1.30

AUMC (µg-hr 2 -ml- 1 )

89.34 ± 17.77

MRT (min)
PNI

237.00 ± 35.1
0.21 ±

0.05

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-5 for CY 216 (0.7 mg/kg s.c.) and
protamine (1.4 mg/kg i.v.) group.
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TABLE 23

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

HeptestR
Heparin (0.35 mg/kg i.v.)

CY 216 (0.35 mg/kg) i.v.)

AUC
(µg-hr-ml- 1 )

3.73 ±

0.56

6. 54 ±

1. 67*

AUMC
(µg-hr 2 -ml- 1 )

1.55 ±

1.00

11.20 ±

0.45

MRT (min)
Clp
(ml-min- 1 -kg- 1 )

24.00 ± 12.00

114. 72 ± 13.68*

1.59 ±

0.23

1.07 ±

0.18*

0.04 ±

0.02

0.02 ±

0.01

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-3 for heparin (0.35 mg/kg i.v.) group.
N-4 for CY 216 (0.35 mg/kg i.v.) group. Statistical analysis was
performed by an unpaired student's t-test:
for AUC:t-3.476, df-6, p <.05
for MRT:t-4.128, df-6, p <.05
for Clp:t-6.666, df-6, p <.05
for Vd:t=0.398, df-6, p >.70 N.S.
* represents a significant difference from heparin (0.35 mg/kg i.v.)
group.
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TABLE 24

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

HeptestR
He~arin (0.7 mgLkg i,v, l

CY 216 (0, 7 mgLkg) i.v. l

AUC
(µg-hr-ml- 1 )

18.36 ±

1.28

27.15 ±

3.45*

AUMC

18.37 ±

2.94

24.84 ±

5.56

58.80 ±

6.79

53.28 ±

7.27

Clp
(ml-min- 1 -kg- 1 )

0.65 ±

0.05

0.56 ±

0.14*

Vd
(l-kg- 1 )

0.04 ±

0.01

0.02 ±

0.00

(µg-hr 2 -ml- 1 )

MRT (min)

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-5 for both groups. Statistical
analysis was performedby an unpaired student's t-test:

for AUC:t-2.540, df-9, p <.05
for MRT:t-0.128, df-9, p >.50 N.S.
for Clp:t-2.488, df-9, p <.05
for Vd:t-0.416, df-9, p >.50 N.S.
* represents a significant difference from the heparin (0.7 mg/kg i.v.)
group.
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TABLE 25

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

HeptestR
Heparin (0.7 mg/kg i.v.)
with
Protamine (0.7 mg/kg i.v.)

CY 216 (0.7 mg/kg i.v.)
with
Protamine (0,7 mg/kg i,v,)

AUC
(µg-hr-ml- 1 )

12.41 ± 2.14

18.96 ± 0.64*

AUMC
(µg-hr 2 -ml- 1 )

12.63 ± 2.99

23.90 ± 3.31

MRT (min)

59.40 ± 7.50

75.20 ± 9.01

PNI

0.30 ± 0.06

0.30 ± 0.01

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-4 for both groups. Statistical analysis
was performed by an unpaired student's t-test:
for AUC:t-2.601, df-7, p >.05
for MRT:t-1.187, df-7, p >.20 N.S.
for PNI:t-0.186, df-7, p >.50 N.S.
* represents a significant difference from the heparin (0.7 mg/kg i.v.)
with protamine (0.7 mg/kg i.v.) group.
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TABLE 26

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

HeptestR
Heparin (0.7 mg/kg i.v.)
with
Protamine (1.4 mg/kg i.v.)

AUC
(µg-hr-ml- 1 )

3.72 ±

0.52

AUMC
(µg-hr 2 -ml- 1 )

5 .42 ±

1.48

MRT (min)
PNI

81. 60 ± 10. 98
0.80 ±

0.01

CY 216 (0.7 mg/kg i.v.)
with
Protamine (1.4 mg/kg i.v.)
12.01 ± 1.09*
9 .13

± 1. 70

46.20 ± 4.20*
0.56 ± 0.04*

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-5 for heparin (0.7 mg/kg i.v.) and
protamine (1.4 mg/kg i.v.) group. N-4 for CY 216 (0.7 mg/kg i.v.) and
protamine (1.4 mg/kg i.v.) group. Statistical analysis was performed by
an unpaired student's t-test:
for AUC:t-3.878, df-8, p <.05
for MRT:t-9.043, df-8, p <.05
for PNI:t-4.247, df-8, p >.05
* represents a significant difference from heparin (0.7 mg/kg iv.) and
protamine (1.4 mg/kg i.v.) group.
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TABLE 27

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

HeptestR
Heparin (0.7 mg/kg i.v.)
with
Protarnine (2.1 mg/kg i.v.)

CY 216 (0.7 mg/kg i.v.)
with
Protamine (2.1 mg/kg i.v.)

AUC
(µg-hr-ml -l)

2.17 ±

0.27

11.210 ±

0.64*

AUMC

2.73±

1.13

19.250 ±

4.94

(µg-hr 2 -ml- 1 )
MRT (min)
PNI

75.20 ± 28.40
0.88 ±

0.01

100. 200 ± 21. 70*
0.59 ±

0.01

Primate pharmacodynamic time course parameters were determined by a
noncompartrnental model.
Data represents a mean± S.E. N-4 for heparin (0.7 mg/kg i.v.) and
protarnine (2.1 mg/kg i.v.) group. N-3 for CY 216 (0.7 mg/kg i.v.) and
protarnine (2.1 mg/kg i.v.) group. Statistical anqalysis was performed
by an unpaired student's t-test:
for AUC:t-12.862, df-6, p <.05
for MRT:t-1.755, df-6, p <.10 N.S.
for PNI:t-11.218, df-6, p <.05
* represents a significant difference from heparin (0.7 mg/kg i.v.) and
protarnine (2.1 mg/kg i.v.) group.

206

TABLE 28

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test: Heptest
Heparin (0.7 mg/kg s.c.)
AUC
(µg-hr-ml- 1 )
AUMC

CY 216 (0.7 mg/kg) s.c.)

4.33 ±

1.33

31. 61 ±

4. 32 *

20.23 ±

6.64

178.24 ±

29.89

276.00 ±

6.46

3.70 ±

0.44

0.39 ±

0.01 ±

0.00

0.001 ±

(µg-hr 2 -ml- 1 )
MRT (min)
Clp
(ml-min- 1 -kg- 1 )

335 .10 ± 11. 87*

o.os*
o.oo*

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-5 for heparin (0.7 mg/kg s.c.) and
protamine (0.7 mg/kg i.v.) group. N-4 for CY 216 (0.7 mg/kg s.c.) and
protamine (0.7 mg/kg i.v.) group. Statistical analysis was performed by
an unpaired student's t-test:
for AUC:t-6.683, df-8, p <.05
for MRT:t-3.006, df-8, p <.05
for Clp:t-2.988, df=8, p <.05
for Vd:t-2.813, df-8, p <.OS
* represents a significant difference from the heparin (0.7 mg/kg s.c.)
group.
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TABLE 29

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

HeptestR
Heparin (0.7 mg/kg s.c.)
with
Protamine (0.7 mg/kg i.v.)

CY 216 (0.7 mg/kg s.c.)
with
Protamine (0.7 mg/kg i.v.)

AUC
(µg-hr-ml- 1 )

2.77 ±

0.29

20.62 ±

3.86*

AUMC

8.93 ±

1.08

77.86 ± 16.28

(µg-hr 2 -ml- 1 )
MRT (min)

PNI

192.60 ± 10.45
0.51 ±

0.05

225.00 ± 7.17*
0 ±

0.19*

Primate pharmacodynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-5 for heparin (0.7 mg/kg s.c.) and
protamine (0.7 mg/kg i.v.) group. N-4 for CY 216 (0.7 mg/kg s.c.) and
protamine (0.7 mg/kg i.v.) group. Statistical analysis was performed by
an unpaired student's t-test:
for AUC:t-5.110, df-8, p <.05
for MRT: t-2.401, df-8, P <.05
for PNI: t-8.746, df-8, p >.05
* represents a significant difference from heparin (0.7 mg/kg s.c.) and
protamine (0.7 mg/kg i.v.) group.
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TABLE 30

COMPARATIVE PHARMACODYNAMIC TIME COURSE PARAMETERS
OF PRIMATES ADMINISTERED HEPARIN OR CY 216

Test:

HeptestR
CY 216 (0.7 mg/kg s.c.) with
Protamine (1.4 mg/kg i.v.)

AUC (µg-ml- 1 )

10.08 ± 1.47

AUMC (µg-hr 2 -ml- 1 )

42.36 ± 4.44

MRT (min)
PNI

257.40 ± 11.70
0.03 ±

0.14

Primate pharmacdynamic time course parameters were determined by a
noncompartmental model.
Data represents a mean± S.E. N-5 for CY 216 (0.7 mg/kg s.c.) and
protamine (1.4 mg/kg i.v.) group.
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TABLE 31

% NEUTRALIZATION OF INTRAVENOUSLY ADMINISTERED
HEPARIN OR CY 216

Test:

Anti-Xa

Protamine:Heparin (mg/kg)
or
frotamine:CY 216 (mgLkg}
%N

1:1
(% I.)*

%N

2;1
(% I.)*

Heparin (100 µg/kg i.v.)
in rabbits

90

(25.0)

90

(25.0)

Heparin (2 mg/kg i.v.)
in rabbits

96

(70. 2)

100

(70. 2)

Heparin (0.7 mg/kg i.v.)
in primates

88

(92)

89.6

(92.0)

CY 216 (100 µg/kg i.v.)
in rabbits

0

(1.8)

0

(1.8)

CY 216 (2 mg/kg i.v.)
in rabbits

so

(50.9)

75

(50.9)

CY 216 (0.7 mg/kg i.v.)
in primates

89.3

(91)

79.8

(91)

%N

100

92.7

3;1
(% I.)*

(92)

(91)

* - heparin or CY 216 activity (pre protamine).

Percent neutralization for the amidolytic anti Xa data obtained from the
rabbit stasis thrombosis experiments (100 µg/kg i.v.), the rabbit blood
loss experiments (2 mg/kg i.v.) and the primate pharmacodynamic
experiments were calculated as described in methods. Percent N was
calculated at the 30 minute time period for the primates and the 10
minute time period for the rabbits.
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TABLE 32

% NEUTRALIZATION OF INTRAVENOUSLY ADMINISTERED
HEPARIN OR CY 216

Test:

Anti-Ila

Protamine:Heparin (mg/kg)
or
Protamine:CY 216 (mgLkg)
%N

1;1
(% I.)*

%N

2:1
(% I.)*

Heparin (100 µg/kg i.v.)
in rabbits

96

(32.4)

92

(32.4)

Heparin (2 mg/kg i.v.)
in rabbits

94

(92.4)

99

(92.4)

Heparin (0.7 mg/kg i.v.)
in primates

91

(90.6)

89.6

(90.6)

CY 216 (100 µg/kg i.v.)
in rabbits

0

(5.8)

0

(5.8)

CY 216 (2 mg/kg i.v.)
in rabbits

64

(72.1)

100

(72.1)

CY 216 (0.7 mg/kg i.v.)
in primates

89

(68.2)

80

(68.2)

*

%N

3:1
(% I.)*

100

(90.6)

83

(68.2)

- heparin or CY 216 activity (pre protamine).

Percent neutralization for the amidolytic anti Ila data obtained from
the rabbit stasis thrombosis experiments (100 µg/kg i.v.), the rabbit
blood loss experiments (2 mg/kg i.v.) and the primate pharrnacodynamic
experiments were calculated as described in methods. Percent N was
calculated at the 30 minute time period for the primates and the 10
minute time period for the rabbits.
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TABLE 33

% NEUTRALIZATION OF SUBCUTANEOUSLY ADMINISTERED
HEPARIN OR CY 216
Test:

Anti-Xa

Protamine:Heparin (mg/kg)
or
lrotamine:CY 216 (mg/kg)

1:1
% N

(% I.)*

Heparin (1 mg/kg s.c.) in rabbits

19

(15.8)

Heparin (2.5 mg/kg S. C.) in rabbits

94

(30.0)

Heparin (0.7 mg/kg s .c.) in primates

18

(7. 3)

CY

216 (1 mg/kg s.c.) in rabbits

33

(22.5)

CY

216 (2.5 mg/kg s .c.) in rabbits

31

(40.3)

CY

216 (0.7 mg/kg s .c.) in primates

41

(53.0)

* - heparin or CY 216 activity (pre protarnine).

Percent neutralization for the amidolytic anti Xa data obtained from the
rabbit stasis thrombosis experiments (1 mg/kg s.c.), the rabbit ear
blood loss experiments (2.5 mg/kg s.c.) and the primate pharmacodynarnic
experiments was calculated as described in methods. Percent N was
calculated at the 245 minute time period for the primates and the 120
time period for the rabbits.
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TABLE 34

% NEUTRALIZATION OF SUBCUTANEOUSLY ADMINISTERED
HEPARIN OR CY

Test:

216

Anti-Ila

Protamine:Heparin (mg/kg)
or
Protamine:CY 216 (mg/kg)

1:1
%

N

(% I.)*

Heparin (1 mg/kg s.c.) in rabbits

14

(16.2)

Heparin (2.5 mg/kg s .c.) in rabbits

95

(73.0)

Heparin (0. 7 mg/kg s .c.) in primates

28.6

(7.0)

CY 216 (1 mg/kg s.c.) in rabbits

0

(7 .0)

CY 216 (2.5 mg/kg s .c.) in rabbits

91

(51.3)

CY 216 (0.7 mg/kg S. C.) in primates

71

(13.0)

* - heparin or CY 216 activity (pre protamine).

Percent neutralization for the amidolytic anti Ila data obtained from
the rabbit stasis thrombosis experiments (1 mg/kg s.c.), the rabbit ear
blood loss experiments (2.5 mg/kg s.c.) and the primate pharmacodynamic
experiments was calculated as described in methods. Percent N was
calculated at the 245 minute time period for the primates and the 120
time period for the rabbits.

CHAPTER VIII
FIGURES

IN VITRO SUPPLEMENTATION OF HEPARIN TO POOLED PLASMA
TEST:APTT
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Figure 1. Heparin was supplemented to NHP, NMP, NRP and NratP in a
concentration range of 0-10 µg/ml.
Anticoagulant activity was
determined by the APTT. Data represents a mean± S.E. The experiment
was performed in triplicate on seperate days.
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IN VITRO SUPPLEMENTATION OF CY 216 TO POOLED PLASMA
TEST:APTT
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Figure 2.
CY 216 was supplemented to NHP, NMP, NRP and NratP in a
concentration·· range of 0-10 µ.g/ml.
Anticoagulant activity was
determined by the APTT. Data represents a mean± S.E. The experiment
was performed in triplicate on separate days.
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IN VITRO SUPPLEMENTATION OF HEPARIN TO POOLED PLASMA
TEST:HEPTEST
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Figure 3.
Heparin was supplemented to NHP, NMP, NRP and NratP in a
concentration range of 0-10 µg/ml. Antiprotease activity was determined
by the Heptes tR.
Data represents a mean ± S. E.
The experiment was
performed in triplicate on separate days.
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IN VITRO SUPPLEMENTATION OF CY 216 TO POOLED PLASMA
TEST:HEPTEST
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Figure 4.
CY 216 was supplemented to NHP, NMP, NRP and NratP in a
concentration range of 0-10 µg/ml. Antiprotease activity was determined
by the HeptestR.
Data represents a mean± S.E.
The experiment was
performed in triplicate on separate days.
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IN VITRO SUPPLEMENTATION OF HEPARIN TO POOLED PLASMA
TEST:ANTI XA
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Figure 5.
Heparin was supplemented to NHP, NMP, NRP and NratP in a
concentration range of 0-10 µg/ml. Antiprotease activity was determined
by an amidolytic anti Xa assay.
Data represents a mean± S.E. The
experiment was performed in triplicate on separate days.
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IN VITRO SUPPLEMENTATION OF CY 216 TO POOLED PLASMA
TEST:ANTI XA
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Figure 6.
CY 216 was supplemented to NHP, NMP, NRP and NratP in a
concentration range of 0-10 µg/ml. Antiprotease activity was determined
by an amidolytic anti Xa assay.
Data represents a mean± S.E.
The
experiment was performed in triplicate on separate days.
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IN VITRO SUPPLEMENTATION OF HEPARIN TO POOLED PLASMA
TEST :ANTI IIA
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Figure 7.
Heparin was supplemented to NHP, 1'.'M.P, NRP and NratP in a
concentration range of 0-10 µg/ml. Antiprotease activity was determined
by an amidolytic anti Ila assay.
Data represents a mean± S.E.
The
experiment was performed in triplicate on separate days.
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IN VITRO SUPPLEMENTATION OF CY 216 TO POOLED PLASMA
TEST:ANTI IIA
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Figure 8.
CY 216 was supplemented to NHP, NMP, NRP and NratP in a
concentration range of 0-10 µg/ml. Antiprotease activity was determined
by an amidolytic anti Ila assay.
Data represents a mean± S.E.
The
experiment was performed in triplicate on separate days.
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Fig'll'.te 9. Heparin or CY 216 was supplemented to NHP (upper panel)
or ... t:o::NMP (lower panel) to obtain a final concentration of 5
µg/rnL 'Pr.otamine sulfate was added to the heparin and CY 216
solut\qns to obtain final protamine concentrations of 2.5 µg/ml,
5.0 µg/ml and 10 µg/ml.
Anticoagulant activity was determined
µsing the APTT. The control value for NHP was 33.2 ± 0.4 seconds
and the control value for NMP was 22. 3 ± 0. 3 seconds.
Data
represents a mean± S.E.
The experiments were performed five
times on separate days.
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IN VITRO ANTICOAGULANT ACTIVITY OF HEPARIN AND CY 216
AFTER PROTAMINE ADMINISTRATION
TEST:APTT
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Figur� �1'0., Heparin or CY 216 was supplemented to NHP (upper panel) or
to NMP,·: (l;o·wer panel) to obtain a final concentration of 5 µg/ml.
Protami�e .. suifate was added to the heparin and CY 216 solutions to
obtain finsl•protamine concentrations of 2.5 µg/ml, 5.0 µg/ml and 10
µg/ml. · Anficoagulant activity was determined using the thrombin time.
The control value for NHP was 27.2 ± 0.7 seconds and the control value
for NMP was 33.5 ± 0.3 seconds. Data represents a mean ± S.E. The
experiments were performed five times on separate days.

.
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IN VITRO ANTICOAGULANT ACTIVITY OF HEPARIN AND CY 216
AFTER PROTAMINE ADMINISTRATION
TEST:THROMBIN TIME (5 U/ml)
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Figur.e ll~: Heparin or CY 216 was supplemented to NHP (upper panel) or
to NM.P.' · (.i'ower panel) to obtain a final concentration of 5 µg/ml.
Probamiti~ s~lf 9 te was added to the heparin and CY 216 solutions to
obtain fi.naJ: protamine concentrations of 2. 5 µg/ml, 5. 0 µg/ml and 10
µg/ml.· A~ticoagulant activity was determined using the HeptestR.
The
control value for NHP was 17.6 ± 1.6 seconds and the control value for
NMP was 21. 5 ± 0 .1 seconds.
Data represents a mean ± S. E.
The
experim_ents were performed five times on separate days.
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IN VITRO ANTICOAGULANT ACTIVITY OF HEPARIN AND CY 216
AFTER PROTAMINE ADMINISTRATION
TEST:HEPTEST
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Fig_wre:12. Heparin or CY 216 was supplemented to NHP (upper panel) or
to NM?, (iow~r panel) to obtain a final concentration of 5 µg/ml.
Protami,ne • sulfate was added to the heparin and CY 216 solutions to
obtain. final protamine concentrations of 2.5 µg/ml, 5.0 µg/ml and 10
µg/ml.
Antiprotease activity was determined using an amidolytic anti
Xa assay. The control values for NHP and NMP were 0 % inhibition. Data
represents a mean± S.E. The experiments were performed five times on
separate days.
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IN VITRO ANTIPROTEASE ACTIVITY OF HEPARIN AND CY 216
AFTER PROTAMINE ADMINISTRATION
TEST:ANTI XA
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F:i:'gu_re 13.
Heparin or CY 216 was supplemented to NHP (upper
panel,) or to NMP to obtain a final concentration of 5 µg/ml.
Protamin~ sulfate was added to the heparin and CY 216 solutions
to.obt,ain final protamine concentrations of 2.5 µg/ml, 5.0 µg/ml
and 10 µg/ml.
Antiprotease activity was determined using an
amidoly_tic anti Ila assay. The control values for NHP and NMP were
0 %,inhibition.
Data represents a mean± S.E. The experiments
were performed five times on separate days.
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IN VITRO ANTIPROTEASE ACTIVITY OF HEPARIN AND CY 216
AFTER PROTAMINE ADMINISTRATION
TEST:ANTI IIA
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EFFECT OF PROTAMINE SULFATE
IN A LASER-INDUCED THROMBOSIS MODEL
LASER INJURIES
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Figure 14.
Two groups of rats were used in this study.
Group I
received a laser injury consisting of 0.18 \ifatts for 1/30 second.
Protamine sulfate (0. 74 mg/kg i. v.) was administered to the second
group of rats via the tail vein, 15 minutes prior to laser injury. The
number of laser injuries needed to produce a thrombus at least as long
and as broad of the diameter of the vessel was recorded.
Data
represents a mean ± S. E.
N - 11 for the contro 1 group.
N - 3 for
protamine (0.74 mg/kg i.v.) group. Statistical analysis was performed
by an unpaired student's t test:
t- 1.110, df-13, p>.20, N.S.
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PROTAMINE NEUTRALIZATION OF HEPARIN
IN A LASER-INDUCED THROMBOSIS MODEL
LASER INJURIES
8

7
6

*

*

5
4
3

2
1
HEPARIN

1 mg/klJ Lv.
Nm PROTAMIHE
0.:32 ~ Lv.

HEPARIN
1 mg/leg Lv.

»m PROTAlillHE
O.MmsJk;Lv.

Figure 15. Heparin (1 mg/kg i.v.) was administered to 3 groups of rats
via the tail vein 15 minutes prior to laser injury. Two groups of rats
received either protamine (0.32 or 0.64 mg/kg i.v.), 5 minutes after
heparin and was allowed to circulate for 10 minutes. Immediately after,
a laser injury was inflicted at the mesenteric vessel wall. The number
of laser injuries needed to produce the standard thrombus was recorded.
Data represents a mean± S.E. N - 11 for control group.
N - 4 for
heparin (1 mg/kg i.v.) group.
N - 6 for heparin (1 mg/kg i.v.) and
protamine (0.32 mg/kg i.v.) group. N - 5 for heparin (1 mg/kg i.v). and
protamine (0.64 mg/kg i.v.) group. Statistical analysis was performed
by a one way ANOVA: F(3,22) - 26.7555, p <.05 and followed by a NewmanKeuls multiple comparison test. * represents a significant difference
from control the group.
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PROTAMINE NEUTRALIZATION OF HEPARIN
IN A LASER-INDUCED THROMBOSIS MODEL
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Figure 16. CY 216 (1 mg/kg i.v.) was administered to rats via the tail
vein 15 minutes prior to laser injury.
One group of rats received
protamine (0.74 mg/kg i.v.) 5 minutes after CY 216 and was allowed to
circulate for 10 minutes.
Immediately after a laser injury was
inflicted at the mesenteric vessel wall. The number of laser injuries
needed to produce the standard thrombus was recorded. Data represents
a mean± S.E.
N - 11 for control group.
N - 5 for CY 216 (1 mg/kg
i.v.) group. N - 7 for CY 216 (1 mg/kg i.v.) and protamine (0.74 mg/kg
i.v.) group. Statistical analysis was performed by a one way ANOVA:
F(2, 20) - 6. 608, p <. 05 and followed by a Newman-Keuls multiple
comparison test.* represents a significant difference from the control
group.
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EFFECT OF HEPARIN AND CY 216
IN A LASER-INDUCED THROMBOSIS MODEL
LASER INJURIES
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Figure 17.
Heparin (10 mg/kg s. c.) or CY 216 (10 mg/kg s .c.) was
administered to rats 2 hours prior to laser injury. The number of laser
injuries needed to produce the standard thrombus was recorded. Data
represents a mean± S.E. N - 11 for control group. N - 5 for heparin
(10 mg/kg s.c.) group and N - 5 for CY 216 (10 mg/kg s.c.) group.
Statistical analysis was performed by a one way ANOVA: F(2,18) -47.681,
p <.05 and followed by a Newman-Keuls multiple comparison test.
* represents significant difference from control group.
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CLOT SCORES OBTAINED IN A RABBIT STASIS THROMBOSIS M_ODEL
AFTER PROTAMINE ADMINISTRATION
CLOT SCORE
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Figure 18.
Rabbits were anaesthetized and segments of the rabbit
jugular veins were surgically exposed.
Protamine (100 or 500 µg/kg
i.v.) or an equivalent volume of saline was administered via the rabbit
ear vein and allowed to circulate for 10 minutes at which time, blood
was drawn by cardiac puncture and a thrombogenic challenge comprised of
PCC/RVV was given. After exactly 20 seconds, both jugular veins were
ligated for 10 minutes, excised and evaluated for degree of clot
formation as described in the methods section. Data represents a mean
± S.E. N - 5 for control group. N - 3 for protamine (100 µg/kg i.v.)
group.
N - 3 for protamine (500 µgjkg i. v.) group.
Statistical
analysis was performed by a Kruskal-~allis test: H - 2.610, p >.10,
N.S.
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CLOT SCORES OBTAINED IN A RABBIT STASIS THROMBOSIS MODEL
AFTER HEPARIN ADMINISTRATION
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Figure 19.
Four groups consisting of five rabbits each were
anaesthetized and segments of the jugular veins were surgically exposed.
Heparin (25 µgjkg i.v.), heparin (50 µg/kg i.v.) or heparin (100 µgjkg
i.v.) or an equivalent volume of saline was administered via the ear
vein and allowed to circulate for 10 minutes at which time a
thrombogenic challenge comprised of PCC/RVV was given. After exactly
20 seconds both jugular veins were ligated for 10 minutes, excised and
evaluated for degree of clot formation. Data represents a mean± S.E.
Statistical analysis was performed by a Kruskal-'\.iallis test: H -14.308,
P <.05 and followed by a nonparametric Tukey multiple comparison test.
* represents a significant difference from control group.

237

EX VIVO ANTI XA AND ANTI IIA ACTIVITY AFTER HEPARIN
ADMINISTRATION TO RABBITS
~

INHIBITION
100
TIME:PRECHALLENGE

•

ANTI XA
~ANTI IIA

75

50

*

25

*
o------_.____.__,x.;~--_.__---'-..IIQiC~--'--_.__.........,..___ ____,

HEPARIN

HEPARIN

25 }J9/kg i.v.

50 }Jg/kg i.v.

HEPARIN
100 pg/kg i.v.

Figure 20.
Three groups consisting of five rabbits each were
anaesthetized and segments of the jugular veins were surgically exposed.
Heparin (25 µgjkg i.v.), heparin (50 µgjkg i.v.) or heparin (100 µg/kg
i.v.) or an equivalent volume of saline was administered via the ear
vein and allowed to circulate for 10 minutes at which time blood was
dra-.."Il by cardiac puncture.
Antiprotease activities were determined
using amidolytic anti Xa and amidolytic anti Ila assays. Control values
for normal rabbit plasma were 0 % inhibition. Data represents a mean
± S.E. Statistical analysis was performed by a two way ANOVA:
Factor A (heparin dose): F(2,24) - 10.059 p <.05
Factor B (test): F(l,24) - 0.672 p >.50 N.S.
Factor Ax B: F(2,24) - 0.444 p >.50 N.S.
followed by Newman-Keuls multiple comparison tests. * represents a
significant difference from the control group.
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CLOT SCORES OBTAINED IN A RABBIT STASIS THROMBOSIS MODEL
AFTER CY 216 ADMINISTRATION
CLOT SCORE
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Figure 21.
Four groups consisting of five rabbits each were
anaesthetized and segments of the jugular veins were surgically exposed.
CY 216 (25 µgjkg i.v.), CY 216 (50 µgjkg i.v.) or CY 216 (100 µg/kg
i.v.) or an equivalent volume of saline was administered via the ear
vein and allowed to circulate for 10 minutes at which time a
thrombogenic challenge comprised of PCC/RVV was given. After exactly
20 seconds both jugular veins were ligated for 10 minutes, excised and
evaluated for degree of clot formation. Data represents a mean± S.E.
Statistical analysis was performed by a Kruskal-iJallis test:
H 26.988, p <.05 and followed by a nonparametric Tukey multiple comparison
test. * represents a significant difference from control group.
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EX VIVO ANTI XA AND ANTI IIA ACTIVITY AFTER CY 216 ·.
ADMINISTRATION TO RABBITS
% INHIBITION
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Figure 22.
Three groups consisting of five rabbits each were
anaesthetized and segments of the jugular veins were surgically exposed.
CY 216 (25 µg/kg i.v.), CY 216 (50 µg/kg i.v.) or CY 216 (100 µg/kg i.v.)
or an equivalent volume of saline was administered via the ear vein and
allowed to circulate for 10 minutes at which time blood was drawn by
cardiac puncture.
Anti protease activities were determined using the
amidolytic anti Xa and amidolytic anti IIa assays. Control values for
normal rabbit plasma was 0% inhibition. Data represents a mean± S.E.
Statistical analysis were performed by a two way ANOVA:
Factor A (CY 216 dose): F(2,24) - 1.070 p >.50 N.S.
Factor B (test): F(l,24) - 0.843 p >.50 N.S.
Factor Ax B: F(2,24) - 1.408 p >.50 N.S.
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CLOT SCORES OBTAINED IN A RABBIT STASIS THROMBOSIS MODEL
CLOT SCORE
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Figure 23. Seven groups consisting of five rabbits each were anaesthetized and segments of the jugular veins were surgically exposed.
Heparin (100 µg/kg i. v.) or CY 216 (100 µg/kg i. v.) was administered via
the ear vein and allowed to circulate for 10 minutes and blood was drawn
by cardiac puncture. To groups of rabbits which received protamine (100
µgjkg i. v. or 200 µg/kg i. v.) , this drug was administered 5 minutes
after heparin (100 µg/kg i.v.) or CY 216 (100 µgjkg i.v.) and allowed
to circulate for 5 minutes at which time blood was drawn. Immediately
after blood draw, a thrombogenic challenge comprised of PCC/RVV was
given. After exactly 20 seconds both jugular veins were ligated for 10
minutes, excised and evaluated for degree of clot formation. Data
represents a mean± S.E. Statistical analysis was performed by a two
,,:ay ANOVA:
Factor A (drug treatment): F(2,36) - 18.049 p < .05
Factor B (protamine dose): F(2,36) - 16.810 p > .20 N.S.
Factor Ax B: F(4,36) - 5.453 p <.05
followed by a Newman-Keuls multiple comparison test. * represents a
signifiacant difference from the control group.

241

EX \/NO ANTI XA ACTIVITY AFTER PROTAMINE NEUlRALIZAllON
OF HEPARIN OR CY 216 IN RABBITS
~
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Figure 24. Seven groups consisting of five rabbits each were anaesthetized and segments of the jugular veins were surgically exposed.
Heparin (100 µg/kg i. v.) or CY 216 (100 µg/kg i. v.) was administered via
the ear vein and allowed to circulate for 10 minutes and blood was draw'"Il
by cardiac puncture. To groups of rabbits which received protamine (100
µg/kg i. v. or 200 µg/kg i. v. ) , this drug was ad.ministered 5 minutes
after heparin (100 µg/kg i.v.) or CY 216 (100 µg/kg i.v.) and allowed
to circulate for 5 minutes at which time blood was dra~'"Il. Antiprotease
activity was determined using an amidolytic anti Xa assay.
Data
represents a mean± S.E. Statistical analysis was performed by a two
way /illOVA:
Factor A (drug treatment): F(2,36) - 5.167 p < .OS
Factor B (protamine dose): F(2,36) - 1.635 p > .20 N.S.
Factor Ax B: F(4,36) - 5.104 p <.05
followed by a Ne~'Illan-Keuls multiple comparison test. * represents a
signifiacant difference from the control group.
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EX VNO ANTI IIA ACTMlY AFTER PROTAMINE NEUTRALIZATION
OF HEPARIN OR CN 216 IN RABBITS
% INHIBmON
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Figure 25.
Seven groups consisting of five rabbits each were
anaesthetized and segments of the jugular veins were surgically exposed.
Heparin (100 J.Lg/kg i. v.) or CY 216 (100 J,Lg/kg i. v.) was administered via
the ear vein and allowed to circulate for 10 minutes and blood was drawn
by cardiac puncture. To groups of rabbits which received protamine (100
µg/kg i. v. or 200 J,Lg/kg i. v.), this drug was administered 5 minutes
after heparin (100 J,Lg/kg i.v.) or CY 216 (100 µg/kg i.v.) and allowed
to circulate for 5 minutes at which time blood was drawn. Antiprotease
activity was determined using an amidolytic anti Ila assay.
Data
represents a mean± S.E. Statistical analysis was performed by a two
way ANOVA:
Factor A (drug treatment): F(2,36) - 25.553 p <.05
Factor B (protamine dose): F(2,36) - 16.684 p <.05
Factor Ax B: F(4,36) - 4.850 p <.05
followed by a Newman-Keuls multiple comparison test. * represents a
significant difference from control group.
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CLOT SCORES OBTAINED IN A RABBIT STASIS THROMBOSIS MODEL
CLOT SCORE
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Figure 2~. Five groups consisting of five rabbits each were
anaesthetized and segments of the jugular veins were surgically exposed.
Heparin (1 mg/kg s.c.) or CY 216 (1 mg/kg s.c.) was administered and
allowed to circulate for 2 hours. Blood was drawn by cardiac puncture.
To groups of rabbits which received protamine (1 mg/kg i.v.), this drug
was administered 2 hours after heparin (1 mg/kg s.c.) or CY 216 (1 mg/kg
s.c.) and allowed to circulate for 5 minutes at which time blood was
drawn. Immediately after blood draw, a thrombogenic challenge comprised
of PCC/RVV was given. After exactly 20 seconds both jugular veins were
ligated for 10 minutes, excised and the jugular vein segments were
evaluated for degree of clot formation. Data represents a mean± S.E.
Statistical analysis was performed by a two way ANOVA:
Factor A (drug treatment): F(2,24) - 5.298 p <.05
Factor B (protamine dose): F(2,24) - 1.739 p >.20 N.S.
Factor Ax B: F(4,24) - 5.428 p <.05
followed by a Ne .."lllan Keuls multiple comparison test. * represents a
significant difference from the control group.
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EX VIVO ANTI XA ACTIVllY OF RABBITS
AFTER DRUG ADMINISTRATION
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Figure 27. Five groups consisting of five rabbits each were
anaesthetized and segments of the jugular veins were surgically exposed.
Heparin (1 mg/kg s.c.) or CY 216 (1 mg/kg s.c.) was administered and
allowed to circulate for 2 hours at which time blood was drawn by
cardiac puncture.
To groups of rabbits which received protamine (1
mg/kg i.v.), this drug was administered 2 hours after heparin (1 mg/kg
s.c.) or CY 216 (1 mg/kg s.c.) and allowed to circulate for 5 minutes
at which time blood was drawn. Antiprotease activity was determined
using an amidolytic anti Xa assay. Statistical analysis was performed
by a two way ANOVA:
Factor A (drug treatment): F(2,24) - 13.401 p <.05
Factor B (protamine dose): F(l,24) - 6.079 p <.05
Factor Ax B: F(2,24) - 6.557 p <.05
followed by a Ne,nnan-Keuls multiple comparison test. * represents a
significant difference from the control group.
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EX VIVO ANTI IIA ACTIVl1Y OF RABBITS
AFrER DRUG ADMINISTRATION
% INHIBITION
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Figure 28.
Five groups consisting of five rabbits each were
anaesthetized and segments of the jugular veins were surgically exposed.
Heparin (1 mg/kg s.c.) or CY 216 (1 mg/kg s.c.) was administered and
allowed to circulate for 2 hours at which time blood was drawn by
cardiac puncture.
To groups of rabbits which received protamine (1
mg/kg i.v.), this drug was administered 2 hours after heparin (1 mg/kg
s.c.) or CY 216 (1 mg/kg s.c.) and allowed to circulate for 5 minutes
at which time blood was drawn. Antiprotease activity was determined
using an amidolytic anti Ila assay. Statistical analysis was performed
by a two way ANOVA:
Factor A (drug treatment): F(2,24) - 8.446 p <.05
Factor B (protamine dose): F(l,24) - .620 p >.50 N.S.
Factor Ax B: F(2,24) - .246 p >.50 N.S.
followed by a Newman-Keuls multiple comparison test. * represents a
significant difference from the control group.
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EFFECT OF VARIOUS DRUGS IN A RAT TAIL BLEEDING MOOEL
SECONDS
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Figure 29. Groups of rats received either protamine (1 mg/kg i.v.),
heparin (2 mg/kg i.v.), CY 216 (2 mg/kg i.v.) or an equivalent volume
of saline via the tail vein.
After 10 minutes bleeding time
determinations were performed as described in the methods section. Data
represents a mean± S.E.M. N - 9 for saline group. N - 7 for protamine
(1 mg/kg i.v.) group. N - 7 for heparin (2 mg/kg i.v.) group. N - 7
for CY 216 (2 mg/kg i.v.) group. Statistical analysis was performed by
a one way ANOVA: F(3,26) - 12.482 p <.05 followed by a Newman-Keuls
multiple comparison test:* represents a significant difference from CY
216 (2 mg/kg i.v.) group.

247

NEUTRALIZATION OF HEPARIN AND CY 216 IN A
RAT TAIL BLEEDING MODEL
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Figure 30. Groups of rats received either heparin (2 mg/kg i.v.), CT
216 (2 mg/kg i.v.) or an equivalent volume of saline via the tail vein.
To rats which recieved protamine, this drug was administered 5 minutes
after heparin or CT 216. After 10 minutes post heparin (or CT 216),
bleeding time determinations were performed as described in the methods
section. Data represents a mean± S.E.M. N - 9 for saline group. N
- 7 for heparin (2 mg/kg i.v.) group. N - 7 for CT 216 (2 mg/kg i.v.)
group. N - 7 for heparin (2 mg/kg i.v.) and protamine (2 mg/kg i.v.)
group. N - 7 for CT 216 (2 mg/kg i. v.) and protamine (2 mg/kg i. v.)
group. Statistical analysis was performed by a one way ANOVA: F(4,32)
- 9.458 p <.05 followed by a Newman-Keuls multiple comparison test: *
represents a significant difference from CT 216 (2 mg/kg i.v.) group.
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NEUTRALIZATION OF HEPARIN AND CY 216 IN A
RAT TAIL BLEEDING MODEL
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Figure 31. Groups of rats received heparin (2.5 mg/kg s.c.), CT 216
(2.5 mg/kg s.c.) or an equivalent volume of saline. Two groups of rats
received protamine (2.5 mg/kg i.v.) in addition to heparin (2.5 mg/kg
s. c.) or CT (2. 5 mg/kg s. c.)
After 120 minutes, bleeding time
determinations were performed as described in the methods section. Data
represents a mean± S.E. N - 9 for saline group. N - 7 for all other
groups. Statistical analysis was performed by a one way AN0VA: F(4,32)
- 1.294 p >.50 N.S.
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EFFECT OF PROTAMINE IN A RABBIT EAR MODEL OF BLOOD LOSS
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Figure 32.
Individual groups of rabbi ts were administered either
protamine (2 or 3 mg/kg i. v.) or an equivalent volume of saline which
was allowed to circulate for 10 minutes. At this time, blood was drawn
by cardiac puncture and 5 uniform incisions were made in the rabbit ear.
Blood loss was determined by immersing the ear in a saline bath (1
liter) at 37°C for 10 minutes. Red cell count in the bath solution was
determined using a Hycel cell counter. The results are expressed as
RBCs x 105/liter. Data represents a mean ± S. E. N - 5 for saline group.
N - 4 for protamine (3 mg/kg i.v.) group. N - 3 for protamine (2 mg/kg
i. v. ) group .
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EX VIVO ANTICOAGULANT ACTMTY AFTER PROTAMINE
ADMINISTRATION TO RABBITS
TEST:APTT
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Figure 33. Individual groups of rabbits were administered protamine (2
or 3 mg/kg i. v.) or. an equivalent volume of saline.
Each drug was
allowed to circulate for 10 minutes at which time blood was drawn by
cardiac puncture. Anticoagulant activity was determined by the APTT.
Data represents a mean ± S. E. N - 5 for control group.
N - 4 for
pro ta.mine (3 mg/kg i. v.) group.
N - 3 for pro ta.mine (2 mg/kg i. v.)
group.
Statistical analysis was performed by a one way ANOVA:

F(2,9) - 4.628, p >.05, N.S.
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EFFECT OF HEPARIN IN A RABBIT EAR MODEL OF BLOOD LOSS
RBC'S x 1o9/LITER
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Figure 34. Individual groups of rabbits were administered heparin (1
or 2 mg/kg i.v.) or an equivalent volume of saline which was allowed to
circulate for 10 minutes.
At this time, blood ,;.as drawn by cardiac
puncture and 5 uniform incisions were made in the rabbit ear. Blood
loss ,;.as determined by immersing the ear in a saline bath (1 liter) at
37°C for 10 minutes. Red cell count in the bath solution ,;.as determined
using a Hycel cell counter.
The results were expressed as RBCs x
105/liter. Data represents a mean± S.E. N - 5 for saline group. N - 6
for heparin (1 mg/kg i.v.) group. N - 14 for heparin (2 mg/kg i.v.)
group. Statistical analysis ,;.as performed by a one way ANOVA: F(2,22)
- 8.473, p <.05 followed by a Newman-Keuls multiple comparison test.*
represents a significant difference from the control group.
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Figure 35. Individual groups of rabbits were administered heparin (1
mg/kg i. v.) or heparin (2 mg/kg i. v.) or an equivalent volume of saline.
The drugs were allowed to circulate for 10 minutes at which time blood
was drawn by cardiac puncture. Antiprotease activity was determined by
an amidolytic anti Xa assay. Data represents a mean± S.E. N - 5 for
saline group.
N - 6 for heparin (1 mg/kg i. v.) group.
N - 14 for
heparin (2 mg/kg i.v.) group. Statistical analysis was performed by a
one way ANOVA:
F(2,22) - 32.433, p <.05 followed by a Newman-Keuls
multiple comparison test. * represents a significant difference from
the control group.
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EX VNO ANTI llA ACTIVIlY AFTER HEPARIN
ADMINISTRATION TO RABBITS
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Figure 36. Individual groups of rabbits were administered either heparin
(1 or 2 mg/kg i.v.) or an equivalent volume of saline. The drugs were
allowed to circulate for 10 minutes at which time blood was drawn by
cardiac puncture. Antiprotease activity was determined by an amidolytic
anti Ila assay. Data represents a mean± S.E. N - 5 for saline group.
N - 6 for heparin (1 mg/kg i.v.) group. N - 14 for heparin (2 mg/kg
i.v.) group. Statistical analysis was performed by a one way ANOVA:
F(2,22) - 34.378, p <.OS followed by a Newman-Keuls multiple comparison
test.* represents a significant difference from control group.
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EFFECT OF CY 216 IN A RABBIT EAR MODEL OF BLOOD LOSS
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Figure 37. Individual groups of rabbits were administered, CY 216 (1,
2 or 3 mg/kg i.v.) or an equivalent volume of saline which was allowed
to circulate for 10 minutes. At this time, blood was drawn by cardiac
puncture and 5 uniform incisions were made in the ear. Blood loss was
determined by immersing the ear in a saline bath (1 liter) at 37°C for
10 minutes. Red cell count in the bath solution was determined using
a Hycel cell counter. The results were expressed as RBCs x 109 /liter.
Data represents a mean± S.E. N - 14 for CY 216 (2 mg/kg i.v.) group.
N - 5 for all other groups. Statistical analysis was performed by a one
way AN0VA:
F(3,25) - 8.505, p <.05 and followed by a Newman-Keuls
multiple comparison test.
* represents significant difference from
control group.
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EX VNO ANTI XA ACTIVllY AFTER CY 216
ADMINISTRATION TO RABBITS
~
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Figure 38.
Individual groups of rabbits were administered CY 216
(1 mg/kg i.v.), CY 216 (2 mg/kg i.v.) or CY 216 (3 mg/kg i.v.) or an·
equivalent volume of saline. The drugs were allowed to circulate for
10 minutes at which time blood was drawn by cardiac puncture.
Antiprotease activity was determined by an amidolytic anti Xa assay. Data
represents a mean± S.E. N - 14 for CY 216 (2 mg/kg i.v.) group. N - 5
for all other groups. Statistical analysis was performed by a one way
AN0VA: F(3,25) - 16.450, p <.05 and followed by a Newman-Keuls multiple
comparison test. * represents a significant difference from the control
group.
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EX VNO ANTI llA ACTIVITY AFTER CY 21 6
ADMINISTRATION TO RABBITS
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Figure 39. Individual groups of rabbits were administered CY 216 (l, 2
or 3 mg/kg i.v.) or an equivalent volume of saline.
The drugs were
allowed to circulate for 10 minutes at which time blood was drawn by
cardiac puncture. Antiprotease activity ·.:as determined by an amidolytic
anti Ila assay. Data represents a mean± S.E. N - 14 for CY 216 (2
mg/kg i.v.) group. N - 5 for all other groups. Statistical analysis
was performed by a one way AN0VA: F(3,25) - 78.307, p <.05 and followed
by a Newman-Keuls multiple comparison test.* represents a significant
difference from the control group.
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PROTAMINE NEUTRALIZATION OF HEPARIN AND c:'f 216
IN A RABBIT EAR MODEL OF BLOOD LOSS
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Figure 40. Seven groups of rabbits were administered heparin (2 mg/kg
i.v.) or CY 216 (2 mg/kg i.v.) or an equivalent volume of saline via the
right ear vein. Each drug was allowed to circulate for 10 minutes at
which time blood .:as drawn by cardiac puncture and blood loss was
determined. Four groups received protamine (2 or 3 mg/kg i.v.) via the
left ear vein, 5 minutes after the administration of heparin (2 mg/kg
i.v.) or CY 216 (2 mg/kg i.v.) and blood was drawn by cardiac puncture.
Five uniform incisions were made in the ear. Blood loss was determined
by immersing the ear in a saline bath (1 liter) at 37°C for 10 minutes.
Red cell count in the bath solution was determined using a Hycel sell
counter.
The results were expressed as RBCs x 108/liter.
Data
represents a mean± S.E. N - 6 for heparin (2 mg/kg i.v.) or CY 216 (2
mg/kg i.v.) and protamine (2 mg/kg i.v.). N - 5 for all other groups.
Statistical analysis was performed by a two way ANOVA:
Factor A (drug treatment): F(2,36) - 17.494 p <.05
Factor B (protamine dose): F(2,36) - 12.806 p <.05
Factor Ax B: F(4,36) - 6.318 p <.05
followed by a Newman-Keuls multiple comparison test. * represents a
significant difference from the control group.
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EX VIVO ANTI XA ACTIVITY AFTER PROTAMINE NEUTRALIZATION
OF HEPARIN OR CY 216 IN RABBITS
% INHIBITION
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4. CY 216 2 mg/kg i.v.
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Figure 41. Individual groups of rabbits were administered heparin (2
mg/kg i.v.) or CY 216 (2 mg/kg i.v.) or an equivalent volume of saline
via the right ear vein.
Each drug was allowed to circulate for 10
minutes at which time blood was drawn by cardiac puncture and blood loss
~as determined. Four groups received protamine (2 or 3 mg/kg i.v.) via
the left ear vein, 5 minutes after the administration of heparin (2
mg/kg i.v.) or CY 216 (2 mg/kg i.v.) and blood was drawn by cardiac
puncture. Antiprotease activity was determined by an amidolytic anti
Xa assay. Data represents a mean± S.E. N - 6 for heparin or CY 216
(2 mg/kg i.v.) and protamine (2 mg/kg i.v.) group. N - 5 for all other
groups. Statistical analysis was performed by a two way ANOVA:
Factor A (drug treatment): F(2,36) - 29.090 p <.05
Factor B (protamine dose): F(2,36) - 62.246 p <.05
Factor Ax B: F(4,36) - 18.790 p <.05
followed by a New-man-Keuls multiple comparison test.
* represents a significant difference from control group.
** represents a significant difference from heparin (2 mg/kg i.v.) and
Protamine (2 mg/kg i.v.) group.
*** represents a significant difference from heparin (2 mg/kg i.v.) and
protamine (3 mg/kg i.v.) group.
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EX VIVO ANTI IIA ACTIVITY AFTER PROTAMINE NEUTRALIZATION
OF HEPARIN OR CY 21 6 IN RABBITS
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Figure 42. Individual groups of rabbits were administered an equivalent
amount of saline, heparin (2 mg/kg i.v.) or CY 216 (2 mg/kg i.v.) via
the right ear vein. Each drug was allowed to circulate for 10 minutes
at which time blood was dra~-n by cardiac puncture and blood loss was
determined. Four groups received protamine (2 or 3 mg/kg i.v.) via the
left ear vein, 5 minutes after the administration of heparin (2 mg/kg
i.v.) or CY 216 (2 mg/kg i.v.) and blood was drawn by cardiac puncture.
Antiprotease activity was determined by a amidolytic anti Ila assay.
Data represents a mean± S.E. N - 6 for heparin or CY 216 (2 mg/kg
i.v.) and protamine (1 mg/kg i.v.) group. N - 5 for all other groups.
Statistical analysis was performed by a two way ANOVA:
Factor A (drug treatment): F(2,36) - 71.372 p <.OS
Factor B (protamine dose): F(2,36) - 213.532 p <.OS
Factor Ax B: F(4,36) - 55.335 p <.05
followed by a Newman-Keuls multiple comparison test.
* represents significant difference from the control group.
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PROTAMINE NEUTRALIZATION OF HEPARIN AND CY 216
IN A RABBIT EAR MODEL OF BLOOD LOSS
RBCs x 1o9/liter

1.0..----------------------1. HEPARIN 3 mg/kg s.c.
2. HEPARIN 3 mg/kq a.c. +
PROTAMINE 3 mg/kg t.v.
3. Cf 216 3 mg/kg a.c.
4. Cf 216 3 mg/kg s.c. +
PROTAMINE 3 mg/kg t.v.
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Figure_ 43.
Individual groups consisting of five rabbits each were
administered heparin or CY 216 (3 mg/kg s.c.) or an equivalent volume
of saline via the right ear vein. The drugs were allowed to circulate
for 120 minutes at which time blood was drawn by cardiac puncture. Blood
loss was determined by immersing the ear in a saline bath (1 liter) at
37°C for 10 minutes. Red cell count in the bath solution was determined
using a Hycel cell counter.
The results were expressed as RBCs x
10;/liter.
Data represents a mean ± S.E.
Statistical analysis was
performed by a two way ANOVA:
Factor A (drug treatment): F(2,24) - .601 p >.50 N.S.
Factor B (protamine dose): F(l,24) - 18.175 p <.05
Factor Ax B: F(2,24) - 4.239 p >.05 N.S.
followed by a Ne~"lllan Keuls multiple comparison test. * represents a
significant difference from the CY 216 (3 mg/kg s.c.) and protamine (3
mg/kg i.v.) group.
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EX VIVO ANTI XA ACTMlY AFTER PROTAMINE NEUTRALIZATION
OF HEPARIN OR CY 216 IN RABBITS
% INHIBffiON
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Figure 44.
Individual groups consisting of five rabbits each were
administered heparin (3 mg/kg s.c.) or CY 216 (3 mg/kg s.c.) Each agent
was allowed to circulate for 120 minutes at which time blood was drawn
by cardiac puncture. Two groups received protamine sulfate (3 mg/kg
i.v.) 120 minutes after the administration of heparin (3 mg/kg s.c.) or
CY 216 (3 mg/kg s.c.). Protamine was allowed to circulate for 5 minutes
at which time blood was drawn by cardiac puncture.
Antiprotease
activity was determined by an amidolytic anti Xa assay. Data represents
a mean± S.E. Statistical analysis was performed by a two way ANOVA:
Factor A (drug treatment): F(2,24) - 26.802 p <.05
Factor B (protamine dose): F(l,24) - 17.158 p <.05
Factor Ax B: F(2,24) - 8.056 p <.05
followed by a Newman-Keuls multiple comparison test.
* represents a significant difference from the control group.
** represents a significant difference from the heparin (3 mg/kg s.c.)
and protamine (3 mg/kg i.v.) group.

262

EX VIVO ANTI IIA ACTIVITY AFTER PROTAMINE NEUTRALIZATION
OF HEPARIN OR CY 216 IN RABBITS
% INHIBITION
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Figure 45.
Individual groups consisting of five rabbits each were
administered heparin (3 mg/kg s.c.) or CY 216 (3 mg/kg s.c.). The drugs
were allowed to circulate for 120 minutes at which time blood was dra~"Il
by cardiac puncture. Two groups received protamine sulfate (3 mg/kg
i.v.) 120 minutes after the administration of heparin (3 mg/kg s.c.) or
CY 216 (3 mg/kg s.c.). Protamine was allowed to circulate for 5 minutes
at which time blood was dra~"Il by cardiac puncture.
Antiprotease
activity was determined by an amidolytic anti Ila assay.
Data
represents a mean± S.E. Statistical analysis was performed by a two
•.-ay ANOVA:
Factor A (drug treatment): F(2,24) - 198.315 p <.05
Factor B (protamine dose): F(l,24) - 488.486 p <.05
Factor Ax B: F(2,24) - 162.957 p <.05
follo.;ed by a Ne~-man-Keuls multiple comparison test. * represents a
significant difference from the control group.
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TIME COURSE OF PROTAMINE (2.1 mg/kg i.v.) IN PRIMATES
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Figure 46. A group of five primates was administered protamine (2.1
mg/kg i.v.). Blood samples were drawn at 0, 5, 30, 60 and 120 minutes.
Anticoagulant and antiprotease activity was determined using the APTT,
thrombin time and HeptestR. Each data point represents a mean± S.E.
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TIME COURSE OF PROTAMINE (2.1 mg/kg i.v.) IN PRIMATES
% INHIBmON
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Figure 47. A group of 5 primates was administered protamine (2.1 mg/kg
i. v.).
Blood samples were drawn at O, 5, 30, 60 and 120 minutes.
Antiprotease activities were determined using amidolytic anti Xa and
amidolytic anti Ila assays. Each data point represents a mean± S.E.
Statistical anlysis was performed by a two way ANOVA:
Factor A (time): F(4,40) - 3.160 p>.05 N.S.
Factor B (test): F(l,40) - 26.873 p<.05
Factor Ax B: F(4,40) - 3.160 p>.05 N.S.
followed by a Newman-Keuls multiple comparison test. * represents a
significant difference from the control group.
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TIME COURSE OF PROTAMINE SULFATE (2.1 mg/kg i.v.) IN PRIMATES
AS DETERMINED BY AN INDIRECT METHOD
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Figure 48. A group of four primates was administered protamine
(2.1 mg/kg i.v.). Blood samples were drawn at 0, 5, 30, 60 and
180 minutes. The plasma samples were centrifuged and frozen at 70°C. The pharmacodyna.mics of protamine were assayed indirectly
by supplementing 0. 63 ml of plasma obtained after prot:amine
administration to the primates with 70 µl of heparin 25 µg/ml.
T'ne final concentration of heparin in the plasma sample was 2.5
µg/ml.
HeptestR was performed. Data represents a mean± S.E.
Statistical analysis was performed by a two way ANOVA:
Factor A (time): F(4,40) - 1.728 p>.50 N.S.
Factor B (protamine dose): F(l,40) - .167 p>.50 N.S.
Factor (Ax B): F(4,40) - 1.728 p>.50 N.S.
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Fi,gu're,.49. Four groups of primates were included in this study. The
fi:r:~t ~group (N - 4) was administered heparin (0. 7 mg/kg i. v.) (upper
pa~el:). · Th~ other three groups (N - 5) received heparin (0. 7 mg/kg
i.v.)''fpl;J..owed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five
minutes after heparin administration (lower panel). Blood samples from
~ach of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes.
An additional blood sample was obtained at 15 minutes from primates
which w~re treated with protamine at the 5 minute time period.
Anticoagulant activity was determined using the APTT. Each data point
represents a mean± S.E. Statistical analysis was performed by a two
way ANOVA:
Factor A (time): F(3,40) - 3.398 p>.05 N.S.
Factor B (protamine dose): F(2,40) - 25.634 p<.05
Factor Ax B: F(6,40) - 1.300 p>.20 N.S.
followed by a Newman-Keuls multiple comparison test. * represents a
significant difference from heparin (0.7 mg/kg i.v.) and protamine (1.4
mg/kg i.v.) group and heparin (0.7 mg/kg i.v.) and protamine (2.1 mg/kg
i. v. ) group .
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY
OF HEPARIN IN PRIMATES
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Figur-ii: 5C( . Four groups of primates were included in this study.
The· firs.t group (N - 4) was administered heparin (0.7 mg/kg i.v.),
(upper patlei). The other three groups (N - 5) received heparin (0.7
mg/kg"i.v..) followed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg
i. v·.), five minutes after heparin administration (lower panel).
B.lood samples from each of these 4 groups were drawn at 0, 5, 30,
60, 180 an·d 360 minutes. An additional blood sample was obtained
at 15 minutes from primates which were treated with protamine at the
5 minute time period. Anticoagulant activity was determined using
the thrombin time.
Each data point represents a mean ± S. E.
Statistical analysis was performed by a two way AN0VA:
Factor A (protamine dose): F(2,29) - 1.863 p>.50 N.S.
Factor A (time): F(2,29) - 6.648 p<.01
Factor Ax B: F(4,29) - 3.121 p>.05 N.S.
followed by a Newman-Keuls Multiple comparison test. * represents
a significant difference from heparin (0.7 mg/kg i.v.) and protamine
( 1 . 4 mg/kg i. v. ) group and the heparin ( 0. 7 mg/kg i . v. ) and
protamine (2.1 mg/kg i.v.) group.
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY
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Figur:·~. 51·.• · Four groups of primates were included in this study. The
fir-st g:t;oup (N - 4) was administered heparin (0. 7 mg/kg i. v.) (upper
panel) . .'•Tl\e other three groups (N - 5) received heparin (0. 7 mg/kg
i.v.)·fo~lowed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five
minutes after heparin administration (lower panel). Blood samples from
each of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes.
An additional blood sample was obtained at 15 minutes from primates
which 'were treated with protamine at the 5 minute time period.
Antiprotease activity was determined by the HeptestR. Each data point
represents a mean± S.E.
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY
OF HEPARIN IN PRIMATES
TEST:HEPTEST
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Figure ~;'i:, · F~ur • groups of primates were included in this study. The
first group,.(N - 4) was administered heparin (0.7 mg/kg i.v.), (upper
panel). · The other three groups (N - 5) received heparin (0. 7 mg/kg
i.v.) .followed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five
minutes after heparin administration (lower panel). Blood samples from
each of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes.
An additional blood sample was obtained at 15 minutes from primates
which were treated with protamine at the 5 minutes time period.
Antiprotease activity was determined using an amidolytic anti Xa assay.
Each data point represents a mean± S.E.
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Figur~~si. °Foyr groups of primates were included in this study. The
first gr~up •(N - 4) was administered heparin (0.7 mg/kg i.v.), (upper
panel)•, · The other three groups (N - 5) received heparin (0. 7 mg/kg
i.v,) foliowed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five
minutes after heparin administration (lower panel). Blood samples from
each of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes.
An additional blood sample was obtained at 15 minutes from primates
which received protamine at the 5 minute time period.
Antiprotease
activity was determined using an amidolytic anti Ila assay. Each data
point represents a mean± S.E.
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY
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TEST:ANTI IIA
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Figu:i:f 54. Four groups of primates were included in this study. The
firs·t' ·&rou'p (.N - 4) was administered CY 216 (0.7 mg/kg i.v.) (upper
panel).',Xhe other three groups (N - 5) received CY 216 (0.7 mg/kg i.v.)
followed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five
minutes after heparin administration (lower panel). Blood samples from
each of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes.
An additional blood sample was obtained at 15 minutes from primates
which· were treated with protarnine at the 5 minute time period.
Anticoagulant activity activity was determined using the APTT. Each
data point represents a mean± S.E.
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY
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· Fi:gwTe 55. Four groups of primates were included in this study.
'·Th~·fit'st group (N - 4) was administered CY 216 (0.7 mg/kg i.v.),
(upper, pa'hel).
The other three groups (N - 5) received CY 216
(0.1"mg/kg i.v.) followed by protamine sulfate (0.7, 1.4, or 2.1
mg/k.g i. V.), five minutes after heparin administration ( lower
panel). Blood samples from each of these 4 groups were drawn at
0, 5, 30, 60, 180, and 360 minutes. An additional blood sample
was obtained at 15 minutes from primates which were treated with
protamine at the 5 minute time period. Anticoagulant activity was
determined using the thrombin time. Each data point represents
a mean± S.E.
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY
OF CY 216 IN PRIMATES
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F�sur�·· 5,6. Four groups of primates were included in this study. The
fir'st group, (N - 4) was administered CY 216 (0.7 mg/kg i. v.), (upper
panef}. •The other three groups (N - 5) received CY 216 (0.7 mg/kg i.v.)
followed by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five
JI1inutes after heparin administration (lower panel). Blood samples from
each of these 4 groups were drawn at 0, 5, 30, 60, 180, and 360 minutes.
An additional blood sample was obtained from primates which were treated
with protamine at the 5 minute time period. Antiprotease activity was
determined by the HeptestR. Each data point represents a mean± S.E.
0
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY
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Figu·r.~ :5?,, ·. Four groups of primates were included in this study. The
fir~t'. '·group (N - 4) was administered CY 216 (0. 7 mg/kg i. v.), (upper
panel). ~~h~ other three groups (N - 5) received CY 216 (0.7 mg/kg i.v.)
follo'::led· by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five
minutes a-fter heparin administration (lower panel). Blood samples from
each of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes.
An additi~nal blood sample was obtained at 15 minutes from primates
which .were treated with protamine at the 5 minute time period.
Antiprotease activity was determined using an amidolytic anti Xa assay.
Each data point represents a mean ± S. E.
Statistical anlaysis was
performed by a two way AN.OVA:
Factor A (time): F(4,60) - 48.857 p <.001
Factor B (protamine dose): F(4,60) - 32.178 p <.001
Factor Ax B: F(8,60) - .737 p >.50 N.S.
followed by a Newman-Keuls multiple comparison test.
* represents a
significant difference from the CY 216 (0.7 mg/kg i.v.) and protamine
(2.1 mg/kg i.v.) group.
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY
OF CY 216 IN PRIMATES
TEST:ANTI XA
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Figure:5~_.
Four groups of primates were included in this study.
The
first~group (N - 4) was administered CY 216 (0.7 mg/kg i.v.), (upper
panel).·, The other three groups (N - 5) received CY 216 (0.7 mg/kg i.v.)
followed'•by protamine sulfate (0.7, 1.4, or 2.1 mg/kg i.v.), five
minutes after heparin administration (lower panel). Blood samples from
each of these 4 groups were drawn at 0, 5, 30, 60, 180 and 360 minutes.
An additional blood sample was obtained at 15 minutes from primates
which were treated with protamine at the 5 minute time period.
Antiprotease activity activity was determined using an amidolytic anti
Ila assay.
Each data point represents a mean ± S. E.
Statistical
analysis was performed by a two way ANOVA:
Factor A (time):
F:(3,48) - 1056.337 p<.001
Factor B (protamine dose): F(2,48) - .033 p>.50 N.S.
Factor Ax B: F(6,48) - .267 p>.50 N.S.
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY
OF CY 216 IN PRIMATES
TEST:ANTI IIA
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVllY OF
HEPARIN IN PRIMATES
TEST: HEPTEST
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Figure 59. T..o groups of primates were included in this study.
The
first group (N - 5), (open circles) was administered heparin (0.7 mg/kg
s.c.). The second group (N - 4), (closed circles) received heparin (0.7
mg/kg s.c.) followed by protamine sulfate (0.7 mg/kg i.v.) 240 minutes
after heparin administration. Blood samples were dra~--n at 0, 120, 240,
360 and 540 minutes. An additional blood sample was obtained at 245
minutes from primates which were treated with protamine. A final blood
sample was dra~--n at 720 minutes from the heparin group. Antiprotease
activity was determined using the HeptestR. Each data point represents
a mean± S.E.
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVITYOF CY 216 IN PRIMATES
TEST:HEPTEST
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Figure 60. Two groups of primates were included in this study. The
first group (N - 5), (open circles) was ad.ministered CY 216 (0.7 mg/kg
s.c.). The second group (N - 4), (closed circles) received CY 216 (0.7
mg,lkg s.c.) followed by protamine sulfate (1.4 mg/kg i.v.) 240 minutes
after heparin ad.ministration. Blood samples were drawn at 0, 120, 240,
360 & SL.O minutes.
An additional blood sample .,as obtained at 245
~inutes from primates which were treated with protamine. A final blood
sample was dra~-n at 720 minutes from the heparin group. Antiprotease
activity was dete=mined using a clot based assay (HeptestR). Each data
point represents a mean± S.E.
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF
HEPARIN IN PRIMATES
TEST: ANTI XA
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Figure 61.
Two groups of primates were included in this study. The
first group (N - 5), (open circles) was administered heparin (0.7 mg/kg
s.c.). The second group (N - 4), (closed circles) received heparin (0.7
mg/kg s.c.) followed by prota.mine sulfate (0.7 mg/kg i.v.) 245 minutes
after heparin administration. Blood samples were dra~"n at 0, 120, 240,
360 and 540 minutes. An additional blood sample was obtained at 245
minutes from primates which received protamine. A final blood sample
~as dra~-n at 720 minutes from the heparin group. Antiprotease activity
~as. determined using an a.midolytic anti Xa assay.
Each data point
represents a mean± S.E.
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TIME COURSE OF THE PHARMACODYNAMIC ACT1Vl1Y OF
CY 216 IN PRIMATES
TEST:ANTI XA
100-----------------------,
o-o CY 216 0.7 mg/kg s.c.
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Figure 62. Two groups of primates were included in this study.
Yne
first group (N - 5), (open circles) was administered CY 216 (0.7 mg/kg
s.c.). Yne second group (N - 4), (closed circles) received CY 216 (0.7
mg/kg s.c.) followed by protamine sulfate (0.7 mg/kg i.v.) 240 minutes
after heparin administration. Blood samples were dra~'Tl at 0, 120, 240,
360 and 540 minutes. An additional blood sample was obtained at 240
minutes for primates which received protamine. A final blood sample was
dra~"!l at 720 minutes from the heparin group. Antiprotease activity was
determined using an amidolytic anti Xa assay.
Each data point
represents a mean± S.E.
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APPENDIX VII
Molecular Weight Profile of Protamine
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kesults and Conditions of GPC analvsis
third
Reoort Method:
third
Analvsis Method:
Nor,e
Calibration Method:
third
Norm~l1zat1on:
18.00 min
Baseline:
Start
5.00 min
End
50
Number of Data Points in Baseline Region
15.00 min
Processina:
Start
5.00 min
End
(l
Number of-Slices
100
Area Rejection
Negative Slices
Disabled
Molecular Weicht calculation bv Narrow Standard Calibration Curve.
Mark-~ouwink ~quation:
Not Used.
Number Averaae
Weight Aver ... ~e
Z Averaoe
V iscositv Averaoe
z .., l Aver ... ae -

1216
3036
3612
3036
3855

Intrinsic Viscosity
Peak Molecular Weight
Dispersitv
Z avg / W .:1vg
Z+l avg/ W avg

0.0000
3953
2. 49644:,
1.189657
1.269650
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APPENDIX VIII

Rabbit Stasis Thrombosis Model Showing
Ligatures on Isolated Jugular Veins

(Walenga, J.M., 1987.)
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APPENDIX IX
Diagram of the Clot Grading System Used in the
Rabbit Stasis Thrombosis Model

i

(Walenga, J.M., 1987.)
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APPENDIX X
Rabbit Ear Bleeding Model

Diagram Showing the Location of Incisions Made in the Rabbit Ear Blood
Loss Model.
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CUMULATIVE RESULTS OF PRIMATE BLOOD CHEMISTRY PROFILES
Date of Blood Draw

---

CL (meq/1)
I<"' (meq/1)

Na+ (meq/1)
Total bilirubin
(mg/dl)
GOT (IU/1)
GPT (IU/1)

6-7-88
116. 0± 10.4
4,1±

Normal Range*

11-7-88
110. 7± 2. 5

0.7

8. 2±13. 6

149.8± 12.8

151.4± 3.2

0,1±

0.3

84.0 - 126.0
2.3 -

6.7

102.0 - 166.0

0.3± 0.3

0.1 -

2.0

60.9± 53.3

N/A

16.0 -

97.0

114.4±236.3

N/A

0.0 -

68.0

creatinine (mg%)
Uric acid (mg%)

1.0±

0.7

0,8± 0.3

0.1 -

2.8

0.9±

1. 7

1.4± 1. 3

0.1 -

1.4

ca2+ (mg%)

9.6±

1.4

10.0± 0.6

6.9 - 13.0

147.4±267.8

147.9±84.7

9.7 - 89.0

72.9±143.2

78.2±43.0

N/A

1.0

7.2± 0.3

4.9 - 9.3

215.5±170.6

N/A

Alkaline
phosphatase (U)
GT (IU/1)
Total protein (g/dl)
Triglyceride (mg/dl)
Carbohydrate (mm/1)

6.8±

160.8±394.1
22.4±

8.7

4.5±

1.4

4.6±

0.3

2.8 - 5.2

BUN (mg%)

16.8± 10.4

17.1±

4.1

8.0 - 40.0

Glucose (mg%)

72.5±159.2

87.7±73.0

Cholesterol (mg%)

173.8±115.6

178.0±28.8

108.0 - 263.0

LDH (IU/1)

583.3±549.4

819.1±187.4

N/A

3.3±3.1

3. 2±1. 3

3.1 - 7.1

Albumin (g/dl)

Phosphorous (mg%)

N/A

N/A

46.0

-

178.0

Primate blood chemistry profiles were performed before beginning the
pharrnacodynamic studies and at their completion by the Loyola University
Clinical Chemistry Department. Values represent x ± S.D. N=l2 for 6-788, N=lO for 11-7-88.
*Normal ranges for rhesus monkeys were obtained from McClure (1975)
N/A - not available.
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APPENDIX XIb
CUMULATIVE RESULTS OF PRIMATE HEMATOLOGIC PROFILES

WBC (xl0 3)
RBC (xl0 6 )
HGB (g/dl)
HGT (%)
MCV (µm3)

6-7-88

11-7-88

5. 8±1. 4

6.1±1.3

2.5 -

26.7

5.6±0.7

5.4±0.7

3.6 -

7.0

13. 5±1.4

12.4±1.9

8.8 -

16.5

40.4±3.5

37.8±4.8

26.0 -

48.0

72 .0±4. 2

70.0±6.7

58.1 - 116. 9

Normal Range*

MCH (µµg)
MCHC (g/dl)

24. 0±1.4

22.9±2.6

18.5 -

36.6

33.4±2.8

32.6±1.3

25.6 -

40.2

ROW

13. 8±1.4

14.1±2.6

357.7±84.4

173.3±168.9

9.3±2.7

10.0± 1.0

20.5±106.2

14.1± 9.0

8.0 -

92.0

1. 2±6. 6

2.8± 1.0

0.69 -

14.5

N/A

1. 5±0. 6

PLT (xl0 3)
MPV (µm3)
Lymphocyte (%)
Lymphocyte (x10 3)
TPA (ng/ml)

N/A
109.0 - 597.0
N/A

N/A

Primate blood hematologic profiles were performed before beginning the
pharmacodynamic studies and at their completion by the Loyola University
Clinical Chemistry Department. Values represent x ± S.D. N-12 for
6-7-88, N=lO for 11-7-88.
*Normal ranges for rhesus monkeys were obtained from McClure (1975).
N/A - not available
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APPENDIX XIc
CUMULATIVE RESULTS OF PRIMATE COAGULATION PROFILES
6-7-88

11-7-88

APTT (seconds)

27.4±4.2

29.6±2.6

TT (SU/ml) (seconds)

30.9±5.2

24.8±4,8

Heptest (seconds)

21.5±3.1

22. 5±1. 3

primate coagulation profiles were performed before beginning the
pharmacodynamic studies and at their completion. Values represent x ±
s.D. N-12 for 6-7-88, N=lO for 11-7-88.
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CALIBRATION CURVE OF HEPARIN SUPPLEMENTED TO NMP
USED TO CALCULATE PHARMACODYNAMIC TIME COURSE PARAMETERS
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pg/ml

4.0
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APPENDIX Xllb

CALIBRATION CURVE OF HEPARIN SUPPLEMENTED TO NMP
5£D TO CALCULATE PHARMACODYNAMIC TIME COURSE PARAMETERS
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CALIBRATION CURVE OF CY 216 SUPPLEMENTED TO NMP
USED TO CALCULATE PHARMACODYNAMIC TIME COURSE PARAMETERS
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APPENDIX Xlld

CALIBRATION CURVE OF CY 216 SUPPLEMENTED TO NMP
USED TO CALCULATE PHARMACODYNAMIC PARAMETERS
SECONDS
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APPENDIX Xlle

IN VITRO SUPPLEMENTATION OF HEPARIN TO NRP

100.0

z

75.0

0
I-

m

50.0

I

z

2.5

5.0

7.5

10.0

µg/ml HEPARIN

Heparin was supplemented to NRP in a concentration range of 0-10 µg/ml.
Antiprotease activity was determined by the amidolytic anti Xa and anti
. Ila methods.
Data represents a mean ± S. E.
The experiment was
performed in triplicate on separate days.
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IN VITRO SUPPLEMENTATION OF CY 216 TO NRP

100.0

z

75.0

0

o-oANTI IIA
•-•ANTI XA

._..
(D

50.0

:c

z

~

25.0

0.0e..::;;.a__ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ __
0.0

2.5

5.0

7.5

10.0

JJ9/ml CY 216

CY 216 was supplemented to NRP in a concentration range of 0-10 µg/ml.
Antiprotease activity was determined by the amidolytic anti Xa and anti
Ila methods.
Data represents a mean ± S. E.
The experiment was
performed in triplicate on separate days.
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Heparin H 503
Proton NMR (300 MHz) in D2Q

S.50

S.00

,.so

4.00

1H NMR Spectrum (300 MHz) in

S.50

PPH

n2o

3.00

2.50

2.00

1.50
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APPENDIX XIV
CY 211 PII BATCH PS33 XH,IH

s.ao

a.oo

,.so

,.oo

0

3.ao
PPM

1H NMR Spectrum (300 MHz) in DzO

3,oo

2.so

2.00

1.ao
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lH NMR SPECTRA (300 MHz) in DCl

Protamine 20 mg/0.5 ml DClN 0.lN

~II

Pratamine 20 mg and 1 mg Heparin
0.5 ml DClN0.lN

I
.I ..
PPH
5.00
4.00
2.00
1.00
1H h1MR Spectra (300 MHz) in DCL
The upper spectrum is protarnine.
ffilli I ,](I__

The lower spectra is heparin and protamine.

The box is an enlarge-

ment of the lower spectrum in the range of 3-5 ppm.

The arrow

represents an area of change in the chemical shift as compared to
the upper spectrum.
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APPENDIX XVI
CONVERSION OF GRAVIMETRIC AMOUNTS OF HEPARIN, CY 216 AND
PROTAMINE TO APPROXIMATE MOLAR RANGES

S12ecies
In Vitro

Cone. (µgml)
Dose (mgL'.kg2

He12arin
(µg/moles)

CY 216
(µg/moles)

Protamine
(µg/moles)

0.6
1. 25
2.50
5.0
10.0

.01-0.32
.02-0.66
.04-1.31
.09-2.63
.18-5.26

.04-0.86
.07-1.80
.15-3.60
.30-7.20
.59-14.3

.09-0.40
.18-0.83
.36-1.67
.72-3.33
1.4-6.66

Primate

0.7
1.4
2.1

.01-.37

. 04-1. 00

.10-.47
.20-.93
. 30-1. 40

Rabbit

0.1
0.2
1.0
2.0
2.5

.002-.05
. 004- .11
.02-.53
.04-1.05
.04-1.32

. 006- .14
.01-.29
.06-1.4
.12-2.9
.15-3.6

.01-.07
.03-.13
.14-.67
.29-1.33
.36-1.7

Rat

.32
.64

.010-.168
.012-.337
.013-.379
.018-.526
.036-1.052

.02-.46
. 04-. 91
.042-1.03
.06-1.43
.12-2.86

.05-.21
.09-.43
.10-.48
.14-.67
.29-1.3

. 72

1.0
2.0

The following molecular weight ranges were used for the ocnversion from
gravimeter to molar amounts. Heparin (57,000 - 1,900) daltons; CY 216
(17,000 - 700) daltons; Protamine (7,000 - 1,500) daltons.
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APPENDIX XVII
DOSAGES OF HEPARIN, CY 216 AND PROTAMINE WHICH WERE ADMINISTERED
DURING THE ANIMAL EXPERIMENTS AS COMPARED TO DOSAGES
USED DURING CARDIOPULMONARY BYPASS

Species

Weight(kg)

Dose (mg/kg)

Total mg

Blood
Volume
(mg/kg b. w. )

Drug
Concentration
(µg/ml)

Primate

heparins

8.0

0.70

5.6

75c

9

Rabbit

heparins

2.5

0.10

0.25

53c

2

2.0

5.0

1.0

0.25

2.5

0.63

Rat

Man

heparins

Heparin
Protamine

0.25

70

2.0a_3_ob
2.5a

140.0
175.0

38
65c

15
39

78.6d

25-38
32

Concentrations were calculated for dosages of heparin, CY 216 and protamine which were used during the
experiments and which are used for man during cardiopulmonary bypass procedures.
a.
b.
c.
d.

Dosages·used at Foster McGaw Hospital.
Physician's Desk Reference 1989.
Davis P. Personal Communication
Goodman and Gilman's The Pharmacological Basis of Therapeutics. MacMillan Publishing Company, 1985.

w
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w
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APPENDIX XVIII
RATIO OF PROTAMINE TO HEPARIN AT W'HICH
COMPLETE NEUTRALIZATION OCCURRED

Tost

In Vitro (NHP)

In Rabbits

APTT

1:1

1:1

1:1

Thrombin Time

1:1

3:2

1:1

HeptestR

2:1

3:2

1:1

Anti-Xa

2:1

1:1

1:1

Anti-Ila

2:1

1:1

1:1

In Primates

Ratios were calculated from data obtained from the rabbit ear blood loss
experiments and the primate pharmacodynamic time course experiments.
Blood was drawn 5 minutes after the administration of protamine in the
rabbit experiment and 15 minutes after the administration of protamine
in the primate experiments.
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APPENDIX XIX
RATIO OF PROTAMINE TO CY 216 AT WHICH
COMPLETE NEUTRALIZATION OCCURRED
In Primates

Test
-=---

In Vitro NHP

In Rabbits

APTT

2:1

1:1

1:1

Thrombin Time

1:2

3:2

1:1

HeptestR

>2:1

>3:2

1:1

Anti-Xa

>2:1

>2:1

2:1

2:1

1:1

1:1

Anti-Ila

Ratios were calculated from data obtained from the rabbit ear blood loss
experiments and the primate pharmacodynamic time course experiments.
Blood was drawn 5 minutes after the administration of protamine in the
rabbit experiment and 15 minutes after the administration of protamine
in the primate experiments.
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APPENDIX XX

TLc :\m11w-Aci<l Sequence, of Component, of Sain:i'1l
Table \'lll-6. Pcpridc, obtained by :\cutra] Prntca,c d,.:c-tic,n
Salmine Al

Structure

Recc>\Try
(mole/mole)

Pro· Arg · Arg · Arg · Arg
Pro·Arg·Arg·Arg·Arg·Scr
Arg·Ser
Pro· Arg · Arg · Arg

I
I

0.37
0.42
0.44

(Ser)· Ser· Ser· Arg · Pro

0.96

\"al· Arg·Arg ·Arg ·Arg· Arg· Pro• Arg
Arg · Arg ·Pro· Arg
Val· Arg · Arg · Arg

0.80
0.12
0.07

\:al· Ser·Arg·Arg· Arg·Arg· Arg·Arg
\·al · Ser·Arg· Arg · Arg·Arg•Arg·Arg·Gly
Val· Ser·Arg· Arg · Arg

0.83

Gly·Gly·Arg·Arg·Arg·Arg
Gly · Arg · Arg · Arg· Arg

0.48
0.50

0.10

(Adapted from Ando T. et. al. Protamine - LSolation.
Characterization, Structure and Function, Springer, Berlin
Heidelberg, New York, 1973).

H2
<±>H3 NCH2 CH2 CH2CH2 NCH 2 CH 2CH2 NHp

(±)

SPERMIDINE
(Dentsman S.C. et. al. Biochemical and Biophysical Research
Communication 149:(1) 194-201, 1987).
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APPENDIX XXI
Noncompartmental Model Diagram

TEST-INPUT
MEASUREMENTS

I

?

I
kz1

a1 = MASS 1

Oz= MASSz

v 1 = VOLUME 1

Vz = VOLUMEz
/

$INKS

~01

1'
FIG. 2. Mon general 2-compartrnent (2-pooH model. with lnput and
output in the.same pool.

(Bourne D.W.A. et.al.

Pharmacokinetics for the non-mathematical,

MTP Press Limited, Lancaster, Australia, 1988).
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Interactions of an Oligosaccharide
Factor Xa, Thrombin, AT III and Protamine

(al

lbl

•-~--•• MNhoPQ__
0
BQ_

lc1_8_Fxa-

Mechanismll

~,

~,---

~ssible interactions of an oligosaccharide, the approximate size of the
antithrombin binding region, and of a full-sized heparin chain, with antithrombin (AT), factor Xa (Xa), thrombin (Ila) and protamine (prot.). a)
an oligosaccharide containing only the antithrombin binding sequence binds
to AT and accelerates the inhibition of Xa but not Ila (b). It cannot bind
to protamine and its anti-factor Xa activity is therefore resistant to
neutralization. (c). Protamine can bind to a full-sized heparin and
neutralize its anti-factor Xa and antithrombin activities.
Two mechanisms (d) can be proposed to explain this neutralizing action. In
mechanism I the neutralizing protein binds to a site adjacent to the antithrombin binding site and sterically hinders formation of the antithrombinP:oteinase complex. Alternatively, in mechanism II the neutralizing protein
b~nd~ immediately adjacent to (and perhaps overlapping with) the antithrombin
binding site and displaces the inhibitor from the polysaccharide chain.
(Adapted from Lane D.A., Heparin Neutralizing Proteins in Blood. Structure
~Activities of Heparin and Related Mucopolysaccharides. Annals of the
ew York Academy of Sciences 566: 473-475, 1989.)
The differential neutralization of FraxiparineRobser.ved in the Xa (Heptest
and amidolytic Xa) assays may be due to the fact that oligosa:cha~ides
lmw <5,OOO) comprise almost 80% of this agent. Thus, protam~ne 1s un~b~e
~o completely neutralize these activities effectively and residual act1v1ty
15 Observed.
On the other hand, the anti-Iia activities as measured by
thrombin time and Alla are effectively neutralized by pro~amine.
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APPENDIX XXIIIa
IN VITRO SUPPLEMENTATION OF HEPARIN TO NHP
APTT
(seconds)

Heptest
(seconds)

Anti-Xa
(% inhibition)

Anti- Ila
(% inhibition)

10.0

>150

228.5 ± 14.6

90.8 ± 0.6

91.0 ± 1.0

5.0

>150

116.0 ± 2.2

72.0 ± 3.0

84.2 ± 2.4

concentration
_ (µ~/ml)

2.5

80.4 ± 4.4

78.3 ± 1.2

49.8 ± 4.7

58.8 ± 2.9

1. 25

50.9 ± 4.1

56.3 ± 1. 7

38.8 ± 5.7

44.8 ± 7.5

0.6

37.5 ± 1. 3

32.7 ± 2.7

16.7 ± 4.4

15.8 ± 3.7

0.0

30.5 ± 2.2

15.5 ± 1. 2

0 ± 0

Data represents a mean± S.E., N=5.

0 ± 0
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APPENDIX XXIIIb
IN VITRO SUPPLEMENTATION OF HEPARIN TO NMP
Anti-Ila
Anti-Xa
(% inhibition) (% inhibition)

Concentration
(µg/ml)

APTT
(seconds)

10.0

>150

287.9

±

7.6

94.3

±

4.0

92.7

±

1.6

5.0

>150

145.3

±

1.6

80.3

±

3.2

88.0

±

1. 7

±

1. 3

50.3

±

1.2

83.3

±

3.5

±

2.5

Heptest
(seconds)

2.5

78.5

±

1. 3

78.9

1. 25

42.6

±

1. 2

54.0 ± 1.5

26.0 ± 2.6

50.3

0.6

32.7 ± 1.2

35.5 ± 0.5

11. 7 ± 0.6

35.7 ± 2.5

0.0

24.5 ± 1. 6

18.0 ± 0.3

Data represents a mean± S.E., N=3.

0

±

0

0

±

0
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IN VITRO SUPPLEMENTATION OF HEPARIN TO NRP
Concentration
(µg/ml)

APTT
(seconds)

Heptest
(seconds)

10.0

>300

>300

Anti-IIa
Anti-Xa
(%inhibition)
inhibition)
(%
93.3 ± 3.0

83.0 ± 5.0

5.0

>279.3 ± 21.1

>300

57.3 ± 5.1

72.0 ± 9.0

2.5

157.7 ± 16.4

188.9 ± 8.3

43.7 ± 8.8

49.7 ± 8.6

1. 25

100.4 ± 17.2

60.9 ± 0.6

22.0 ± 9.2

27.7 ± 6.6

0.6

77. 7 ± 1.4

40.0 ± 3.3

3.5 ± 0.4

10.0 ± 1.5

0.0

56.6 ± 0.8

20.5 ± 1. 7

0 ± 0

0 ± 0

Data represents a mean± S.E., N-3.
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APPENDIX XXIlld
IN VITRO SUPPLEMENTATION OF HEPARIN TO NRatP
Concentration
(µ~/ml)
10.0

APTT
(seconds)

Heptest
(seconds)

>150

>300

Anti-Ila
Anti-Xa
(% inhibition) (% inhibition)
85.0 ± 0.6

86.3 ± 2.4

5.0

78.l ± 5.3

163.8 ± 30.9

60.0 ± 3.6

59.3 ± 0.6

2.5

36.4 ± 1.8

100.2 ± 12.5

32.7 ± 3.5

46.0 ± 6.6

1. 25

26.l ± 0.8

76.1 ±

3.3

19.3 ± 4.3

17.7 ± 14.9

0.6

22.6 ± 0.7

69.6 ± 1.5

3.0 ± 7.3

0.0

16.1 ± 0.9

56.6 ±

Data represents a mean± S.E., N-3.

0.8

0 ± 0

9.3 ±
0 ± 0

9.5
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APPENDIX XXIIIe
IN VITRO SUPPLEMENTATION OF CY 216 TO NHP
Concentration
{µg/ml)

APTT
{seconds)

Heptest
{seconds)

Anti-Ila
Anti-Xa
(% inhibition) (% inhibition)

10.0

67.2

±

0.8

112.7

±

3.2

65.2

±

3.8

56.2

±

7.9

5.0

51. 2

±

1. 9

81. 5

±

5.5

45.4

±

4.8

37.0

±

2.2

2.5

40.8

±

0.6

66.4

±

1.2

37.3

±

2.2

13.6

±

3.0

1. 25

36.7

±

0.3

54.7

±

1. 6

27.0

±

3.8

8.4

±

2.2

0.6

34.8

±

0.6

38.2

±

1. 6

14.2

±

6.6

3.4

±

1.8

0.0

30.5

±

2.2

15.5

±

1.2

Data represents a mean± S.E., N~5.

0 ± 0

0 ± 0
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APPENDIX XXIIIf
IN VITRO SUPPLEMENTATION OF CY 216 TO NMP
Concentration
(µg/ml)

APTT
(seconds)

Hep test
(seconds)

Anti- Xa
(% inhibition)

Anti- Ila
(%inhibition)

>150

71. 3 ± 3.1

70.0 ± 6.2

10.0

72. 7 ± 4.3

5.0

46.9 ± 0.6

41.0 ± 0

51.0 ± 2.6

53.3 ± 3.2

2.5

35.4 ± 0.8

21.3±0.7

25.6 ± 1.2

34.3 ± 5.1

1. 25

32.5 ± 3.3

17.3 ± 0.1

12.3 ± 0.6

22.3 ± 4.6

0.6

27.2 ± 1. 2

15.0 ± 0.0

6.0 ± 1.0

16.0 ± 2.6

0.0

24.5 ± 1. 6

18.0 ± 0.3

0 ± 0

Data represents a mean± S.E., N=3.

0 ± 0
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APPENDIX XXIIIg
IN VITRO SUPPLEMENTATION OF CY 216 TO NRP
Concentration
(µg/ml)
10.0

APTT
(seconds)
99.9 ± 0

Heptest
(seconds)

Anti-Xa
Anti-Ila
(% inhibition) (% inhibition)

147.5 ± 17.6

31.0 ± 7.1

45.0 ± 2.8

5.0

83.9 ± 5.4

64.5 ± 2.0

26.0 ± 2.0

31. 0 ± 5.0

2.5

64.0 ± 1. 7

46.5 ± 1.8

13.3 ± 5.7

17.7 ± 4.8

1. 25

67.1 ± 3.1

39.1 ± 1. 9

9.7 ± 5.3

9.3 ± 0.7

0.6

62.5 ± 3.7

34.6 ± 2.6

5.3 + 2.8

2 ± 1. 6

0.0

56.6 ± 0.8

20.5 ± 1. 7

0 ± 0

Data represents a mean± S.E., N=3.

0 + 0
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APPENDIX XXIIIh
IN VITRO SUPPLEMENTATION OF CY 216 TO NRatP
Concentration
(µg/ml)

APTT
(seconds)

Heptest
(seconds)

Anti-Ila
Anti-Xa
inhibition)
(%
inhibition)
(%

10.0

43.6 ± 1. 9

195.1 ± 2.2

62.7 ± 2.2

60.7 ± 2.8

5.0

31. 3 ± 0.9

107.8 ± 3.2

38.0 ± 1.6

38.0 ± 3.6

2.5

25.1 ± 0.1

82.8 ± 2.2

20.3 ± 2.1

25.7 ± 3.0

1. 25

22.8 ± 0.3

75.3 ± 1.1

8.7 ± 4.6

17.7 ± 12.4

0.6

21.7±0.1

72. 9 ± 1. 2

6.3 ± 1.5

5.3 ± 5.4

0.0

16.1 ± 0.9

56.6 ± 0.8

0 ± 0

0 ± 0

Data represents a mean± S.E., N-3.

APPENDIX XXIIIi
IN VITRO ANTICOAGULANT AND ANTIPROTEASE ACTIVITY OF
HEPARIN AFTER PROTAMINE ADMINISTRATION
Plasma system: NHP
Heparin Concentration:
Protamine Concentration
(µg/ml)

5 µg/ml

APTT
(seconds)

Thrombin Time (SU/ml)
(seconds)

Heptest
(seconds)

Anti-Xa
% Inhibition

%

Anti-Ila
Inhibition
2.5 + 1.5

40.6 + 1.1

27.8

±

3.2

30.7

±

3.5

1. 2

±

1.1

5.0

43.6

±

1. 7

37.8

±

5.4

45.7

±

7.8

7.8

±

2.7

12.8

±

4. 5

2.5

94.9

±

7.3

>150

86.7

±

3.6

40.6

±

5.1

42.6

±

7.3

>150

119.0

±

9.6

67.2

±

1. 6

79.0

±

0.0

0

±

0

0

±

0

10.0

0
Saline control

>150
33.2

±

0.4

Data represents a mean± S.E., N=S.

27.2 ± 0.7

17.6 ± 1. 6

APPENDIX XXIIIj
IN VITRO ANTICOAGUIANT AND ANTIPROTEASE ACTIVITY OF
CY 216 AFTER PROTAMINE ADMINISTRATION
Plasma system: NHP
CY 216 Concentration:
Protamine Concentration
(µg/ml)

APTT
(seconds)

5 µg/ml
Thrombin Time (SU/ml)
(seconds)

Heptest
(seconds)

Anti-Xa
% Inhibition

%

Anti-Ila
Inhibition

10.0

46.6

±

1.4

33.3

±

2.6

69.0

±

1. 5

25.2

±

4.9

4.8

±

3.6

5.0

49.2

±

1.5

37.8

±

4.0

77 .0

±

3.7

28.3

±

1.0

5.8

±

2.5

2.5

49.8

±

1. 3

47.0 ± 3.3

76.4 ± 4.6

30.2

±

1.8

17.0 ± 3.6

0

55.5 ± 1.4

>150

87.5 ± 2.5

38.5

±

2.6

30.8 ± 3.2

Saline control

33.2 ± 0.4

27.2 ± 0.7

0

±

0

Data represents a mean± S.E., N=5.

17.6

±

1. 6

0

+

0

APPENDIX XXIV
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APPENDIX XXIVa

CUMUIATIVE RESULTS OBTAINED IN A LASER-INDUCED THROMBOSIS MODEL
Treatment

N

x + S.E ..

Control (power - 1.8, objective - 1/30)

11

2.3

±

0.04

Control (power - 1.2, objective - 1/15)

5

3.1

±

0.2

Heparin 1 mg/kg i.v.

4

5.1

±

0.23

Heparin 1 mg/kg i.v. and Protamine
0.32 mg/kg i.v.

6

5.7

±

0.22

Heparin 1 mg/kg i.v. and Protamine
0. 64 mg/kg i. V.

5

3.2 ± 0.16

CY 216 1 mg/kg i.v.

5

3.9 + 0.08

CY 216 1 mg/kg i.v. and Protamine
0. 74 mgjkg i. V.

7

2.5 ± 0.20

Protamine 0.74 mg/kg i.v.

3

4.8 ± 0.45

Heparin 10 mg/kg i.v.

3

from 5 to >15

Heparin 10 mg/kg s.c.

5

5.8 ± 0.12

CY 216 10 mg/kg s.c.

5

5.2 ± 0.26

APPENDIX XXIVb
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CUMUI.ATIVE BLEEDING TIMES OBTAINED IN
RAT TAIL BLEEDING MODEL

A

Treatment

N

Saline

9

355.0 ± 27.7

Protamine
1 mg/kg i.v.

7

531.4 ± 48.3

Heparin
2 mg/kg i.v.

7

CY 216
2 mg/kg i.v.

7

272.1 ± 28.2

Heparin 2 mg/kg i.v.
and protamine
2 mg/kg i.v.

7

406.4

CY 216 2 mg/kg i.v.
and protamine
2 mg/kg i.v.

7

340.7 ± 50.7

Heparin
2.5 mg/kg s.c.

7

324.3

CY 216
2.5 mg/kg s.c.

7

255.0 ± 40.2

Heparin
2.5 mg/kg s.c. and
protamine
2. 5 mg.kg i.v.

7

405.0 ± 54.2

CY 216
2.5 mg/kg s.c. and
protamine
2.5 mg/kg i.v.

7

356.4 ± 64.3

Data represents a mean± S.E.

Tail Transection Time (seconds)

,. 6 77 . 1

±

87 . 1

± 46.2

± 51.7

APPENDIX XXIVc
EX VIVO ACTIVITY AND BLOOD LOSS VALUES AFTER PROTAMINE ADMINISTRATION TO RABBITS
Time:

Pre-challenge

Treatment

N

APTT
(seconds)

TT SU
(seconds)

Heptest
(seconds)

Anti-Xa
(% Inhibition)

%

Anti-Ila
Inhibition

Blood Loss
(RBCs x 10 9/
liter)

Control

5

83. 2±11. 5

30.1±3.3

24.8±3.0

0

0

0.10±0.01

Protamine
3 mg/kg i.v.

4

133. 9± 5.4

37. 0±1. 5

26.4±3.7

2. 0±1. 7

0

0.2±0.1

Protamine
2 mg/kg i.v.

3

115.4±12.9

33.2±7.3

22.4±0.7

0

0.04±0.01

Data represents a mean± S.E.

0

APPENDIX XXIVd
EX VIVO ACTIVITY AND BLOOD LOSS VALUES AFTER HEPARIN AND PROTAMINE ADMINISTRATION TO RABBITS

Treatment

N

APTT
(seconds)

Heparin
1 mg/kg i.v.

6

>297.9±2,0

Heparin
2 mg/kg i.v.

14

>300

Anti-Xa
(% Inhibition)

Anti-Ila
(% Inhibition)

>300

>271. 5±5. 0

23.8±10.4

64.8±15.3

0.48±0,15

>300

>300

70.2± 4.9

92,4± 0.8

0.80±0,11

3,0±3,0

5,8± 3.9

0.36±0,11

0,8±0,8

0.09±0,02

Heparin
2 mg/kg i. v.
with Protamine
2 mg/kg i. v.

6

82.7±11,5

160.5±38.9

166.0±55.5

Heparin
2 mg/kg i. v.
with Protamine
3 mg/kg i.v.

5

87.6±7,5

33.4±2,4

58.4± 3.7

Data represents a mean± S.E.

Blood Loss
(RBCs x 10 9/
liter)

Heptest
(seconds)

TT SU
(seconds)

0.0±0,0

APPENDIX XXIVe
EX VIVO ACTIVITY AND BLOOD LOSS VALUE AFTER CY 216 AND PROTAMINE ADMINISTRATION TO RABBITS
Blood Loss
(RBCs x 10 9
liter)

Treatment

N

APTT
(seconds)

TT SU
(seconds)

Heptest
(seconds)

CY 216
1 mg/kg i.v.

5

>150

>150

138.1±7,0

42.3±2,0

49.5±1.8

0.42±0.10

CY 216
2 mg/kg i.v.

14

>150

>150

>296.1±3,9

50.9±6,9

72, 1±3. 0

0.30±0,08

CY 216
3 mg/kg i.v.

5

>150

>150

>150

65.0±6.9

82.8±5,8

0.84±0,22

CY 216
2 mg/kg i.v.
with Protamine
2 mg/kg i.v.

5

CY 216
2 mg/kg i. v.
with Protamine
3 mg/kg i.v.

5

111. 3±24. 5

108.1±14.5

Anti-Xa
(% Inhibition)

Anti- Ila
(% Inhibition)

118.6±47.5

138.1±45.5

26.0±14.0

25.8±7.8

0.06±0.02

47.1±10.5

153.0±47.1

12.6±4.8

0.14±0.17

0.06±0.02

Data represents a mean± S.E.

l.,.)

00

0

APPENDIX XXIVf
EX VIVO ACTIVITY AND BLOOD LOSS VALUES AFTER HEPARIN OR CY 216 AND PROTAMINE ADMINISTRATION TO RABBITS

Anti-Xa
(% Inhibition)

Blood Loss
(RBCs x 10 9
liter)

N

TT SU
(seconds)

Heparin
3 mg/kg s.c.

5

>130.8±11. 7

>150

>216.9±49.4

37.0±8.0

81.0±7 .0

0.16±0.02

Heparin
3 mg/kg s.c.
with Protamine
3 mg/kg i.v.

5

80.1±9.0

27.5±2.0

42.3±7.3

1. 8±1. 7

3.6±2.0

0.08±0.07

CY 216
3 mg/kg s.c.

5

89.2±18.4

>150

67.7±18.2

40.3±8.9

51. 3±4. 5

0.18±0.04

CY 216
3 mg/kg s.c.
with Protamine
3 mg/kg i.v.

5

71. 7±16. 7

31.0±3.1

62.9±12.5

28.0±9.6

4. 5±2. 6

0.09±0.03

Data represents a mean± S.E.

Heptest
(seconds)

Anti-Ila
(% Inhibition)

APTT
(seconds)

Treatment

APPENDIX XXV

APPENDIX XXVa
EX VIVO ACTIVITY AND CLOT SCORES AFTER PROTAMINE ADMINISTRATION TO RABBITS
Time:

Pre-challenge

Treatment

N

APTT
(seconds)

TT SU
(seconds)

Heptest
(seconds)

Anti-Xa
(% Inhibition)

%

Anti-Ila
Inhibition

Clot Score

Control

s

83. 9±1.0

32.0±4.1

30.8±3.8

0

0

3.1±0.3

Protamine
100 µg/kg i.v.

s 102.3±9.0

35.3±3.3

28.7±4.2

0

0

2.8±0.3

Protamine
500 µg/kg i.v.

s

10

2.3±0.2

83.7

72.6

37.7

7.5

Data represents a mean± S.E.

l,.)

00
l,.)

APPENDIX XXVb
EX VIVO ACTIVITY AND CLOT SCORES AFTER HEPARIN AND PROTAMINE ADMINISTRATION TO RABBITS
Time:

Pre-challenge

N

APTT
(seconds)

TT SU
(seconds)

Heptest
(seconds)

Heparin
25 µg/kg i. v.

5

124.7±13.2

46. 7±4.4

44.9±9.7

4.8±2.9

2.0±0.9

1.4±0. 2

Heparin
50 µg/kg i. v.

5

111. 2±17. 2

132.3±57.1

76.8±10.6

5.0± 2.1

14.3±8.0

0.5±0.2

Heparin
100 µg/kg i.v.

5

146.8±29.7

128.9±27.7

25.0±10.4

32.4±9.0

0.6±0.3

Heparin
100 µg/kg i. v.
with Protamine
100 µg/kg i.v.

5

57.6±10.2

40.3±5.2

37.2±6.8

2.6±1.0

1. 25±2. 5

2.7±0.3

Heparin
100 µg/kg i.v.
with Protamine
200 µg/kg i.v.

5

122.9±12.3

37. 5±1. 9

47.0±2.0

2.4±2.4

12.4±3.9

2.9±0.3

Treatment

Data represents a mean± S.E.

>150±0

Anti-Xa
(% Inhibition)

Anti-Ila
% Inhibition

Clot Score

APPENDIX XXVc
EX VIVO ACTIVITY AND CLOT SCORES AFTER CY 216 AND PROTAMINE ADMINISTRATION TO RABBITS
Time:

Pre-challenge

Treatment

N

APTT
(seconds)

TT SU
(seconds)

Heptest
(seconds)

(% Inhibition)

Anti-Xa
%

Anti- Ila
Inhibition

Clot Score

CY 216
25 µg/kg i.v.

5

58.0±6.4

37. 0±1. 6

42.4±4.1

1. 8±1. 2

1. 2±1. 2

2.2±0.5

CY 216
50 µg/kg i.v.

5

49.1±14.4

50.7±9.3

42.1±2.1

5.0±4.6

1. 3±1.4

1. 5±0. 2

CY 216
100 µg/kg i.v.

5

67.7±12.9

49.1±10.7

63. 6±11. 8

12.8±8.7

5.8±4.5

0.4±0.2

CY 216
100 µg/kg i. v.
with Protamine
100 µg/kg i.v.

5

58.0±13.6

34.1±3.4

46.2±4.1

8.8±2.8

7 .4±1. 9

1. 7±0.4

CY 216
100 µg/kg i.v.
with Protamine
200 µg/kg i.v.

5

38.4±3.1

43 .4±1. 3

9.2±2.4

6.4±2.8

2,2±0.2

113±6.6

Data represents a mean± S.E.
w

00
V,

APPENDIX XXVd
EX VIVO ACTIVITY AND CLOT SCORES AFTER HEPARIN AND CY 216 AND PROTAMINE ADMINISTRATION TO RABBITS
Time:

Pre-challenge

Treatment

N

APTT
(seconds)

TT SU
(seconds)

Heptest
(seconds)

Anti-Xa

(% Inhibition)

%

Anti-Ila
Inhibition

Clot Score

Heparin
1 mg/kg s.c.

5

61.0±10.5

128.8±13,4

62.4±12.9

15.8±4,5

16.2±3,9

1. 5±0 .4

Heparin
1 mg/kg s.c.
with protamine
1 mg/kg i.v.

5

78.8±18.7

85.9±25.1

39.5±5,7

12.8±3,9

18.5±9,4

2.8±0,4

CY 216
1 mg/kg s.c.

5

95.4±4,4

54.8±8,9

42.7±12.6

22.5±6,4

7. 0±1. 9

1. 9±0 .4

CY 216
1 mg/kg s.c.
with Protamine
1 mg/kg i.v.

5

73. 7±12.0

37.8±5,2

58.4±10.9

15.0±2,9

9,8±2,5

2.0±0.4

Data represents a mean± S.E.

APPENDIX XXVI

APPENDIX XXVIa
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF HEPARIN IN PRIMATES
Dose:

0.7 mg/kg i.v.
Thrombin Time (5 U/ml)
(seconds)

HeptestR
(seconds)

Time
(minutes)

APTT
(seconds)

0

24.4 ± 1.3

28.l ± 0

25.4 ± 2.3

5

>150 ± 0

>150 ± 0

>300 ± 0

30

>150 ± 0

>150 ± 0

Anti-Xa
(% inhibition)
0 ± 0

Anti- Ila
(% inhibition)
0 ± 0

92.0 ± 2.2

90.6 ± 2.9

269.4 ± 30.5

83.4 ± 8.1

87.8 ± 2.0

60

129.4 ± 10.4

>150 ± 23.4

178.7 ± 24.3

77 .0 ± 4.8

85.0 ± 2.5

180

33.5 ± 6.1

80.2 ± 6.0

55.3 ± 6.0

17,0±6.1

28.4 ± 7.4

360

25.9 ± 1.6

25.9 ± 1. 2

23.0 ± 1. 2

4.2 ± 2.4

9.2 ± 4.1

Data represents a mean± S.E., N-4.

l.,.)

00
00

APPENDIX XXVIb
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF HEPARIN
AND PROTAMINE SULFATE IN PRIMATES
Heparin dose: 0 . 7 mg/kg i. v.
Protamine dose: 0 . 7 mg/kg i. v .
Time
(minutes)

APTT
(seconds)

Thrombin Time (5 U/ml)
(seconds)

HeptestR
(seconds)

0

36.7

±

5.3

19.8

±

3.1

20.2 + 1.4

5

>150

±

0

>150

±

0

>300

±

Anti-Xa

Anti-Ila

(% inhibition)

(% inhibition)

+

0

±

1.8

94.3

114.0 ±

6.7

49.8 + 8.5

0

0

97.3

0

±

0

±

0.5

15

86.8 ± 18.0

89.2 ± 11.2

79.9 ± 2.9

30

56.1

7.5

73.9 ±

7.5

67.6 ± 3.0

45.8 ± 12.8

35.0 ± 3.0

60

55.1 + 10.7

25.5 ±

3.8

63.7 ± 2.0

26.8 ±

4.6

31. 6 + 4.3

180

46.8 ±

7.7

16.3 ±

2.0

24.8 ± 0.7

6.0 ±

3.3

5.1

360

23.6 +

1. 3

17.0 +

1.5

26.1 ± 0.3

4.8 ±

2.0

0.8 + 0.8

±

±

2.3

Data represents a mean± S.E., N=5.
Protamine was administered immediately after the 5 minute blood draw.

w

00
\0

APPENDIX XXVIc
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF HEPARIN IN PRIMATES
Heparin dose: 0 . 7 mg/kg i . v .
Protamine dose: 1. 4 mg/kg i. v .
Time
(minutes)

APTT
(seconds)

0

25.l ± 2.5

5

>150

15

Thrombin Time (5 U/ml)
(seconds)

HeptestR
(seconds)

Anti-Xa

Anti- Ila

(% inhibition)

(% inhibition)

0 +

0

0 ± 0

17.2 ± 0.8

26.5 ± 2.0

>150 + 0

>300 + 0

79.6 ±

4. 7

94.4 ± 1. 3

34.1 ± 3.6

68.6 ± 40.8

60.4 + 5.5

58.6 ±

6.1

26.4 ± 7.7

30

28.6 ± 1. 9

26.7 +

1.5

60.3 ± 1. 6

49.3 ±

7.9

40.6 ± 6.6

60

28.0 + 2.9

22.5 ±

0.4

49.0 ± 2.2

50.3 ± 12.1

28.0 ± 2.1

180

24.7 ± 1. 6

21.4 ±

0.8

29.0 + 0.8

21. 3 ±

1. 2

5.6 + 3.6

360

25.0 ± 2.1

18.8 ±

0.8

20.5 ± 0.8

4.8 ±

2.4

2.4 + 2.4

Data represents a mean± S.E., N=5.
Protamine was administered immediately after the 5 minute blood draw.
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APPENDIX XXVId
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF HEPARIN IN PRIMATES
Heparin dose: 0 . 7 mg/kg i. v .
Protamine dose: 2 . 1 mg/kg i. v.
Time
(minutes)

APTT
(seconds)

Thrombin Time (5 U/ml)
(seconds)

HeptestR
(seconds)

0

25.2 + 1.0

25.0 ±

1.4

5

>150 + 0

>150 ±

0

15

28.2 + 1.0

50.6 ± 10.4

37.0 ±

30

30.0 ± 0

94.0 ± 12.2

60

25.8 ± 1.0

63.5 ±

180

23.6 ± 1.4

360

15.4 ± 2.0

Anti-Xa

Anti-Ila

(% inhibition)

18.4 ± 1.5

0

234.1 ± 46.5

90.5 ±

±

0

(% inhibition)
0

±

0

2.6

90.3 ± 4.3

1.4

52.8 ± 12.4

16.8 ± 2.8

28.5 ±

0.5

15.0 ±

0.9

18.0 ± 0.8

7.5

29.7 ±

5.2

24.3 ± 11.5

4.3 + 3.4

37.0 ±

3.6

25.6 ±

1. 7

14.2 ±

8.0

7.6 ± 2.6

23.3 +

2.5

21. 9 ±

1.1

7.3 ±

5.9

6.7 + 5.3

Data represents a mean± S.E., N=5.
Protamine was administered immediately after the 5 minutes blood draw.

APPENDIX XXVIe
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF CY 216 IN PRIMATES
Dose:

0.7 mg/kg i. v.

Time
(minutes)

APTT
_lc:econds)

Thrombin Time (5 U/ml)
(seconds)

0

24.6 + 2.3

5

129.4 ± 20.7

30

39.4 ± 3.9

121. 8 ± 16.5

60

33.9 ± 2.3

180
360

HeptestR
(seconds)

28.4 ± 3.9

31. 3 ± 1. 7

>150 ± 0

>300 ± 0

Anti-Xa
(% inhibition)

Anti- Ila
(% inhibition)

0 ± 0

0

91.0 ± 2.4

68.2 ± 7.9

120.4 ± 20.4

57.3 ± 9.4

39.0 ± 10.0

110.7 ± 24.0

92.1 ± 8.9

49.2 ± 5.0

27.8 ± 8.8

26.1 ± 1.4

31. 7 ± 3.8

55.4 ± 3.2

19.2 ± 5.4

8.4 ± 3 .4

23.8 ± 1.4

30.2 ± 6.0

38.7 ± 3.8

3 .4 ± 1. 6

4.0 + 0.0

Data represents a mean± S.E., N=4.

APPENDIX XXVIf
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF CY 216 AND
PROTAMINE SULFATE IN PRIMATES
CY 216 dose:
Protamine dose:

0.7 mg/kg i.v.
0.7 mg/kg i, V.

Time
(minutes)

APTT
(seconds)

0

25.0 ± 2.6

21.4 + 2.5

21.4 ± 1.2

5

98.6 ± 29.9

>150 + 0

>300 ± 0

15

37.4 ± 4.1

31. 8 ± 4.8

30

34.5 ± 3.3

60

Thrombin Time (5 U/ml)
(seconds)

HeptestR
(seconds)

Anti-Xa

Anti- Ila

(% inhibition)

(% inhibition)

0 ± 0

0 ± 0

93.6 ± 3.0

81. 6 ± 3.8

126.1 ± 14.1

68.4 ± 7.8

21. 8 ± 9.0

29.7 ± 2.4

132 .4 ± 19.0

77 .8 ± 5.2

41. 8 ± 7.1

34.2 + 2.1

35.5 ± 4.2

92. 9 ± 2.4

67.3 ± 7.8

41. 3 ± 6.0

180

28.0 ± 1. 2

18.9 ± 2.3

60.2 ± 3.1

42.6 ± 8.1

6.5 + 2.0

360

24.6 ± 3.4

20.4 ± 1. 3

39.5 ± 0.9

22.8 ± 4.8

8.0 + 6.2

Data represents a mean± S.E., N=5.
Protamine was administered immediately after the 5 minute blood draw.

APPENDIX XXVIg
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF CY 216 AND
PROTAMINE SULFATE IN PRIMATES
CY 216 dose:
Protamine dose:
Time
(minutes)

0. 7 mg/kg i. V,
1.4 mg/kg i.v.

APTT
(seconds)

Thrombin Time (5 U/ml)
(seconds)

HeptestR
(seconds)

19.0 ± 0.90

21.0 + 0

0 + 0

0 ± 0

Anti-Xa
(% inhibition)

Anti-Ila

(% inhibition)

0

30.5 ± 3.5

5

>150

135. 9 ± 6.3

>300 ± 0

71. 3 ± 3.1

76.6 ± 6.1

15

43.4 ± 8.1

65.1 ± 13. 9

109.0 ± 7.8

44.5 ± 6.2

33.3 ± 3.6

30

50.4 ± 10.0

72.6 ± 13.5

95.5 ± 5.2

37.5 ± 3.9

20.0 + 11.5

60

39.6 + 6.2

27.9 ± 3.3

83.9 ± 7.8

26.0 ± 10.0

21. 7 ± 11.0

180

35.2 ± 6.1

15.0 + 0.1

55.1 ± 8.1

11. 3 ± 2.1

5.3 ± 3.0

360

45.8 ± 2.0

15.2 ± 0.3

39.8 ± 4.8

5.0 + 5.0

2.5 ± 1.4

Data represents a mean± S.E., N=S.
Protamine was administered immediately after the 5 minute blood draw.

APPENDIX XXVIh
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF
CY 216 AND PROTAMINE SULFATE IN PRIMATES
CY 216 dose: 0 . 7 mg/kg i . v .
Protamine dose: 2.1 mg/kg i.v.
Time
(minutes)

APTT
(seconds)

Thrombin Time (5 U/ml)
(seconds)

0

25.5 ±

0.8

24.8 ±

2.8

5

63.6 + 13.0

>150 +

0

15

34.7 +

1. 3

67.3 ± 15.0

30

37.2 ±

3 .4

20.8 ±

0

60

35.l ±

3.9

24.1 +

HeptestR
(seconds)
20.6 ±

Anti-Xa

(% inhibition)

1.1

288.0 ± 11. 3

0 ± 0

Anti- Ila
(% inhibition)
0 ± 0

98.8 + 0.2

70.7 +

4.6

95.5 ±

7.3

35.8 ± 7.3

33.3 + 12.7

117 .8 ±

6.0

25.6 ± 5.2

27.8 ± 11. 7

1. 2

83.2 ±

1. 2

18.6 ± 2.2

10.5 ±

10.3 ± 10.5

180

27.5 + 1. 2

17.7 ±

0.5

61.0 ±

2.9

12.4 ± 4.2

360

24.6 ± 1. 6

21. 6 ±

0.3

49.9 +

1.4

5.8 ± 2.7

Data represents a mean± S.E., N=5.
Protamine was administered immediately after the 5 minute blood draw.

7.7 +

4.1

3.3

APPENDIX XXVIi
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF HEPARIN IN PRIMATES
Dose:

0.7 mg/kg s.c.

Time
(minutes)

APTT
(seconds)

0

31.8 ± 3.2

25.4 ± 2.7

21. 6 ± 0. 7

0 ± 0

0 ± 0

120

34.7 ± 2.5

37.8 ± 8.0

49.8 ± 3.0

8.2 ± 2.6

5.8 ± 3.7

240

35.5 ± 2.9

29.7 ± 4.6

44.6 ± 4.1

7.3 ± 2.7

7.0 ± 3.3

360

30.6 ± 3.3

27.5 ± 3.4

31.0 ± 2.2

3.8 ± 1.2

4.4 ± 2.3

540

29.0 ± 3.1

25.6 ± 2.6

22.4 ± 1.2

4.4 ± 2.4

1.4 ± 1.4

720

29. 7 ± 3.1

24.9 ± 2.2

24.1 ± 1.4

3.6 ± 0.7

0 ± 0

Thrombin Time (5 U/ml)
(seconds)

Data represents a mean± S.E., N-5.

HeptestR
(seconds)

Anti-Xa
(% inhibition)

Anti-Ila
(% inhibition)

APPENDIX XXVIj
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF HEPARIN WITH
PROTAMINE SULFATE IN PRIMATES
Heparin dose:
Protamine dose:
Time
(minutes)

0.7 mg/kg s.c.
0.7 mg/kg i.v.

APTT
(seconds)

Thrombin Time (5 U/ml)
(seconds)

HeptestR
(seconds)

Anti-Xa
(% inhibition)

Anti-Ila
(% inhibition)

0

25.1 ± 1.0

26.4 ± 0.5

26.0 + 1. 2

0 ± 0

0 ± 0

120

30.2 ± 2.8

30.8 ± 2.4

38.3 ± 5.7

7.8 ± 3.2

7.4 + 3.5

240

26.5 ± 2.2

31. 7 ± 1. 6

40.2 ± 5.8

8.4 ± 2.1

8.4 ± 2.7

245

26.4 ± 2.4

37.3 ± 10.9

26.9 ± 1.8

7.6 + 3.1

4.6 ± 2.7

540

25.1 + 1. 9

26.1 ± 0.9

24.5 ± 1.4

4.4 ± 1.6

3.8 ± 3.8

720

22.3 ± 1. 3

28.4 ± 1. 3

21. 2 + 1.1

7.4 ± 3.3

2.4 + 1. 6

Data represents a mean± S.E., N=5.
Protamine was administered immediately after the 240 minute blood draw.

APPENDIX XXVIk
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF CY 216 IN PRIMATES
Dose:

0.7 mg/kg s.c.
APTT
(seconds)

0

25.54 ± 0.8

27.8 ± 1.1

20.7 ± 0.9

0 ± 0

0 ± 0

120

29.7 ± 1. 2

34.8 ± 1. 9

62.2 ± 3.1

32.2 ± 4.9

9.2 ± 3.2

240

30.0 ± 1.2

38.8 ± 1. 7

60.2 ± 2.0

53.0 ± 5.2

13.3

±

5.2

360

28.8

1.2

19.9

±

0.6

46.3

27.8

6.0

6.6

±

2.7

540

27.4 ± 1.0

21. 6

±

2.1

37.3 ± 2.1

18.8 ± 3.5

12.3

±

2.7

720

28.6

1.5

24.3

±

0.9

36.0

4.8

±

2.0

±

±

Thrombin Time (5 U/ml)
(seconds)

HeptestR
(seconds)

Time
(minutes)

±

±

2.6

2.8

Anti-Xa
(% inhibition)

14.8

±

±

5.3

Anti-Ila

(% inhibition)

Data represents a mean± S.E., N-5.
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TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF CY 216 WITH
PROTAMINE SULFATE IN PRIMATES
CY 216 Dose:
Protamine Dose:
Time
(minutes)

0.7 mg/kg s.c.
0.7 mg/kg i.v.

APTT
(seconds)

Thrombin Time (5 U/ml)
(seconds)

HeptestR
(seconds)

Anti-Xa
(% inhibition)

Anti-Ila
(% inhibition)
0

±

0

0

26.5

±

1.5

26.7

±

1. 6

23.8

±

1.4

0

±

0

120

29.9

±

2.4

32.8

±

2.2

70.9

±

1. 9

31. 5

±

2.8

7.6

±

3.2

240

29.5

±

1. 3

29.9

±

1.0

66.0

±

6.2

31. 2

±

5.0

5.4

±

2.4

245

33.9

±

3.3

30.6

±

3.4

65.8

±

5.0

26.8

±

2.2

0

±

0

540

29.8 ± 1. 3

28.1 ± 1.5

58.8 ± 4.4

29.0 ± 2.5

5.4 ± 1.5

720

29.9 ± 2.0

22.9 ± 3.6

36.4 ± 3.8

19.4

3.6

Data represents a mean± S.E., N=5.
Protamine was administered immediately after the 240 minute blood draw.

±

2.1

±

1.0

APPENDIX XXVIm
TIME COURSE OF THE PHARMACODYNAMIC ACTIVITY OF CY 216 WITH
PROTAMINE SULFATE IN PRIMATES
CY 216 Dose:
Protamine Dose:

0. 7 mg/kg s.c.
1.4 mg/kg i.v.

Time
(minutes)

APTT
(seconds)

0

24.7 ± 0.9

22.5 ± 0.8

20.0 ± 1.1

120

27.8 ± 1. 3

23.9 ± 2.4

58.9 + 2.7

40.3 ± 4.5

12.5 + 0.9

240

27.4 ± 1. 6

29.l ± 2.6

60.9 ± 3.0

42.5 ± 4.3

11.0 + 1. 5

245

30.0 ± 3.0

37.0 ± 9.2

47.6 ± 9.0

35.8 ± 1. 3

2.8 ± 1. 7

540

25.6 ± 1.5

29.7 ± 2.6

52.7 ± 1.2

27.5 ± 5.8

2.0 ± 2.0

360

27.6 ± 1.5

28.5 ± 1. 6

41. 9 ± 3.2

9.0 ± 3.7

0 ± 0

Thrombin Time (5 U/ml)
(seconds)

HeptestR
(seconds)

Anti-Xa
(% inhibition)
0 ± 0

Anti-Ila
(% inhibition)
0 ± 0

Data represents a mean± S.E., N=5.
Protamine was administered immediately after the 240 minutes blood draw.
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APPENDIX XXVIl
COMPARISON OF HEPARIN AND CY 216 SUPPLEMENTED
TO VARIOUS PLASMA PREPARATIONS
Plasma Preparation
Test: APTT
NHP
NMP
NRP
NratP
Test:

Heptest
NHP
NMP
NRP
NratP

Test: Anti-Xa
NHP
NMP
NRP
NratP
Test:

Anti- Ila
NHP
NMP
MRP
NratP

Heparin (µg/ml)

CY 216 (µg/ml)

1. 3
1.4
1. 9
3.8

>10
>10
>10
>10

.82
.82
6.2
2.05

1. 3
1. 3
1. 3
7.5

2.5
2.5
3.8
4.0

6.0
5.0
9.0
7.2

1.5
1. 3
3.3
2.5

8.2
4.6
10.0
7.4

Heparin or CY 216 was supplemented to NHP, NMP, NRP and NratP in a
concentration range of 0-10 µg/ml. For the clotting tests the
concentration of heparin or CY 216 at which the baseline was doubled is
reported. For the amidolytic assays, the concentration which produced
50% inhibition was reported.
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*

My• Weilht A'Nlra1•

Ka •

% Aver•&•

K.n.. •
Mu •

Vi•co•1tJ A-r•&•

lf...o•r Avera,•

Dupenit7 •

I\,

I

1

I OllCOflll(II I ADOfTIVI
I Ma,otf I MG•ON

•

Very slight changes in retention time can cause large charqes in the mea.'1
m:>lecular weight o! polymers.
For this reason it is ir.portant to i.'1~'"Pret
molecular weight data dete.rnu.ned by HPLC relative to various pa.ramete.'"S,
Peak Molecular Weight: In:ilcates the 110lecular weight o! the greatest p:,rtion
O! the eluti.rq materia1,

Mz, M,., ard Mz+l: 'Ihese values are a!!ected by variations in the high ::olec..:.lar
',,18ight region o! the eluti.n; material.
'lllus they cl-.aracterize t.".e high
IICllecular weight o::irponent.s.

Mn: 0--.ara~....e.rizes the low rolecular weight p:,rtion o! t."\e elution curve. '!his
value is sensitive to a lorq tail o! low IICllecular weight c:arp:nents.
Dispersity: \.'hen the polymer is c::at;,ose:i o! a \o/ide ran:;e o! IICllecular \o/eig.';t
c:orrponents this value \o/ill be high. It irdicates t."le r-an;e of oolecular
weights in the materia1.

* Taken from technical manual Waters 410 Chromatography
system
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